
<html lang="en"     class="pb-page"  data-request-id="8321d422-9bec-4250-97c3-eb337ede5f3a"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2017.60.issue-5;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.6b01670"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation" /></meta><meta name="dc.Creator" content="Solomon  Tadesse" /></meta><meta name="dc.Creator" content="Mingfeng  Yu" /></meta><meta name="dc.Creator" content="Laychiluh B.  Mekonnen" /></meta><meta name="dc.Creator" content="Frankie  Lam" /></meta><meta name="dc.Creator" content="Saiful  Islam" /></meta><meta name="dc.Creator" content="Khamis  Tomusange" /></meta><meta name="dc.Creator" content="Muhammed H.  Rahaman" /></meta><meta name="dc.Creator" content="Benjamin  Noll" /></meta><meta name="dc.Creator" content="Sunita K. C.  Basnet" /></meta><meta name="dc.Creator" content="Theodosia  Teo" /></meta><meta name="dc.Creator" content="Hugo  Albrecht" /></meta><meta name="dc.Creator" content="Robert  Milne" /></meta><meta name="dc.Creator" content="Shudong  Wang" /></meta><meta name="dc.Description" content="Cyclin D dependent kinases (CDK4 and CDK6) regulate entry into S phase of the cell cycle and are validated targets for anticancer drug discovery. Herein we detail the discovery of a novel series of..." /></meta><meta name="Description" content="Cyclin D dependent kinases (CDK4 and CDK6) regulate entry into S phase of the cell cycle and are validated targets for anticancer drug discovery. Herein we detail the discovery of a novel series of..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 16, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01670" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2017 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01670" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01670" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01670" /></link>
        
    
    

<title>Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01670" /></meta><meta property="og:title" content="Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0017.jpeg" /></meta><meta property="og:description" content="Cyclin D dependent kinases (CDK4 and CDK6) regulate entry into S phase of the cell cycle and are validated targets for anticancer drug discovery. Herein we detail the discovery of a novel series of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as highly potent and selective inhibitors of CDK4 and CDK6. Medicinal chemistry optimization resulted in 83, an orally bioavailable inhibitor molecule with remarkable selectivity. Repeated oral administration of 83 caused marked inhibition of tumor growth in MV4-11 acute myeloid leukemia mouse xenografts without having a negative effect on body weight and showing any sign of clinical toxicity. The data merit 83 as a clinical development candidate." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01670"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01670">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01670&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01670&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01670&amp;href=/doi/10.1021/acs.jmedchem.6b01670" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 1892-1915</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01645" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01689" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-<i>N</i>-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Solomon++Tadesse">Solomon Tadesse</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-9966-2236" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mingfeng++Yu">Mingfeng Yu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Laychiluh+B.++Mekonnen">Laychiluh B. Mekonnen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-7108-5345" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Frankie++Lam">Frankie Lam</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Saiful++Islam">Saiful Islam</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Khamis++Tomusange">Khamis Tomusange</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Muhammed+H.++Rahaman">Muhammed H. Rahaman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Benjamin++Noll">Benjamin Noll</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sunita+K.+C.++Basnet">Sunita K. C. Basnet</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Theodosia++Teo">Theodosia Teo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hugo++Albrecht">Hugo Albrecht</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-3951-1866" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert++Milne">Robert Milne</a></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shudong++Wang">Shudong Wang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>â </sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-6225-5525" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">â </span> <span class="aff-text">Center for Drug Discovery and Development, Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, and Center for Cancer Biology, University of South Australia, Adelaide, South Australia 5001, Australia</span></div><div class="corresp-info"><strong>*</strong>Phone: +61 8 83022372. Fax: +61 8 83021087. E-mail: <a href="/cdn-cgi/l/email-protection#1f6c776a7b70717831687e71785f6a71766c7e317a7b6a317e6a"><span class="__cf_email__" data-cfemail="addec5d8c9c2c3ca83daccc3caedd8c3c4decc83c8c9d883ccd8">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01670&amp;href=/doi/10.1021%2Facs.jmedchem.6b01670" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 1892â1915</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 3, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 November 2016</li><li><span class="item_label"><b>Published</b> online</span>16 February 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 March 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01670" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01670</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01670"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">6396</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">32</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01670" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Solomon&quot;,&quot;last_name&quot;:&quot;Tadesse&quot;},{&quot;first_name&quot;:&quot;Mingfeng&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Laychiluh&quot;,&quot;last_name&quot;:&quot;B. Mekonnen&quot;},{&quot;first_name&quot;:&quot;Frankie&quot;,&quot;last_name&quot;:&quot;Lam&quot;},{&quot;first_name&quot;:&quot;Saiful&quot;,&quot;last_name&quot;:&quot;Islam&quot;},{&quot;first_name&quot;:&quot;Khamis&quot;,&quot;last_name&quot;:&quot;Tomusange&quot;},{&quot;first_name&quot;:&quot;Muhammed&quot;,&quot;last_name&quot;:&quot;H. Rahaman&quot;},{&quot;first_name&quot;:&quot;Benjamin&quot;,&quot;last_name&quot;:&quot;Noll&quot;},{&quot;first_name&quot;:&quot;Sunita&quot;,&quot;last_name&quot;:&quot;K. C. Basnet&quot;},{&quot;first_name&quot;:&quot;Theodosia&quot;,&quot;last_name&quot;:&quot;Teo&quot;},{&quot;first_name&quot;:&quot;Hugo&quot;,&quot;last_name&quot;:&quot;Albrecht&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;Milne&quot;},{&quot;first_name&quot;:&quot;Shudong&quot;,&quot;last_name&quot;:&quot;Wang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;1892-1915&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01670&quot;},&quot;abstract&quot;:&quot;Cyclin D dependent kinases (CDK4 and CDK6) regulate entry into S phase of the cell cycle and are validated targets for anticancer drug discovery. Herein we detail the discovery of a novel series of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as highly potent and selective inhibitors of CDK4 and CDK6. Medicinal chemistry optimization resulted in 83, an orally bioavailable inhibitor molecule with remarkable selectivity. Repeated oral administration of 83 caused marked inhibition of tumor growth in MV4-11 acute myeloid leukemia mouse xenografts without having a negative effect on body weight and showing any sign of clinical toxicity. The data merit 83 as a clinical development candidate.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01670&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01670" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01670&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01670" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01670&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01670" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01670&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01670&amp;href=/doi/10.1021/acs.jmedchem.6b01670" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01670" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01670" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01670%26sid%3Dliteratum%253Aachs%26pmid%3D28156111%26genre%3Darticle%26aulast%3DTadesse%26date%3D2017%26atitle%3DHighly%2BPotent%252C%2BSelective%252C%2Band%2BOrally%2BBioavailable%2B4-Thiazol-N-%2528pyridin-2-yl%2529pyrimidin-2-amine%2BCyclin-Dependent%2BKinases%2B4%2Band%2B6%2BInhibitors%2Bas%2BAnticancer%2BDrug%2BCandidates%253A%2BDesign%252C%2BSynthesis%252C%2Band%2BEvaluation%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D5%26spage%3D1892%26epage%3D1915%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/jmcmar.2017.60.issue-5/20170309/jmcmar.2017.60.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Cyclin D dependent kinases (CDK4 and CDK6) regulate entry into S phase of the cell cycle and are validated targets for anticancer drug discovery. Herein we detail the discovery of a novel series of 4-thiazol-<i>N</i>-(pyridin-2-yl)pyrimidin-2-amine derivatives as highly potent and selective inhibitors of CDK4 and CDK6. Medicinal chemistry optimization resulted in <b>83</b>, an orally bioavailable inhibitor molecule with remarkable selectivity. Repeated oral administration of <b>83</b> caused marked inhibition of tumor growth in MV4-11 acute myeloid leukemia mouse xenografts without having a negative effect on body weight and showing any sign of clinical toxicity. The data merit <b>83</b> as a clinical development candidate.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75044" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75044" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cell cycle is an ordered sequence of events that leads to the transition from quiescence or cytokinesis to cell proliferation and through its checkpoints ensures genome stability.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It comprises four sequential phases: S phase, when DNA synthesis occurs; M phase, when the cell divides into two daughter cells; G1 phase after mitosis and before S phase, when cellular biosynthetic events take place at high rate and cells grow in size; G2 phase occurring between S and M phases, during which cells prepare for mitosis. Cells decide to enter S phase or remain quiescent using signaling pathways that link extracellular cues (e.g., growth factors) to G1 phase of the cell cycle.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Progression through G1 phase is regulated by retinoblastoma tumor suppressor proteins (Rbs), which repress the activity of E2 promoter binding factor (E2F) transcription factors whose functions are required for transition from G1 to S phase. Phosphorylation of Rb by G1 phase CDKs releases E2F transcription factors, promoting the transcription of genes that encode proteins necessary for DNA replication (e.g., <i>cyclin A</i> and <i>cyclin E</i>). The primary kinases that phosphorylate Rb proteins during G1 phase in mammalian cells are CDK4 and CDK6, hereafter referred to as CDK4/6.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">Previous studies have shown that the CDK4/6-Rb-E2F pathway is disrupted in 90% of cancers.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4-7)</a> Besides, genetic studies have established that CDK4/6 are dispensable for the mitotic cell cycle, evidenced by the fact that mice lacking these kinases are viable and that inactivation of the <i>CDK4/6</i> genes only affects the proliferation of specific cell types.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> Thus, CDK4/6 represent logical targets for the development of small molecules for therapeutic intervention in cancers.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Palbociclib (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>), the first and only approved CDK4/6 inhibitor for the treatment of metastatic breast cancer, has rejuvenated the field of selective CDK inhibitors.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> In addition, CDK4/6 inhibitors are now becoming recognized as important research tools to answer complex biological questions.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12, 13)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the advanced clinical CDK4/6 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As most inhibitors bind to the highly conserved ATP binding site, kinase selectivity remains unconquered. For instance, the in vitro kinase binding profile of the advanced clinical CDK4/6 inhibitors, i.e., palbociclib, ribociclib, and abemaciclib (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) against a near kinome-wide panel disclosed several additional targets.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> The off-targets can impair drug safety and contribute to differential cellular potencies and dissimilar clinical responses. For example, palbociclib and ribociclib have principally bone marrow toxicities with little toxic effect on gastrointestinal tract. In contrast, abemaciclib causes abundant gastrointestinal adverse effects. Palbociclib and ribociclib are dosed intermittently (3 weeks on and 1 week off), while abemaciclib is administered continuously due to a relatively low incidence of neutropenia.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> Jointly, these lines of evidence suggest that new pharmacophores might afford the desired kinase selectivity profiles and thus offer an effective way to minimize undesirable side effects.</div><div class="NLM_p last">In continuation of our search for new and selective CDK-targeting drugs,<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16-18)</a> herein we present the discovery of potent, highly selective, and orally bioavailable CDK4/6 inhibitor <b>83</b>. We demonstrate <b>83</b> exhibits significant anticancer efficacy in an MV4-11 acute myeloid leukemia (AML) subcutaneous xenograft mouse model.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25568" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25568" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Rational Drug Design</h3><div class="NLM_p">Because of evolutionary conservation of the ATP binding site, the discovery of highly selective small molecule ATP antagonistic CDK inhibitors is a daunting task.<a onclick="showRef(event, 'ref10 ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref10 ref19 ref20 ref21">(10, 19-21)</a> In a bid to identify both potent and selective ATP competitive CDK2 or CDK9 inhibitors, we have previously reported the discovery of the 2-anilino-4-(thiazol-5-yl)pyrimidine pharmacophore (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16-18)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structural modifications to 2-anilino-4-(thiazol-5-yl)pyrimidine pharmacophore.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our previous studies on exploration of structureâactivity relationships (SARs) of 2-anilino-4-(thiazol-5-yl)pyrimidines focused on modifications to the aniline and thiazole moieties of the pharmacophore. A large number of 2-anilino-4-(thiazol-5-yl)pyrimidine analogues were synthesized and screened against a wide panel of CDKs, and the results thus obtained disclosed several compounds with modest CDK4 inhibitory potency.<a onclick="showRef(event, 'ref16 ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18">(16-18)</a> We also proposed that incorporation of a geometrically fitting, positively ionizable group into the 2-anilino-4-(thiazol-5-yl)pyrimidine scaffold would result in favorable interaction(s) with the acidic residue(s) Asp99 and/or Glu144 in the ATP binding site of CDK4 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> As hypothesized, amine-substituted anilines positioned at C2 of the pyrimidine ring afforded moderately potent and relatively selective CDK4 inhibitors. In addition, methylation of the bridging NH between the phenyl and pyrimidine moieties led to an inactive compound. This was not surprising because this bridging NH and pyrimidinyl-N1 act as a key hydrogen bond donor and acceptor to interact with the backbone carbonyl and the NH groups of Val in the kinase hinge region, respectively. In another relevant study, it was also speculated that the interactions with the relatively less conserved hinge regions of CDK4/6 would be enhanced by the introduction of aromatic sp<sup>2</sup> nitrogen atom near to the rarely conserved His95 in CDK4 (His100 in CDK6).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In fact, Toogood et al. have shown that amino-pyridinyl compounds possess exquisite selectivity toward CDK4/6 over CDK2 than do their anilino counterparts.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> More recently, the pyridinyl nitrogen atom of abemaciclib has been shown to interact with the imidazole ring of His100 of CDK6 via a water bridge, and such an interaction is also possible in the cases of palbociclib and ribociclib due to the three molecules sharing the common pyrimidineâNHâpyridine motif.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. ATP binding site of CDK6 in complex with the inhibitor palbociclib (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2EUF">2EUF</a>) aligned with that of CDK4 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2W96">2W96</a>). CDK6 is shown in brown and CDK4 in cyan. Palbociclib, shown in green and bound in the ATP binding pocket of the kinases, forms two hydrogen bonds with conserved Val101 and one hydrogen bond with conserved Asp163. The hydrogen bonds are shown in black dashed lines. His95, Asp99, Thr102, and Glu144 of CDK4 are shown in cyan sticks. The figure was prepared using PyMOL1.3 (SchrÃ¶dinger Inc., 2013).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">On the basis of this knowledge, we explored whether structural modifications to the 2-anilino-4-(thiazol-5-yl)pyrimidine pharmacophore would lead to the generation of potent CDK4/6-specific inhibitors. To this end, we replaced the phenyl moiety with a pyridine ring, incorporated a variety of ionizable groups, and introduced an electron withdrawing group at C5 position of the pyrimidine ring. On the other hand, we retained some structural features that were shown to contribute toward the potency of the pharmacophore. The pyrimidine ring, which by virtue of its N1 and N3 is expected to make a hydrogen bond with Val of the hinge region of CDK4/6 and to ensure coplanarity of the pyrimidine and pyridine rings (an essential feature for ATP mimetic kinase inhibitors), respectively, was retained. Our previous studies showed that the thiazole C2-amino site interacted strongly with the Asp145 residue of the DFG motif of CDK2 (Asp167 in CDK9), enhancing the hydrophobic interactions of the thiazol-4-yl methyl group with the Phe80 gatekeeper residues of CDK2 (Phe103 in CDK9),<a onclick="showRef(event, 'ref16 ref17 ref18 ref22'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref22">(16-18, 22)</a> and these interactions are expected with CDK4/6 because the DFG motif and the gatekeeper Phe are highly conserved in the CDK family. As a result, the thiazole C2-amino moiety was not significantly altered. A total of 37 derivatives of 4-(4-methylthiazol-5-yl)-<i>N</i>-(pyridin-2-yl)pyrimidin-2-amine (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) were synthesized accordingly and their CDK inhibitory activities and antiproliferative effects are summarized in <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>â<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Synthetic Chemistry</h3><div class="NLM_p">The synthesis of 4-thiazol-<i>N</i>-(pyridin-2-yl)pyrimidin-2-amine derivatives <b>78</b>â<b>112</b>, <b>115</b>, and <b>116</b> requires the preparation of two pairs of building blocks, i.e., enaminones/guanidines and pyrimidin-2-amines/aryl bromides. The synthetic route to a variety of enaminones and two pyrimidin-2-amines is described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Isothiocyanatocyclopentane <b>2</b> was synthesized from the commercially available cyclopentylamine <b>1</b> using a procedure reported by Munch et al.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Treatment of isothiocyanates <b>2</b> or <b>3</b> (obtained from commercial source) with ammonia afforded <i>N</i>-substituted thioureas <b>4</b>â<b>6</b>, with <i>N</i>,<i>N</i>-disubstituted thiourea <b>5</b> isolated as a byproduct in the synthesis of <b>2</b>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> We speculate that <b>5</b> is formed from dicyclopentylcarbamodithioate, which is formed by the reaction between cyclopentyl(dithiocarboxy)amide intermediate and a halocyclopentane (minor contaminant of cyclopentylamine starting material). The dicyclopentylcarbamodithioate can then be desulfurylated by reacting with Boc<sub>2</sub>O and ammonia to yield <b>5</b>. 5-Acetylthiazoles <b>8</b>â<b>12</b> were prepared by the reaction of 3-chloro-2,4-pentanedione with the prepared thioureas <b>4</b>â<b>6</b> or the commercially available isopropyl thiourea <b>7</b> using HantzschâTraumann thiazole synthesis method<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> with the single exception of analogue <b>9</b>, which was made from a two-step reaction of 1,1,1-trifluoropentane-2,4-dione with [hydroxy(tosyloxy)iodo]benzene and 1-cyclopentylthiourea <b>4</b>, sequentially.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> 5-Acetylthiazoles <b>8</b>â<b>12</b> were readily converted to the corresponding enaminones <b>13</b> and <b>15</b>â<b>20</b> either by refluxing with <i>N</i>,<i>N</i>-dimethylformamide dimethyl acetal (DMF-DMA)<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> or using <i>tert</i>-butoxybis(dimethylamino)methane (Bredereckâs reagent) as previously reported.<a onclick="showRef(event, 'ref18 ref29'); return false;" href="javascript:void(0);" class="ref ref18 ref29">(18, 29)</a> Enaminone <b>13</b> was fluorinated with SelectFluor in methanol on an ice bath to give fluoride <b>14</b>.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The synthesis of pyrimidin-2-amines <b>21</b> and <b>22</b> was achieved by the coupling of enaminones <b>13</b> and <b>14</b> with guanidine hydrochloride, a classical route to construct pyrimidine ring systems.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0010.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Enaminones <b>13</b>â<b>20</b> and Pyrimidin-2-amines <b>21</b> and <b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CS<sub>2</sub>, NEt<sub>3</sub>, Boc<sub>2</sub>O, DMAP, EtOH, rt, 30 min, ice bath, 15 min, rt, 30 min; (b) NH<sub>3</sub>, H<sub>2</sub>O, MeOH, rt, 24 h; (c) 3-chloro-2,4-pentadione, pyridine, MeOH, rt, 4â48 h, or 1,1,1-trifluoropentane-2,4-dione, hydroxyl(tosyloxyl)iodobenzene, MeCN, reflux, 1 h; (d) DMF-DMA, reflux, 3â36 h, or microwave, 150 Â°C, 30 min, or Bredereckâs reagent, reflux, 6 h; (e) SelectFluor, MeOH, ice bath, 4 h; (f) <b>13</b> or <b>14</b>, guanidine hydrochloride, NaOH, 2-methoxyethanol, reflux, 6 h.</p><p><span class="fn-label">Scheme b</span>Intermediates <b>3</b> and <b>7</b> were obtained from commercial sources.</p><p class="last"><span class="fn-label">Scheme c</span>Most likely from dicyclopentylcarbamodithioate, which is formed by the reaction between cyclopentyl(dithiocarboxy)amide intermediate and a halocyclopentane (minor contaminant of cyclopentylamine starting material).</p></p></figure><div class="NLM_p">The synthesis of a wide range of guanidines is depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Nucleophilic substitution of 5-bromo-2-nitropyridine with various <i>N</i>-heterocycles <b>23</b>â<b>32</b> in dimethyl sulfoxide furnished nitro compounds <b>33</b>, <b>34</b>, <b>36</b>, <b>37</b>, and <b>39</b>â<b>44</b> in moderate to excellent yields.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The secondary amino group of <b>34</b> and <b>37</b> was found to interfere with the subsequent guanidine formation with <i>N</i>,<i>N</i>â²-bis-Boc-<i>S</i>-methylisothiourea and therefore was masked by the <i>tert</i>-butyloxycarbonyl (Boc) group to give intermediates <b>35</b> and <b>38</b>, respectively. Nitro compounds <b>33</b>, <b>35</b>, <b>36</b>, and <b>38</b>â<b>44</b> were reduced with gaseous hydrogen in the presence of 10% Pd/C in methanol to give respective amines <b>45</b>â<b>54</b> in good to excellent yields (82â100%); each of the amines <b>45</b>â<b>54</b> and the commercially available pyridine-2-amine <b>55</b> were subsequently coupled with <i>N</i>,<i>N</i>â²-bis-Boc-<i>S</i>-methylisothiourea in the presence of Et<sub>3</sub>N and HgCl<sub>2</sub> to afford bis-Boc-protected guanidine derivatives <b>56</b>â<b>66</b>.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Removal of Boc groups from <b>56</b>â<b>66</b> was carried out in a mixture of TFA and DCM (1:1) at reflux, giving the corresponding guanidines <b>67</b>â<b>77</b> in quantitative yields. The last building block 1-((6-bromopyridin-3-yl)methyl)-4-ethylpiperazine <b>114</b> was prepared in 25% yield by reductive amination of 6-bromopyridine-3-carbaldehyde <b>113</b> with ethylpiperazine using sodium triacetoxyborohydride (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0011.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Guanidine Derivatives <b>67</b>â<b>77</b> and 4-Thiazol-<i>N</i>-(pyridin-2-yl)pyrimidin-2-amines <b>78</b>â<b>112</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 5-bromo-2-nitropyridine, Et<sub>3</sub>N, DMSO, 120 Â°C, 16 h; (b) Boc<sub>2</sub>O, DMAP, Et<sub>3</sub>N, DCM, o/n, rt; (c) H<sub>2</sub>, 10% Pd/C, MeOH, o/n, rt; (d) <i>N</i>,<i>N</i>â²-bis-Boc-<i>S</i>-methylisothiourea, HgCl<sub>2</sub>, Et<sub>3</sub>N, DCM, 0 Â°C to rt, 14 h; (e) TFA/DCM (1:1), reflux, 16 h; (f) <b>13</b>â<b>20</b>, NaOH, 2-methoxyethanol, microwave, 180 Â°C, 1 h.</p><p><span class="fn-label">Scheme b</span>No substitution on carbon 5 of the pyridine ring and obtained from commercial source.</p><p><span class="fn-label">Scheme c</span>No substitution on carbon 5 of the pyridine ring.</p><p class="last"><span class="fn-label">Scheme d</span>See <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> for the structures of <b>78</b>â<b>112</b>.</p></p></figure><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0012.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>115</b> and <b>116</b> via BuchwaldâHartwig Amination<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethylpiperazine, sodium triacetoxyborohydride, DCM, 0 Â°C to rt, 12 h; (b) <b>21</b> or <b>22</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, <i>t</i>-BuONa, 1,4-dioxane, microwave, 150 Â°C, 1 h.</p></p></figure><div class="NLM_p last">Finally, all desired 4-thiazol-<i>N</i>-(pyridin-2-yl)pyrimidin-2-amine derivatives were obtained through either pyrimidine ring cyclization<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> between an enaminone and a guanidine (<b>78</b>â<b>112</b>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>) or BuchwaldâHartwig amination of a bromide and an amine<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> (<b>115</b> and <b>116</b>, <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Each enaminone (<b>13</b>â<b>20</b>) was condensed with an appropriate pyridinyl guanidine (<b>67</b>â<b>77</b>) under our previously reported microwave-assisted conditions,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> giving <b>78</b>â<b>112</b> in poor to moderate yields (5â57%) (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). In parallel, <b>115</b> and <b>116</b> were prepared by the palladium-catalyzed coupling of pyrimidinyl-2-amine <b>21</b> or <b>22</b> with bromide <b>114</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> StructureâActivity Relationship Analysis</h3><div class="NLM_p">The very first 4-(4-methylthiazol-5-yl)-<i>N</i>-(pyridin-2-yl)pyrimidin-2-amine prepared with an ionizable piperazine group on the pyridine ring was <b>78</b>. This molecule was found to exhibit excellent potency (<i>K</i><sub>i</sub> = 1 and 34 nM for CDK4 and CDK6, respectively) and a relatively high selectivity for CDK4/6 over CDK1, CDK2, CDK7, and CDK9. Compound <b>78</b> is also a highly effective antiproliferative agent with a GI<sub>50</sub> (concentration for 50% inhibition of cell proliferation) value of 23 nM against MV4-11. As expected, inhibition of CDK4/6 by <b>78</b> resulted in accumulation of MV4-11 cells in the G1 phase of cell cycle in a concentration dependent manner (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). At the highest concentration (0.40 Î¼M) tested, <b>78</b> accumulated 85% G1 population compared to the 61% in untreated cells. Similar cell cycle effects of palbociclib were also observed. This observation encouraged us to further explore the utility and versatility of the 4-(4-methylthiazol-5-yl)-<i>N</i>-(pyridin-2-yl)pyrimidin-2-amine scaffold as CDK4/6 inhibitors.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cell cycle analysis of <b>78</b>. Compound <b>78</b> induced G1 cell cycle accumulation in MV4-11 cells. The cells were treated with increasing concentrations of <b>78</b> or palbociclib (Palb) for 24 h and analyzed by flow cytometry. The experiments were repeated twice and representative data were presented.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Several structural alterations in relation to the substitution at the amino site of the thiazole moiety were made to examine whether the nature of the substituent would affect enzymatic and cellular efficacies (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Replacement of the cyclopentyl group (<b>78</b> and <b>80</b>) with the bulkier and more rigid aromatic phenyl group (<b>92</b> and <b>93</b>) resulted in a moderate reduction in both CDK4/6 and cellular activity. Similarly, substitution with the smaller and more flexible isopropyl group (<b>78</b>â<b>80</b> and <b>82</b> versus <b>95</b>â<b>98</b>) slightly decreased both CDK inhibitory activity and antiproliferative effect. However, despite its weaker CDK4/6 inhibitory activity (<i>K</i><sub>i</sub> = 41 and 82 nM for CDK4 and CDK6, respectively), <b>99</b> with an isopropyl substituent was more potent than the corresponding cyclopentyl analogue <b>83</b> (<i>K</i><sub>i</sub> = 4 and 30 nM for CDK4 and CDK6, respectively) in terms of antiproliferative activity (GI<sub>50</sub> = 32 and 115 nM for <b>99</b> versus GI<sub>50</sub> = 209 nM and >3 Î¼M for <b>83</b> against MV4-11 and MDA-MB-453, respectively), suggesting off-target effect(s) by <b>99</b>. Increasing the steric bulk at the amino site by introduction of a second alkyl group, i.e., methyl or cyclopentyl, moderately to greatly diminished the potency against both cell lines, which could be at least partially attributed to the reduced CDK7/9 inhibitory activity observed (<b>78</b>, <b>80</b>, and <b>82</b> versus <b>88</b>â<b>90</b>, and <b>78</b> versus <b>91</b>). Collectively, structural modifications made to the amino site of the thiazole ring indicated that monosubstitution of a cyclopentyl group afforded the optimal combination of both enzymatic and cellular potencies as well as the selectivity for CDK4/6. As a result, this functionality was retained and further alterations at C4 position of the thiazole ring were carried out (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Substitution of the methyl group with the bulkier electron withdrawing trifluoromethyl (<b>78</b>, <b>80</b>, <b>82</b>, and <b>83</b> versus <b>100</b>â<b>103</b>) markedly increased the potency against MV4-11 cells with GI<sub>50</sub> values ranging from 1 to 69 nM while the trend was not conclusive for MDA-MB-453 cells. In addition to the increased CDK2/7 inhibitory activity, the inhibition of CDK1, prevalently considered to induce toxicity against both malignant and untransformed cells,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> was found to be significantly enhanced, thus severely jeopardizing the CDK4/6 selectivity profile. Taken together, the data show that the cyclopentylamino and methyl group are optimal at C2 and C4 positions of the thiazole ring, respectively.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structures and in Vitro Biological Activities of 4-(4-Methylthiazol-5-yl)-<i>N</i>-(pyridin-2-yl)pyrimidin-2-amine Derivatives <b>78</b>â<b>99</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0013.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="3" align="center">substituent</th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">CDK inhibition, <i>K</i><sub>i</sub> (Î¼M)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char="Â±">growth inhibition, GI<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>5</sup></th><th class="colsep0 rowsep0" align="center" char=".">4D1<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">6D3<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">1B<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">2A<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">7H<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">9T1<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="Â±">MV4-11</th><th class="colsep0 rowsep0" align="center" char="Â±">MDA-MB-453</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>78</b></td><td class="colsep0 rowsep0" align="left">c-pent</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.034</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">1.108</td><td class="colsep0 rowsep0" align="center">0.220</td><td class="colsep0 rowsep0" align="char" char="Â±">0.023Â Â±Â 0.024</td><td class="colsep0 rowsep0" align="char" char="Â±">0.070Â Â±Â 0.013</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>79</b></td><td class="colsep0 rowsep0" align="left">c-pent</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>NH</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.008</td><td class="colsep0 rowsep0" align="center">4.070</td><td class="colsep0 rowsep0" align="center">0.278</td><td class="colsep0 rowsep0" align="center">0.282</td><td class="colsep0 rowsep0" align="center">0.508</td><td class="colsep0 rowsep0" align="char" char="Â±">0.029Â Â±Â 0.002</td><td class="colsep0 rowsep0" align="char" char="Â±">0.102Â Â±Â 0.117</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>80</b></td><td class="colsep0 rowsep0" align="left">c-pent</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.009</td><td class="colsep0 rowsep0" align="center">2.675</td><td class="colsep0 rowsep0" align="center">0.206</td><td class="colsep0 rowsep0" align="center">0.865</td><td class="colsep0 rowsep0" align="center">0.180</td><td class="colsep0 rowsep0" align="char" char="Â±">0.009Â Â±Â 0.000</td><td class="colsep0 rowsep0" align="char" char="Â±">0.130Â Â±Â 0.011</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>81</b></td><td class="colsep0 rowsep0" align="left">c-pent</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NCH<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="center">3.020</td><td class="colsep0 rowsep0" align="center">0.355</td><td class="colsep0 rowsep0" align="center">0.780</td><td class="colsep0 rowsep0" align="center">0.141</td><td class="colsep0 rowsep0" align="char" char="Â±">0.009Â Â±Â 0.001</td><td class="colsep0 rowsep0" align="char" char="Â±">0.287Â Â±Â 0.070</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>82</b></td><td class="colsep0 rowsep0" align="left">c-pent</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NCOCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.093</td><td class="colsep0 rowsep0" align="center">3.252</td><td class="colsep0 rowsep0" align="center">0.776</td><td class="colsep0 rowsep0" align="center">3.453</td><td class="colsep0 rowsep0" align="center">0.286</td><td class="colsep0 rowsep0" align="char" char="Â±">0.024Â Â±Â 0.028</td><td class="colsep0 rowsep0" align="char" char="Â±">0.591Â Â±Â 0.256</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>83</b></td><td class="colsep0 rowsep0" align="left">c-pent</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">0.030</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">4.683</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="char" char="Â±">0.209Â Â±Â 0.030</td><td class="colsep0 rowsep0" align="char" char="Â±">3.683Â Â±Â 0.285</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>84</b></td><td class="colsep0 rowsep0" align="left">c-pent</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CHNH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.133</td><td class="colsep0 rowsep0" align="center">1.230</td><td class="colsep0 rowsep0" align="center">0.181</td><td class="colsep0 rowsep0" align="center">1.187</td><td class="colsep0 rowsep0" align="center">0.173</td><td class="colsep0 rowsep0" align="char" char="Â±">0.013Â Â±Â 0.005</td><td class="colsep0 rowsep0" align="char" char="Â±">0.055Â Â±Â 0.012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>85</b></td><td class="colsep0 rowsep0" align="left">c-pent</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.070</td><td class="colsep0 rowsep0" align="char" char=".">0.257</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="char" char="Â±">0.191Â Â±Â 0.029</td><td class="colsep0 rowsep0" align="char" char="Â±">7.035Â Â±Â 0.710</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>86</b></td><td class="colsep0 rowsep0" align="left">c-pent</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NSO<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.007</td><td class="colsep0 rowsep0" align="char" char=".">0.055</td><td class="colsep0 rowsep0" align="center">1.100</td><td class="colsep0 rowsep0" align="center">0.077</td><td class="colsep0 rowsep0" align="center">2.640</td><td class="colsep0 rowsep0" align="center">1.321</td><td class="colsep0 rowsep0" align="char" char="Â±">0.176Â Â±Â 0.009</td><td class="colsep0 rowsep0" align="char" char="Â±">0.215Â Â±Â 0.052</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>87</b></td><td class="colsep0 rowsep0" align="left">c-pent</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NSP<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">0.570</td><td class="colsep0 rowsep0" align="char" char=".">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">ND</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="char" char="Â±">0.300Â Â±Â 0.035</td><td class="colsep0 rowsep0" align="char" char="Â±">4.379Â Â±Â 0.691</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>88</b></td><td class="colsep0 rowsep0" align="left">c-pent</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="center">1.39</td><td class="colsep0 rowsep0" align="center">0.174</td><td class="colsep0 rowsep0" align="center">3.20</td><td class="colsep0 rowsep0" align="center">1.801</td><td class="colsep0 rowsep0" align="char" char="Â±">0.285Â Â±Â 0.041</td><td class="colsep0 rowsep0" align="char" char="Â±">0.402Â Â±Â 0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>89</b></td><td class="colsep0 rowsep0" align="left">c-pent</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">0.476</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">1.800</td><td class="colsep0 rowsep0" align="char" char="Â±">0.020Â Â±Â 0.015</td><td class="colsep0 rowsep0" align="char" char="Â±">3.360Â Â±Â 0.286</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>90</b></td><td class="colsep0 rowsep0" align="left">c-pent</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NCOCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="char" char=".">0.031</td><td class="colsep0 rowsep0" align="center">3.17</td><td class="colsep0 rowsep0" align="center">0.121</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="char" char="Â±">0.328Â Â±Â 0.007</td><td class="colsep0 rowsep0" align="char" char="Â±">6.864Â Â±Â 0.798</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>91</b></td><td class="colsep0 rowsep0" align="left">c-pent</td><td class="colsep0 rowsep0" align="left">c-pent</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="char" char=".">0.071</td><td class="colsep0 rowsep0" align="char" char=".">0.539</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="char" char="Â±">0.714Â Â±Â 0.179</td><td class="colsep0 rowsep0" align="char" char="Â±">0.373Â Â±Â 0.117</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>92</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="char" char=".">0.066</td><td class="colsep0 rowsep0" align="center">2.04</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">1.66</td><td class="colsep0 rowsep0" align="center">0.436</td><td class="colsep0 rowsep0" align="char" char="Â±">0.056Â Â±Â 0.011</td><td class="colsep0 rowsep0" align="char" char="Â±">0.279Â Â±Â 0.044</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>93</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.019</td><td class="colsep0 rowsep0" align="char" char=".">0.485</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="char" char="Â±">0.508Â Â±Â 0.042</td><td class="colsep0 rowsep0" align="char" char="Â±">0.494Â Â±Â 0.081</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>94</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">NCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.026</td><td class="colsep0 rowsep0" align="char" char=".">0.100</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">1.04</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">2.00</td><td class="colsep0 rowsep0" align="char" char="Â±">0.421Â Â±Â 0.044</td><td class="colsep0 rowsep0" align="char" char="Â±">0.150Â Â±Â 0.029</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>95</b></td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="center">3.140</td><td class="colsep0 rowsep0" align="center">0.240</td><td class="colsep0 rowsep0" align="center">0.775</td><td class="colsep0 rowsep0" align="center">2.420</td><td class="colsep0 rowsep0" align="char" char="Â±">0.093Â Â±Â 0.010</td><td class="colsep0 rowsep0" align="char" char="Â±">0.031Â Â±Â 0.002</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>96</b></td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>NH</td><td class="colsep0 rowsep0" align="char" char=".">0.016</td><td class="colsep0 rowsep0" align="char" char=".">0.028</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">0.800</td><td class="colsep0 rowsep0" align="center">1.16</td><td class="colsep0 rowsep0" align="center">0.925</td><td class="colsep0 rowsep0" align="char" char="Â±">0.255Â Â±Â 0.085</td><td class="colsep0 rowsep0" align="char" char="Â±">0.938Â Â±Â 0.068</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>97</b></td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.015</td><td class="colsep0 rowsep0" align="center">3.815</td><td class="colsep0 rowsep0" align="center">0.399</td><td class="colsep0 rowsep0" align="center">0.760</td><td class="colsep0 rowsep0" align="center">0.773</td><td class="colsep0 rowsep0" align="char" char="Â±">0.075Â Â±Â 0.005</td><td class="colsep0 rowsep0" align="char" char="Â±">0.618Â Â±Â 0.193</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>98</b></td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">NCOCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.021</td><td class="colsep0 rowsep0" align="char" char=".">0.105</td><td class="colsep0 rowsep0" align="center">2.695</td><td class="colsep0 rowsep0" align="center">0.200</td><td class="colsep0 rowsep0" align="center">4.385</td><td class="colsep0 rowsep0" align="center">3.717</td><td class="colsep0 rowsep0" align="char" char="Â±">2.071Â Â±Â 0.321</td><td class="colsep0 rowsep0" align="char" char="Â±">0.344Â Â±Â 0.126</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>99</b></td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="char" char=".">0.041</td><td class="colsep0 rowsep0" align="char" char=".">0.082</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">0.127</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="char" char="Â±">0.032Â Â±Â 0.003</td><td class="colsep0 rowsep0" align="char" char="Â±">0.115Â Â±Â 0.024</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">palbociclib</td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.027</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">0.364</td><td class="colsep0 rowsep0" align="char" char="Â±">0.050Â Â±Â 0.004</td><td class="colsep0 rowsep0" align="char" char="Â±">0.326Â Â±Â 0.047</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last"><i>K</i><sub>m</sub> values were used as ATP concentrations. Apparent inhibition constants (<i>K</i><sub>i</sub>) were calculated using the half maximal inhibition (IC<sub>50</sub>) and the appropriate <i>K</i><sub>m</sub>(ATP) of each kinase as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. NA indicates no inhibition or compound activity that could not be fit to an IC<sub>50</sub> curve. ND designates not determined.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Antiproliferative activity was determined by 72 h resazurin and MTT assays using MV4-11 and MDA-MB-453 cell lines, respectively. The data given are derived from at least two replicates.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">4D1, 6D3, 1B, 2A, 7H, and 9T1 represent CDK4-cyclin D1, CDK6-cyclin D3, CDK1-cyclin B, CDK2-cyclin A, CDK7-cyclin H, and CDK9-cyclin T1, respectively.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">NSP indicates no substitution at C5 of the pyridine ring.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structures and Biological Activities of <i>N</i>-Cyclopentyl-5-(2-(pyridin-2-ylamino)pyrimidin-4-yl)-4-(trifluoromethyl)thiazol-2-amine Derivatives <b>100</b>â<b>104</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0014.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center">substituent</th><th class="rowsep1 colsep0" colspan="5" align="center" char=".">CDK inhibition, <i>K</i><sub>i</sub> (Î¼M)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char="Â±">growth inhibition, GI<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sup>5</sup></th><th class="colsep0 rowsep0" align="center" char=".">4D1<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">6D3<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">1B<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">2A<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">7H<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">9T1<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="Â±">MV4-11</th><th class="colsep0 rowsep0" align="center" char="Â±">MDA-MB-453</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>100</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="char" char=".">0.008</td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="center">0.220</td><td class="colsep0 rowsep0" align="char" char=".">0.022</td><td class="colsep0 rowsep0" align="center">0.194</td><td class="colsep0 rowsep0" align="char" char=".">0.258</td><td class="colsep0 rowsep0" align="char" char="Â±">0.002Â Â±Â 0.001</td><td class="colsep0 rowsep0" align="char" char="Â±">0.081Â Â±Â 0.039</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>101</b></td><td class="colsep0 rowsep0" align="left">NCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="center">0.241</td><td class="colsep0 rowsep0" align="char" char=".">0.022</td><td class="colsep0 rowsep0" align="center">0.189</td><td class="colsep0 rowsep0" align="char" char=".">0.831</td><td class="colsep0 rowsep0" align="char" char="Â±">0.001Â Â±Â 0.001</td><td class="colsep0 rowsep0" align="char" char="Â±">0.420Â Â±Â 0.120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>102</b></td><td class="colsep0 rowsep0" align="left">NCOCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="center">0.297</td><td class="colsep0 rowsep0" align="char" char=".">0.014</td><td class="colsep0 rowsep0" align="center">2.615</td><td class="colsep0 rowsep0" align="char" char=".">>5</td><td class="colsep0 rowsep0" align="char" char="Â±">0.012Â Â±Â 0.001</td><td class="colsep0 rowsep0" align="char" char="Â±">0.077Â Â±Â 0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>103</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="char" char=".">0.008</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="char" char=".">0.154</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="char" char=".">>5</td><td class="colsep0 rowsep0" align="char" char="Â±">0.069Â Â±Â 0.013</td><td class="colsep0 rowsep0" align="char" char="Â±">0.415Â Â±Â 0.103</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>104</b></td><td class="colsep0 rowsep0" align="left">NCHO</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">0.007</td><td class="colsep0 rowsep0" align="center">0.345</td><td class="colsep0 rowsep0" align="char" char=".">0.015</td><td class="colsep0 rowsep0" align="center">1.900</td><td class="colsep0 rowsep0" align="char" char=".">>5</td><td class="colsep0 rowsep0" align="char" char="Â±">0.004Â Â±Â 0.001</td><td class="colsep0 rowsep0" align="char" char="Â±">0.336Â Â±Â 0.188</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last"><i>K</i><sub>m</sub> values were used as ATP concentrations. Apparent inhibition constants (<i>K</i><sub>i</sub>) were calculated using the half-maximal inhibition (IC<sub>50</sub>) and the appropriate <i>K</i><sub>m</sub>(ATP) of each kinase as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. NA indicates no inhibition or compound activity that could not be fit to an IC<sub>50</sub> curve.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Antiproliferative activity was determined by 72 h resazurin and MTT assays using MV4-11 and MDA-MB-453 cell lines, respectively. The data given are derived from at least two replicates.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">4D1, 6D3, 1B, 2A, 7H, and 9T1 represent CDK4-cyclin D1, CDK6-cyclin D3, CDK1-cyclin B, CDK2-cyclin A, CDK7-cyclin H, and CDK9-cyclinT1, respectively.</p></div></div></div><div class="NLM_p">With the optimal thiazole moiety in hand, we next explored a variety of substituents at C5 position of the pyridine ring. Given that a basic amino substituent at this position was previously shown to improve both kinase selectivity and pharmaceutical properties,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> our effort mainly focused on introduction of various nitrogen-containing cyclic substituents. In fact, analysis of the crystal structure of palbociclib bound to CDK6 revealed that the piperazine ring sits in the kinase channel near the solvent accessible region and thus is capable of accommodating a wide variety of substituents (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The secondary amino site of the piperazine ring is expected to be protonated at physiological pH and consequently interact with Thr102 in CDK4 (Thr107 of CDK6), which corresponds to the unfavorable (due to electrostatic repulsion) positively charged Lys residues of CDK1/2, rendering the selectivity toward CDK4/6 over these kinases. In contrast, in CDK9, the corresponding residue is Gly, which can be in contact with the protonated amino site and thus contribute to CDK9 inhibition, albeit with a higher inhibition constant. In our current study, extending the cyclic secondary amino site of <b>78</b> further into the solvent channel gave rise to the exocyclic primary amino compound <b>84</b>, which exhibited decreased potency for CDK6 and selectivity for CDK4 over CDK2 and a marginally increased activity against both cell lines (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). The piperidine analogue <b>85</b>, lacking the secondary amino site, was 70- and >7-fold less potent against CDK4 and CDK6, respectively, than <b>78</b> (<i>K</i><sub>i</sub> = 70 and 257 nM for <b>85</b> versus <i>K</i><sub>i</sub> = 1 and 34 nM for <b>78</b> toward CDK4 and CDK6, respectively). The absence of a heterocyclic substituent on the pyridine ring (<b>87</b>) was not tolerated, with a <i>K</i><sub>i</sub> value of 570 nM for CDK4. The significant loss of the CDK4 inhibitory potency in the cases of <b>85</b> and <b>87</b> confirmed the requirement of an appropriate heterocyclic substituent at the C5 position of the pyridine ring for CDK4/6 inhibition. Nevertheless, these two compounds exhibited good antiproliferative activity against MV4-11 cells, indicating potential off-targets. Elongation of the linker by insertion of a methylene spacer between the pyridine ring and the piperazine moiety (<b>115</b> and <b>116</b> versus <b>81</b> and <b>108</b>) did not significantly impact the CDK4/6 selectivity and cellular potency (<a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>, <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structures and in Vitro Biological Activities of <i>N</i>-Cyclopentyl-5-(2-((5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine Derivatives <b>115</b> and <b>116</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0015.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" align="center">substituent</th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">CDK inhibition, <i>K</i><sub>i</sub> (Î¼M)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char="Â±">growth inhibition, GI<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sup>4</sup></th><th class="colsep0 rowsep0" align="center" char=".">4D1<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">6D3<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">1B<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">2A<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">7H<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">9T1<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="Â±">MV4-11</th><th class="colsep0 rowsep0" align="center" char="Â±">MDA-MB-453</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>115</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.009</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="char" char=".">0.416</td><td class="colsep0 rowsep0" align="char" char=".">0.211</td><td class="colsep0 rowsep0" align="char" char=".">1.98</td><td class="colsep0 rowsep0" align="char" char="Â±">0.019Â Â±Â 0.003</td><td class="colsep0 rowsep0" align="char" char="Â±">0.069Â Â±Â 0.023</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>116</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.014</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="char" char=".">0.620</td><td class="colsep0 rowsep0" align="char" char=".">0.630</td><td class="colsep0 rowsep0" align="char" char=".">3.57</td><td class="colsep0 rowsep0" align="char" char="Â±">0.010Â Â±Â 0.002</td><td class="colsep0 rowsep0" align="char" char="Â±">0.622Â Â±Â 0.208</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last"><i>K</i><sub>m</sub> values were used as ATP concentrations. Apparent inhibition constants (<i>K</i><sub>i</sub>) were calculated using the half maximal inhibition (IC<sub>50</sub>) and the appropriate <i>K</i><sub>m</sub>(ATP) value of each kinase as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. NA indicates no inhibition or compound activity that could not be fit to an IC<sub>50</sub> curve.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Antiproliferative activity was determined by 72 h resazurin and MTT assays using MV4-11 and MDA-MB-453 cell lines, respectively. The data given are derived from at least two replicates.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">4D1, 6D3, 1B, 2A, 7H, and 9T1 represent CDK4-cyclin D1, CDK6-cyclin D3, CDK1-cyclin B, CDK2-cyclin A, CDK7-cyclin H, and CDK9-cyclinT1, respectively.</p></div></div></div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Structures and in Vitro Biological Activities of <i>N</i>-Cyclopentyl-5-(5-fluoro-2-(pyridin-2-ylamino)pyrimidin-4-yl)-4-methylthiazol-2-amine Derivatives <b>105</b>â<b>112</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0016.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col><col align="char" char="." /></col><col align="center" /></col><col align="center" /></col><col align="char" char="Â±" /></col><col align="char" char="Â±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" align="center">substituent</th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">CDK inhibition, <i>K</i><sub>i</sub> (Î¼M)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="2" align="center" char="Â±">growth inhibition, GI<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R<sup>5</sup></th><th class="colsep0 rowsep0" align="center" char=".">4D1<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">6D3<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">1B<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">2A<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">7H<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center">9T1<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char="Â±">MV4-11</th><th class="colsep0 rowsep0" align="center" char="Â±">MDA-MB-453</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>105</b></td><td class="colsep0 rowsep0" align="left">NH</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.007</td><td class="colsep0 rowsep0" align="center">2.235</td><td class="colsep0 rowsep0" align="char" char=".">0.256</td><td class="colsep0 rowsep0" align="center">0.790</td><td class="colsep0 rowsep0" align="center">0.787</td><td class="colsep0 rowsep0" align="char" char="Â±">0.053Â Â±Â 0.004</td><td class="colsep0 rowsep0" align="char" char="Â±">0.780Â Â±Â 0.598</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>106</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>NH</td><td class="colsep0 rowsep0" align="char" char=".">0.014</td><td class="colsep0 rowsep0" align="char" char=".">0.010</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="char" char=".">0.417</td><td class="colsep0 rowsep0" align="center">0.815</td><td class="colsep0 rowsep0" align="center">0.679</td><td class="colsep0 rowsep0" align="char" char="Â±">0.029Â Â±Â 0.002</td><td class="colsep0 rowsep0" align="char" char="Â±">0.083Â Â±Â 0.009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>107</b></td><td class="colsep0 rowsep0" align="left">NCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="center">2.330</td><td class="colsep0 rowsep0" align="char" char=".">0.103</td><td class="colsep0 rowsep0" align="center">2.020</td><td class="colsep0 rowsep0" align="center">0.505</td><td class="colsep0 rowsep0" align="char" char="Â±">0.073Â Â±Â 0.028</td><td class="colsep0 rowsep0" align="char" char="Â±">0.202Â Â±Â 0.030</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>108</b></td><td class="colsep0 rowsep0" align="left">NCH<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.002</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="char" char=".">0.349</td><td class="colsep0 rowsep0" align="center">0.685</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="char" char="Â±">0.013Â Â±Â 0.002</td><td class="colsep0 rowsep0" align="char" char="Â±">0.066Â Â±Â 0.019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>119</b></td><td class="colsep0 rowsep0" align="left">NCOCH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.034</td><td class="colsep0 rowsep0" align="char" char=".">0.023</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="char" char=".">0.228</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">4.990</td><td class="colsep0 rowsep0" align="char" char="Â±">0.015Â Â±Â 0.002</td><td class="colsep0 rowsep0" align="char" char="Â±">8.107Â Â±Â 1.147</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>110</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="char" char=".">0.020</td><td class="colsep0 rowsep0" align="center">4.350</td><td class="colsep0 rowsep0" align="char" char=".">0.104</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="char" char="Â±">0.290Â Â±Â 0.062</td><td class="colsep0 rowsep0" align="char" char="Â±">1.437Â Â±Â 0.304</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>111</b></td><td class="colsep0 rowsep0" align="left">NSO<sub>2</sub>CH<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.039</td><td class="colsep0 rowsep0" align="char" char=".">0.101</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="char" char=".">0.348</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">>5</td><td class="colsep0 rowsep0" align="char" char="Â±">2.628Â Â±Â 0.582</td><td class="colsep0 rowsep0" align="char" char="Â±">2.813Â Â±Â 0.089</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>112</b></td><td class="colsep0 rowsep0" align="left">CHN(CH<sub>3</sub>)<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="char" char=".">0.031</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="char" char=".">1.150</td><td class="colsep0 rowsep0" align="center">NA</td><td class="colsep0 rowsep0" align="center">1.091</td><td class="colsep0 rowsep0" align="char" char="Â±">0.454Â Â±Â 0.040</td><td class="colsep0 rowsep0" align="char" char="Â±">0.356Â Â±Â 0.024</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last"><i>K</i><sub>m</sub> values were used as ATP concentrations. Apparent inhibition constants (<i>K</i><sub>i</sub>) were calculated using the half maximal inhibition (IC<sub>50</sub>) and the appropriate <i>K</i><sub>m</sub>(ATP) of each kinase as described in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>. NA indicates no inhibition or compound activity that could not be fit to an IC<sub>50</sub> curve.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Antiproliferative activity was determined by 72 h resazurin and MTT assays using MV4-11 and MDA-MB-453 cell lines, respectively. The data given are derived from at least two replicates.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">4D1, 6D3, 1B, 2A, 7H, and 9T1 represent CDK4-cyclin D1, CDK6-cyclin D3, CDK1-cyclin B, CDK2-cyclin A, CDK7-cyclin H, and CDK9-cyclinT1, respectively.</p></div></div></div><div class="NLM_p">Recently, we successfully optimized the pharmacokinetic (PK) properties of CDK9 inhibitors by introduction of a fluorine atom at C5 position of the pyrimidine ring.<a onclick="showRef(event, 'ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref36 ref37">(36, 37)</a> This strategy was also deployed in the current study to seek potent and selective CDK4/6 inhibitors with improved bioavailability. In addition, we envisioned that the electronegative fluorine atom would acidify the bridging NH between the pyrimidine and pyridine rings, thereby increasing the strength of the hydrogen bonding with the carbonyl group of Val in the hinge region.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Regrettably, all the attempts thus made led to little success in further improving CDK4/6 inhibitory activity and selectivity, antiproliferative potency (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>), and PK properties (data not shown). Nonetheless, probably due to its bulkier ionizable amino site in the vicinity of Thr102, the 4-(dimethylamino)piperidine analogue <b>112</b> possesses an increased selectivity toward CDK4.</div><div class="NLM_p last">Interestingly, all morpholine-containing compounds <b>83</b>, <b>99</b>, <b>103</b>, and <b>110</b> displayed excellent selectivity toward CDK4/6 over the other CDKs tested (<a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). Particularly, <b>83</b> showed >1200-fold selectivity over CDK2 and was inactive against the rest of CDKs tested. Setting a maximum <i>K</i><sub>i</sub> value of 10 nM and a minimum selectivity of 100-fold for CDK4 as criteria, we have identified nine compounds, i.e., <b>78</b>, <b>79</b>, <b>83</b>, <b>89</b>, <b>97</b>, <b>107</b>, <b>108</b>, <b>112</b>, and <b>116</b>, as highly selective CDK4/6 inhibitors, all of which exhibited potent cellular antiproliferative activities in cancer cell lines.</div></div><div id="sec2_99" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Kinase Selectivity Profiling of <b>83</b></h3><div class="NLM_p">Upon identification of nine potent compounds with high selectivity for CDK4/6 over the other CDK family members tested, a selection of compounds, i.e., <b>78</b>, 83, <b>107</b>, and <b>112</b>, were further screened against a panel of 50 different kinases (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b01670/suppl_file/jm6b01670_si_001.pdf" class="ext-link">Table S1</a>). Compounds <b>78</b> and <b>107</b> potently inhibited (<10% kinase residual activity at 10 Î¼M) a number of kinases including CK1Î´, DAPK1, DYRK1A/B, FGFR1, Flt1, Flt3, Flt4, HIPK2, JNK3, Mnk2, Pim-1, and SGK. In contrast, DYRK1A/B and HIPK2 were the only two other kinases significantly affected by <b>112</b>. Strikingly, <b>83</b> was the most selective CDK4/6 inhibitor with no appreciable effect on other kinases tested. The subsequent profiling of <b>83</b> against a wider panel of 369 kinases at the concentration of 1 Î¼M (â¼250 Ã <i>K</i><sub>i</sub>) (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>, Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b01670/suppl_file/jm6b01670_si_001.pdf" class="ext-link">Table S2</a>) revealed that <b>83</b> is exceptionally selective for CDK4/6 within the human kinome; DYRK2/3, LIMK1, and STK16, all of which are not commonly associated with cancer, were the only other kinases significantly inhibited by this compound. To the best of our knowledge, the kinase selectivity of <b>83</b> is superior to those of CDK4/6 inhibitors previously reported.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a></div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Kinome-wide selectivity of <b>83</b> at 1 Î¼M. Red, yellow, and green colors indicate kinase residual activity of <10%, 10â20%, and >20%, respectively. Individual kinase residual activity values are given in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b01670/suppl_file/jm6b01670_si_001.pdf" class="ext-link">Table S2</a>. The human kinome map is adapted with permission from Reaction Biology Corp.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Antiproliferative Activity of <b>83</b></h3><div class="NLM_p">The most selective CDK4/6 inhibitor <b>83</b> was further tested against a panel of 12 cancerous and two nontransformed cell lines to examine whether the antiproliferative effect was cell-type specific (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Compound <b>83</b> potently inhibited the proliferation of seven cell lines (MOLM13, NB4, M229, M249, M249R, A2780, and PC-3) with GI<sub>50</sub> values between 0.038 and 0.681 Î¼M, and moderately restrained the growth of two cell lines (MCF-7 and M238), with a GI<sub>50</sub> value of 1.887 and 2.200 Î¼M, respectively. The remaining three cancer cell lines were not sensitive to <b>83</b>, with a GI<sub>50</sub> value of >10 Î¼M. In comparison, palbociclib was more effective against the cancer cell lines except in the cases of melanoma cancer cells M229, M249, and M247R. Both <b>83</b> and palbociclib exerted little toxic effects on nontransformed human prostatic epithelial cell BPH-1 and the normal lung fibroblast MRC-5.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Antiproliferative Activity of <b>83</b> against a Panel of Human Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center">growth inhibition, GI<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">origin</th><th class="colsep0 rowsep0" align="center">cell lines</th><th class="colsep0 rowsep0" align="center"><b>83</b></th><th class="colsep0 rowsep0" align="center">palbociclib</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">breast</td><td class="colsep0 rowsep0" align="left">MCF-7</td><td class="colsep0 rowsep0" align="center">1.887Â Â±Â 0.130</td><td class="colsep0 rowsep0" align="center">0.557Â Â±Â 0.057</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">MDA-MB-468</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">5.960Â Â±Â 2.400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">leukemia</td><td class="colsep0 rowsep0" align="left">MOLM13</td><td class="colsep0 rowsep0" align="center">0.385Â Â±Â 0.098</td><td class="colsep0 rowsep0" align="center">0.062Â Â±Â 0.012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">NB4</td><td class="colsep0 rowsep0" align="center">0.681Â Â±Â 0.018</td><td class="colsep0 rowsep0" align="center">0.066Â Â±Â 0.012</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">melanoma</td><td class="colsep0 rowsep0" align="left">M229</td><td class="colsep0 rowsep0" align="center">0.150Â Â±Â 0.007</td><td class="colsep0 rowsep0" align="center">1.220Â Â±Â 0.610</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">M238</td><td class="colsep0 rowsep0" align="center">2.200Â Â±Â 0.430</td><td class="colsep0 rowsep0" align="center">1.970Â Â±Â 0.260</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">M249</td><td class="colsep0 rowsep0" align="center">0.082Â Â±Â 0.002</td><td class="colsep0 rowsep0" align="center">1.990Â Â±Â 0.520</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">M249R</td><td class="colsep0 rowsep0" align="center">0.038Â Â±Â 0.005</td><td class="colsep0 rowsep0" align="center">2.960Â Â±Â 0.220</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ovarian</td><td class="colsep0 rowsep0" align="left">A2780</td><td class="colsep0 rowsep0" align="center">0.058Â Â±Â 0.017</td><td class="colsep0 rowsep0" align="center">0.032Â Â±Â 0.008</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">prostate</td><td class="colsep0 rowsep0" align="left">Du-145</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">5.792Â Â±Â 0.801</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">C4â2B</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">4.150Â Â±Â 1.100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">PC-3</td><td class="colsep0 rowsep0" align="center">0.150Â Â±Â 0.007</td><td class="colsep0 rowsep0" align="center">0.071Â Â±Â 0.009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">nontransformed</td><td class="colsep0 rowsep0" align="left">BPH-1</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">7.442Â Â±Â 0.552</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">MRC-5</td><td class="colsep0 rowsep0" align="center">>10</td><td class="colsep0 rowsep0" align="center">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Antiproliferative activity was determined by 72 h resazurin or MTT assays. The data given are derived from two replicates.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Cellular Mechanism of Action of <b>83</b></h3><div class="NLM_p">To evaluate whether the observed antiproliferative activity of <b>83</b> is derived from the inhibition of cellular CDK4/6, we examined the status of Rb phosphorylation at the CDK4/6-specific site Ser780, cell cycle distribution, and apoptosis induction. Western blot analysis showed that <b>83</b> inhibited phosphorylation of the Rb protein (at Ser780) in MV4-11 cells in a dose-dependent manner upon 12 and 24 h treatments (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). In comparison, much faster and stronger inhibition of both total Rb and Rb phosphorylation was observed upon treatment with palbociclib. This finding is consistent with a previous study, where plabociclib was shown not only to decrease the protein levels of Rb and phosphorylated Rb but also the transcription of <i>Rb1</i> gene.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> As phosphorylated Rb protein is required for G1 to S transition of the cell cycle, selective inhibition of Rb phosphorylation at CDK4/6-specific site should cause G1 cell cycle arrest. As expected, a dose-dependent accumulation of cells in G1 phase was observed following 24 h treatment with <b>83</b> or palbociclib (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). This G1 phase arrest was maintained with 10 Ã GI<sub>50</sub> Î¼M (and higher concentrations, data not shown) for both compounds, signifying no off-target cell-cycle activity. The lack of an increase in the population of sub-G1 cells (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>) in both cases is in agreement with the absence of noticeable apoptosis (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). This was not unexpected, as previous studies have demonstrated that CDK4/6 inhibitors induced either cytostasis or apoptosis depending on the type of cells, concentration of drug, and duration of treatement.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40, 41)</a> Taken together, these results indicate that <b>83</b> effectively triggers G1 cell cycle arrest by inhibiting the CDK4/6-mediated phosphorylation of Rb without causing significant cell death in MV4-11 cells.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Western blot analysis of MV4-11 cancer cells following treatment with <b>83</b> or palbociclib for 12 or 24 h. Both <b>83</b> and palbociclib (palb) inhibited the phosphorylation of Rb at Ser780. Î²-Actin was used as a loading control. The data are representative of two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cell cycle effects of <b>83</b> and palbociclib on MV4-11 cells. Cells were treated with increasing concentrations of <b>83</b> or palbociclib (palb) for 24 h, harvested, fixed, and stained with propidium iodide prior to flow cytometric analysis. The experiments were repeated twice. Representative data were selected to generate this figure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effects of <b>83</b> and palbociclib on the induction of apoptosis. Treatment with <b>83</b> or palbociclib (palb) showed little effect on the induction of apoptosis in MV4-11 cells. The cells were exposed to increasing concentrations of each compound for 24 h and analyzed by annexin V/propidium iodide double staining. The data are representative of two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Biopharmaceutical Profiling of <b>83</b></h3><div class="NLM_p">In light of its excellent in vitro biological profile, <b>83</b> was further subjected to in vitro biopharmaceutical and in vivo pharmacokinetic evaluations. To assess the safety and potential oral bioavailability of <b>83</b>, the in vitro ADME properties of <b>83</b> were determined. CYP450 and hERG (human ether-a-go-go related gene) channel inhibition screens were used to evaluate the potential of <b>83</b> toward drugâdrug interactions and cardiac liability, respectively. As shown in <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>, <b>83</b> exhibited a very good safety profile with IC<sub>50</sub> > 25 Î¼M against five common CYP450 isoforms and with IC<sub>50</sub> > 10 Î¼M against hERG. <b>83</b> was found to be highly permeable with apparent permeability coefficient (<i>P</i><sub>app</sub>) of 10.1 Ã 10<sup>â6</sup> cm/s, suggesting high intestinal absorption. The efflux ratio (ER) of <b>83</b> was 0.4, demonstrating that <b>83</b> was not subjected to active efflux that is usually indicated by a value >2. <b>83</b> has high lipophilicity with a log <i>D</i><sub>7.4</sub> value of 4.4 (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Biopharmaceutical Profiles of <b>83</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">inhibition of CYP450 (IC<sub>50</sub>, Î¼M)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">CYP3A4</td><td class="colsep0 rowsep0" align="left">>25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">CYP2D6</td><td class="colsep0 rowsep0" align="left">>25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">CYP1A</td><td class="colsep0 rowsep0" align="left">>25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">CYP2C9</td><td class="colsep0 rowsep0" align="left">>25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">CYP2C19</td><td class="colsep0 rowsep0" align="left">>25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">inhibition of hERG (IC<sub>50</sub>)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">Î¼M</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">partition coefficient<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">log <i>D</i><sub>7.4</sub></td><td class="colsep0 rowsep0" align="left">4.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dissociation constant<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">p<i>K</i><sub>a</sub></td><td class="colsep0 rowsep0" align="left">3.98,Â 5.68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco2 permeability<a class="ref internalNav" href="#t6fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">AâB <i>P</i><sub>app</sub> (10<sup>â6</sup> cm/s)</td><td class="colsep0 rowsep0" align="left">10.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">BâA <i>P</i><sub>app</sub> (10<sup>â6</sup> cm/s)</td><td class="colsep0 rowsep0" align="left">3.98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="left">efflux ratio</td><td class="colsep0 rowsep0" align="left">0.396</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Human liver microsomes and NADPH in the presence of a cytochrome P450 isoform-specific probe substrate: midazolam for CYP3A4, dextromethorphan for CYP2D6, ethoxyresorufin for CYP1A, tolbutamide for CYP2C9, and mephenytoin for CYP2C19.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">CHO-hERG cells were used for the cardiac toxicity assay. The data is usually categorized into the following classification bands: highly potent IC<sub>50</sub> < 0.1 Î¼M; potent IC<sub>50</sub> = 0.1â1 Î¼M; moderately potent IC<sub>50</sub> = 1â10 Î¼M; weak or no inhibition IC<sub>50</sub> > 10 Î¼M.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Determined using a pH-metric method.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">By Shake Flask.</p></div><div class="footnote" id="t6fn5"><sup>e</sup><p class="last">Apparent permeability coefficient measured by Caco-2 assay. Efflux ratio = (mean <i>P</i><sub>app</sub> BâA/mean <i>P</i><sub>app</sub> AâB).</p></div></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Pharmacokinetic Properties of <b>83</b></h3><div class="NLM_p">Encouraged by the in vitro DMPK profile of <b>83</b>, single-dose PK studies were then performed with male albino Wistar rats at 5 mg/kg by IV and 20 mg/kg by PO and with male BALB/c mice at 2 mg/kg by IV and 10 mg/kg by PO, and the results are summarized in <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>. When <b>83</b> was administered via intravenous route, its systemic plasma clearance (CL) of 3.5 L/hÂ·kg in mice or 0.71 L/hÂ·kg in rats was low relative to the hepatic blood flow rate of the respective murine species. The large volume of distribution observed (<i>V</i><sub>ss</sub> = 5.6 and 1.5 L/kg in mice and rats, respectively) suggested extravascular distribution. Maximal plasma concentrations (<i>C</i><sub>max</sub>) of 1.6 Î¼M in mouse and 1.4 Î¼M in rat were achieved at 2.0 and 3.7 h, respectively, after oral dosing. <b>83</b> exhibited good oral half-life (<i>t</i><sub>1/2</sub>) in both species, with <i>t</i><sub>1/2</sub> = 5 h in mouse and <i>t</i><sub>1/2</sub> = 2.8 h in rat. Its oral bioavailability was moderate (<i>F</i> = 27%) in rats and excellent (<i>F</i> = 100%) in mice, achieving the AUC<sub>0â<i>t</i></sub> = 5.9 Î¼MÂ·h in mice and AUC<sub>0â<i>t</i></sub> = 15.9 Î¼MÂ·h in rats. The plasma concentrationâtime profile of <b>83</b> following IV and PO administration to rats and mice are shown in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b01670/suppl_file/jm6b01670_si_001.pdf" class="ext-link">Figures S1 and S2</a>.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Pharmacokinetic Parameters of <b>83</b> in Rats and Mice</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">rat</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">mouse</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center" char=".">IV</th><th class="colsep0 rowsep0" align="center" char=".">PO</th><th class="colsep0 rowsep0" align="center" char=".">IV</th><th class="colsep0 rowsep0" align="center" char=".">PO</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dose (mg/kg)</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (L/hÂ·kg)</td><td class="colsep0 rowsep0" align="char" char=".">0.71</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0â<i>t</i></sub> (Î¼MÂ·h)</td><td class="colsep0 rowsep0" align="char" char=".">15.9</td><td class="colsep0 rowsep0" align="char" char=".">15.9</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">5.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (Î¼M)</td><td class="colsep0 rowsep0" align="char" char=".">38.8</td><td class="colsep0 rowsep0" align="char" char=".">1.4</td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">3.7</td><td class="colsep0 rowsep0" align="char" char=".">-</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">25.1</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr></tbody></table></div></div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Pharmacological Safety and in Vivo Anticancer Activity of <b>83</b></h3><div class="NLM_p">The favorable pharmacokinetic profile of <b>83</b> along with its highly desirable cellular activity and CDK4/6 inhibitory potency and selectivity warranted its advancement into in vivo safety and efficacy studies. First, we intended to determine the maximum tolerated dose of <b>83</b> in mice, but the compound did not cause any adverse effect on body weight or any other signs of overt toxicity at daily doses up to 100 mg/kg. Therefore, we assessed the in vivo anticancer activity of <b>83</b> in a subcutaneous human MV4-11 MLL-AML xenograft murine model. Tumor-bearing mice were treated orally with <b>83</b> (100 mg/kg, QD) for 33 consecutive days and left untreated for another 50 days. The treatment resulted in the marked inhibition of tumor growth (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>A,B) and a prolongation of animal life span (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>C). Tumor volume compared to control (T/C) significantly diminished to 30% on day 31 (<i>p</i> < 0.00001), and on day 33 of treatment the tumor growth inhibition (TGI) was 76%. Strikingly, <b>83</b> induced a complete and sustained tumor regression in three out of nine mice, and no tumor regrowth was observed during the 50 days post-treatment (<a class="ref internalNav" href="#fig9" aria-label="Figures 9">Figures 9</a>B,C). The regression and delay in tumor growth were translated to the increased survival rate of the treated group (median survival period = 55 days) when compared to vehicle-treated mice (median survival time = 33 days) (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>C), suggesting that <b>83</b> was highly efficacious against MV4-11 xenograft. Compound <b>83</b> exhibited excellent safety characteristics without having a negative effect on body weight and any signs of overt toxicity (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>D).</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vivo anticancer efficacy of <b>83</b>. (A) Female nude (nu/nu) BALB/c mice at 6â8 weeks of age with subcutaneously implanted MV4-11 leukemia xenograft were orally treated with 100 mg/kg of <b>83</b> (<i>n</i> = 9) or vehicle (1% CMC, <i>n</i> = 9) daily for 33 days. Treatment with <b>83</b> significantly reduced tumor burden in comparison to vehicle-treated controls. Significant reduction in tumor volume (<i>p</i> < 0.05) was observed in drug treated group from day 5 until the end of experiment when compared with vehicle treated group. (B) Tumor volumes of each mouse on day 31. (C) KaplanâMeier analysis of animal survival following treatment with <b>83</b> or vehicle. (D) <b>83</b> was well tolerated without causing a negative effect on body weight in MV4-11 leukemia xenograft bearing mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85231" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85231" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have discovered a new series of potent inhibitors of CDK4/6 and provided rationale for the observed biological activities. One of the lead compounds of this class, <b>83</b>, was identified as a CDK4/6-specific inhibitor with little or no effect on a large panel of kinases. Compound <b>83</b> exhibited cellular CDK4/6 targeted mechanism of action, favorable pharmacokinetics, and significant anticancer efficacy in animal models. With its high oral activity along with excellent safety profile, <b>83</b> offers a very exciting prospect as a clinical development candidate.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18224" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18224" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Chemistry</h3><div class="NLM_p">Chemical reagents and solvents were purchased from commercial sources and were used as received. Microwave-assisted synthesis was performed in an Asynt DrySyn insert (10 mL, Isleham, UK) using a CEM Discover SP and Explorer 48/72/96 microwave system (Matthews, NC, USA) controlled by Synergy software (Firmware version DSCA02.17). Reaction yields were not optimized and refer to pure, isolated products of a single experiment.</div><div class="NLM_p">Thin-layer chromatography was performed on Merck silica gel 60 F254 precoated aluminum plates (0.2 mm) and visualized under UV light (254 nm). Flash column chromatography was carried out using fritted solid loaders packed with Scharlau silica gel (0.04â0.06 mm) on Biotage FlashMaster Personal<sup>+</sup> flash chromatography or using glass columns. High-resolution mass spectra were recorded using an AB SCIEX TripleTOF 5600 mass spectrometer (Concord, ON, Canada), and ionization of all samples was carried out using ESI. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were obtained using a Bruker Avance III HD spectrometer (Faellanden, Switzerland) at 500 and 125 MHz, respectively, and were analyzed using a Bruker Topspin 3.2 program. Chemical shifts are reported in parts per million (ppm) and are referenced to <sup>1</sup>H signals of residual nondeuterated solvents and to <sup>13</sup>C signals of the deuterated solvents. Multiplicity of <sup>1</sup>H NMR signals is reported as s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m = multiplet, and br = broad. Coupling constants <i>J</i> (Hz) are quoted to the nearest 0.1 Hz. Melting points were determined using an open capillary on a Stuart SMP10 melting point apparatus and are uncorrected.</div><div class="NLM_p">The purity of compounds used for biological evaluation was determined to be greater than 95% using Shimadzu Prominence UFLC system (UltraFast Liquid Chromatograph, Kyoto, Japan) equipped with a CBM-20A communications bus module, a DGU-20A5R degassing unit, an LC-20AD liquid chromatograph pump, an SIL-20AHT autosampler, an SPD-M20A photo diode array detector, a CTO-20A column oven, and a Phenomenex Kinetex 5 Î¼ C<sub>18</sub> 100A 250 mm Ã 4.60 mm column. Method A (gradient 5â95% MeOH containing 0.1% formic acid (FA) over 7 min at a flow rate of 1 mL/min, followed by 95% MeOH containing 0.1% FA over 13 min) and method B (gradient 5â95% MeCN containing 0.1% FA over 7 min at a flow rate of 1 mL/min, followed by 95% MeCN containing 0.1% FA over 13 min) were used for analytical RP-HPLC. Data acquired were processed using LabSolutions Analysis Data System. In addition, all inhibitor compounds were screened for potential PAINS using PAINS filters: FAF-Drugs3 and cbligand. No hit was recorded to contain PAINS substructures.</div><div id="sec4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> General Synthetic Procedure 1: 5-Acetylthiazole Formation</h4><div class="NLM_p last">To a solution of 3-chloro-2,4-pentadione (1.0 equiv) in MeOH were added the appropriate thiourea (1.0 equiv) and pyridine (1.0 equiv). The reaction mixture was stirred at room temperature for 4â48 h, washed with saturated aqueous NaHCO<sub>3</sub>, and concentrated under reduced pressure, and the residue was purified by FlashMaster Personal<sup>+</sup> chromatography (silica gel, DCM ramping to DCM:MeOH = 95:5) or filtered to give 5-acetylthiazole derivatives.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> General Synthetic Procedure 2: Enaminone Formation</h4><div class="NLM_p last">A solution of 5-acetylthiazole derivative (1.0 equiv) in DMFâDMA (2.0â7.0 equiv) was heated at reflux for 6â36 h and concentrated under reduced pressure. The residue was triturated with diethyl ether and filtered. The solid obtained was purified by flash column chromatography (silica gel: solvent system I, PE ramping to PE:EtOAc = 50:50; II, DCM ramping to EtOAc; or III, DCM ramping to DCM:MeOH = 94:6) to afford the desired enaminone.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> General Synthetic Procedure 3: Pyrimidine Amine Formation</h4><div class="NLM_p last">A mixture of enaminone (1.0 equiv), NaOH (2.0 equiv), and guanidine hydrochloride (2.0 equiv) in 2-methoxethanol was heated at reflux for 6 h and concentrated under reduced pressure. The residue was purified by FlashMaster Personal<sup>+</sup> chromatography (silica gel, DCM ramping to DCM:MeOH = 96:4) to give the desired pyrimidine amine derivative.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> General Synthetic Procedure 4: Substitution of Bromide with Secondary Amines</h4><div class="NLM_p last">To a solution of 5-bromo-2-nitropyridine (1.0 equiv) in DMSO were added heterocyclic secondary amine derivatives (1.0â2.5 equiv) and triethylamine (3.0â6.0 equiv). The reaction mixture was heated at 120 Â°C overnight and cooled down to room temperature; triethylamine was removed under reduced pressure. The residue was triturated with EtOAc and filtered. The solid was purified by FlashMaster Personal<sup>+</sup> chromatography (silica gel: solvent system Im PE ramping to EtOAc; II, DCM ramping to EtOAc; or III, DCM ramping to DCM:MeOH = 90:10) to give the desired tertiary amine derivative.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> General Synthetic Procedure 5: Reduction of Nitro Compounds to Amines</h4><div class="NLM_p last">To a suspension of a nitro compound (1.0 equiv) in MeOH was added 10% Pd/C (0.01 equiv). The reaction mixture was stirred at room temperature under H<sub>2</sub> overnight and filtered through a pad of Celite. The solids were washed with methanol. The filtrate and washing were combined and concentrated under reduced pressure to give the desired amine which was used in the next step without purification.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> General Synthetic Procedure 6: Mercury-Promoted Guanylation Reaction</h4><div class="NLM_p last">To a solution of an amine (1.0 equiv), <i>N</i>,<i>N</i>â²-bis-Boc-<i>S</i>-methylisothiourea (1.1â1.5 equiv), and triethylamine (3.5 equiv) in DCM on an ice bath was added HgCl<sub>2</sub> (1.1â2.0 equiv). The reaction mixture was stirred on the ice bath for 30 min and at room temperature overnight and filtered through a pad of Celite. The solids were washed with DCM (250 mL), and the filtrate and washing were combined and concentrated under reduced pressure and in vacuo. The residue was dissolved in DCM (300 mL), washed with brine (3 Ã 200 mL) and H<sub>2</sub>O (3 Ã 200 mL), and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel: solvent system I, PE ramping to EtOAc; or II, DCM ramping to DCM:MeOH = 95:5) to give the desired bis-Boc-protected guanidine.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> General Synthetic Procedure 7: TFA-Mediated Boc Removal</h4><div class="NLM_p last">Bis<b>-</b>Boc-protected guanidine (1.0 equiv) was dissolved in a mixture of TFA (10 equiv)/DCM (1:1). The reaction mixture was heated at reflux overnight, concentrated under reduced pressure, triturated with diethyl ether, and filtered to give the desired guanidine, which was directly used in the next step without further purification.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> General Synthetic Procedure 8: Pyrimidine Cyclization</h4><div class="NLM_p last">To a mixture of a guanidine trifluoroacetate derivative (2.0 equiv) and an appropriate enaminone (1.0 equiv) in 2-methoxyethanol was added NaOH (2.0 equiv). The reaction mixture was heated at 180 Â°C under microwave irradiation for 1â2 h, cooled to room temperature, and concentrated under reduced pressure. The residue was purified by FlashMaster Personal<sup>+</sup> chromatography (silica gel: solvent system I, PE ramping to EtOAc; II, DCM ramping to DCM:MeOH = 90:10; or III, DCM ramping to DCM:MeOH:NH<sub>4</sub>OH = 90:10:1) to give the desired product.</div></div><div id="sec4_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> 1,1-Dicyclopentylthiourea (<b>5</b>)</h4><div class="NLM_p last">Thiourea <b>5</b> was isolated as a byproduct in the preparation of <b>4</b>. White solid (1.00 g, 5%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.33â1.38 (m, 4H), 1.48â1.52 (m, 4H), 1.58â1.63 (m, 4H), 1.82â1.88 (m, 4H), 4.37 (s, 2H), 7.15 (s, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 23.9, 33.2, 55.8, 180.2 (seven carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 213.1425 [M + H]<sup>+</sup>; calcd for C<sub>11</sub>H<sub>21</sub>N<sub>2</sub>S<sup>+</sup> [M + H]<sup>+</sup> 213.1420.</div></div><div id="sec4_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 1-(2-(Cyclopentylamino)-4-methylthiazol-5-yl)ethan-1-one (<b>8</b>)</h4><div class="NLM_p last">Acetylthiazole <b>8</b> was prepared from <b>4</b> (2.00 g, 13.9 mmol) according to general synthetic procedure 1. White solid (1.20 g, 35%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.67â1.87 (m, 6H), 2.04â2.10 (m, 2H), 2.50 (s, 3H), 2.64 (s, 3H), 3.71 (s, 1H), 10.21 (s, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 15.5, 23.4, 29.2, 31.9, 57.3 (six carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 225.1032 [M + H]<sup>+</sup>; calcd for C<sub>11</sub>H<sub>17</sub>N<sub>2</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 225.1056.</div></div><div id="sec4_9_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 1-(2-(Cyclopentylamino)-4-(trifluoromethyl)thiazol-5-yl)ethan-1-one (<b>9</b>)</h4><div class="NLM_p last">To a solution of 1,1,1-trifluoropentane-2,4-dione (2.00 g, 12.8 mmol) in MeCN (30 mL) were added [hydroxyl(tosyloxyl)iodo]benzene (6.00 g, 15.4 mmol). The reaction mixture was stirred at reflux for 1 h and cooled. <b>4</b> (2.20 g, 15.4 mmol) was added and the mixture refluxed for 4 h, cooled to room temperature, and concentrated under reduced pressure. The solid obtained was purified by FlashMaster Personal<sup>+</sup> chromatography (silica gel, PE ramping to PE:EtOAc = 8:2) to give <b>9</b> as a yellow solid (2.10 g, 58%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.50â1.56 (m, 4H), 1.65â1.67 (m, 2H), 1.91â1.94 (m, 2H), 2.40 (s, 3H), 3.86 (s, 1H), 9.03 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 23.3, 29.3, 31.8, 56.7, 116.8, 119.0, 121.2, 123.3, 124.9, 141.5 (q, <i>J</i> = 37.5, 169.3, 186.9. HRMS (ESI-TOF): <i>m</i>/<i>z</i> 279.0782 [M + H]<sup>+</sup>; calcd for C<sub>11</sub>H<sub>14</sub>F<sub>3</sub>N<sub>2</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 279.0773.</div></div><div id="sec4_9_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 1-(2-(Dicyclopentylamino)-4-methylthiazol-5-yl)ethan-1-one (<b>10</b>)</h4><div class="NLM_p last">Acetylthiazole <b>10</b> was prepared from <b>5</b> (1.00 g, 4.70 mmol) according to general synthetic procedure 1. White solid (1.40 g, 100%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.59â1.63 (m, 2H), 1.80â1.88 (m, 8H), 1.97â2.00 (m, 2H), 2.09â2.13 (m, 2H), 2.36â2.37 (m, 2H), 2.50 (s, 3H), 2.72 (s, 3H), 3.72 (m, 1H), 5.57 (m, 1H,). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 16.1, 23.6, 24.2, 25.2, 30.3, 31.4, 33.1, 52.8, 60.2, 62.6, 114.6, 116.9, 119.6, 146.0, 167.6, 188.3. MS (ESI-TOF): <i>m</i>/<i>z</i> 293.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> 1-(4-Methyl-2-(phenylamino)thiazol-5-yl)ethan-1-one (<b>11</b>)</h4><div class="NLM_p last">Acetylthiazole <b>11</b> was prepared from <b>6</b> (5.00 g, 33.0 mmol) according to general synthetic procedure 1. White solid (6.49 g, 85%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 2.42 (s, 3H), 2.54 (s, 3H), 7.03â7.06 (m, 1H), 7.34â7.37 (m, 2H), 7.60 (d, 2H, <i>J</i> 7.5), 10.74 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.5, 29.8, 118.1, 122.2, 129.2, 140.0, 156.7, 165.2, 189.2 (three carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 233.0750 [M + H]<sup>+</sup>; calcd for C<sub>12</sub>H<sub>13</sub>N<sub>2</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 233.0743.</div></div><div id="sec4_9_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> 1-(2-(Isopropylamino)-4-methylthiazol-5-yl)ethan-1-one (<b>12</b>)</h4><div class="NLM_p last">Acetylthiazole <b>12</b> was prepared from <b>7</b> (5.00 g, 42.3 mmol) according to general synthetic procedure 1. Yellow solid (5.40 g, 64%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) <i>Î´.</i> 1.15 (s, 3H), 1.16 (s, 3H), 2.31 (s, 3H), 2.42 (s, 3H), 3.75 (br s, 1H), 8.35 (d, 1H, <i>J</i> 7.5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.5, 22.0, 29.4, 46.5, 120.6, 157.8, 169.0, 188.0 (one carbon signal overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 199.0901 [M + H]<sup>+</sup>; calcd for C<sub>9</sub>H<sub>15</sub>N<sub>2</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 199.0900.</div></div><div id="sec4_9_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>E</i>)-1-(2-(Cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>13</b>)</h4><div class="NLM_p last">Enaminone <b>13</b> was prepared from <b>8</b> (1.00 g, 4.46 mmol) according to general synthetic procedure 2 and purified by solvent system II. Light-yellow solid (1.00 g, 77%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.50â1.73 (m, 6H), 2.00â2.06 (m, 2H), 2.54 (s, 3H), 2.94 (br s, 6H), 3.75 (app s, 1H), 5.29 (d, 1H, <i>J</i> 12.0), 5.84 (s, 1H), 7.65 (d, 1H, <i>J</i> 12.0). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 18.5, 23.7, 33.1, 57.7, 94.5, 122.7, 152.7, 154.5, 169.2, 181.1 (four carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 280.1507 [M + H]<sup>+</sup>; calcd for C<sub>14</sub>H<sub>22</sub>N<sub>3</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 280.1478.</div></div><div id="sec4_9_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (<i>E</i>)-1-(2-(Cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one (<b>14</b>)</h4><div class="NLM_p last">To a well-stirred solution of <b>13</b> (559 mg, 2.00 mmol) in MeOH (15 mL) on an ice bath was added SelectFluor (1.06g, 3.00 mmol), and the mixture was stirred for 4 h. The mixture was concentrated and purified by FlashMaster Personal<sup>+</sup> chromatography (silica gel, PE ramping to EtOAc) to give <b>14</b> as a yellow solid (350 mg, 33%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.55â1.74 (m, 6H), Î´ 2.02â2.08 (m, 2H), 2.54 (s, 3H), 3.08 (s, 6H), 3.75 (m, 1H), 6.88 (d, 1H, <i>J</i> 25.0). MS (ESI-TOF): <i>m</i>/<i>z</i> 298.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>E</i>)-1-(2-(Cyclopentyl(methyl)amino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>15</b>)</h4><div class="NLM_p last">A solution of <b>8</b> (1.70 g, 7.58 mmol) in DMFâDMA (6.00 mL, 45.2 mmol) was heated at 150 Â°C under microwave irradiation for 30 min, cooled to room temperature, and concentrated under reduced pressure. The solid obtained was purified by FlashMaster Personal<sup>+</sup> chromatography (silica gel, DCM ramping to EtOAc) to give <b>15</b> as a light-yellow solid (900 mg, 41%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.58â1.74 (m, 6H), 1.92â1.97 (m, 2H), 2.58 (s, 3H), 2.96 (br s, 9H), 4.47 (m, 1H), 5.31 (d, 1H, <i>J</i> 12.0), 7.65 (d, 1H, <i>J</i> 12.0). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 18.5, 23.7, 33.1, 57.7, 94.5, 122.7, 152.7, 154.5, 169.2, 181.1 (four carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 294.1638 [M + H]<sup>+</sup>; calcd for C<sub>15</sub>H<sub>24</sub>N<sub>3</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 294.1635.</div></div><div id="sec4_9_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> (<i>E</i>)-1-(2-(Cyclopentylamino)-4-(trifluoromethyl)thiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>16</b>)</h4><div class="NLM_p last">Enaminone <b>16</b> was prepared from <b>9</b> (2.00 g, 3.59 mmol) according to general synthetic procedure 2 and purified by solvent system III. Yellow solid (1.40 g, 58%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.49â1.55 (m, 4H), 1.64â1.66 (m, 2H), 1.89â1.91 (m, 2H), 2.82 (s, 3H), 3.12 (s, 3H), 3.83 (m, 1H), 5.25 (d, 1H, <i>J</i> 12.0), 7.60 (d, 1H, <i>J</i> 12.0), 8.41 (d, 1H, <i>J</i> 6.5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 23.3, 32.0, 37.0, 44.5, 56.4, 93.9, 117.5, 119.6, 121.8, 124.0, 128.3, 136.7 (q, <i>J</i> 25.0) 154.2, 167.2, 176.9. HRMS (ESI-TOF): <i>m</i>/<i>z</i> 334.1200 [M + H]<sup>+</sup>; calcd for C<sub>14</sub>H<sub>19</sub>F<sub>3</sub>N<sub>3</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 334.1195.</div></div><div id="sec4_9_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> (<i>E</i>)-1-(2-(Dicyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>17</b>)</h4><div class="NLM_p last">Enaminone <b>17</b> was prepared from <b>10</b> (1.80 g, 6.16 mmol) according to general synthetic procedure 2 and purified by solvent system I. Brown solid (275 mg, 10%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.46â1.51 (m, 4H), 1.52â1.55 (m, 4H), 1.64â1.70 (m, 4H), 1.76â1.80 (m, 2H), 1.85â1.87 (m, 2H), 2.32â2.39 (m, 2H), 2.54 (s, 3H), 2.83 (br s, 3H), 3.02 (br s, 3H), 3.30 (m, 1H), 4.42 (m, 1H), 5.10 (d, 2H, <i>J</i> 12.0), 7.57 (d, 2H, <i>J</i> 12.5). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 14.2, 24.2, 25.9, 27.8, 33.8, 56.8, 65.8, 94.9, 108.7, 144.2, 151.6, 152.5, 181.1 (six carbon signals overlapping or obscured). MS (ESI-TOF): <i>m</i>/<i>z</i> 248.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> (<i>E</i>)-3-(Dimethylamino)-1-(4-methyl-2-(phenylamino)thiazol-5-yl)prop-2-en-1-one (<b>18</b>)</h4><div class="NLM_p last">A mixture of <b>11</b> (1.00 g, 4.30 mmol) and Bredereckâs reagent (1.70 mL, 8.60 mmol) was heated at reflux for 6 h. The reaction mixture was cooled and triturated with DCM (5 mL) to give a yellowish solid. The solid was then purified by FlashMaster Personal<sup>+</sup> chromatography (silica gel, PE ramping to PE:EtOAc = 50:50) to give <b>18</b> as a brown solid (927 mg, 75%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 2.60 (s, 3H), 2.88 (br s, 6H), 5.32 (d, 1H, <i>J</i> 12.0), 7.09â7.13 (m, 1H), 7.34â7.39 (m, 4H), 7.70 (d, 1H, <i>J</i> 12.0). 8.75 (s, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 18.5, 37.4, 45.1, 94.6, 119.5, 122.8, 124.0, 129.6, 139.9, 153.2, 165.4, 181.1 (three carbon signals overlapping or obscured). MS (ESI-TOF): <i>m</i>/<i>z</i> 288.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> (<i>E</i>)-3-(Dimethylamino)-1-(4-methyl-2-(methyl(phenyl)amino)thiazol-5-yl)prop-2-en-1-one (<b>19</b>)</h4><div class="NLM_p last">Enaminone <b>19</b> was prepared from <b>11</b> (2.50 g, 11.0 mmol) according to general synthetic procedure 2 and purified by solvent system II. Reddish-brown solid (649 mg, 20%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 2.63 (s, 3H), 2.82 (br s, 3H), 3.02 (br s, 3H), 3.53 (s, 3H), 5.19 (d, 1H, <i>J</i> 12.5), 7.26â7.30 (m, 1H), 7.38â7.45 (m, 4H), 7.62 (d, 1H, <i>J</i> 12.5). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 302.1322 [M + H]<sup>+</sup>; calcd for C<sub>16</sub>H<sub>20</sub>N<sub>3</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 302.1322.</div></div><div id="sec4_9_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> (<i>E</i>)-3-(Dimethylamino)-1-(2-(isopropylamino)-4-methylthiazol-5-yl)prop-2-en-1-one (<b>20</b>)</h4><div class="NLM_p last">Enaminone <b>20</b> was prepared from <b>12</b> (5.00 g, 25.2 mmol) according to general synthetic procedure 2 and purified by solvent system I. Yellow solid (5.43 g, 85%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.15 (s, 3H), 1.16 (s, 3H), 2.41 (s, 3H), 2.81 (s, 3H), 3.06 (s, 3H), 3.71 (m, 1H,), 5.20 (d, 1H, <i>J</i> 12.5), 7.49 (d, 1H, <i>J</i> 12.0), 7.88 (d, 1H, <i>J</i> 7.5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.3, 22.2, 46.2, 93.7, 121.0, 152.2, 153.0, 167.0, 179.2 (three carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 254.1322 [M + H]<sup>+</sup>; calcd for C<sub>12</sub>H<sub>20</sub>N<sub>3</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 254.1322.</div></div><div id="sec4_9_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 5-(2-Aminopyrimidin-4-yl)-<i>N</i>-cyclopentyl-4-methylthiazol-2-amine (<b>21</b>)</h4><div class="NLM_p last">Pyrimidine amine <b>21</b> was prepared from <b>13</b> (500 mg, 3.58 mmol) according to general synthetic procedure 3. Brown solid (222 mg, 45%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.51â1.53 (m, 4H), 1.65â1.67 (m, 2H), 1.90â1.93 (m, 2H), 2.50 (s, 3H), 3.87 (m, 1H), 6.45 (s, 2H), 6.64 (d, 1H, <i>J</i> 5.5), 8.05 (d, 1H, <i>J</i> 7.0), 8.10 (d, 1H, <i>J</i> 5.5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.7, 23.8, 33.2, 57.7, 106.9, 128.0, 139.4, 150.8, 152.0, 157.6, 160.1, 162.7, 169.5. HRMS (ESI-TOF): <i>m</i>/<i>z</i> 276.1288 [M + H]<sup>+</sup>; calcd for C<sub>13</sub>H<sub>18</sub>N<sub>5</sub>S<sup>+</sup> [M + H]<sup>+</sup> 276.1277.</div></div><div id="sec4_9_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 5-(2-Amino-5-fluoropyrimidin-4-yl)-<i>N</i>-cyclopentyl-4-methylthiazol-2-amine (<b>22</b>)</h4><div class="NLM_p last">Pyrimidine amine <b>22</b> was prepared from <b>14</b> (2.00 g, 6.72 mmol) according to general synthetic procedure 3. Yellow solid (1.00 g, 50%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.54â1.75 (m, 6H), 2.04â2.11 (m, 2H), 2.52 (d, 3H, <i>J</i> 2.5), 3.80 (m, 1H), 5.00 (s, 2H), 5.75 (d, 1H, <i>J</i> 6.0), 8.07 (d, 1H, <i>J</i> 3.5). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 18.6 (d, <i>J</i> 5.0), 18.7, 30.7, 109.7 (d, <i>J</i> 8.0), 145.5, 145.7, 147.0, 147.0, 147.7, 153.7, 159.8, 170.3 (d, <i>J</i> 4.5) (one carbon signal overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 294.1188 [M + H]<sup>+</sup>; calcd for C<sub>13</sub>H<sub>17</sub>FN<sub>5</sub>S<sup>+</sup> [M + H]<sup>+</sup> 294.1183.</div></div><div id="sec4_9_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 1-(4-(6-Nitropyridin-3-yl)piperazin-1-yl)ethan-1-one (<b>33</b>)</h4><div class="NLM_p last">Nitro compound <b>33</b> was prepared from acetylpiperazine <b>23</b> (5.00 g, 39.0 mmol) according to general synthetic procedure 4 and purified by solvent system III. Yellow solid (5.66 g, 92%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 2.16 (s, 3H), 3.47 (t, 2H, <i>J</i> 5.5), 3.52 (t, 2H, <i>J</i> 5.5), 3.71 (t, 2H, <i>J</i> 5.5), 3.83 (t, 2H, <i>J</i> 5.5), 7.23 (dd, 1H, <i>J</i> 9.5 and 3.0), 8.14 (d, 1H, <i>J</i> 3.0), 8.20 (d, 1H, <i>J</i> 9.0). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 21.3, 40.5, 45.3, 46.6, 46.7, 119.7, 121.1, 134.0, 148.3, 149.5, 169.2. HRMS (ESI-TOF): 251.1130 [M + H]<sup>+</sup>; calcd for C<sub>11</sub>H<sub>15</sub>N<sub>4</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 251.1139.</div></div><div id="sec4_9_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 4-(6-Nitropyridin-3-yl)piperazin-1-ium Bromide (<b>34</b>)</h4><div class="NLM_p last">Nitro compound <b>34</b> was prepared from piperazine <b>24</b> (2.40 g, 27.8 mmol) according to general synthetic procedure 4 to give <b>34</b> as a light-yellow solid (2.05 g, 58%), which was directly used in the next step without further purification. MS (ESI-TOF): <i>m</i>/<i>z</i> 209.1 [M â Br]<sup>+</sup>.</div></div><div id="sec4_9_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>tert</i>-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-carboxylate (<b>35</b>)</h4><div class="NLM_p last">To a solution of <b>34</b> (2.05 g, 7.09 mmol) and Boc<sub>2</sub>O (2.50 g, 11.4 mmol) in DCM (15 mL) was added Et<sub>3</sub>N (4.00 mL, 28.7 mmol). The reaction mixture was stirred at room temperature for 8 h and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, PE ramping to PE:EtOAc = 1:1) to give <b>35</b> as a yellow solid (1.60 g, 73%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.48 (s, 9H), 3.45 (t, 4H, <i>J</i> 5.5), 3.63 (t, 4H, <i>J</i> 5.0), 7.20 (dd, 1H, <i>J</i> 9.5 and 3.5), 8.12 (d, 1H, <i>J</i> 3.0), 8.17 (d, 1H, <i>J</i> 9.0). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 28.4, 46.6, 80.6, 119.8, 120.9, 133.9, 148.0, 149.7, 154.4 (five carbon signals overlapping or obscured). MS (ESI-TOF): <i>m</i>/<i>z</i> 309.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 1-Methyl-4-(6-nitropyridin-3-yl)piperazine (<b>36</b>)</h4><div class="NLM_p last">Nitro compound <b>36</b> was prepared from piperazine <b>25</b> (6.66 mL, 60.0 mmol) according to general synthetic procedure 4. Dark-brown solid (8.09 g, 72%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 2.35 (s, 3H), 2.56 (t, 4H, <i>J</i> 5.0), 3.45 (t, 4H, <i>J</i> 5.0), 7.18 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.11 (d, 1H, <i>J</i> 3.0), 8.14 (d, 1H, <i>J</i> 9.5). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 46.2, 46.7, 54.4, 119.9, 120.6, 133.8, 147.8, 149.9 (two carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 223.1192 [M + H]<sup>+</sup>; calcd for C<sub>10</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 223.1190.</div></div><div id="sec4_9_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 1-(6-Nitropyridin-3-yl)-1,4-diazepane (<b>37</b>)</h4><div class="NLM_p last">Nitro compound <b>37</b> was prepared from homopiperazine <b>26</b> (5.03 g, 50.2 mmol) according to general synthetic procedure 4. The residue was diluted with saturated aqueous Na<sub>2</sub>CO<sub>3</sub> solution (100 mL), basified to pH 14 with 2.0 M NaOH, and extracted with DCM (6 Ã 100 mL). The organic extracts were combined and concentrated under reduced pressure to give <b>37</b> as an orange solid (5.67 g, 51%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.10; mp 127â128 Â°C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.90â1.96 (m, 2H), 2.85 (t, 2H, <i>J</i> 6.0), 3.07 (t, 2H, <i>J</i> 5.5), 3.64 (t, 2H, <i>J</i> 5.5), 3.71 (t, 2H, <i>J</i> 6.0), 7.01 (dd, 1H, <i>J</i> 9.5 and 3.0), 7.98 (d, 1H, <i>J</i> 3.0), 8.14 (d, 1H, <i>J</i> 9.0) (one proton signal (NH) not observed). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 28.6, 48.1, 48.2, 48.4, 52.5, 117.8, 120.4, 131.5, 146.6, 148.4. HRMS (ESI-TOF-TOF) <i>m</i>/<i>z</i> 223.1190 [M + H]<sup>+</sup>; calcd for C<sub>10</sub>H<sub>15</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> 223.1190 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> <i>tert</i>-Butyl 4-(6-Nitropyridin-3-yl)-1,4-diazepane-1-carboxylate (<b>38</b>)</h4><div class="NLM_p last">To a solution of <b>37</b> (4.17 g, 20.0 mmol) and triethylamine (5.58 mL, 40.0 mmol) in DCM (250 mL) on an ice bath were added DMAP (489 mg, 4.00 mmol) and Boc<sub>2</sub>O (6.55 g, 30.0 mmol). The reaction mixture was stirred on the ice bath for 1 h and at room temperature overnight, washed with 0.5 M HCl (100 mL), H<sub>2</sub>O (100 mL), and brine (100 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, DCM ramping to DCM:MeOH = 96:4) to give <b>38</b> as a yellow solid (5.84 g, 90%). <i>R</i><sub>f</sub> (DCM:MeOH = 95:5) 0.45; mp 146â147 Â°C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.33 (s, 3H), 1.37 (s, 6H), 1.94â1.98 (m, 2H), 3.28 (t, 1H, <i>J</i> 6.0), 3.37 (t, 1H, <i>J</i> 5.5), 3.61â3.70 (m, 6H), 7.03 (dd, 1H, <i>J</i> 9.0 and 3.5), 7.97 (d, 1H, <i>J</i> 3.0), 8.13 (d, 1H, <i>J</i> 9.0). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) (<i>tert</i>-butyl 4-(6-nitropyridin-3-yl)-1,4-diazepane-1-carboxylate exists as two rotamers in approximately 4.5:5.5 ratio) Î´ 24.2, 24.4 (one carbon), 28.1 (three carbons), 45.5, 45.6, 45.7, 46.2, 48.6, 48.9, 49.9, 50.0 (four carbons), 79.9, 80.0 (one carbon), 118.0, 118.1 (one carbon), 120.1, 120.2 (one carbon), 131.1, 131.2 (one carbon), 146.5, 147.3, 147.4 (one carbon), 154.4, 154.9 (one carbon). HRMS (ESI-TOF) <i>m</i>/<i>z</i> 323.1718 [M + H]<sup>+</sup>; calcd for C<sub>15</sub>H<sub>23</sub>N<sub>4</sub>O<sub>4</sub><sup>+</sup> 323.1714 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 4-(6-Nitropyridin-3-yl)morpholine (<b>39</b>)</h4><div class="NLM_p last">Nitro compound <b>39</b> was prepared from morpholine <b>27</b> (1.30 mL, 14.8 mmol) according to general synthetic procedure 4 and purified by solvent system III. Yellow solid (2.29 g, 100%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 3.41 (t, 4H, <i>J</i> 5.0), 3.89 (t, 4H, <i>J</i> 5.0), 7.23 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.14 (d, 1H, <i>J</i> 3.0), 1.18 (d, 1H, <i>J</i> 9.0). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 46.8, 66.3, 119.8, 120.8, 133.8, 148.3, 150.1 (two carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 210.0858 [M + H]<sup>+</sup>; calcd for C<sub>9</sub>H<sub>11</sub>N<sub>3</sub>O<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 210.0873.</div></div><div id="sec4_9_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 1-Ethyl-4-(6-nitropyridin-3-yl)piperazine (<b>40</b>)</h4><div class="NLM_p last">Nitro compound <b>40</b> was prepared from 1-ethylylpiperazine <b>28</b> (7.00 mL, 55.2 mmol) according to general synthetic procedure 4. Yellow solid (9.80 g, 92%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.44 (t, <i>J</i> 7.5), 2.63 (t, 4H, <i>J</i> 5.5), 3.13 (q, 2H, <i>J</i> 7.5), 3.48 (t, 4H, <i>J</i> 5.5), 7.19 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.13 (d, 1H, <i>J</i> 3.0), 8.15 (d, 1H, <i>J</i> 9.5). MS (ESI-TOF): <i>m</i>/<i>z</i> 237.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 2-Nitro-5-(piperidin-1-yl)pyridine (<b>41</b>)</h4><div class="NLM_p last">Nitro compound <b>41</b> was prepared from piperidine <b>29</b> (2.40 g, 27.8 mmol) according to general synthetic procedure 4. The solid was washed with H<sub>2</sub>O (100 mL) and purified by solvent system III. Yellow solid (4.06 g, 78%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.69 (s, 6H), 3.45 (t, 4H), 7.13 (dd, 1H, <i>J</i> 9.0 and 2.5), 8.07 (d, 1H, <i>J</i> 2.5), 8.10 (d, 1H, <i>J</i> 9.0). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 24.0, 25.2, 48.1, 120.0, 133.6, 146.9, 150.0 (three carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 208.1081 [M + H]<sup>+</sup>; calcd for C<sub>10</sub>H<sub>14</sub>N<sub>3</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 208.1077.</div></div><div id="sec4_9_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>,<i>N</i>-Dimethyl-1-(6-nitropyridin-3-yl)piperidin-4-amine (<b>42</b>)</h4><div class="NLM_p last">Nitro compound <b>42</b> was prepared from dimethylaminopiperidine <b>30</b> (2.50 g, 19.5 mmol) according to general synthetic procedure 4 and purified by solvent system III. Yellow solid (1.5 g, 37%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.51 (m, 2H), 1.94 (app d, 2H, <i>J</i> 12.0), 2.39 (s, 6H), 2.78 (app br s, H), 3.02 (m, 2H), 1.94 (app d, 2H, <i>J</i> 13.5), 7.49 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.13 (d, 1H, <i>J</i> 9.0), 8.26 (d, 1H, <i>J</i> 9.5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 25.3, 45.0, 61.9, 119.9, 120.9, 133.8, 146.6, 149.1 (four carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 251.1506 [M + H]<sup>+</sup>; calcd for C<sub>12</sub>H<sub>19</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 251.1503.</div></div><div id="sec4_9_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 1-(Methylsulfonyl)-4-(6-nitropyridin-3-yl)piperazine (<b>43</b>)</h4><div class="NLM_p last">Nitro compound <b>43</b> was prepared from 1-methylsulfonylpiperazine <b>31</b> (4.2 g, 25.4 mmol) according to general synthetic procedure 4 and purified by solvent system II. Yellow solid (3.00 g, 41%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 2.93 (s, 3H), 3.26 (t, 4H, <i>J</i> 5.5), 3.65 (t, 4H, <i>J</i> 5.0), 7.54 (dd, 1H, <i>J</i> 9.5 and 3.0), 8.18 (d, 1H, <i>J</i> 9.0), 8.30 (d, 1H, <i>J</i> 3.0). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 34.2, 44.7, 45.8, 119.8, 121.3, 134.1, 147.1, 149.4 (two carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 287.0815 [M + H]<sup>+</sup>; calcd for C<sub>10</sub>H<sub>15</sub>N<sub>4</sub>O<sub>4</sub>S<sup>+</sup> [M + H]<sup>+</sup> 287.0809.</div></div><div id="sec4_9_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>tert</i>-Butyl (1-(6-Nitropyridin-3-yl)piperidin-4-yl)carbamate (<b>44</b>)</h4><div class="NLM_p last">Nitro compound <b>44</b> was prepared from 4-Boc-aminopiperazine <b>32</b> (5.92 g, 29.6 mmol) according to general synthetic procedure 4 and purified by solvent system I. Yellow solid (5.42 g, 75%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.43 (s, 9H), 1.49â1.52 (m, 2H), 2.10 (app dd, 2H), 3.08â3.14 (m, 2H), 3.73 (app s, H), 3.89 (app d, 2H), 4.53 (s, H), 7.18 (dd, 1H, <i>J</i> 9.5 and 3.5), 8.10 (d, 1H, <i>J</i> 3.0), 8.12 (d, 1H, <i>J</i> 9.5). MS (ESI-TOF): <i>m</i>/<i>z</i> 323.1696 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 1-(4-(6-Aminopyridin-3-yl)piperazin-1-yl)ethan-1-one (<b>45</b>)</h4><div class="NLM_p last">Nitro compound <b>33</b> (2.51 g, 10.0 mmol) was reduced according to general synthetic procedure 5 to give <b>45</b> as a brown solid (2.20 g, 100%). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 221.1390 [M + H]<sup>+</sup>; calcd for C<sub>11</sub>H<sub>17</sub>N<sub>4</sub>O<sup>+</sup> [M + H]<sup>+</sup> 221.1397.</div></div><div id="sec4_9_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>tert</i>-Butyl 4-(6-Aminopyridin-3-yl)piperazine-1-carboxylate (<b>46</b>)</h4><div class="NLM_p last">Nitro compound <b>35</b> (1.60 g, 5.19 mmol) in MeOH (15 mL) was reduced according to general synthetic procedure 5 to give <b>46</b> as a gray solid (1.20 g, 83%). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 279.1836 [M + H]<sup>+</sup>; calcd for C<sub>14</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 279.1816.</div></div><div id="sec4_9_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 5-(4-Methylpiperazin-1-yl)pyridin-2-amine (<b>47</b>)</h4><div class="NLM_p last">Nitro compound <b>36</b> (1.80 g, 8.10 mmol) was reduced according to general synthetic procedure 5 to give <b>47</b> as a brown solid (1.66 g, 100%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 2.34 (s, 3H), 2.58 (t, 4H, <i>J</i> 5.0), 3.05 (t, 4H, <i>J</i> 5.0), 3.83 (br s, 2H), 6.47 (d, 1H, <i>J</i> 9.0), 7.17 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.76 (d, 1H, <i>J</i> 3.0). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 46.3, 50.8, 55.2, 109.2, 128.9, 137.2, 140.8, 153.1 (two carbon signals overlapping or obscured). HRMS (ESI-TOF) <i>m</i>/<i>z</i> 193.1466 [M + H]<sup>+</sup>; calcd for C<sub>10</sub>H<sub>17</sub>N<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup> 193.1448.</div></div><div id="sec4_9_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>tert</i>-Butyl 4-(6-Aminopyridin-3-yl)-1,4-diazepane-1-carboxylate (<b>48</b>)</h4><div class="NLM_p last">Nitro compound <b>37</b> (5.80 g, 18.0 mmol) was reduced according to general synthetic procedure 5 to give <b>48</b> as a dark-purple glue (5.26 g, 100%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.56. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.37 (s, 3H), 1.42 (s, 6H), 1.90â1.95 (m, 2H), 3.21 (t, 1H, <i>J</i> 6.0), 3.32 (t, 1H, <i>J</i> 5.5), 3.41â3.46 (m, 4H), 3.52â3.56 (m, 2H), 3.96 (br s, 2H), 6.47 (d, 1H, <i>J</i> 8.5), 6.96 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.61 (app s, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) (<i>tert</i>-butyl 4-(6-aminopyridin-3-yl)-1,4-diazepane-1-carboxylate exists as two rotamers in approximately 4.5:5.5 ratio) Î´ 25.5, 25.6 (one carbon), 28.4, 28.5 (three carbons), 45.7, 46.1, 46.4, 46.5, 48.7, 49.3, 50.7, 50.9 (four carbons), 79.6, 79.7 (one carbon), 109.9, 110.0 (one carbon), 123.6, 123.9 (one carbon), 131.9, 132.2 (one carbon), 137.4, 137.7 (one carbon), 150.1, 150.2 (one carbon), 155.2, 155.5 (one carbon). HRMS (ESI-TOF) <i>m</i>/<i>z</i> 293.1972 [M + H]<sup>+</sup>; calcd for C<sub>15</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> 293.1972 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 5-Morpholinopyridin-2-amine (<b>49</b>)</h4><div class="NLM_p last">Nitro compound <b>39</b> (1.46 g, 6.96 mmol) in MeOH (50 mL) was reduced according to general synthetic procedure 5 to give <b>49</b> as a brown solid (1.24 g, 99%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 2.89 (t, 4H, <i>J</i> 4.5), 3.69 (t, 4H, <i>J</i> 4.5), 5.42 (s, 2H), 6.42 (d, 1H, <i>J</i> 9.0), 7.15 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.61 (d, 1H, <i>J</i> 3.0). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 50.4, 66.2, 108.4, 127.9, 135.8, 138.9, 154.5 (two carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 180.1159 [M + H]<sup>+</sup>; calcd for C<sub>9</sub>H<sub>13</sub>N<sub>3</sub>O<sup>+</sup> [M + H]<sup>+</sup> 180.1131.</div></div><div id="sec4_9_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 5-(4-Ethylpiperazin-1-yl)pyridin-2-amine (<b>50</b>)</h4><div class="NLM_p last">Nitro compound <b>40</b> (9.80 g, 41.5 mmol) was reduced according to general synthetic procedure 5 to give <b>50</b> as a brown solid (9.00 g, 100%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.45 (t, <i>J</i> 7.5, 3H), 2.81 (app br s, 4H), 3.13 (q, 2H, <i>J</i> 7.5), 3.29 (app br s, 4H), 3.36 (br s, 2H), 6.51 (d, 1H, <i>J</i> 9.0), 7.21 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.77 (d, 1H, <i>J</i> 3.0). MS (ESI-TOF): <i>m</i>/<i>z</i> 207.1 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 5-(Piperidin-1-yl)pyridin-2-amine (<b>51</b>)</h4><div class="NLM_p last">Nitro compound <b>41</b> (3.70 g, 15.9 mmol) was reduced according to general synthetic procedure 5 to give <b>51</b> as a dark-brown solid (3.10 g, 97%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.53 (m, 2H), 1.71 (m, 4H), 2.97 (t, 4H, <i>J</i> 5.5), 4.15 (s, 2H), 6.47 (d, 1H, <i>J</i> 9.0), 7.18 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.77 (d, 1H, <i>J</i> 3.0). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 24.1, 26.1, 52.5, 109.3, 129.7, 137.2, 142.0, 152.7 (two carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 178.1347 [M + H]<sup>+</sup>; calcd for C<sub>10</sub>H<sub>16</sub>N<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 178.1339.</div></div><div id="sec4_9_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 5-(4-(Dimethylamino)piperidin-1-yl)pyridin-2-amine (<b>52</b>)</h4><div class="NLM_p last">Nitro compound <b>42</b> (1.50 g, 5.99 mmol) was reduced according to general synthetic procedure 5 to give <b>52</b> as a white solid (1.20 g, 91%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.55 (m, 2H), 1.88 (app d, 2H, <i>J</i> 12.0), 2.37 (s, 6H), 2.45 (app br s, H), 2.51 (m, 2H), 3.39 (app d, 2H, <i>J</i> 12.0), 5.40 (s, 2H), 6.40 (d, 1H, <i>J</i> 9.0), 7.17 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.62 (d, 1H, <i>J</i> 3.0). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 27.5, 50.0, 61.5, 108.3, 128.8, 136.6, 138.9, 154.4, (four carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 221.1756 [M + H]<sup>+</sup>; calcd for C<sub>12</sub>H<sub>21</sub>N<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup> 221.1761.</div></div><div id="sec4_9_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 5-(4-(Methylsulfonyl)piperazin-1-yl)pyridin-2-amine (<b>53</b>)</h4><div class="NLM_p last">Nitro compound <b>43</b> (2.50 g, 8.71 mmol) was reduced according to general synthetic procedure 5 to give <b>53</b> as a brown solid (1.80 g, 82%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 2.91 (s, 3H), 3.00 (t, 4H, <i>J</i> 5.0), 3.22 (t, 4H, <i>J</i> 4.5), 6.41 (d, 1H, <i>J</i> 8.5), 7.19 (dd, 1H, <i>J</i> 9.5 and 3.0), 7.64 (d, 1H, <i>J</i> 3.0). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 33.8, 33.9, 50.1, 108.2, 128.8, 137.0, 138.3, 154.9 (two carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 257.1068 [M + H]<sup>+</sup>; calcd for C<sub>10</sub>H<sub>17</sub>N<sub>4</sub>O<sub>2</sub>S<sup>+</sup> [M + H]<sup>+</sup> 257.1067.</div></div><div id="sec4_9_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> <i>tert</i>-Butyl (1-(6-Aminopyridin-3-yl)piperidin-4-yl)carbamate (<b>54</b>)</h4><div class="NLM_p last">Nitro compound <b>44</b> (4.00 g, 12.4 mmol) was reduced according to general synthetic procedure 5 to give <b>54</b> as a gray solid (3.27g, 90%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.44 (s, 9H), 1.50â1.57 (m, 2H), 2.02 (app d, 2H), 2.72 (app t, 2H), 3.31 (app d, 2H), 3.55 (app s, H), 3.88 (br, 2H), 4.55 (s, H), 6.47 (d, 1H, <i>J</i> 9.0), 7.16 (dd, 1H, <i>J</i> 9.5 and 3.5), 7.73 (d, 1H, <i>J</i> 2.5). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 293.3830 [M + H]<sup>+</sup>; calcd for C<sub>14</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 293.3831.</div></div><div id="sec4_9_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 1-Acetyl-4-(6-(2,3-bis(<i>tert</i>-butoxycarbonyl)guanidino)pyridin-3-yl)piperazine (<b>56</b>)</h4><div class="NLM_p last">Compound <b>56</b> was prepared from <b>45</b> (2.21 g, 10.0 mmol) according to general synthetic procedure 6 and purified by solvent system II. Light-yellow solid (3.82 g, 82%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.53 (s, 18 H), 2.14 (s, 3H), 3.13 (t, 2H, <i>J</i> 5.5), 3.18 (t, 2H, <i>J</i> 5.5), 3.63 (t, 2H, <i>J</i> 5.5), 3.78 (t, 2H, <i>J</i> 5.5), 7.29 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.87 (d, 1H, <i>J</i> 7.5), 7.99 (d, 1H, <i>J</i> 2.5), 10.90 (br s, 1H), 11.58 (br s, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 21.5, 28.2, 28.3, 28.4, 41.2, 46.1, 49.3, 49.6, 53.6, 81.1, 84.5, 116.9, 125.2, 126.8, 136.7, 143.7, 144.3, 153.1, 153.4, 162.6, 169.1 (one carbon signal overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 463.2668 [M + H]<sup>+</sup>; calcd for C<sub>22</sub>H<sub>35</sub>N<sub>6</sub>O<sub>5</sub><sup>+</sup> [M + H]<sup>+</sup> 463.2663.</div></div><div id="sec4_9_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> <i>tert</i>-Butyl 4-(6-(2,3-Bis(<i>tert</i>-butoxycarbonyl)guanidino)pyridin-3-yl)piperazine-1-carboxylate (<b>57</b>)</h4><div class="NLM_p last">Compound <b>57</b> was prepared from <b>46</b> (1.30 g, 4.67 mmol) according to general synthetic procedure 6 and purified by solvent system I. White solid (1.00 g, 41%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.46 (s, 9H), 1.52 (s, 18H), 3.10 (t, 4H, <i>J</i> 5.0), 3.57 (t, 4H, <i>J</i> 5.0), 7.27 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.92 (app br s, 1H), 7.96 (d, 1H, <i>J</i> 3.0), 10.85 (s, 1H), 11.54 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>) Î´ 28.4, 49.3, 80.0, 126.4, 144.3, 154.6 (19 carbon signals overlapping or obscured). MS (ESI-TOF): <i>m</i>/<i>z</i> 521.3.</div></div><div id="sec4_9_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 1-Methyl-4-(6-(2,3-bis(<i>tert</i>-butoxycarbonyl)guanidino)pyridin-3-yl)piperazine (<b>58</b>)</h4><div class="NLM_p last">Compound <b>58</b> was prepared from <b>47</b> (1.64 g, 8.53 mmol) according to general synthetic procedure 6 purified by solvent system II. Beige solid (2.23g, 60%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.53 (s, 18H), 2.35 (s, 3H), 2.58 (t, 4H, <i>J</i> 5.0), 3.18 (t, 4H, <i>J</i> 5.0), 7.27 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.97 (d, 1H, <i>J</i> 2.0), 8.19 (d, 1H, <i>J</i> 6.5), 10.7 (br s, 1H), 11.52 (br s, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 28.2, 28.3, 46.3, 49.3, 54.9, 79.8, 83.8, 116.6, 125.6, 136.5, 143.3, 144.5, 152.9, 163.5 (seven carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 435.2712 [M + H]<sup>+</sup>; calcd for C<sub>21</sub>H<sub>35</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup>[M + H]<sup>+</sup> 435.2714.</div></div><div id="sec4_9_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> <i>tert</i>-Butyl 4-(6-(2,3-Bis(<i>tert</i>-butoxycarbonyl)guanidino)pyridin-3-yl)-1,4-diazepane-1-carboxylate (<b>59</b>)</h4><div class="NLM_p last">Compound <b>59</b> was prepared from <b>48</b> according to general synthetic procedure 6 and purified by solvent system I. Yellow foam (5.70 g, 59%). <i>R</i><sub>f</sub> (DCM:MeOH = 98:2) 0.24. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.40 (s), 1.43 (s), 1.51(s), 1.52 (s) (total 27H), 1.94â1.98 (m, 2H), 3.18 (t, 1H, <i>J</i> 6.0), 3.29 (t, 1H, <i>J</i> 5.5), 3.52â3.55 (m, 6H), 7.05 (dd, 1H, <i>J</i> 9.0 and 2.5), 7.78 (app s, 1H), 8.15 (d, 1H, <i>J</i> 9.0), 10.63 (br s, 1H), 11.50 (br s, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) (<i>tert</i>-butyl 4-(6-(2,3-bis(<i>tert</i>-butoxycarbonyl)guanidino)pyridin-3-yl)-1,4-diazepane-1-carboxylate exists as two rotamers in approximately 4.5:5.5 ratio.) Î´ 24.8, 24.9 (one carbon), 28.2, 28.3, 28.4, 28.5 (nine carbons), 45.8, 46.0, 46.4, 46.7, 47.9, 48.4, 50.4, 50.6 (four carbons), 79.7, 79.8, 79.9 (one carbon), 83.7, 117.2, 117.3 (one carbon), 120.7, 120.8 (one carbon), 131.5, 131.6 (one carbon), 140.5, 140.6, 140.7, 140.9 (two carbons), 152.8, 152.9 (one carbon), 155.0, 155.4, 163.5. HRMS (ESI-TOF) <i>m</i>/<i>z</i> 535.3246 [M + H]<sup>+</sup>; calcd for C<sub>26</sub>H<sub>43</sub>N<sub>6</sub>O<sub>6</sub><sup>+</sup> 535.3239 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 4-(6-(2,3-Bis(<i>tert</i>-butoxycarbonyl)guanidino)pyridin-3-yl-)morpholine (<b>60</b>)</h4><div class="NLM_p last">Compound <b>60</b> was prepared from <b>49</b> (1.65 g, 9.21 mmol) according to general synthetic procedure 6 and purified by solvent system I. Yellow solid (1.48 g, 38%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.56 (s, 18H), 3.21 (t, 4H, <i>J</i> 5.0), 3.87 (t, 4H, <i>J</i> 5.0), 7.09 (d, 1H, <i>J</i> 5.0), 7.29 (d, 1H, <i>J</i> 9.0), 7.29 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.02 (d, 1H, <i>J</i> 2.0), 11.25 (br s, 1H), 11.74 (broad s, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 28.2 (<i>J</i> 25.0), 49.4, 66.8, 79.8, 83.8, 116.6, 123.4, 136.1, 143.7, 144.5, 153.0 (<i>J</i> 12.5), 163.4 (eight carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 422.2370 [M + H]<sup>+</sup>; calcd for C<sub>20</sub>H<sub>32</sub>N<sub>5</sub>O<sub>5</sub><sup>+</sup> [M + H]<sup>+</sup> 422.2398.</div></div><div id="sec4_9_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 1-Ethyl-4-(6-(2,3-bis(<i>tert</i>-butoxycarbonyl)guanidino)pyridin-3-yl)piperazine (<b>61</b>)</h4><div class="NLM_p last">Compound <b>61</b> was prepared from <b>50</b> (9.00 g, 43.6 mmol) according to general synthetic procedure 6 and purified by solvent system I. White solid (9.98 g, 51%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.11 (t, 3H, <i>J</i> 7.0), 1.51 (app d, 18H, <i>J</i> 2.0), 2.46 (q, 2H, <i>J</i> 7.0), 2.60 (t, 4H, <i>J</i> 5.0), 3.17 (t, 4H, <i>J</i> 5.0), 7.27 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.97 (d, 1H, <i>J</i> 3.0), 8.20 (d, 1H, <i>J</i> 8.5), 10.70 (s, 1H), 11.51 (s, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 12.1, 28.1, 28.3, 49.3, 52.4, 52.6, 79.1, 83.8, 116.6, 125.5, 136.4, 143.3, 144.6, 152.9, 163.5 (seven carbon signals overlapping or obscured). HRMS (ESI-TOF) <i>m</i>/<i>z</i> 449.2870 [M + H]<sup>+</sup>; calcd for C<sub>22</sub>H<sub>37</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup> 449.2871.</div></div><div id="sec4_9_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> <i>N</i>-(6-(2,3-Bis(<i>tert</i>-butoxycarbonyl)guanidino)pyridin-3-yl-)piperidine (<b>62</b>)</h4><div class="NLM_p last">Compound <b>62</b> was prepared from <b>51</b> (3.10 g, 17.5 mmol) according to general synthetic procedure 6 and purified by solvent system I. White solid (4.00 g, 55%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.51 (d, 18H, <i>J</i> 4.0), 1.57 (m, 2H), 1.70 (t, 4H, <i>J</i> 5.5), 3.11 (t, 4H, <i>J</i> 5.5), 7.26 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.96 (d, 1H, <i>J</i> 3.0), 8.17 (d, 1H, <i>J</i> 8.0), 10.68 (s, 1H), 11.51 (s, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 24.1, 25.7, 28.1, 28.3, 50.8, 79.7, 82.1, 83.7, 116.5, 126.0, 136.8, 142.8, 145.5, 149.8, 152.9, 163.5 (five carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 420.2604 [M + H]<sup>+</sup>; calcd for C<sub>21</sub>H<sub>34</sub>N<sub>5</sub>O<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup> 420.2605.</div></div><div id="sec4_9_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 4-Dimethylamino-1-(6-(2,3-bis(<i>tert</i>-butoxycarbonyl)guanidino)pyridin-3-yl)piperidine (<b>63</b>)</h4><div class="NLM_p last">Compound <b>63</b> was prepared from <b>52</b> (1.20 g, 5.45 mmol) according to general synthetic procedure 6 and purified by solvent system II. White solid (1.20 g, 48%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.51 (s, 18H), 1.72 (m, 2H), 2.06 (app d, 2H, <i>J</i> 12.0), 2.50 (s, 6H), 2.70 (m, 3H), 3.62 (app d, 2H, <i>J</i> 12.5), 7.21 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.89 (d, 1H, <i>J</i> 2.5), 8.12 (s, 1H), 10.63 (s, 1H), 11.45 (s, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 26.7, 28.0, 28.1, 31.2, 40.4, 48.8, 62.4, 116.5, 126.2, 136.7, 143.4, 143.9, 152.8, 163.2 (nine carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 463.3027 [M + H]<sup>+</sup>; calcd for C<sub>23</sub>H<sub>39</sub>N<sub>6</sub>O<sub>4</sub><sup>+</sup> [M + H]<sup>+</sup> 463.3027.</div></div><div id="sec4_9_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 1-Methylsulfonyl-4-(6-(2,3-bis(<i>tert</i>-butoxycarbonyl)guanidino)pyridin-3-yl)piperazine (<b>64</b>)</h4><div class="NLM_p last">Compound <b>64</b> was prepared from <b>53</b> (1.80 g, 7.02 mmol) according to general synthetic procedure 6 and purified by solvent system II. Beige solid (1.20 g, 22%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.52 (s, 18H), 2.83 (s, 3H), 3.25 (t, 4H, <i>J</i> 5.0), 3.39 (t, 4H, <i>J</i> 4.5), 7.29 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.98 (d, 1H, <i>J</i> 2.0), 8.23 (s, 1H), 10.76 (s, 1H), 11.52 (s, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 28.2, 28.3, 34.7, 45.7, 49.6, 53.6, 80.0, 84.0, 116.8, 126.8, 137.4, 143.8, 144.4, 153.1, 163.3 (six carbon signals overlapping or obscured). HRMS (ESI): <i>m</i>/<i>z</i> 499.2336 [M + H]<sup>+</sup>; calcd for C<sub>21</sub>H<sub>35</sub>N<sub>6</sub>O<sub>6</sub>S<sup>+</sup>[M + H]<sup>+</sup> 499.2333.</div></div><div id="sec4_9_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> <i>tert</i>-Butyl (1-(6-(2,3-Bis(<i>tert</i>-butoxycarbonyl)guanidino)pyridin-3-yl)piperidin-4-yl)carbamate (<b>65</b>)</h4><div class="NLM_p last">Compound <b>59</b> was prepared from <b>54</b> (3.70 g, 12.7 mmol) according to general synthetic procedure 6 and purified by solvent system I. Yellow solid (4.00 g, 57%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.50 (app d, 29H), 2.03 (app d, 2H), 2.81 (app t, 2H), 3.51 (app d, 2H), 3.59 (br s, 1H), 4.51 (app br s, 1H), 7.24 (app br s, 1H), 7.95 (app s, 1H), 8.18 (app s, 1H, <i>J</i> 2.5), 10.69 (s, 1H), 11.50 (s, 1H). MS (ESI-TOF): <i>m</i>/<i>z</i> 535.3485 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 2-(2,3-Bis(<i>tert</i>-butoxycarbonyl)guanidino)pyridine (<b>66</b>)</h4><div class="NLM_p last">Compound <b>66</b> was prepared from pyridin-2-amine <b>55</b> (2.78 g, 29.5 mmol) according to general synthetic procedure 6 and purified by solvent system I and recrystallized with DCM and hexane. White solid (4.18 g, 42%). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.52 (s, 18H), 7.01 (dd, 1H, <i>J</i> 7.0 and 5.0), 7.70 (t, 1H, <i>J</i> 7.0), 8.29 (d, 1H, <i>J</i> 4.0), 8.37 (app br s, 1H), 10.89 (br s, 1H), 11.53 (br s, 1H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 28.2, 28.3, 80.1, 84.0, 116.2, 120.0, 138.3, 148.2, 150.7, 152.8, 153.2, 163.3 (four carbon signals overlapping or obscured). HRMS (ESI-TOF) <i>m</i>/<i>z</i> 337.1885 [M + H]<sup>+</sup>; calcd for C<sub>16</sub>H<sub>25</sub>N<sub>4</sub>O<sub>4</sub><sup>+</sup> 337.1870 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 1-(5-(4-Acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>67</b>)</h4><div class="NLM_p last">Guanidine <b>67</b> was prepared from <b>56</b> (724 mg, 1.56 mmol) according to general synthetic procedure 7. Beige solid (410 mg, 100%). MS (ESI-TOF): <i>m</i>/<i>z</i> 263.2 [M â TFA + H]<sup>+</sup>.</div></div><div id="sec4_9_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 1-(5-(Piperazin-1-yl)pyridin-2-yl)guanidine (<b>68</b>)</h4><div class="NLM_p last">Guanidine <b>68</b> was prepared from <b>57</b> (1.00 g, 1.92 mmol) according to general synthetic procedure 7. The residue was redissolved in MeOH (50 mL), and a suspension of excess Ambersep 900 resin (hydroxide form, preswelled with H<sub>2</sub>O for 30 min and MeOH for 30 min) in MeOH (50 mL) was added. The mixture was stirred at room temperature overnight and filtered, and the solid was washed with MeOH (50 mL). The filtrate and washing were combined and concentrated under reduced pressure to give <b>68</b> as a beige solid (423 mg, 100%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 3.01 (t, 4H, <i>J</i> 5.0), 3.17 (t, 4H, <i>J</i> 5.0), 6.97 (d, 1H, <i>J</i> 9.0), 7.57 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.95 (d, 1H, <i>J</i> 2.5), 8.33 (br s, 3H) (two NH proton signals not observed). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 44.2, 47.6, 113.7, 127.6, 133.3, 143.6, 144.6, 155.1 (two carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 221.1526 [M + H]<sup>+</sup>; calcd for C<sub>10</sub>H<sub>17</sub>N<sub>6</sub><sup>+</sup> [M + H]<sup>+</sup> 221.1509.</div></div><div id="sec4_9_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 1-(5-(4-Methylpiperazin-1-yl)pyridine-2-yl)guanidine (<b>69</b>)</h4><div class="NLM_p last">Guanidine <b>69</b> was prepared from <b>58</b> (2.20 g, 5.06 mmol) according to general synthetic procedure 7. The residue was redissolved in MeOH (50 mL), and a suspension of excess Ambersep 900 resin (hydroxide form, preswelled with H<sub>2</sub>O for 30 min and MeOH for 30 min) in MeOH (50 mL) was added. The mixture was stirred at room temperature overnight and filtered, and the solid was washed with MeOH (50 mL). The filtrate and washing were combined and concentrated under reduced pressure to give <b>69</b> as a beige solid (1.19 g, 100%). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) Î´ 2.34 (s, 3H), 2.61 (t, 4H, <i>J</i> 5.0), 3.11 (t, 4H, <i>J</i> 5.0), 6.74 (d, 1H, <i>J</i> 9.0), 7.32 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.85 (d, 1H, <i>J</i> 3.0) (four NH proton signals not observed due to H/D exchange). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD) Î´ 46.1, 50.8, 55.9, 119.2, 129.1, 135.3, 142.5, 157.3, 158.7 (two carbon signals overlapping or obscured). MS (ESI-TOF): <i>m</i>/<i>z</i> 235.2 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 1-(5-(1,4-Diazepan-1-yl)pyridin-2-yl)guanidine Di(2,2,2-trifluoroacetate) (<b>70</b>)</h4><div class="NLM_p last">Guanidine <b>70</b> was prepared from <b>59</b> (802 mg, 1.50 mmol) according to general synthetic procedure 7. Yellow glue (494 mg, 100%). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) Î´ 2.18â2.24 (m, 2H), 3.31 (t, 2H, <i>J</i> 7.0), 3.42 (t, 2H, <i>J</i> 5.0), 3.60 (t, 2H, <i>J</i> 7.0), 3.80 (t, 2H, <i>J</i> 5.0), 6.97 (d, 1H, <i>J</i> 9.0), 7.39 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.91 (d, 1H, <i>J</i> 3.0) (seven proton signals (NH<sub>2</sub> and 3 Ã NH and 2 Ã COOH) not observed due to H/D exchange). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD) Î´ 26.4, 46.6, 46.8, 47.2, 48.3, 115.0, 117.9 (q, <i>J</i> 287.5), 124.6, 131.2, 143.0, 144.0, 156.8, 162.7 (q, <i>J</i> 37.5). HRMS (ESI-TOF) <i>m</i>/<i>z</i> 235.1674 [M â 2CF<sub>3</sub>COOH + H]<sup>+</sup>; calcd for C<sub>11</sub>H<sub>19</sub>N<sub>6</sub><sup>+</sup> 235.1666 [M â 2CF<sub>3</sub>COOH + H]<sup>+</sup>.</div></div><div id="sec4_9_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 1-(5-Morpholinopyridin-2-yl)guanidine (<b>71</b>)</h4><div class="NLM_p last">Guanidine <b>71</b> was prepared from <b>60</b> (857 mg, 2.03 mmol) according to general synthetic procedure 7. The residue was added to a suspension of Ambersep 900 resin (hydroxide form) and stirred for 70 min, filtered, and washed with MeOH. The filtrate and washing were combined and dried under reduced pressure to give <b>71</b> as pale-yellow solid (296 mg, 66%). MS (ESI-TOF): <i>m</i>/<i>z</i> 222.1419 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 1-(5-(4-Ethylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>72</b>)</h4><div class="NLM_p last">Guanidine <b>72</b> was prepared from <b>61</b> (2.20 g, 4.46 mmol) according to general synthetic procedure 7. Yellow solid (1.70 g, 100%). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 249.1803 [M + H]<sup>+</sup>; calcd for C<sub>12</sub>H<sub>21</sub>N<sub>6</sub><sup>+</sup> [M + H]<sup>+</sup> 249.1822.</div></div><div id="sec4_9_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 1-(5-(Piperidin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>73</b>)</h4><div class="NLM_p last">Guanidine <b>73</b> was prepared from <b>62</b> (4.00 g, 9.12 mmol) according to general synthetic procedure 7. White solid (2.30 g, 100%). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 220.1558 [M + H]<sup>+</sup>; calcd for C<sub>11</sub>H<sub>18</sub>N<sub>5</sub><sup>+</sup> [M + H]<sup>+</sup> 220.1557.</div></div><div id="sec4_9_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 1-(5-(4-(Dimethylamino)piperidin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>74</b>)</h4><div class="NLM_p last">Guanidine <b>74</b> was prepared from <b>63</b> (1.20 g, 2.59 mmol) according to general synthetic procedure 7. Yellow solid (1.80 g, 100%). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 263.1979 [M + H]<sup>+</sup>; calcd for C<sub>13</sub>H<sub>23</sub>N<sub>6</sub><sup>+</sup> [M + H]<sup>+</sup> 263.1979.</div></div><div id="sec4_9_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 1-(5-(4-(Methylsulfonyl)piperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>75</b>)</h4><div class="NLM_p last">Guanidine <b>75</b> was prepared from <b>64</b> (1.80 g, 3.89 mmol) according to general synthetic procedure 7. Gray solid (1.52 g, 100%). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 299.1286 [M + H]<sup>+</sup>; calcd for C<sub>11</sub>H<sub>19</sub>N<sub>6</sub>O<sub>2</sub>S<sup>+</sup> [M + H]<sup>+</sup> 299.1285.</div></div><div id="sec4_9_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 1-(5-(4-Aminopiperidin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>76</b>)</h4><div class="NLM_p last">Guanidine <b>76</b> was prepared from <b>65</b> (2.00 g, 3.74 mmol) according to general synthetic procedure 7. Yellow solid (568 mg, 65%). MS (ESI-TOF): <i>m</i>/<i>z</i> 235.1788 [M + H]<sup>+</sup>.</div></div><div id="sec4_9_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 1-(Pyridin-2-yl)guanidine 2,2,2-trifluoroacetate (<b>77</b>)</h4><div class="NLM_p last">Guanidine <b>77</b> was prepared from <b>66</b> (3.60 g, 10.7 mmol) according to general synthetic procedure 7. White solid (2.65 g, 99%). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) Î´ 7.04 (dt, 1H, <i>J</i> 7.5 and 0.5), 7.18 (ddd, 1H, <i>J</i> 7.5 and 5.0 and 1.0), 7.85 (ddd, 1H, <i>J</i> 9.5 and 7.5 and 2.0), 8.34 (ddd, 1H, <i>J</i> 5.0 and 2.0 and 1.0) (five proton signals (NH<sub>2</sub> and 2Ã NH and COOH) not observed due to H/D exchange). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD) Î´ 114.3, 118.2 (q, <i>J</i> 287.5), 120.8, 140.6, 147.8, 153.5, 157.2, 163.3 (q, <i>J</i> 37.5). HRMS (ESI-TOF) <i>m</i>/<i>z</i> 137.0827 [M â CF<sub>3</sub>COOH + H]<sup>+</sup>; calcd for C<sub>6</sub>H<sub>9</sub>N<sub>4</sub><sup>+</sup> 137.0822 [M â CF<sub>3</sub>COOH + H]<sup>+</sup>.</div></div><div id="sec4_9_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> <i>N</i>-Cyclopentyl-4-methyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl) thiazol-2-amine (<b>78</b>)</h4><div class="NLM_p last">1-(5-(Piperazin-1-yl)pyridin-2-yl)guanidine (<b>68</b>, 441 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>13</b>, 279 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system III and recrystallized with DCM and MeOH to give <b>78</b> as a dark-yellow solid (70.0 mg, 16%). <i>R</i><sub>f</sub> (DCM:MeOH:NH<sub>4</sub>OH = 9:1:0.5) 0.10; mp 210â212 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) 1.49â1.68 (m, 7H), 1.89â1.94 (m, 2H), 2.46 (s, 3H), 2.85 (t, 4H, <i>J</i> 4.5), 3.02 (t, 4H, <i>J</i> 5.0), 3.98 (m, 1H), 6.90 (d, 1H, <i>J</i> 5.5), 7.36 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.98 (d, 1H, <i>J</i> 3.0), 8.07 (d, 1H, <i>J</i> 9.0), 8.18 (d, 1H, <i>J</i> 7.0), 8.33 (d, 1H, <i>J</i> 5.5), 9.33 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 19.2, 23.8, 32.7, 45.9, 50.2, 56.3, 107.6, 113.7, 117.8, 125.5, 135.9, 143.5, 146.1, 152.9, 158.0, 159.0, 159.2, 168.4 (four carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 437.2222 [M + H]<sup>+</sup>; calcd for C<sub>22</sub>H<sub>29</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 437.2230. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 10.10 min, purity >99%; method B, <i>t</i><sub>R</sub> 7.78 min, purity >99%.</div></div><div id="sec4_9_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 5-(2-((5-(1,4-Diazepan-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-<i>N</i>-cyclopentyl-4-methylthiazol-2-amine (<b>79</b>)</h4><div class="NLM_p last">1-(5-(1,4-Diazepan-1-yl)pyridin-2-yl)guanidine di(2,2,2-trifluoroacetate) (<b>70</b>, 469 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>13</b>, 279 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II to give <b>79</b> as yellow solid (35 mg, 8%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.10; mp 211â213 Â°C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.56â1.79 (m, 6H), 1.89â1.94 (m, 2H), 2.06â2.12 (m, 2H), 2.54 (s, 3H), 2.84 (t, 2H, <i>J</i> 6.0), 3.06 (t, 2H, <i>J</i> 5.5), 3.54 (t, 2H, <i>J</i> 5.0), 3.59 (t, 2H, <i>J</i> 6.0), 3.86â3.92 (m, 1H), 5.43 (d, 1H, <i>J</i> 7.0), 6.81 (d, 1H, <i>J</i> 5.5), 7.09 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.64 (s, 1H), 7.82 (d, 1H, <i>J</i> 3.0), 8.16 (d, 1H, <i>J</i> 9.0), 8.30 (d, 1H, <i>J</i> 5.5). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 18.8, 23.9, 29.8, 33.3, 48.1, 48.4, 48.5, 52.3, 57.6 107.5, 113.9, 120.0, 121.1, 131.7, 140.7, 143.1, 152.2, 157.5, 159.1, 159.6, 169.3 (two carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 451.2384 [M + H]<sup>+</sup>; calcd for C<sub>23</sub>H<sub>31</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 451.2387. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 9.91 min, purity >97%; method B, <i>t</i><sub>R</sub> 7.49 min, purity >99%.</div></div><div id="sec4_9_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> <i>N</i>-Cyclopentyl-4-methyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine (<b>80</b>)</h4><div class="NLM_p last">1-(5-(4-Methylpiperazin-1-yl)pyridine-2-yl)guanidine (<b>69</b>, 468 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>13</b>, 279 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II to give <b>80</b> as a yellow solid (100 mg, 22%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.10; mp 203â205 Â°C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.51â1.71 (m, 6H), 1.99â2.05 (m, 2H), 2.35 (s, 3H), 2.48 (s, 3H), 2.62 (t, 4H, <i>J</i> 5.0), 3.14 (t, 4H, <i>J</i> 5.0), 3.79 (br, 1H)), 6.03 (br, 1H), 6.78 (d, 1H, <i>J</i> 5.0), 7.27 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.96 (d, 1H, <i>J</i> 3.0), 8.10 (s, 1H), 8.21 (d, 1H, <i>J</i> 9.0), 8.29 (d, 1H, <i>J</i> 5.0). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 18.5, 23.9, 33.2, 45.9, 49.7, 54.9, 57.7, 107.8, 113.2, 119.6, 126.8, 142.7, 146.7, 151.7, 157.6, 158.9, 159.4, 167.9, 169.5 (four carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 451.2396 [M + H]<sup>+</sup>; calcd for C<sub>23</sub>H<sub>31</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 451.2387. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 9.56 min, purity >99%; method B, <i>t</i><sub>R</sub> 9.50 min, purity >98%.</div></div><div id="sec4_9_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> <i>N</i>-Cyclopentyl-5-(2-((5-(4-ethylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine (<b>81</b>)</h4><div class="NLM_p last">1-(5-(4-Ethylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>72</b>, 496 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>13</b>, 279 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II and recrystallized from MeOH to give <b>81</b> as a yellow solid (117 mg, 25%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.32; mp 210â213 Â°C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.14 (t, 3H, <i>J</i> 7.0), 1.56â1.76 (m, 6H), 2.06â2.12 (m, 2H), 2.49 (q, 2H, <i>J</i> 7.5), 2.54 (s, 3H), 2.64 (s, 3H), 3.19 (t, 4H, <i>J</i> 4.5), 3.14 (t, 4H, <i>J</i> 5.0), 3.86 (app s, 1H), 5.77 (s, 1H), 6.84 (d, 1H, <i>J</i> 5.0), 7.34 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.94 (d, 1H, <i>J</i> 3.0), 7.94 (s, 1H), 8.01 (d, 1H, <i>J</i> 3.0), 8.26 (d, 1H, <i>J</i> 9.0), 8.33 (d, 1H, <i>J</i> 5.5). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 12.1, 18.7, 23.9, 33.3, 50.0, 52.5, 52.8, 57.6, 107.9, 113.2, 119.7, 126.6, 136.7, 143.0, 146.5, 152.2, 157.5, 158.9, 159.5, 169.5 (four carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 465.2541 [M + H]<sup>+</sup>; calcd for C<sub>24</sub>H<sub>33</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 465.2543. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 13.24 min, purity >98%; method B, <i>t</i><sub>R</sub> 8.96 min, purity >99%.</div></div><div id="sec4_9_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 1-(4-(6-((4-(2-(Cyclopentylamino)-4-methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one (<b>82</b>)</h4><div class="NLM_p last">1-(5-(4-Acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>67</b>, 524 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>13</b>, 279 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II to give <b>82</b> as a light-yellow solid (153 mg, 32%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.59; mp 207â210 Â°C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.57â1.75 (m, 6H), 2.05â2.11 (m, 2H), 2.14 (s, 3H), 2.54 (s, 3H), 3.08â3.14 (m, 4H), 3.63 (t, 2H, <i>J</i> 5.0), 3.79 (t, 2H, <i>J</i> 5.0), 3.87 (m, 1H), 5.70 (s, 1H), 6.86 (d, 1H, <i>J</i> 5.0), 7.33 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.03 (d, 1H, <i>J</i> 2.0), 8.19 (br s, 1H,), 8.31 (d, 1H, <i>J</i> 9.0), 8.35 (d, 1H, <i>J</i> 5.0). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 18.7, 21.5, 23.9, 33.3, 41.4, 46.4, 50.3, 50.7, 57.7, 108.0, 113.1, 119.7, 127.5, 137.5, 142.5, 147.3, 157.5, 158.8, 159.5, 169.2, 169.4 (three carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 479.2340 [M + H]<sup>+</sup>; calcd for C<sub>24</sub>H<sub>31</sub>N<sub>8</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 479.2336 Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 10.86 min, purity >99%; method B, <i>t</i><sub>R</sub> 8.51 min, purity >98%.</div></div><div id="sec4_9_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> <i>N</i>-Cyclopentyl-4-methyl-5-(2-((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine (<b>83</b>)</h4><div class="NLM_p last">1-(5-Morpholinopyridin-2-yl)guanidine (<b>71</b>, 442 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>13</b>, 279 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II and recrystallized with Et<sub>2</sub>O to give <b>83</b> as a dark-brown solid (130 mg, 30%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.30; mp 262â263 Â°C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.57â1.74 (m, 6H), 2.06â2.12 (m, 2H), 2.55 (s, 3H), 3.13 (t, 4H, <i>J</i> 4.5), 3.88 (t, 4H, <i>J</i> 4.5), 5.67 (d, <i>J</i> 4.5, 1H), 6.85 (d, 1H, <i>J</i> 5.5), 7.32 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.02 (d, 1H, <i>J</i> 3.0), 8.16 (s, 1H), 8.30 (d, 1H, <i>J</i> 9.5), 8.35 (d, 1H, <i>J</i> 5.5). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 18.8, 23.9, 33.3, 50.2, 57.6, 67.0, 107.9, 113.2, 119.8, 126.4, 136.5, 142.8, 146.8, 152.4, 157.5, 158.9, 159.5, 169.4 (four carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 438.2088 [M + H]<sup>+</sup>; calcd for C<sub>22</sub>H<sub>28</sub>N<sub>7</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 438.2071. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 10.92 min, purity >99%; method B, <i>t</i><sub>R</sub> 9.51 min, purity >99%.</div></div><div id="sec4_9_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 5-(2-((5-(4-Aminopiperidin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-<i>N</i>-cyclopentyl-4-methylthiazol-2-amine (<b>84</b>)</h4><div class="NLM_p last">1-(5-(4-Aminopiperidin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>76</b>, 702 mg, 3.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>13</b>, 558 mg, 2.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system III and recrystallized with <i>n</i>-hexane and DCM to give <b>84</b> as a dark-yellow solid (90 mg, 10%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.10; mp 185â186 Â°C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.50â1.77 (m, 10H), 1.95 (d, 2H, <i>J</i> 10.5), 2.07â2.13 (m, 2H), 2.54 (s, 3H), 2.75â2.85 (m, 3H), 3.53â3.56 (m, 2H), 3.85â3.91 (m, 1H), 5.43 (d, 1H, <i>J</i> 5.0), 6.84 (d, 1H, <i>J</i> 5.5), 7.34 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.75 (s, 1H), 8.00 (d, 1H, <i>J</i> 3.0), 8.25 (d, 1H, <i>J</i> 9.0), 8.32 (d, 1H, <i>J</i> 5.5). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 18.8, 23.9, 33.3, 35.8, 48.6, 49.6, 57.6, 89.8, 107.9, 113.1, 119.9, 127.2, 137.1, 143.2, 146.2, 152.5, 157.5, 158.9, 159.5, 169.4 (three carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 451.2415 [M + H]<sup>+</sup>; calcd for C<sub>23</sub>H<sub>31</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 451.2387. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 9.34 min, purity >95%; method B, <i>t</i><sub>R</sub> 8.06 min, purity >95%.</div></div><div id="sec4_9_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> <i>N</i>-Cyclopentyl-4-methyl-5-(2-((5-(piperidin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine (<b>85</b>)</h4><div class="NLM_p last">1-(5-(Piperidin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>73</b>, 439 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>13</b>, 279 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II and recrystallized with DCM and MeOH to give <b>85</b> as yellow solid (250 mg, 57%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.63; mp 220â221 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.53 (br s, 6H), 1.64 (br s, 6H), 1.93 (br s, 2H), 2.46 (s, 3H), 3.07 (t, 4H, <i>J</i> 10.0), 3.98 (br s, H), 6.89 (d, 1H, <i>J</i> 5.0), 7.37 (app d, 1H, <i>J</i> 9.0), 7.99 (s, 1H), 8.06 (d, 1H, <i>J</i> 9.0), 8.18 (s, 1H), 8.33 (d, 1H, <i>J</i> 5.0), 9.26 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.7, 23.4, 25.2, 50.1, 55.8, 58.0, 60.0, 73.9, 107.1, 113.3, 117.3, 125.5, 136.0, 143.2, 145.4, 152.5, 157.6, 158.6, 158.8, 168.0 (three carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 436.2280 [M + H]<sup>+</sup>; calcd for C<sub>23</sub>H<sub>30</sub>N<sub>7</sub>S<sup>+</sup> [M + H]<sup>+</sup> 436.2278. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 12.08 min, purity >99%; method B, <i>t</i><sub>R</sub> 9.36 min, purity >99%.</div></div><div id="sec4_9_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> <i>N</i>-Cyclopentyl-4-methyl-5-(2-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine (<b>86</b>)</h4><div class="NLM_p last">1-(5-(4-(Methylsulfonyl)piperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>75</b>, 596 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>13</b>, 279 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II to give <b>86</b> as a brown solid (62 mg, 12%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.50; mp 197â198 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) 1.54â1.57 (m, 4H), 1.66â1.69 (m, 2H), 1.91â1.95 (m, 2H), 2.47 (s, 3H), 2.94 (s, 3H), 2.23 (t, 4H, <i>J</i> 3.5), 3.27 (t, 4H, <i>J</i> 3.5), 3.98 (m, 1H), 6.91 (d, 1H, <i>J</i> 5.5), 7.43 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.05 (d, 1H, <i>J</i> 3.0), 8.12 (d, 1H, <i>J</i> 9.0), 8.19 (d, 1H, <i>J</i> 7.0), 8.34 (d, 1H, <i>J</i> 5.5), 9.36 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.7, 23.4, 32.2, 33.9, 45.3, 48.6, 55.8, 107.3, 113.2, 117.3, 125.9, 136.4, 141.9, 146.4, 152.6, 157.6, 158.7, 158.7, 168.0 (four carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 515.2004 [M + H]<sup>+</sup>; calcd for C<sub>23</sub>H<sub>31</sub>N<sub>8</sub>O<sub>2</sub>S<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 515.2006. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 10.48 min, purity >97%; method B, <i>t</i><sub>R</sub> 8.61 min, purity >99%.</div></div><div id="sec4_9_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> <i>N</i>-Cyclopentyl-4-methyl-5-(2-(pyridin-2-ylamino)pyrimidin-4-yl)thiazol-2-amine (<b>87</b>)</h4><div class="NLM_p last">1-(Pyridin-2-yl)guanidine 2,2,2-trifluoroacetate (<b>77</b>, 272 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>13</b>, 279 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II to give <b>87</b> as an orange solid (150 mg, 43%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.52; mp 221â222 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) 1.50â1.57 (m, 4H), 1.66â1.69 (m, 2H), 1.91â1.95 (m, 2H), 2.48 (s, 3H), 3.98 (m, 1H), 6.99 (m, 2H), 7.74 (m, 1H), 8.23 (d, 1H, <i>J</i> 7.0), 8.26 (d, 1H, <i>J</i> 8.5), 8.29 (m, 1H), 8.39 (d, 1H, <i>J</i> 5.5), 9.59 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.7, 23.4, 32.2, 55.8, 107.9, 112.5, 117.1, 117.3, 137.5, 147.9, 152.9, 153.1, 157.6, 158.6, 158.7, 168.0 (two carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 353.1555 [M + H]<sup>+</sup>; calcd for C<sub>18</sub>H<sub>21</sub>N<sub>6</sub>S<sup>+</sup> [M + H]<sup>+</sup> 353.1543. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 10.45 min, purity >97%; method B, <i>t</i><sub>R</sub> 9.24 min, purity >98%.</div></div><div id="sec4_9_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> <i>N</i>-Cyclopentyl-<i>N</i>,4-dimethyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine (<b>88</b>)</h4><div class="NLM_p last">1-(5-(Piperazin-1-yl)pyridin-2-yl)guanidine (<b>68</b>, 319 mg, 1.45 mmol) and (<i>E</i>)-1-(2-(cyclopentyl(methyl)amino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>15</b>, 250 mg, 0.85 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II and recrystallized with hexane to give <b>88</b> as a reddish-brown solid (113 mg, 25%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.50; mp 166â169 Â°C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.58â1.79 (m, 6H), 1.96â2.02 (m, 2H), 2.11 (br, 1H), 2.56 (s, 3H), 3.01 (s, 3H), 3.06 (t, 4H, <i>J</i> 6), 3.10 (t, 4H, <i>J</i> 6.0), 4.55 (m, 1H), 6.82 (d, 1H, <i>J</i> 5.5), 7.32 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.02 (d, 1H, <i>J</i> 3.0), 8.13 (br, 1H), 8.28 (d, 1H, <i>J</i> 9.0), 8.32 (d, 1H, <i>J</i> 5.5). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 19.1, 24.3, 28.5, 32.2, 46.1, 51.2, 53.6, 61.5, 107.9, 113.0, 118.8, 126.9, 136.9, 143.2, 146.8, 153.1, 157.3, 158.9, 159.7, 170.6 (three carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 451.2387 [M + H]<sup>+</sup>; calcd for C<sub>23</sub>H<sub>31</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 451.2387. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 10.28 min, purity >95%; method B, <i>t</i><sub>R</sub> 8.69 min, purity >95%.</div></div><div id="sec4_9_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> <i>N</i>-Cyclopentyl-<i>N</i>,4-dimethyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine (<b>89</b>)</h4><div class="NLM_p last">1-(5-(4-Methylpiperazin-1-yl)pyridine-2-yl)guanidine (<b>69</b>, 468 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentyl(methyl)amino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>15</b>, 293 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system III and recrystallized with MeOH to give <b>89</b> as a yellow solid (149 mg, 32%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.38; mp 169â170 Â°C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.65â1.76 (m, 6H), 1.99â2.02 (m, 2H), 2.56 (s, 3H), 2.75 (s, 3H), 3.16 (br s, 4H), 3.47 (t, 4H, <i>J</i> 5.0), 4.58 (m, 1H), 6.86 (d, 1H, <i>J</i> 5.5), 7.36 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.05 (d, 1H, <i>J</i> 3.0), 8.07 (s, 1H), 8.32 (d, 1H, <i>J</i> 5.5), 8.35 (d, 1H, <i>J</i> 9.0). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 19.2, 24.4, 28.6, 32.3, 44.4, 48.6, 48.6, 54.2, 108.2, 112.9, 118.7, 127.9, 138.8, 141.3, 148.1, 153.4, 157.2, 158.7, 159.8, 170.7 (four carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 465.2530 [M + H]<sup>+</sup>; calcd for C<sub>24</sub>H<sub>33</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 465.2543. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 10.15 min, purity >96%; method B, <i>t</i><sub>R</sub> 8.47 min, purity >96%.</div></div><div id="sec4_9_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 1-(4-(6-((4-(2-(Cyclopentyl(methyl)amino)-4-methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one (<b>90</b>)</h4><div class="NLM_p last">1-(5-(4-Acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>67,</b> 525 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentyl(methyl)amino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>15</b>, 293 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II and recrystallized with Et<sub>2</sub>O to give <b>90</b> as a yellow solid (300 mg, 61%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.53; mp 153â154 Â°C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.61â1.76 (m, 6H), 1.97â2.02 (m, 2H), 2.15 (s, 3H), 2.57 (s, 3H), 3.01 (s, 3H), 3.09 (t, 2H, <i>J</i> 5.0), 3.13 (t, 2H, <i>J</i> 5.0), 3.63 (t, 2H, <i>J</i> 5.0), 3.79 (t, 2H, <i>J</i> 5.0), 4.56 (m, 1H), 6.85 (d, 1H, <i>J</i> 5.5), 7.34 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.93 (s, 1H), 8.00 (d, 1H, <i>J</i> 3.0), 8.31 (s, 1H), 8.32 (d, 1H, <i>J</i> 5.0). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 19.2, 21.5, 24.4, 28.6, 32.3, 41.5, 46.4, 50.4, 50.7, 61.6, 108.1, 113.0, 118.7, 127.6, 137.6, 142.4, 147.4, 153.3, 157.2, 158.8, 159.8,169.1, 170.7 (two carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 493.2482 [M + H]<sup>+</sup>; calcd for C<sub>25</sub>H<sub>33</sub>N<sub>8</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 493.2493. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 11.55 min, purity >96%; method B, <i>t</i><sub>R</sub> 9.57 min, purity >96%.</div></div><div id="sec4_9_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> <i>N</i>,<i>N</i>-Dicyclopentyl-4-methyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine (<b>91</b>)</h4><div class="NLM_p last">1-(5-(Piperazin-1-yl)pyridin-2-yl)guanidine (<b>68</b>, 441 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(dicyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>17</b>, 200 mg, 0.580 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II and recrystallized with DCM and MeOH to give <b>91</b> as a yellow solid (60 mg, 21%). <i>R</i><sub>f</sub> (DCM:MeOH:NH<sub>4</sub>OH = 9:1:0.5) 0.1; mp 198â199 Â°C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) 1.53â1.59 (m, 8H), 1.74â1.76 (m, 4H), 1.85â1.89 (m, 2H), 1.91â1.98 (m, 2H), 2.42â2.47 (m, 1H), 2.58 (s, 3H), 3.05 (t, 4H, <i>J</i> 3.0), 3.10 (t, 4H, <i>J</i> 3.0), 3.41â3.44 (m, 1H), 4.47â4.54 (m, 1H), 6.61 (d, 1H, <i>J</i> 5.5), 7.32 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.70 (s, 1H), 7.98 (d, 1H, <i>J</i> 3.0), 8.25 (d, 1H, <i>J</i> 9.0), 8.28 (d, 1H, <i>J</i> 5.5). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 15.2, 24.4, 26.0, 28.1, 34.0, 46.2, 51.3, 57.5, 106.4, 109.4, 113.2, 126.7, 136.8, 140.9, 143.5, 146.5, 151.7, 157.4, 158.7, 159.9 (seven carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 505.2873 [M + H]<sup>+</sup>; calcd for C<sub>27</sub>H<sub>37</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 505.2856. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 8.57 min, purity >98%; method B, <i>t</i><sub>R</sub> 7.33 min, purity >96%.</div></div><div id="sec4_9_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> 4-Methyl-<i>N</i>-phenyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine (<b>92</b>)</h4><div class="NLM_p last">1-(5-(Piperazin-1-yl)pyridin-2-yl)guanidine (<b>68</b>, 468 mg, 2.00 mmol) and (<i>E</i>)-3-(dimethylamino)-1-(4-methyl-2-(phenylamino)thiazol-5-yl)prop-2-en-1-one (<b>18</b>, 287 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system III to give <b>92</b> as a light-yellow solid (178 mg, 40%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.10; mp 228â230 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 2.58 (s, 4H), 2.86 (t, 4H, <i>J</i> 4.5), 3.03 (t, 4H, <i>J</i> 4.0), 7.00 (m, 2H), 7.35 (m, 3H), 7.65 (d, 2H, <i>J</i> 8.0), 8.00 (d, 1H, <i>J</i> 2.5), 8.06 (d, 1H, <i>J</i> 9.0), 8.41 (d, 1H, <i>J</i> 5.0), 9.46 (s, 1H), 10.53 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.7, 45.4, 49.7, 107.7, 113.5, 117.6, 119.6, 122.1, 124.9, 129.1, 135.5, 140.6, 143.2, 145.5, 151.3, 158.2, 158.3, 158.9, 163.5 (five carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 445.1918 [M + H]<sup>+</sup>; calcd for C<sub>23</sub>H<sub>25</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 445.1917. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 10.01 min, purity >99%; method B, <i>t</i><sub>R</sub> 8.17 min, purity >99%..</div></div><div id="sec4_9_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> 4-Methyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-<i>N</i>-phenylthiazol-2-amine (<b>93</b>)</h4><div class="NLM_p last">1-(5-(4-Methylpiperazin-1-yl)pyridine-2-yl)guanidine (<b>69</b>, 468 mg, 2.00 mmol) and (<i>E</i>)-3-(dimethylamino)-1-(4-methyl-2-(phenylamino)thiazol-5-yl)prop-2-en-1-one (<b>18</b>, 287 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II and recrystallized with DCM to give <b>93</b> as a light-yellow solid (220 mg, 48%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.17; mp 210â211 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 2.23 (s, 3H), 2.58 (s, 3H), 3.12 (br, 4H), 3.38 (t, 4H), 7.00 (m, 2H), 7.37 (m, 3H), 7.65 (d, 2H, <i>J</i> 8.0), 8.01 (d, 1H, <i>J</i> 2.0), 8.07 (d, 1H, <i>J</i> 9.0), 8.41 (d, 1H, <i>J</i> 5.0), 9.46 (s, 1H), 10.54 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.7, 45.8, 48.5, 54.5, 107.8, 113.5, 117.7, 119.6, 122.1, 125.0, 129.1, 135.5, 140.6, 142.6, 145.6, 151.4, 158.2, 158.3, 158.9, 163.5 (four carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 459.2063 [M + H]<sup>+</sup>; calcd for C<sub>24</sub>H<sub>27</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 459.2074. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 9.93 min, purity >99%; method B, <i>t</i><sub>R</sub> 9.17 min, purity >99%.</div></div><div id="sec4_9_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> <i>N</i>,4-Dimethyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-<i>N</i>-phenylthiazol-2-amine (<b>94</b>)</h4><div class="NLM_p last">1-(5-(4-Methylpiperazin-1-yl)pyridine-2-yl)guanidine (<b>69</b>, 468 mg, 2.00 mmol) and (<i>E</i>)-3-(dimethylamino)-1-(4-methyl-2-(methyl(phenyl)amino)thiazol-5-yl)prop-2-en-1-one (<b>19</b>, 301 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II and recrystallized with hexane to give <b>94</b> as a reddish-brown solid (184 mg, 39%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.40; mp 212â215 Â°C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 2.36 (s, 3H), 2.59 (app br, 7H), 3.14 (t, 4H, <i>J</i> 5.0), 3.57 (s, 3H), 6.80 (d, 1H, <i>J</i> 5.5), 7.19 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.32 (m, 1H), 7.44 (m, 4H), 8.00 (d, 1H, <i>J</i> 3.0), 8.04 (s, 1H), 8.16 (d, 1H, <i>J</i> 9.0), 8.32 (d, 1H, <i>J</i> 5.5) <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 18.9, 40.1, 46.3, 49.9, 55.1, 108.1, 113.2, 120.6, 125.6, 126.4, 127.2, 130.0, 136.9, 142.8, 145.9, 146.4, 152.3, 157.6, 158.8, 159.5, 169.7 (four carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 473.2220 [M + H]<sup>+</sup>; calcd for C<sub>25</sub>H<sub>29</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 473.2230. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 9.57 min, purity >98%; method B, <i>t</i><sub>R</sub> 7.90 min, purity >98%.</div></div><div id="sec4_9_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> <i>N</i>-Isopropyl-4-methyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine (<b>95</b>)</h4><div class="NLM_p last">To a suspension of 1-(4-(6-((4-(2-(isopropylamino)-4-methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one (<b>98</b>, 143 mg, 0.320 mmol) in methanol HCl (32%, 3 mL) was added and reflexed overnight. The reaction mixture was concentrated and purified by FlashMaster Personal<sup>+</sup> chromatography (silica gel, DCM ramping to DCM:MeOH:NH<sub>4</sub>OH = 90:10:1) to give <b>95</b> as a yellow solid (120 mg, 92%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1 + 3 drops of 32% aqueous ammonia) 0.12; mp 218â220 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.19 (d, 6H, <i>J</i> 6.5), 2.46 (s, 3H), 2.87 (t, 4H, <i>J</i> 5.0), 3.03 (t, 4H, <i>J</i> 5.5), 3.80â3.87 (m, 1H), 6.90 (d, 1H, <i>J</i> 5.5), 7.37 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.00 (d, 1H, <i>J</i> 3.0), 8.05 (d, 2H, <i>J</i> 7.5), 8.08 (d, 1H, <i>J</i> 9.0), 8.33 (d, 1H, <i>J</i> 5.5), 9.29 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.7, 22.3, 45.2, 46.1, 49.5, 107.2, 113.3, 117.1, 125.0, 135.5, 142.9, 145.7, 152.4, 157.6, 158.6, 158.8, 167.5 (three carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 411.2072 [M + H]<sup>+</sup>; calcd for C<sub>20</sub>H<sub>27</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 411.2074.Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 8.43 min, purity >96%; method B, <i>t</i><sub>R</sub> 7.61 min, purity >99%.</div></div><div id="sec4_9_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> 5-(2-((5-(1,4-Diazepan-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-<i>N</i>-isopropyl-4-methylthiazol-2-amine (<b>96</b>)</h4><div class="NLM_p last">1-(5-(1,4-Diazepan-1-yl)pyridin-2-yl)guanidine di(2,2,2-trifluoroacetate) (<b>70</b>, 469 mg, 2.00 mmol) and (<i>E</i>)-3-(dimethylamino)-1-(2-(isopropylamino)-4-methylthiazol-5-yl)prop-2-en-1-one (<b>20</b>, 253 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II to give <b>96</b> as an orange solid (114 mg, 34%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.10; mp 163â164 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.19 (d, 6H, <i>J</i> 6.5), 2.04â2.09 (m, 2H), 2.47 (s, 3H), 3.16 (s, 1H, <i>J</i> 5.5), 3.27 (s, 2H, <i>J</i> 5.0), 3.50 (d, 2H, <i>J</i> 6.0), 3.70 (t, 2H, <i>J</i> 5.0), 3.80â3.86 (m, 1H), 6.87 (d, 1H, <i>J</i> 5.5), 7.24 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.89 (d, 1H, <i>J</i> 3.0), 8.03 (d, 2H, <i>J</i> 5.5), 8.05 (d, 1H, <i>J</i> 4.0), 8.31 (d, 1H, <i>J</i> 5.5), 8.75 (s, 1H). 9.15 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.7, 22.3, 24.7, 44.9, 45.3, 45.4, 46.0, 46.8, 107.0, 113.9, 116.1, 117.1, 118.5, 121.1, 131.7, 139.8, 143.7, 152.3, 157.6, 158.8, 167.5. HRMS (ESI-TOF): <i>m</i>/<i>z</i> 425.2231 [M + H]<sup>+</sup>; calcd for C<sub>21</sub>H<sub>29</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 425.2230 Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 8.48 min, purity >95%; method B, <i>t</i><sub>R</sub> 7.69 min, purity >98%.</div></div><div id="sec4_9_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> <i>N</i>-Isopropyl-4-methyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine (<b>97</b>)</h4><div class="NLM_p last">1-(5-(4-Methylpiperazin-1-yl)pyridine-2-yl)guanidine (<b>69</b>, 468 mg, 2.00 mmol) and (<i>E</i>)-3-(dimethylamino)-1-(2-(isopropylamino)-4-methylthiazol-5-yl)prop-2-en-1-one (<b>20</b>, 253 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II to give <b>97</b> as a yellow solid (131 mg, 31%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.70; mp 175â177 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.19 (d, 6H, <i>J</i> 6.5), 2.22 (s, 3H), 2.46 (br s, 7H), 3.11 (t, 4H, <i>J</i> 5.0), 3.81â3.85 (m, 1H), 6.90 (d, 1H, <i>J</i> 5.5), 7.38 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.00 (d, 1H, <i>J</i> 3.0), 8.04 (d, 2H, <i>J</i> 7.5), 8.08 (d, 1H, <i>J</i> 9.0), 8.34 (d, 1H, <i>J</i> 5.5), 9.32 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.7, 22.3, 45.8, 46.0, 48.5, 54.5, 107.2, 113.2, 117.2, 125.0, 135.4, 142.4, 145.7, 152.4, 157.6, 158.6, 158.7, 167.5 (three carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 425.2235 [M + H]<sup>+</sup>; calcd for C<sub>21</sub>H<sub>29</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 425.2230. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 8.56 min, purity >99%; method B, <i>t</i><sub>R</sub> 7.73 min, purity >99%..</div></div><div id="sec4_9_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> 1-(4-(6-((4-(2-(Isopropylamino)-4-methylthiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one (<b>98</b>)</h4><div class="NLM_p last">1-(5-(4-Acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>67</b>, 525 mg, 2.00 mmol) and (<i>E</i>)-3-(dimethylamino)-1-(2-(isopropylamino)-4-methylthiazol-5-yl)prop-2-en-1-one (<b>20</b>, 253 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II to give <b>98</b> as an orange solid (80 mg, 18%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.63; mp 232â234 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.19 (d, 6H, <i>J</i> 6.5), 2.05 (s, 3H), 2.46 (s, 3H), 3.06 (t, 2H, <i>J</i> 5.0), 3.13 (t, 2H, <i>J</i> 5.0), 3.59 (q, 4H, <i>J</i> 5.5), 3.81â3.85 (m, 1H), 6.91 (d, 1H, <i>J</i> 5.5), 7.40 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.02 (d, 1H, <i>J</i> 3.0), 8.05 (m, 2H, <i>J</i> 7.5), 8.10 (d, 1H, <i>J</i> 9.0), 8.33 (d, 1H, <i>J</i> 5.5), 9.31 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.7, 22.2, 22.3, 40.6, 45.4, 46.1, 48.8, 49.3, 107.3, 113.2, 117.1, 125.7, 136.1, 142.2, 146.2, 152.5, 157.6, 158.6, 158.7, 167.5, 168.3 (one carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 453.2187 [M + H]<sup>+</sup>; calcd for C<sub>22</sub>H<sub>29</sub>N<sub>8</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 453.2180. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 10.03 min, purity >99%; method B, <i>t</i><sub>R</sub> 8.85 min, purity >99%.</div></div><div id="sec4_9_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> <i>N</i>-Isopropyl-4-methyl-5-(2-((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)thiazol-2-amine (<b>99</b>)</h4><div class="NLM_p last">1-(5-Morpholinopyridin-2-yl)guanidine (<b>71</b>, 443 mg, 2.00 mmol) and (<i>E</i>)-3-(dimethylamino)-1-(2-(isopropylamino)-4-methylthiazol-5-yl)prop-2-en-1-one (<b>20</b>, 253 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II to give <b>99</b> pressure as a yellow solid (200 mg, 48%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.63; mp 237â238 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.19 (d, 6H, <i>J</i> 6.5), 2.45 (s, 3H), 3.09 (t, 4H, <i>J</i> 4.0), 3.76 (t, 4H, <i>J</i> 4.0), 3.81â3.85 (m, 1H), 6.90 (d, 1H, <i>J</i> 5.5), 7.39 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.01 (d, 1H, <i>J</i> 2.5), 8.05 (d, 2H, <i>J</i> 7.5), 8.10 (d, 1H, <i>J</i> 9.0), 8.34 (d, 1H, <i>J</i> 5.5), 9.33 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.7, 22.3, 46.1, 48.9, 66.0, 107.2, 113.2, 117.1, 124.8, 135.3, 142.4, 146.0, 152.5, 157.6, 158.6, 158.7, 167.5 (three carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 412.1912 [M + H]<sup>+</sup>; calcd for C<sub>20</sub>H<sub>26</sub>N<sub>7</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 412.1914. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 10.21 min, purity >99%; method B, <i>t</i><sub>R</sub> 9.08 min, purity >99%.</div></div><div id="sec4_9_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> <i>N</i>-Cyclopentyl-5-(2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-(trifluoromethyl)thiazol-2-amine (<b>100</b>)</h4><div class="NLM_p last">1-(5-(Piperazin-1-yl)pyridin-2-yl)guanidine (<b>68</b>, 441 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-(trifluoromethyl)thiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>16</b>, 333 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system III to give <b>100</b> as an orange solid (260 mg, 53%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.35; mp 207â208 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.50â1.59 (m, 4H), 1.65â1.70 (m, 2H), 1.92â1.97 (m, 2H), 2.26 (s, 1H), 2.84 (t, 4H, <i>J</i> 5.0), 3.02 (t, 4H, <i>J</i> 5.0), 3.96 (m, 1H), 6.96 (d, 1H, <i>J</i> 6.0), 7.37 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.98 (d, 1H, <i>J</i> 4.0), 7.99 (d, 1H, <i>J</i> 1.0), 8.50 (d, 1H, <i>J</i> 5.5), 8.59 (d, 1H, <i>J</i> 6.5), 9.59 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 23.3, 32.0, 45.5, 49.7, 56.1, 108.8, 113.7, 119.7, 121.9, 124.8, 125.0, 135.4, 136.8, 143.4, 145.0, 155.6, 158.9, 159.0, 168.2 (three carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 491.1952 [M + H]<sup>+</sup>; calcd for C<sub>22</sub>H<sub>26</sub>F<sub>3</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 491.1948. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 10.31 min, purity >99%; method B, <i>t</i><sub>R</sub> 8.30 min, purity >98%.</div></div><div id="sec4_9_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> <i>N</i>-Cyclopentyl-5-(2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-(trifluoromethyl)thiazol-2-amine (<b>101</b>)</h4><div class="NLM_p last">1-(5-(4-Methylpiperazin-1-yl)pyridine-2-yl)guanidine (<b>69</b>, 468 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-(trifluoromethyl)thiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>16</b>, 148 mg, 0.50 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II and to give <b>101</b> as a brown solid (30.0 mg, 6%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.28; mp 209â210 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.56â1.59 (m, 4H), 1.67â1.69 (m, 2H), 1.93â1.97 (m, 2H), 2.21 (s, 1H), 2.46 (t, 4H, <i>J</i> 5.0), 3.12 (t, 4H, <i>J</i> 5.0), 3.96 (m, 1H), 6.96 (d, 1H, <i>J</i> 6.0), 7.39 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.00 (d, 1H, <i>J</i> 9.0), 8.01 (d, 1H, <i>J</i> 3.0), 8.50 (d, 1H, <i>J</i> 5.5), 8.59 (d, 1H, <i>J</i> 7.0), 9.62 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 23.3, 32.0, 45.8, 48.4, 54.5, 54.9, 56.1, 108.8, 113.6, 119.7, 124.8, 135.4, 136.8, 137.1, 142.8, 145.1, 155.6, 155.9, 159.1, 168.2 (three carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 505.2103 [M + H]<sup>+</sup>; calcd for C<sub>23</sub>H<sub>28</sub>F<sub>3</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 505.2104. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 10.49 min, purity >96%; method B, <i>t</i><sub>R</sub> 9.46 min, purity >97%.</div></div><div id="sec4_9_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> 1-(4-(6-((4-(2-(Cyclopentylamino)-4-(trifluoromethyl)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one (<b>102</b>)</h4><div class="NLM_p last">1-(5-(4-Acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>67</b>, 524 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-(trifluoromethyl)thiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>16</b>, 333 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II to give <b>102</b> as a brown solid (50.0 mg, 9%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.40; mp 200â201 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.53â1.59 (m, 4H), 1.67â1.69 (m, 2H), 1.94â1.97 (m, 2H), 2.05 (s, 3H), 3.08 (t, 2H, <i>J</i> 4.5), 3.14 (t, 2H, <i>J</i> 4.5), 3.59 (app d, 4H, <i>J</i> 4.5), 3.95 (m, 1H), 6.97 (d, 1H, <i>J</i> 5.0), 7.43 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.02 (s, 1H), 8.04 (d, 1H, <i>J</i> 3.0), 8.50 (d, 1H, <i>J</i> 5.5), 8.59 (d, 1H, <i>J</i> 6.5), 9.66 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 21.2, 23.3, 32.0, 45.4, 48.7, 49.1, 56.1, 109.0, 113.6, 119.7, 121.9, 125.0, 125.6, 136.1, 136.9, 142.5, 145.7, 155.7, 158.9, 159.1, 168.2 (three carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 533.2053 [M + H]<sup>+</sup>; calcd for C<sub>24</sub>H<sub>27</sub>F<sub>3</sub>N<sub>8</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 533.2058. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 12.56 min, purity >97%; method B, <i>t</i><sub>R</sub> 9.39 min, purity >95%.</div></div><div id="sec4_9_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> <i>N</i>-Cyclopentyl-5-(2-((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)-4-(trifluoromethyl)thiazol-2-amine (<b>103</b>)</h4><div class="NLM_p last">1-(5-Morpholinopyridin-2-yl)guanidine (<b>71</b>, 442 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-(trifluoromethyl)thiazol-5-yl)-3-(dimethylamino)prop-2-en-1-one (<b>16</b>, 333 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system I to give <b>103</b> as an orange solid (200 mg, 41%). <i>R</i><sub>f</sub> (PE:EtOAc = 1:1) 0.40; mp 229â230 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.52â1.59 (m, 4H), 1.64â1.69 (m, 2H), 1.92â1.99 (m, 2H), 3.09 (t, 4H, <i>J</i> 4.5), 3.75 (t, 4H, <i>J</i> 4.5), 3.95 (m, 1H), 6.97 (d, 1H, <i>J</i> 5.0), 7.41 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.01 (s, 1H), 8.02 (d, 1H, <i>J</i> 2.5), 8.51 (d, 1H, <i>J</i> 5.5), 8.59 (d, 1H, <i>J</i> 6.5), 9.64 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 23.8, 33.2, 50.1, 57.9, 66.9, 109.8 (d, <i>J</i> 4.8), 113.1, 126.2, 136.5, 143.1, 146.3, 156.6, 157.7, 158.8, 169.2 (seven carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 492.1786 [M + H]<sup>+</sup>; calcd for C<sub>22</sub>H<sub>24</sub>F<sub>3</sub>N<sub>7</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 498.1788. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 12.90 min, purity >97%; method B, <i>t</i><sub>R</sub> 9.69 min, purity >99%.</div></div><div id="sec4_9_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> 4-(6-((4-(2-(Cyclopentylamino)-4-(trifluoromethyl)thiazol-5-yl)pyrimidin-2-yl)amino)pyridin-3-yl)piperazine-1-carbaldehyde (<b>104</b>)</h4><div class="NLM_p last">Compound <b>104</b> was obtained as beige solid (25.0 mg, 7%) byproduct in the process of synthesizing and purifying <b>100</b>. <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.63; mp 238â239 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.53â1.59 (m, 4H), 1.67â1.69 (m, 2H), 1.94â1.97 (m, 2H), 3.08 (t, 2H, <i>J</i> 5.0), 3.14 (t, 2H, <i>J</i> 5.0), 3.59 (m, 4H), 3.96 (m, 1H), 6.97 (d, 1H, <i>J</i> 4.5), 7.45 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.03 (d, 1H, <i>J</i> 9.0), 8.05 (d, 1H, <i>J</i> 3.0), 8.09 (s, 1H), 8.50 (d, 1H, <i>J</i> 5.5), 8.59 (d, 1H, <i>J</i> 7.0), 9.67 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 23.3, 32.0, 44.5, 48.6, 49.8, 56.1, 109.0, 113.5, 119.7, 121.9, 125.0, 125.6, 136.1, 136.9, 137.1, 142.5, 145.8, 155.7, 158.9, 159.1, 160.9, 168.2 (one carbon signal overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 519.1897 [M + H]<sup>+</sup>; calcd for C<sub>23</sub>H<sub>26</sub>F<sub>3</sub>N<sub>8</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 519.1906. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 11.57 min, purity >91%; method B, <i>t</i><sub>R</sub> 9.39 min, purity >95%.</div></div><div id="sec4_9_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> <i>N</i>-Cyclopentyl-5-(5-fluoro-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine (<b>105</b>)</h4><div class="NLM_p last">1-(5-(Piperazin-1-yl)pyridin-2-yl)guanidine (<b>68</b>, 441 mg, 2.00 mmol) and ((<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one (<b>14</b>, 297 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system III to give <b>105</b> as a yellow solid (101 mg, 22%). <i>R</i><sub>f</sub> (DCM:MeOH:NH<sub>4</sub>OH = 9:1:0.5) 0.30; mp 207â208 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) 1.54â1.57 (m, 4H), 1.66â1.69 (m, 2H), 1.92â1.95 (m, 2H), 2.47 (s, 3H), 3.26 (t, 4H, <i>J</i> 2.5), 3.31 (t, 4H, <i>J</i> 2.5), 3.95 (m, 1H), 7.46 (dd, 1H, <i>J</i> 9.0 and 3.0), 8.00 (d, 1H, <i>J</i> 9.0), 8.05 (d, 1H, <i>J</i> 3.0), 8.25 (d, 1H, <i>J</i> 7.0), 8.42 (d, 1H, <i>J</i> 3.5), 8.84 (d, 1H, <i>J</i> 3.5), 9.57 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 19.0 (<i>J</i> 4.7), 23.3, 32.2, 42.7, 46.2, 56.0, 109.2, 113.0, 126.0, 136.2, 141.4, 145.3, 145.5, 146.5, 146.7, 147.1, 147.2, 148.5, 155.0, 155.2, 169.4 (<i>J</i> 4.7) (one carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 455.2139 [M + H]<sup>+</sup>; calcd for C<sub>22</sub>H<sub>28</sub>FN<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 455.2136. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 9.55 min, purity >99%; method B, <i>t</i><sub>R</sub> 7.86 min, purity >99%.</div></div><div id="sec4_9_89" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> 5-(2-((5-(1,4-Diazepan-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-<i>N</i>-cyclopentyl-4-methylthiazol-2-amine (<b>106</b>)</h4><div class="NLM_p last">1-(5-(1,4-Diazepan-1-yl)pyridin-2-yl)guanidine di(2,2,2-trifluoroacetate) (<b>70</b>, 469 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one (<b>14</b>, 297 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II to give <b>106</b> as a yellow solid (100 mg, 21%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.15; mp 170â171 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.49â1.59 (m, 4H), 1.64â1.72 (m, 2H), 1.92â1.95 (m, 2H), 2.05â2.09 (m, 2H), 2.47 (d, 3H, <i>J</i> 2.0), 2.55 (s, 1H), 3.16 (br s, 2H), 3.27 (d, 2H, <i>J</i> 4.0), 3.70 (t, 2H, <i>J</i> 5.0), 3.94â3.98 (m, 1H), 7.32 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.87 (d, 1H, <i>J</i> 2.5), 7.89 (d, 1H, <i>J</i> 3.0), 8.27 (d, 1H, <i>J</i> 7.0), 8.40 (d, 1H, <i>J</i> 3.5), 8.9 (br s, 1H), 9.54 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 19.0 (<i>J</i> 4.7), 23.3, 24.6, 32.2, 34.3, 44.9, 45.3 (<i>J</i> 8.6), 46.8, 56.0, 109.1 (<i>J</i> 8.1), 114.2, 116.1, 118.5, 140.0, 143.4, 145.3 (<i>J</i> 25.4), 146.4, 147.2 (<i>J</i> 11.6), 148.3, 155.0, 155.3, 158.2, 169.4 (<i>J</i> 4.5). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 469.2297 [M + H]<sup>+</sup>; calcd for C<sub>23</sub>H<sub>30</sub>FN<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 469.2293. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 9.53 min, purity >97%; method B, <i>t</i><sub>R</sub> 8.53 min, > purity 99%.</div></div><div id="sec4_9_90" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> <i>N</i>-Cyclopentyl-5-(5-fluoro-2-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine (<b>107</b>)</h4><div class="NLM_p last">1-(5-(4-Methylpiperazin-1-yl)pyridine-2-yl)guanidine (<b>69</b>, 234 mg, 1.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one (<b>14</b>, 148 mg, 0.500 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system III to give <b>107</b> as a dark-brown solid (100 mg, 5%). <i>R</i><sub>f</sub> (DCM:MeOH:NH<sub>4</sub>OH = 9:1) 0.35; mp 207â209 Â°C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.52â1.79 (m, 6H), 1.06â2.12 (m, 2H), 2.38 (s, 3H), 2.55 (s, 3H), 2.63 (t, 4H, <i>J</i> 5.0), 3.18 (t, 4H, <i>J</i> 5.0), 3.84 (m, 1H), 5.56 (d, <i>J</i> 6.0, 1H), 7.31 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.82 (s, 1H), 7.99 (d, 1H, <i>J</i> 3.0), 8.18 (d, 1H, <i>J</i> 9.0), 8.23 (d, 1H, <i>J</i> 3.5). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 19.0, 19.1, 23.8, 33.3, 46.2, 49.8, 55.1, 57.6, 89.8, 111.9, 112.6, 126.7, 136.8, 142.9, 145.3, 146.5, 147.3, 148.2, 149.4, 155.2, 170.7 (two carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 469.2287 [M + H]<sup>+</sup>; calcd for C<sub>23</sub>H<sub>30</sub>FN<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 469.2293. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 10.37 min, purity >97%; method B, <i>t</i><sub>R</sub> 8.42 min, purity >98%.</div></div><div id="sec4_9_91" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> <i>N</i>-Cyclopentyl-5-(2-((5-(4-ethylpiperazin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-4-methylthiazol-2-amine (<b>108</b>)</h4><div class="NLM_p last">1-(5-(4-Ethylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>72</b>, 497 mg, 2.00 mmol) and ((<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one (<b>14</b>, 297 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II to give <b>108</b> as a yellow solid (74 mg, 15%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.45; mp 169â170 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.03 (t, 3H, <i>J</i> 7.0), 1.50â1.57 (m, 4H), 1.66â1.69 (m, 2H), 1.90â1.95 (m, 2H), 2.37 (q, 2H, <i>J</i> 7.0), 2.46 (d, 3H, <i>J</i> 2.5), 3.11 (t, 4H, <i>J</i> 5.0), 3.32 (s, 4H), 3.96 (app s, 1H), 7.39 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.94 (d, 1H, <i>J</i> 9.0), 7.97 (d, 1H, <i>J</i> 3.0), 8.23 (d, 1H, <i>J</i> 7.0), 8.40 (d, 1H, <i>J</i> 3.5), 9.44 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 12.0, 19.0 (<i>J</i> 5.1), 23.4, 32.2, 48.6, 51.7, 52.2, 56.0, 109.3, 113.2, 125.1, 135.3, 142.6, 145.4, 145.6, 145.7, 146.4, 147.0, 147.1, 148.4, 154.9, 155.3 (two carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 483.2442 [M + H]<sup>+</sup>; calcd for C<sub>24</sub>H<sub>32</sub>FN<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 483.2449. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 9.78 min, purity >98%; method B, <i>t</i><sub>R</sub> 7.88 min, purity >99%.</div></div><div id="sec4_9_92" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> 1-(4-(6-((4-(2-(Cyclopentylamino)-4-methylthiazol-5-yl)-5-fluoropyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)ethan-1-one (<b>109</b>)</h4><div class="NLM_p last">1-(5-(4-Acetylpiperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>67,</b> 524 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one (<b>14</b>, 297 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II to give <b>109</b> as a light-yellow solid (153 mg, 32%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.60; mp 206â209 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.51â1.75 (m, 4H), 1.66â1.68 (m, 2H), 1.92â1.95 (m, 2H), 2.04 (s, 3H), 2.47 (d, 3H, <i>J</i> 2.0), 3.06 (t, 2H, <i>J</i> 5.0), 3.12 (t, 2H, <i>J</i> 5.0), 3.58 (t, 4H, <i>J</i> 5.0), 3.96 (t, 1H), 7.43 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.98 (d, 1H, <i>J</i> 9.0), 8.01 (d, 1H, <i>J</i> 3.0), 8.24 (d, 1H, <i>J</i> 7.0), 8.42 (d, 1H, <i>J</i> 3.5), 9.51 (br s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 19.0 (d, <i>J</i> 4.7), 23.3, 25.7, 32.2, 47.9, 56.0, 58.0, 60.0, 62.2, 73.9, 109.2 (d, <i>J</i> 8.3), 113.2, 118.5, 125.9, 136.1, 141.9, 145.3, 145.5, 146.4, 147.0, 147.1, 148.4, 154.9, 155.2 (d, <i>J</i> 2.4), 157.6, 157.9, 158.1, 169.4 (three carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 497.2245 [M + H]<sup>+</sup>; calcd for C<sub>24</sub>H<sub>30</sub>FN<sub>8</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 497.2242 Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 11.02 min, purity >97%.; method B, <i>t</i><sub>R</sub> 9.91 min, purity >96%.</div></div><div id="sec4_9_93" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> <i>N</i>-Cyclopentyl-5-(2-((5-morpholinopyridin-2-yl)amino)pyrimidin-4-yl)-4-(trifluoromethyl)thiazol-2-amine (<b>110</b>)</h4><div class="NLM_p last">To a mixture of crude 1-(5-morpholinopyridin-2-yl)guanidine (<b>71</b>, 442 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one (<b>14</b>, 297 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II and recrystallized with DCM and MeOH to give <b>110</b> as a brown solid (120 mg, 26%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.34; mp 199â200 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.50â1.57 (m, 4H), 1.66â1.69 (m, 2H), 1.90â1.95 (m, 2H), 2.47 (d, 1H, <i>J</i> 2.5), 3.09 (t, 4H, <i>J</i> 5.0), 3.75 (t, 4H, <i>J</i> 5.0), 3.96 (m, 1H), 7.42 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.96 (d, 1H, <i>J</i> 9.0), 7.98 (d, 1H, <i>J</i> 3.0), 8.24 (d, 1H, <i>J</i> 7.0), 8.41 (d, 1H, <i>J</i> 7.0), 9.52 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.9 (d, <i>J</i> 5.1), 23.3, 32.2, 48.8, 48.4, 56.0, 66.0, 89.2, 109.2 (d, <i>J</i> 8.4), 113.2, 125.1, 134.9, 142.5, 145.3, 145.5, 145.9, 146.4, 147.0, 147.1, 148.4, 154.9, 155.2, 169.4. HRMS (ESI-TOF): <i>m</i>/<i>z</i> 456.1976 [M + H]<sup>+</sup>; calcd for C<sub>22</sub>H<sub>25</sub>F<sub>3</sub>N<sub>7</sub>OS<sup>+</sup> [M + H]<sup>+</sup> 456.1967. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 11.28 min, purity >96%; method B, <i>t</i><sub>R</sub> 8.93 min, > 99%.</div></div><div id="sec4_9_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> <i>N</i>-Cyclopentyl-5-(5-fluoro-2-((5-(4-(methylsulfonyl)piperazin-1-yl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine (<b>111</b>)</h4><div class="NLM_p last">1-(5-(4-(Methylsulfonyl)piperazin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>75</b>, 596 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one (<b>14</b>, 297 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system II to give <b>111</b> as yellow solid (53 mg, 10%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.5; mp 168â169 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) 1.51â1.57 (m, 4H), 1.66â1.68 (m, 2H), 1.91â1.95 (m, 2H), 2.47 (s, 3H), 2.94 (s, 3H), 3.22 (t, 4H, <i>J</i> 5.0), 3.26 (t, 4H, <i>J</i> 5.0), 3.95â3.97 (m, 1H), 7.46 (dd, 1H, <i>J</i> 9.0 and 2.5), 7.98 (d, 1H, <i>J</i> 9.0), 8.02 (d, 1H, <i>J</i> 2.5), 8.24 (d, 1H, <i>J</i> 7.0), 8.42 (d, 1H, <i>J</i> 3.5), 9.57 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 19.0 (<i>J</i> 4.7), 23.3, 32.2, 33.9, 45.2, 48.6, 56.0, 109.2 (<i>J</i> 8.1), 113.2, 126.3, 141.9, 145.3, 145.5, 146.3, 146.4, 147.1, 147.2, 148.4, 155.0, 155.2, 169.4 (two carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 533.1916 [M + H]<sup>+</sup>; calcd for C<sub>23</sub>H<sub>30</sub>FN<sub>8</sub>O<sub>2</sub>S<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 533.1912. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 10.96 min, purity >99%; method B, <i>t</i><sub>R</sub> 10.25 min, purity >98%.</div></div><div id="sec4_9_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> <i>N</i>-Cyclopentyl-5-(2-((5-(4-(dimethylamino)piperidin-1-yl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-4-methylthiazol-2-amine (<b>112</b>)</h4><div class="NLM_p last">1-(5-(4-(Dimethylamino)piperidin-1-yl)pyridin-2-yl)guanidine trifluoroacetate (<b>74</b>, 524 mg, 2.00 mmol) and (<i>E</i>)-1-(2-(cyclopentylamino)-4-methylthiazol-5-yl)-3-(dimethylamino)-2-fluoroprop-2-en-1-one (<b>14</b>, 297 mg, 1.00 mmol) were coupled according to general procedure 8, and the residue was purified using solvent system III to give <b>112</b> as a yellow solid (134 mg, 27%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.15; mp 172â173 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.49â1.56 (m, 6H), 1.64â1.70 (m, 2H), 1.84 (d, 3H, <i>J</i> 11.5), 1.90â1.96 (m, 2H), 2.20 (s, 7H), 2.46 (s, 3H), 2.65 (t, 2H, <i>J</i> 11.0), 3.63 (d, 1H, <i>J</i> 12.0), 3.92â3.99 (m, 1H), 7.39 (dd, 1H, <i>J</i> 9.0 and 3.0), 7.93 (d, 1H, <i>J</i> 9.0), 7.98 (d, 1H, <i>J</i> 2.5), 8.23 (1H, <i>J</i> 7.0), 8.40 (d, 1H, <i>J</i> 3.0), 9.41 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 19.0 (<i>J</i> 5.4), 23.8, 28.4, 33.3, 41.9, 50.1, 57.6, 62.0, 111.9, 112.0, 112.6, 127.1, 137.1, 143.2, 145.1, 145.3, 146.3, 147.3, 148.1 (<i>J</i> 12.4), 149.3, 155.1 (<i>J</i> 2.5), 170.3 (<i>J</i> 4.9) (three carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 497.2608 [M + H]<sup>+</sup>; calcd for C<sub>25</sub>H<sub>34</sub>FN<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 497.2606. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 9.81 min, purity >95%; method B, <i>t</i><sub>R</sub> 8.75 min, purity >99%.</div></div><div id="sec4_9_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> 1-((6-Bromopyridin-3-yl)methyl)-4-ethylpiperazine (<b>114</b>)</h4><div class="NLM_p last">To a solution of 6-bromo-pyridine-3-carbaldehyde (<b>113</b>, 5.00 g, 26.9 mmol) in DCM (100 mL) 1-ethylpiperazine (3.80 mL, 26.9) was added. Then, sodium triacetoxyborohydride (6.30 g, 29.6 mmol) was added in portions, and the mixture stirred at room temperature for 12 h. The residue was diluted with 5% brine (50 mL), basified with 2 M aqueous NaOH, and extracted with DCM (3 Ã 150 mL). The organic extracts were combined and concentrated under reduced pressure. The residue was purified by FlashMaster Personal<sup>+</sup> chromatography (silica gel, DCM ramping to DCM:MeOH = 96:4) to give <b>114</b> as a brown solid (1.91 g, 25%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 1.00 (t, 3H, <i>J</i> 7.0), 2.34 (q, 2H, <i>J</i> 7.0), 2.41 (br s, 8H), 3.44 (s, 2H), 7.36 (d, 1H, <i>J</i> 8.0), 7.48 (dd, 1H, <i>J</i> 8.0 and 2.5), 8.20 (d, 1H, <i>J</i> 2.5). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 12.1, 52.3, 52.7, 53.1, 59.4, 127.8, 133.3, 139.4, 140.8, 150.7 (two carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 284.0761 [M(<sup>79</sup>Br) + H]<sup>+</sup>; calcd for C<sub>12</sub>H<sub>19</sub>BrN<sub>3</sub><sup>+</sup> [M(<sup>79</sup>Br) + H]<sup>+</sup> 284.0757; <i>m</i>/<i>z</i> 286.0739 [M(<sup>81</sup>Br) + H]<sup>+</sup>; calcd for C<sub>12</sub>H<sub>19</sub>BrN<sub>3</sub><sup>+</sup> [M(<sup>81</sup>Br) + H]<sup>+</sup> 286.0736.</div></div><div id="sec4_9_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> <i>N</i>-Cyclopentyl-5-(2-((5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)amino)pyrimidin-4-yl)-4-methylthiazol-2-amine (<b>115</b>)</h4><div class="NLM_p last">To a solution of 5-(2-aminopyrimidin-4-yl)-<i>N</i>-cyclopentyl-4-methylthiazol-2-amine (<b>21</b>, 275 mg, 1.00 mmol) in 1,4-dioxane (3 mL) were added 1-((6-bromopyridin-3-yl)methyl)-4-ethylpiperazine (<b>114</b>, 341 mg, 1.20 mmol), Pd<sub>2</sub>dba<sub>3</sub> (45.8 mg, 0.05 mmol), xantphos (58.0 mg, 0.100 mmol), and <i>t</i>- BuONa (144 mg, 1.50 mmol) and heated under microwave irradiation at 150 Â°C for 1 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by FlashMaster Personal<sup>+</sup> chromatography (silica gel, DCM ramping to DCM:MeOH:NH4OH = 9:1:0.3) and recrystallized with DCM and MeOH to give <b>115</b> as a white solid (200 mg, 42%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.13; mp 226â228 Â°C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 1.09 (t, 3H, <i>J</i> 7.0), 1.58â1.76 (m, 6H), 2.08â2.14 (m, 2H), 2.43 (q, 2H, <i>J</i> 7.0), 2.55 (br s, 11H), 3.48 (s, 2H), 3.86â3.92 (m, 1H), 5.42 (d, 2H, <i>J</i> 7.0), 6.90 (d, 1H, <i>J</i> 5.5), 7.68 (dd, 1H, <i>J</i> 9.0 and 2.5), 7.89 (s, 1H), 8.19 (d, 1H, <i>J</i> 2.0), 8.35â8.38 (m, 2H). <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) Î´ 1.1 (<i>J</i> 13.2), 12.1, 18.9, 23.9, 33.3, 52.4, 53.1, 57.6, 60.0, 108.3, 112.2, 119.8, 127.1, 139.1, 148.7, 152.2, 152.7, 157.5, 158.8, 159.6, 169.5 (four carbon signals overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 479.2703 [M + H]<sup>+</sup>; calcd for C<sub>25</sub>H<sub>35</sub>N<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 479.2700. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 9.33 min, purity >98%; method B, <i>t</i><sub>R</sub> 7.67 min, purity >99%.</div></div><div id="sec4_9_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> <i>N</i>-Cyclopentyl-5-(2-((5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl)amino)-5-fluoropyrimidin-4-yl)-4-methylthiazol-2-amine (<b>116</b>)</h4><div class="NLM_p last">To a solution of 5-(2-amino-5-fluoropyrimidin-4-yl)-<i>N</i>-cyclopentyl-4-methylthiazol-2-amine (<b>22</b>, 200 mg, 0.680 mmol) in 1,4-dioxane (3 mL) were added 1-((6-bromopyridin-3-yl)methyl)-4-ethylpiperazine (<b>144</b>, 233 mg, 0.820 mmol), Pd<sub>2</sub>dba<sub>3</sub>(31.0 mg, 0.034 mmol), xantphos (41.0 mg, 0.070 mmol), and <i>t</i>- BuONa (98.0 mg, 1.02 mmol) and heated under microwave irradiation at 150 Â°C for 1 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The residue was purified by FlashMaster Personal<sup>+</sup> chromatography (silica gel, DCM ramping to DCM:MeOH = 93:7) to give <b>116</b> as an orange solid (100 mg, 29%). <i>R</i><sub>f</sub> (DCM:MeOH = 9:1) 0.40; mp 175â176 Â°C. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 0.99 (t, 3H, <i>J</i> 7.0), 1.49â1.59 (m, 4H), 1.64â1.72 (m, 2H), 1.90â1.97 (m, 2H), 2.38 (br s, 10H), 2.48 (d, 3H, <i>J</i> 2.5), 3.42 (s, 2H), 3.95â3.98 (m, 1H), 7.64 (dd, 1H, <i>J</i> 8.5 and 2.0), 8.10 (d, 1H, <i>J</i> 8.5), 8.16 (d, 1H, <i>J</i> 2.0), 8.27 (d, 1H, <i>J</i> 7.0), 8.46 (d, 1H, <i>J</i> 3.5), 9.77 (s, 1H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 18.9 (<i>J</i> 5.1), 23.3, 32.2, 51.4, 52.1, 56.0, 58.7, 78.7, 79.0, 79.2, 109.2 (<i>J</i> 8.2), 111.8, 123.6, 138.3, 145.3, 145.5, 146.6, 147.1, 147.2, 148.1, 148.6, 152.2, 154.9, 155.1 (one carbon signal overlapping or obscured). HRMS (ESI-TOF): <i>m</i>/<i>z</i> 497.2601 [M + H]<sup>+</sup>; calcd for C<sub>25</sub>H<sub>34</sub>FN<sub>8</sub>S<sup>+</sup> [M + H]<sup>+</sup> 497.2606. Anal. RP-HPLC: method A, <i>t</i><sub>R</sub> 9.89 min, purity >96%; method B, <i>t</i><sub>R</sub> 8.66 min, purity >98%.</div></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i131" class="anchor-spacer"></div><h3 class="article-section__title" id="_i131"> Kinase Assay</h3><div class="NLM_p last">Half-maximal inhibition (<a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>â<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>) and kinome-wide selectivity of <b>83</b> were measured by Kinase HotSpot radioisotope based assay platform using <sup>33</sup>P (Reaction Biology Corporation, PA, USA). The assay protocols are available at <a href="http://www.reactionbiology.com/webapps/site/KinaseProfiling.aspx" class="extLink">http://www.reactionbiology.com/webapps/site/KinaseProfiling.aspx</a>. <i>K</i><sub>i</sub> values were calculated from half-maximal inhibition (IC<sub>50</sub>) values using the ChengâPrusoff equation:<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a><i>K</i><sub>i</sub> = IC<sub>50</sub>/[1 + ([ATP]/<i>K</i><sub>m</sub> (app) ATP)], where [ATP] is the ATP concentration used for the IC<sub>50</sub> determination and <i>K</i><sub>m</sub> (app) (ATP) for each kinase is determined experimentally. Percentages of residual kinase activity upon treatment with <b>78</b>, <b>83</b>, <b>107</b>, or <b>112</b> were measured using the Millipore KinaseProfiler services (Millipore UK Ltd., Dundee, UK) according to the detailed procedures described at <a href="http://www.millipore.com/drugdiscovery/dd3/" class="extLink">http://www.millipore.com/drugdiscovery/dd3/</a>, where ATP concentration for each kinase assay was set within 15 Î¼M of the apparent <i>K</i><sub>m</sub> for ATP where determined.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i132" class="anchor-spacer"></div><h3 class="article-section__title" id="_i132"> Cell Culture</h3><div class="NLM_p last">All cell lines were obtained from the cell bank at the Centre for Drug Discovery and Development, University of South Australia. The cell lines were maintained following ATCC recommendation either in RPMI-1640 (Roswell Park Memorial Institute), DMEM (Dulbeccoâs Modified Eagleâs Medium), or MEM (Minimum Essential Media) with 10% fetal bovine serum. All cell lines were cultured at 37 Â°C in a humidified incubator in the presence of 5% CO<sub>2</sub>. All cells were mycoplasma tested.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i133" class="anchor-spacer"></div><h3 class="article-section__title" id="_i133"> Cell Viability Assays</h3><div class="NLM_p last">MTT (Life Technologies, Mulgrave, VIC, Australia) and resazurine (Sigma-Aldrich, Castle Hill, NSW, Australia) assays were performed on solid tumor cell lines and leukemia cell lines, respectively, as previously reported.<a onclick="showRef(event, 'ref16 ref43'); return false;" href="javascript:void(0);" class="ref ref16 ref43">(16, 43)</a> Compound concentrations required to inhibit 50% of cell growth (GI<sub>50</sub>) were calculated using nonlinear regression analysis.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i134" class="anchor-spacer"></div><h3 class="article-section__title" id="_i134"> Western Blot Assay</h3><div class="NLM_p last">Western blotting was performed as described previously.<a onclick="showRef(event, 'ref16 ref18 ref43'); return false;" href="javascript:void(0);" class="ref ref16 ref18 ref43">(16, 18, 43)</a> The following antibodies obtained from Cell Signaling Technology (Danvers, MA, USA) were used for protein detection: total Rb, phosphorylated Rb Ser780, and Î²-actin. Both antimouse and antirabbit immunoglobulin G (IgG) horseradish peroxidase (HRP)-conjugated antibodies were obtained from Dako, Kingsgrove, NSW, Australia.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i135" class="anchor-spacer"></div><h3 class="article-section__title" id="_i135"> Cell Cycle Analysis</h3><div class="NLM_p last">Cell cycle analysis was performed as described previously.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Cells were seeded at 8 Ã 10<sup>4</sup> cells per well using 6-well plate and incubated overnight at 37 Â°C, 5% CO<sub>2</sub>. After treatment with each compound, the cells were incubated for 24 h. Cells were transferred to FACS tubes and centrifuged at 300<i>g</i> for 5 min. Cell pellets were collected and resuspended in 1 mL of PBS and centrifuged at 300<i>g</i> for 5 min. The supernatant PBS was removed, and cell pellets were fixed by adding 500 Î¼L ice-cold 70% EtOH dropwise on ice for 15 min and collected again after being centrifuged at 300<i>g</i> for 5 min. The supernatant ethanol was removed, and collected pellets were incubated with propidium iodide cell cycle solution in PBS (50 Î¼g/mL propidium iodide, 0.1 mg/mL RNase A, 0.05% Triton X-100) at room temperature for 1.5 h and analyzed with a Gallios flow cytometer (Beckman Coulter, Brea, CA, USA). Data were analyzed using Kaluza v1.2 (Beckman Coulter, Brea, CA, USA).</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i136" class="anchor-spacer"></div><h3 class="article-section__title" id="_i136"> Detection of Apoptosis</h3><div class="NLM_p last">Apoptosis study was performed as described previously.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Cells were seeded at 8 Ã 10<sup>4</sup> cells per well using a 6-well plate and incubated overnight at 37 Â°C, 5% CO<sub>2</sub>. After treatment with each compound, the cells were incubated for 24 h. Cells were transferred to FACS tubes and centrifuged at 300<i>g</i> for 5 min. Cell pellets were collected and resuspended in 1 mL of warm PBS and centrifuged at 300<i>g</i> for 5 min. The supernatant PBS was removed and cell pellets were diluted to 1 Ã 10<sup>5</sup> cells/mL with warm PBS and centrifuged at 300<i>g</i> for 5 min. The supernatant PBS was removed, and cell pellets were resuspended with 1 mL of ice-cold PBS and centrifuged at 300<i>g</i> for 5 min. The supernatant PBS was removed, and cell pellets were resuspended with 100 Î¼L of 1Ã binding buffer. Then 3 Î¼L of Annexin V and 3 Î¼L of propidium iodide were added to each sample with slight vortexing and cells were incubated in the dark for 15 min. After incubation 200 Î¼L of 1Ã binding buffer was added to each sample and analyzed by the Gallios flow cytometer (Beckman Coulter, Brea, CA, USA). Data were analyzed using Kaluza v1.2 (Beckman Coulter, Brea, CA, USA).</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i137" class="anchor-spacer"></div><h3 class="article-section__title" id="_i137"> Biopharmaceutical Profiling</h3><div class="NLM_p last">The assays were performed at Cyprotex Ltd. (Macclesfield, UK). hERG inhibition was assessed using automated patch clamp electrophysiology measurement in CHO-hERG cells.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> CYP450 inhibition assay was measured by incubating the compounds with human liver microsomes and NADPH in the presence of CYP450-isoform specific probe substrate.<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46, 47)</a> Test compound partitioning between octanol and aqueous buffer was carried out using the shake-flask method.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Compound p<i>K</i><sub>a</sub> values were determined using a pH-metric titration method (GLpKa; Sirius).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Apparent permeability coefficients were measured using a Caco-2 cell layer assay.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i138" class="anchor-spacer"></div><h3 class="article-section__title" id="_i138"> PK Determination</h3><div class="NLM_p last">For pharmacokinetic measurements, healthy male adult BALB/c mice (weighing 20â25 g) or male albino Wistar rats (weighing 250â350 g) were split into weight matched groups of three per group. Compound <b>83</b> was administered IV (2 mg/kg for mice, 5 mg/kg for rats in a formulation of PEG400/NMP, 9/1, v/v) via the tail vein or by oral gavage (10 mg/kg for mice, 20 mg/kg for rats, compound suspended in 1% carboxy methyl cellulose (CMC), w/v). Blood samples were collected from animals by jugular vein cannula (rats) or under anesthesia by cardiac puncture (mice) at time zero and at intervals up to 24 h. Harvested blood was centrifuged at 7000<i>g</i> for 3 min, and the plasma aspirated and frozen at â20 Â°C until analysis. Quantitative analysis of the compound in plasma was carried out using a validated LC-MS/MS method with a triple TOF-MS 5600 (AB SCIEX). Noncompartmental pharmacokinetics analysis was performed with Phoenix WinNonlin (Pharsight, St. Louis, US) for each concentrationâtime profile. Animal experiments were performed under the approval of the SA Pathology Animal Ethics Committee (Animal Ethics no. 91C-12).</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i139" class="anchor-spacer"></div><h3 class="article-section__title" id="_i139"> Maximum Tolerated Dose Determination</h3><div class="NLM_p last">To determine the in vivo maximum tolerated dose (MTD), <b>83</b> (in 1% CMC) was administered PO to BALB/c mice (<i>n</i> = 3) at a dose of 20 mg/kg once every day for 7 days. To minimize exposure of the animals to any unexpected acute toxicity, the test compound was first administered to a mouse in the group, which was then monitored closely for clinical signs of toxicity for 1 h; when no such signs were observed, the test compound was administered to the remaining two mice in the group. The mice in the test group were then monitored for signs of toxicity at 1, 8, and 24 h after administration. The weights and clinical signs of toxicity of the mice were monitored until the 14th day after administration. Because no significant signs of toxicities were observed in the group treated with 20 mg/kg, the MTD study was repeated at 40 mg/kg resulting in the same finding. Thus, we increased the dose to 100 mg/kg. Similar to the 20 and 40 mg/kg study, no significant changes in weight and signs of clinical toxicities were observed at 100 mg/kg, indicating the MTD was apparently not reached in this study. Accordingly, 100 mg/kg was selected for in vivo efficacy study. All the animal experiments were performed according to the institutional ethical guidelines on animal care and under the approval by the SA Pathology Animal Ethics Committee (Animal Ethics no. U03-14).</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i140" class="anchor-spacer"></div><h3 class="article-section__title" id="_i140"> MV4-11 Xenograft</h3><div class="NLM_p last">Female nude (nu/nu) BALB/c mice (6â8 weeks) were used for the in vivo anticancer activity. All the animal experiments were performed according to the institutional ethical guidelines on animal care and under the approval by the SA Pathology Animal Ethics Committee (Animal Ethics no. U03-14). MV4-11 leukemia xenograft model was established by inoculating 5 Ã 10<sup>6</sup> MV4-11 cells subcutaneously on their hind flanks. The cells were suspended in a 1:1 mixture of RPMI-160 and Matrigel (BD Biosciences, NSW, Australia).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Tumors were allowed to develop, and once the tumor size reached 100â200 mm<sup>3</sup>, mice were allocated into a control or treatment group of nine. An independent-samples <i>t</i> test was conducted to compare baseline tumor volumes of control and treatment groups, and there was no significant difference in the scores for controls (mean tumor volume = 142.04 Â± 28.46) and treatment groups (mean tumor volume = 142.77 Â± 24.22) and <i>p</i> = 0.911, before treatment started. Compound <b>83</b> and vehicle control (1% CMC) were administered by oral gavage daily for 33 consecutive days. Mice were observed for any clinical signs of toxicity and weight loss every day, whereas tumor volume measurements were taken every other day prior to dosing. Tumor volume was measured in cubic millimeters (length Ã width Ã height). Animals were euthanized if the tumor volume exceeded 2000 mm<sup>3</sup> or if weight loss exceeded 15% of their pretreatment mass. Four of the nine mice from the <b>83</b>-treated group survived after the whole study period (83 days) and were humanely killed to terminate the study as the tumor failed to reappear after 50 days of follow-up. Data was analyzed using GraphPad Prism version 6.03 for Windows (GraphPad Software, La Jolla, California, USA). Tumor volume and body weight loss analysis was performed with 2-tailed <i>t</i> test. Survival analysis was performed with GehanâBreslowâWilcoxon test. The results were considered significant when <i>p</i> â¤ 0.05. Tumor growth inhibition (TGI) was calculated using the following formula: %TGI = [((cTVd â cTVi) â (tTVd â tTVi))/(cTVt â cTVi)] Ã 100, where cTVd is tumor volume in control group on day 33 of treatment, cTVi is tumor volume in the control group at baseline, tTVd is tumor volume in the treatment group on day 33, and tTVi is tumor volume in the treatment group at baseline.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i141" class="anchor-spacer"></div><h3 class="article-section__title" id="_i141"> Statistical Analysis</h3><div class="NLM_p last">All experiments were performed in triplicate and repeated at least twice; representative data were selected for generating figures. The statistical difference between treatments and controls was analyzed using Studentâs <i>t</i> test. <i>p</i> â¤ 0.05 was considered statistically significant.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i142"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01670">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12128" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12128" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01670" class="ext-link">10.1021/acs.jmedchem.6b01670</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Percentages of residual kinase activities of <b>78</b>, <b>83</b>, <b>107</b>, and <b>112</b>, kinome-wide selectivity of <b>83</b>, plasma concentrationâtime curves of <b>83</b> in mice and in rats, NMR spectra and HPLC analysis results for <b>83</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01670/suppl_file/jm6b01670_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01670/suppl_file/jm6b01670_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01670/suppl_file/jm6b01670_si_001.pdf">jm6b01670_si_001.pdf (1.04 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01670/suppl_file/jm6b01670_si_002.csv">jm6b01670_si_002.csv (4.72 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01670" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83600" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83600" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shudong Wang</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery and Development, Sansom Institute for Health Research,
School of Pharmacy and Medical Sciences, and Center for Cancer Biology, University of South Australia, Adelaide, South Australia 5001, Australia</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6225-5525" title="Orcid link">http://orcid.org/0000-0001-6225-5525</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#57243f223338393079203639301722393e243679323322793622"><span class="__cf_email__" data-cfemail="3f4c574a5b50515811485e51587f4a51564c5e115a5b4a115e4a">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Solomon Tadesse</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery and Development, Sansom Institute for Health Research,
School of Pharmacy and Medical Sciences, and Center for Cancer Biology, University of South Australia, Adelaide, South Australia 5001, Australia</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9966-2236" title="Orcid link">http://orcid.org/0000-0002-9966-2236</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingfeng Yu</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery and Development, Sansom Institute for Health Research,
School of Pharmacy and Medical Sciences, and Center for Cancer Biology, University of South Australia, Adelaide, South Australia 5001, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laychiluh B. Mekonnen</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery and Development, Sansom Institute for Health Research,
School of Pharmacy and Medical Sciences, and Center for Cancer Biology, University of South Australia, Adelaide, South Australia 5001, Australia</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-7108-5345" title="Orcid link">http://orcid.org/0000-0001-7108-5345</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Frankie Lam</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery and Development, Sansom Institute for Health Research,
School of Pharmacy and Medical Sciences, and Center for Cancer Biology, University of South Australia, Adelaide, South Australia 5001, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Saiful Islam</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery and Development, Sansom Institute for Health Research,
School of Pharmacy and Medical Sciences, and Center for Cancer Biology, University of South Australia, Adelaide, South Australia 5001, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Khamis Tomusange</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery and Development, Sansom Institute for Health Research,
School of Pharmacy and Medical Sciences, and Center for Cancer Biology, University of South Australia, Adelaide, South Australia 5001, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Muhammed H. Rahaman</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery and Development, Sansom Institute for Health Research,
School of Pharmacy and Medical Sciences, and Center for Cancer Biology, University of South Australia, Adelaide, South Australia 5001, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Benjamin Noll</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery and Development, Sansom Institute for Health Research,
School of Pharmacy and Medical Sciences, and Center for Cancer Biology, University of South Australia, Adelaide, South Australia 5001, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sunita K. C. Basnet</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery and Development, Sansom Institute for Health Research,
School of Pharmacy and Medical Sciences, and Center for Cancer Biology, University of South Australia, Adelaide, South Australia 5001, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Theodosia Teo</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery and Development, Sansom Institute for Health Research,
School of Pharmacy and Medical Sciences, and Center for Cancer Biology, University of South Australia, Adelaide, South Australia 5001, Australia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hugo Albrecht</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery and Development, Sansom Institute for Health Research,
School of Pharmacy and Medical Sciences, and Center for Cancer Biology, University of South Australia, Adelaide, South Australia 5001, Australia</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3951-1866" title="Orcid link">http://orcid.org/0000-0002-3951-1866</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert Milne</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery and Development, Sansom Institute for Health Research,
School of Pharmacy and Medical Sciences, and Center for Cancer Biology, University of South Australia, Adelaide, South Australia 5001, Australia</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Conception and overall study design and supervision: S.W. Chemistry experiments and data analysis: S.T. and M.Y. Biological experiments: L.B., F.L., S.I., K.T., S.K.B., T.T., and H.A. In vivo experiments: L.B., M.H.R., B.N., and R.M. Writing, review and/or revision of the manuscript: S.T., M.Y., S.W., L.B., M.H.R., B.N., S.I., and K.T.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d47e12667-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i144">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56847" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56847" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was partially supported by The Financial Markets Foundation for Children (grant no. 2015-137) to S.W. S.T. acknowledges the support from the Australian Government Research Training Program Scholarship.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i145" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i145"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i146" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i146"> Abbreviations Used</h2><tr><td class="NLM_term">AGC</td><td class="NLM_def"><p class="first last">protein kinase A, protein kinase G, and protein kinase C containing families</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">CAMK</td><td class="NLM_def"><p class="first last">calcium/calmodulin-dependent protein kinase</p></td></tr><tr><td class="NLM_term">CK1</td><td class="NLM_def"><p class="first last">casein kinase 1</p></td></tr><tr><td class="NLM_term">CMC</td><td class="NLM_def"><p class="first last">sodium carboxymethyl cellulose</p></td></tr><tr><td class="NLM_term">CMGC</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase, mitogen-activated protein kinase, glycogen synthase kinase 3, and dual specificity protein kinase containing families</p></td></tr><tr><td class="NLM_term">E2F</td><td class="NLM_def"><p class="first last">E2 promoter binding factor</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">Rb</td><td class="NLM_def"><p class="first last">retinoblastoma protein</p></td></tr><tr><td class="NLM_term">SelectFluor</td><td class="NLM_def"><p class="first last">1-chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octanebis(tetrafluoroborate)</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide, STE, homologues of yeast sterile 7, sterile 11, sterile 20 kinases</p></td></tr><tr><td class="NLM_term">T/C</td><td class="NLM_def"><p class="first last">relative tumor growth inhibition of the treated group versus the control group</p></td></tr><tr><td class="NLM_term">TK</td><td class="NLM_def"><p class="first last">tyrosine kinase</p></td></tr><tr><td class="NLM_term">TKL</td><td class="NLM_def"><p class="first last">tyrosine kinase-like</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i147">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68610" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68610" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 51 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Pardee, A. B. A.</span><span> </span><span class="NLM_article-title">Restriction point for control of normal animal cell proliferation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1974</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">1286</span><span class="NLM_x">â</span> <span class="NLM_lpage">1290</span><span class="refDoi">Â DOI: 10.1073/pnas.71.4.1286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1073%2Fpnas.71.4.1286" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1974&pages=1286-1290&author=A.+B.+A.+Pardee&title=Restriction+point+for+control+of+normal+animal+cell+proliferation&doi=10.1073%2Fpnas.71.4.1286"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1073%2Fpnas.71.4.1286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.71.4.1286%26sid%3Dliteratum%253Aachs%26aulast%3DPardee%26aufirst%3DA.%2BB.%2BA.%26atitle%3DRestriction%2520point%2520for%2520control%2520of%2520normal%2520animal%2520cell%2520proliferation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1974%26volume%3D71%26spage%3D1286%26epage%3D1290%26doi%3D10.1073%2Fpnas.71.4.1286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Sisken, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morasca, L.</span><span> </span><span class="NLM_article-title">Intrapopulation kinetics of the mitotic cycle</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1965</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">â</span> <span class="NLM_lpage">189</span><span class="refDoi">Â DOI: 10.1083/jcb.25.2.179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1083%2Fjcb.25.2.179" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1965&pages=179-189&author=J.+E.+Siskenauthor=L.+Morasca&title=Intrapopulation+kinetics+of+the+mitotic+cycle&doi=10.1083%2Fjcb.25.2.179"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1083%2Fjcb.25.2.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.25.2.179%26sid%3Dliteratum%253Aachs%26aulast%3DSisken%26aufirst%3DJ.%2BE.%26aulast%3DMorasca%26aufirst%3DL.%26atitle%3DIntrapopulation%2520kinetics%2520of%2520the%2520mitotic%2520cycle%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1965%26volume%3D25%26spage%3D179%26epage%3D189%26doi%3D10.1083%2Fjcb.25.2.179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Bartek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartkova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, J.</span><span> </span><span class="NLM_article-title">The retinoblastoma protein pathway in cell cycle control and cancer</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">237</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">6</span><span class="refDoi">Â DOI: 10.1006/excr.1997.3776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1006%2Fexcr.1997.3776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=9417859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADyaK2sXnvFWmur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=1997&pages=1-6&author=J.+Bartekauthor=J.+Bartkovaauthor=J.+Lukas&title=The+retinoblastoma+protein+pathway+in+cell+cycle+control+and+cancer&doi=10.1006%2Fexcr.1997.3776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The retinoblastoma protein pathway in cell cycle control and cancer</span></div><div class="casAuthors">Bartek, Jiri; Bartkova, Jirina; Lukas, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">237</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review, with 51 refs.  Recent discoveries in diverse fields of biomedical research have merged to reveal the mol. basis of cell cycle control and a crit. role of subverting this homeostatic mechanism in cancer development.  At the heart of these processes lies a late G1 checkpoint governed by the "RB pathway" whose mol. compn., functions, and cancer-assocd. defects are briefly evaluated in this review.  This exciting new knowledge raises a plethora of conceptual issues in cell biol., with potential practical implications for biotechnol. and medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe8MqG3R3qQLVg90H21EOLACvtfcHk0ljZmr19lTJ7ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnvFWmur4%253D&md5=33d6b7002b41757ade047792873efbf6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1006%2Fexcr.1997.3776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexcr.1997.3776%26sid%3Dliteratum%253Aachs%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DBartkova%26aufirst%3DJ.%26aulast%3DLukas%26aufirst%3DJ.%26atitle%3DThe%2520retinoblastoma%2520protein%2520pathway%2520in%2520cell%2520cycle%2520control%2520and%2520cancer%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D1997%26volume%3D237%26spage%3D1%26epage%3D6%26doi%3D10.1006%2Fexcr.1997.3776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">â</span> <span class="NLM_lpage">231</span><span class="refDoi">Â DOI: 10.1038/35106065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1038%2F35106065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=11902577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=222-231&author=M.+Malumbresauthor=M.+Barbacid&title=Milestones+in+cell+division%3A+to+cycle+or+not+to+cycle%3A+a+critical+decision+in+cancer&doi=10.1038%2F35106065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor cells undergo uncontrolled proliferation, yet tumors most often originate from adult tissues, in which most cells are quiescent.  So, the proliferative advantage of tumor cells arises from their ability to bypass quiescence.  This can be due to increased mitogenic signaling and/or alterations that lower the threshold required for cell-cycle commitment.  Understanding the mol. mechanisms that underlie this commitment should provide important insights into how normal cells become tumorigenic and how new anticancer strategies can be devised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI2EOLFB2ULbVg90H21EOLACvtfcHk0ljZmr19lTJ7ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D&md5=2bd8961854332a30c814f8ac2f9bd6f4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2F35106065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35106065%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DMilestones%2520in%2520cell%2520division%253A%2520to%2520cycle%2520or%2520not%2520to%2520cycle%253A%2520a%2520critical%2520decision%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D222%26epage%3D231%26doi%3D10.1038%2F35106065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Ortega, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cyclin D-dependent kinases, INK4 inhibitors and cancer</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1602</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">â</span> <span class="NLM_lpage">87</span><span class="refDoi">Â DOI: 10.1016/S0304-419X(02)00037-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2FS0304-419X%2802%2900037-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=11960696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD38XktVKgu7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1602&publication_year=2002&pages=73-87&author=S.+Ortegaauthor=M.+Malumbresauthor=M.+Barbacid&title=Cyclin+D-dependent+kinases%2C+INK4+inhibitors+and+cancer&doi=10.1016%2FS0304-419X%2802%2900037-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin D-dependent kinases, INK4 inhibitors and cancer</span></div><div class="casAuthors">Ortega, Sagrario; Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1602</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-87</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The Cyclin D-Cdk4,6/INK4/Rb/E2F pathway plays a key role in controlling cell growth by integrating multiple mitogenic and antimitogenic stimuli.  The components of this pathway are gene families with a high level of structural and functional redundancy and are expressed in an overlapping fashion in most tissues and cell types.  Using classical transgenic technol. as well as gene-targeting in ES cells, a series of mouse models have been developed to study the in vivo function of individual components of this pathway in both normal homeostasis and tumor development.  These models have proven to be useful to define specific as well as redundant roles among members of these cell cycle regulatory gene families.  This pathway is deregulated in the vast majority of human tumors by genetic and epigenetic alterations that target at least some of its key members such as Cyclin D1, Cdk4, INK4a and INK4b, pRb etc.  As a consequence, some of these mols. are currently being considered as targets for cancer therapy, and several novel mols., such as Cdk inhibitors, are under development as potential anti-cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpizIeKkGlMJLVg90H21EOLACvtfcHk0ljZmr19lTJ7ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktVKgu7o%253D&md5=8f5ab2839d58abcb3a7df53269af2913</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0304-419X%2802%2900037-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-419X%252802%252900037-9%26sid%3Dliteratum%253Aachs%26aulast%3DOrtega%26aufirst%3DS.%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCyclin%2520D-dependent%2520kinases%252C%2520INK4%2520inhibitors%2520and%2520cancer%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2002%26volume%3D1602%26spage%3D73%26epage%3D87%26doi%3D10.1016%2FS0304-419X%2802%2900037-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortega, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors</span> <span class="citation_source-journal">Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x">, </span> <span class="NLM_fpage">827</span><span class="NLM_x">â</span> <span class="NLM_lpage">838</span><span class="refDoi">Â DOI: 10.1515/BC.2000.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1515%2FBC.2000.105" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2000&pages=827-838&author=M.+Malumbresauthor=S.+Ortegaauthor=M.+Barbacid&title=Genetic+analysis+of+mammalian+cyclin-dependent+kinases+and+their+inhibitors&doi=10.1515%2FBC.2000.105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1515%2FBC.2000.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FBC.2000.105%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DOrtega%26aufirst%3DS.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DGenetic%2520analysis%2520of%2520mammalian%2520cyclin-dependent%2520kinases%2520and%2520their%2520inhibitors%26jtitle%3DBiol.%2520Chem.%26date%3D2000%26volume%3D381%26spage%3D827%26epage%3D838%26doi%3D10.1515%2FBC.2000.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albassam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryer, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toogood, P. L.</span><span> </span><span class="NLM_article-title">Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1427</span><span class="NLM_x">â</span> <span class="NLM_lpage">1438</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=15542782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslCkt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=1427-1438&author=D.+W.+Fryauthor=P.+J.+Harveyauthor=P.+R.+Kellerauthor=W.+L.+Elliottauthor=M.+Meadeauthor=E.+Trachetauthor=M.+Albassamauthor=X.+Zhengauthor=W.+R.+Leopoldauthor=N.+K.+Pryerauthor=P.+L.+Toogood&title=Specific+inhibition+of+cyclin-dependent+kinase+4%2F6+by+PD+0332991+and+associated+antitumor+activity+in+human+tumor+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts</span></div><div class="casAuthors">Fry, David W.; Harvey, Patricia J.; Keller, Paul R.; Elliott, William L.; Meade, MaryAnne; Trachet, Erin; Albassam, Mudher; Zheng, XianXian; Leopold, Wilbur R.; Pryer, Nancy K.; Toogood, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1427-1438</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PD 0332991 is a highly specific inhibitor of cyclin-dependent kinase 4 (Cdk4) (IC50, 0.011 Î¼mol/L) and Cdk6 (IC50, 0.016 Î¼mol/L), having no activity against a panel of 36 addnl. protein kinases.  It is a potent antiproliferative agent against retinoblastoma (Rb)-pos. tumor cells in vitro, inducing an exclusive G1 arrest, with a concomitant redn. of phospho-Ser780/Ser795 on the Rb protein.  Oral administration of PD 0332991 to mice bearing the Colo-205 human colon carcinoma produces marked tumor regression.  Therapeutic doses of PD 0332991 cause elimination of phospho-Rb and the proliferative marker Ki-67 in tumor tissue and down-regulation of genes under the transcriptional control of E2F.  The results indicate that inhibition of Cdk4/6 alone is sufficient to cause tumor regression and a net redn. in tumor burden in some tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9TOgbe4wrBLVg90H21EOLACvtfcHk0liCHVL9Gr_l4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslCkt7c%253D&md5=70931ebc6abd1c59bf1cc29748b7945f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DMeade%26aufirst%3DM.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DAlbassam%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DPryer%26aufirst%3DN.%2BK.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26atitle%3DSpecific%2520inhibition%2520of%2520cyclin-dependent%2520kinase%25204%252F6%2520by%2520PD%25200332991%2520and%2520associated%2520antitumor%2520activity%2520in%2520human%2520tumor%2520xenografts%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2004%26volume%3D3%26spage%3D1427%26epage%3D1438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">â</span> <span class="NLM_lpage">166</span><span class="refDoi">Â DOI: 10.1038/nrc2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm&doi=10.1038%2Fnrc2602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0liCHVL9Gr_l4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166%26doi%3D10.1038%2Fnrc2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Nevins, J. R.</span><span> </span><span class="NLM_article-title">The Rb/E2F pathway and cancer</span> <span class="citation_source-journal">Hum. Mol. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">â</span> <span class="NLM_lpage">703</span><span class="refDoi">Â DOI: 10.1093/hmg/10.7.699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1093%2Fhmg%2F10.7.699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=11257102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjt1ajsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2001&pages=699-703&author=J.+R.+Nevins&title=The+Rb%2FE2F+pathway+and+cancer&doi=10.1093%2Fhmg%2F10.7.699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The Rb/E2F pathway and cancer</span></div><div class="casAuthors">Nevins, Joseph R.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7, Rev. Issue</span>),
    <span class="NLM_cas:pages">699-703</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Over the past decade, studies focusing on the mechanisms controlling cellular proliferation have converged with equally intensive efforts directed at the anal. of oncogenic pathways assocd. with human cancer.  These convergent studies have revealed the central role played by the pathway that controls the activity of the retinoblastoma tumor suppressor protein (Rb), which in turn regulates the E2F transcription factor.  In particular, it is now clear that the Rb/E2F pathway is crit. in regulating the initiation of DNA replication.  It is also clear that the control of the pathway is disrupted in virtually all human cancers.  Questions remain, however, as to the specific role played by individual activities within the pathway in the control of cell growth and their participation in the development of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0WsC_lYCINLVg90H21EOLACvtfcHk0liCHVL9Gr_l4g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjt1ajsb4%253D&md5=debc3fe6c76f56f488c6a8dada95666e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2F10.7.699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252F10.7.699%26sid%3Dliteratum%253Aachs%26aulast%3DNevins%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520Rb%252FE2F%2520pathway%2520and%2520cancer%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2001%26volume%3D10%26spage%3D699%26epage%3D703%26doi%3D10.1093%2Fhmg%2F10.7.699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Tadesse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumarasiri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Targeting CDK6 in cancer: state of the art and new insights</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3220</span><span class="NLM_x">â</span> <span class="NLM_lpage">3230</span><span class="refDoi">Â DOI: 10.1080/15384101.2015.1084445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1080%2F15384101.2015.1084445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=26315616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVKrsbrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=3220-3230&author=S.+Tadesseauthor=M.+Yuauthor=M.+Kumarasiriauthor=B.+T.+Leauthor=S.+Wang&title=Targeting+CDK6+in+cancer%3A+state+of+the+art+and+new+insights&doi=10.1080%2F15384101.2015.1084445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK6 in cancer: State of the art and new insights</span></div><div class="casAuthors">Tadesse, Solomon; Yu, Mingfeng; Kumarasiri, Malika; Le, Bich Thuy; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3220-3230</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 6 (CDK6) plays a vital role in regulating the progression of the cell cycle.  More recently, CDK6 has also been shown to have a transcriptional role in tumor angiogenesis.  Up-regulated CDK6 activity is assocd. with the development of several types of cancers.  While CDK6 is over-expressed in cancer cells, it has a low detectable level in non-cancerous cells and CDK6-null mice develop normally, suggesting a specific oncogenic role of CDK6, and that its inhibition may represent an ideal mechanism-based and low toxic therapeutic strategy in cancer treatment.  Identification of selective small mol. inhibitors of CDK6 is thus needed for drug development.  Herein, we review the latest understandings of the biol. regulation and oncogenic roles of CDK6.  The potential clin. relevance of CDK6 inhibition, the progress in the development of small-mol. CDK6 inhibitors and the rational design of potential selective CDK6 inhibitors are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV1uu9UWb3XrVg90H21EOLACvtfcHk0liIWN7gPAWJaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVKrsbrN&md5=eefeeab43ed50693886447c122e5002d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1080%2F15384101.2015.1084445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2015.1084445%26sid%3Dliteratum%253Aachs%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DB.%2BT.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTargeting%2520CDK6%2520in%2520cancer%253A%2520state%2520of%2520the%2520art%2520and%2520new%2520insights%26jtitle%3DCell%2520Cycle%26date%3D2015%26volume%3D14%26spage%3D3220%26epage%3D3230%26doi%3D10.1080%2F15384101.2015.1084445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">DiPippo, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, C. M.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibitors for the treatment of breast cancer: past, present, and future</span> <span class="citation_source-journal">Pharmacotherapy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">652</span><span class="NLM_x">â</span> <span class="NLM_lpage">667</span><span class="refDoi">Â DOI: 10.1002/phar.1756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1002%2Fphar.1756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=27087139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A280%3ADC%252BC28bgslCksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=652-667&author=A.+J.+DiPippoauthor=N.+K.+Patelauthor=C.+M.+Barnett&title=Cyclin-dependent+kinase+inhibitors+for+the+treatment+of+breast+cancer%3A+past%2C+present%2C+and+future&doi=10.1002%2Fphar.1756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future</span></div><div class="casAuthors">DiPippo Adam J; Patel Neelam K; Barnett Chad M</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">652-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of metastatic breast cancer (MBC) that is resistant to endocrine therapy presents a significant clinical challenge.  The well-known role of cell cycle dysregulation in these patients is partly mediated by cyclin-dependent kinase (CDK) activity.  Specific cyclin and CDK complexes regulate cell cycle progression by managing the transition through the cell cycle, and inhibition of CDKs represents an important target for novel agents.  First-generation CDK inhibitors (e.g., flavopiridol) were relatively nonselective and had an unacceptable toxicity profile in early trials.  Second-generation CDK inhibitors were designed to target the CDK4 and CDK6 (CDK4/6) pathway and have shown promising clinical activity with an acceptable toxicity profile in patients with MBC.  Palbociclib is a first-in-class CDK4/6 inhibitor that was granted accelerated U.S.  Food and Drug Administration approval in combination with letrozole for the treatment of MBC in the first-line setting (February 2015) as well as in combination with fulvestrant for MBC that had progressed on previous endocrine therapy (February 2016).  Other CDK4/6 inhibitors, including ribociclib and abemaciclib, are under investigation as monotherapy and in combination with endocrine or anti-human epidermal growth receptor 2 therapy for the treatment of MBC.  Ongoing clinical trials should provide additional information to guide the appropriate use of these agents and identify patient populations that could derive the most benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSYivEamzCCty86Js-BCLiifW6udTcc2ealtw47j2n2zbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bgslCksA%253D%253D&md5=cc590c6fb21bbdc1e5384e4020a4123f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fphar.1756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.1756%26sid%3Dliteratum%253Aachs%26aulast%3DDiPippo%26aufirst%3DA.%2BJ.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DBarnett%26aufirst%3DC.%2BM.%26atitle%3DCyclin-dependent%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DPharmacotherapy%26date%3D2016%26volume%3D36%26spage%3D652%26epage%3D667%26doi%3D10.1002%2Fphar.1756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Uras, I. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheicher, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellutti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prchal-Murphy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tigan, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidel, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubicek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexl, V.</span><span> </span><span class="NLM_article-title">Palbociclib treatment of FLT3-ITD<sup>+</sup> AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">2890</span><span class="NLM_x">â</span> <span class="NLM_lpage">2902</span><span class="refDoi">Â DOI: 10.1182/blood-2015-11-683581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1182%2Fblood-2015-11-683581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=27099147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ars7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=2890-2902&author=I.+Z.+Urasauthor=G.+J.+Walterauthor=R.+Scheicherauthor=F.+Belluttiauthor=M.+Prchal-Murphyauthor=A.+S.+Tiganauthor=P.+Valentauthor=F.+H.+Heidelauthor=S.+Kubicekauthor=C.+Schollauthor=S.+Frohlingauthor=V.+Sexl&title=Palbociclib+treatment+of+FLT3-ITD%2B+AML+cells+uncovers+a+kinase-dependent+transcriptional+regulation+of+FLT3+and+PIM1+by+CDK6&doi=10.1182%2Fblood-2015-11-683581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6</span></div><div class="casAuthors">Uras, Iris Z.; Walter, Gina J.; Scheicher, Ruth; Bellutti, Florian; Prchal-Murphy, Michaela; Tigan, Anca S.; Valent, Peter; Heidel, Florian H.; Kubicek, Stefan; Scholl, Claudia; Froehling, Stefan; Sexl, Veronika</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2890-2902</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Up to 30% of patients with acute myeloid leukemia have constitutively activating internal tandem duplications (ITDs) of the FLT3 receptor tyrosine kinase.  Such mutations are assocd. with a poor prognosis and a high propensity to relapse after remission.  FLT3 inhibitors are being developed as targeted therapy for FLT3-ITD+ acute myeloid leukemia; however, their use is complicated by rapid development of resistance, which illustrates the need for addnl. therapeutic targets.  We show that the US Food and Drug Administration-approved CDK4/6 kinase inhibitor palbociclib induces apoptosis of FLT3-ITD leukemic cells.  The effect is specific for FLT3-mutant cells and is ascribed to the transcriptional activity of CDK6: CDK6 but not its functional homolog CDK4 is found at the promoters of the FLT3 and PIM1 genes, another important leukemogenic driver.  There CDK6 regulates transcription in a kinase-dependent manner.  Of potential clin. relevance, combined treatment with palbociclib and FLT3 inhibitors results in synergistic cytotoxicity.  Simultaneously targeting two crit. signaling nodes in leukemogenesis could represent a therapeutic breakthrough, leading to complete remission and overcoming resistance to FLT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsmyPMjz8SYLVg90H21EOLACvtfcHk0liIWN7gPAWJaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ars7zP&md5=63ac18917c968342abf1600403eed3e9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-11-683581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-11-683581%26sid%3Dliteratum%253Aachs%26aulast%3DUras%26aufirst%3DI.%2BZ.%26aulast%3DWalter%26aufirst%3DG.%2BJ.%26aulast%3DScheicher%26aufirst%3DR.%26aulast%3DBellutti%26aufirst%3DF.%26aulast%3DPrchal-Murphy%26aufirst%3DM.%26aulast%3DTigan%26aufirst%3DA.%2BS.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DHeidel%26aufirst%3DF.%2BH.%26aulast%3DKubicek%26aufirst%3DS.%26aulast%3DScholl%26aufirst%3DC.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DSexl%26aufirst%3DV.%26atitle%3DPalbociclib%2520treatment%2520of%2520FLT3-ITD%252B%2520AML%2520cells%2520uncovers%2520a%2520kinase-dependent%2520transcriptional%2520regulation%2520of%2520FLT3%2520and%2520PIM1%2520by%2520CDK6%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D2890%26epage%3D2902%26doi%3D10.1182%2Fblood-2015-11-683581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Goel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolaney, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuzugullu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varadan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicinski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span> </span><span class="NLM_article-title">Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">â</span> <span class="NLM_lpage">269</span><span class="refDoi">Â DOI: 10.1016/j.ccell.2016.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.ccell.2016.02.006" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=255-269&author=S.+Goelauthor=Q.+Wangauthor=A.+C.+Wattauthor=S.+M.+Tolaneyauthor=D.+A.+Dillonauthor=W.+Liauthor=S.+Rammauthor=A.+C.+Palmerauthor=H.+Yuzugulluauthor=V.+Varadanauthor=D.+Tuckauthor=L.+N.+Harrisauthor=K.+K.+Wongauthor=X.+S.+Liuauthor=P.+Sicinskiauthor=E.+P.+Winerauthor=I.+E.+Kropauthor=J.+J.+Zhao&title=Overcoming+therapeutic+resistance+in+HER2-positive+breast+cancers+with+CDK4%2F6+inhibitors&doi=10.1016%2Fj.ccell.2016.02.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DGoel%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWatt%26aufirst%3DA.%2BC.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DDillon%26aufirst%3DD.%2BA.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DRamm%26aufirst%3DS.%26aulast%3DPalmer%26aufirst%3DA.%2BC.%26aulast%3DYuzugullu%26aufirst%3DH.%26aulast%3DVaradan%26aufirst%3DV.%26aulast%3DTuck%26aufirst%3DD.%26aulast%3DHarris%26aufirst%3DL.%2BN.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DLiu%26aufirst%3DX.%2BS.%26aulast%3DSicinski%26aufirst%3DP.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DOvercoming%2520therapeutic%2520resistance%2520in%2520HER2-positive%2520breast%2520cancers%2520with%2520CDK4%252F6%2520inhibitors%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D29%26spage%3D255%26epage%3D269%26doi%3D10.1016%2Fj.ccell.2016.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Sumi, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuenzi, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knezevic, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remsing Rix, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span> </span><span class="NLM_article-title">Chemoproteomics reveals novel protein and lipid kinase targets of clinical CDK4/6 inhibitors in lung cancer</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2680</span><span class="NLM_x">â</span> <span class="NLM_lpage">2686</span><span class="refDoi">Â DOI: 10.1021/acschembio.5b00368</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00368" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2680-2686&author=N.+J.+Sumiauthor=B.+M.+Kuenziauthor=C.+E.+Knezevicauthor=L.+L.+Remsing+Rixauthor=U.+Rix&title=Chemoproteomics+reveals+novel+protein+and+lipid+kinase+targets+of+clinical+CDK4%2F6+inhibitors+in+lung+cancer&doi=10.1021%2Facschembio.5b00368"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00368%26sid%3Dliteratum%253Aachs%26aulast%3DSumi%26aufirst%3DN.%2BJ.%26aulast%3DKuenzi%26aufirst%3DB.%2BM.%26aulast%3DKnezevic%26aufirst%3DC.%2BE.%26aulast%3DRemsing%2BRix%26aufirst%3DL.%2BL.%26aulast%3DRix%26aufirst%3DU.%26atitle%3DChemoproteomics%2520reveals%2520novel%2520protein%2520and%2520lipid%2520kinase%2520targets%2520of%2520clinical%2520CDK4%252F6%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D2680%26epage%3D2686%26doi%3D10.1021%2Facschembio.5b00368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanArsdale, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Spectrum and degree of CDK drug interactions predicts clinical performance</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2273</span><span class="NLM_x">â</span> <span class="NLM_lpage">2281</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-16-0300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1158%2F1535-7163.MCT-16-0300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=27496135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGisbjK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2273-2281&author=P.+Chenauthor=N.+Leeauthor=W.+Huauthor=M.+Xuauthor=R.+A.+Ferreauthor=H.+Lamauthor=S.+Bergqvistauthor=J.+Solowiejauthor=W.+Diehlauthor=Y.+A.+Heauthor=X.+Yuauthor=A.+Nagataauthor=T.+VanArsdaleauthor=B.+W.+Murray&title=Spectrum+and+degree+of+CDK+drug+interactions+predicts+clinical+performance&doi=10.1158%2F1535-7163.MCT-16-0300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance</span></div><div class="casAuthors">Chen, Ping; Lee, Nathan V.; Hu, Wenyue; Xu, Meirong; Ferre, Rose Ann; Lam, Hieu; Bergqvist, Simon; Solowiej, James; Diehl, Wade; He, You-Ai; Yu, Xiu; Nagata, Asako; Van Arsdale, Todd; Murray, Brion W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2273-2281</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biol. perspective but drug development is often hindered by toxicities and inadequate efficacy.  Predicting drug behaviors using cellular and animal models is confounded by redundant kinase activities, a lack of unique substrates, and cell-specific signaling networks.  Cyclin-dependent kinase (CDK) drugs exemplify this phenomenon because they are reported to target common processes yet have distinct clin. activities.  Tumor cell studies of ATP-competitive CDK drugs (dinaciclib, AG-024322, abemaciclib, palbociclib, ribociclib) indicate similar pharmacol. while analyses in untransformed cells illuminates significant differences.  To resolve this apparent disconnect, drug behaviors are described at the mol. level.  Nonkinase binding studies and kinome interaction anal. (recombinant and endogenous kinases) reveal that proteins outside of the CDK family appear to have little role in dinaciclib/palbociclib/ribociclib pharmacol., may contribute for abemaciclib, and confounds AG-024322 anal.  CDK2 and CDK6 cocrystal structures with the drugs identify the mol. interactions responsible for potency and kinase selectivity.  Efficient drug binding to the unique hinge architecture of CDKs enables selectivity toward most of the human kinome.  Selectivity between CDK family members is achieved through interactions with nonconserved elements of the ATP-binding pocket.  Integrating clin. drug exposures into the anal. predicts that both palbociclib and ribociclib are CDK4/6 inhibitors, abemaciclib inhibits CDK4/6/9, and dinaciclib is a broad-spectrum CDK inhibitor (CDK2/3/4/6/9).  Understanding the mol. components of potency and selectivity also facilitates rational design of future generations of kinase-directed drugs.  Mol Cancer Ther; 15(10); 2273-81.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3TbbI98T8v7Vg90H21EOLACvtfcHk0ljRrScuONca7A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGisbjK&md5=112e9e46bb33393516fa94620e6383c6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0300%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DVanArsdale%26aufirst%3DT.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DSpectrum%2520and%2520degree%2520of%2520CDK%2520drug%2520interactions%2520predicts%2520clinical%2520performance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2273%26epage%3D2281%26doi%3D10.1158%2F1535-7163.MCT-16-0300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osnowski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuill, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Midgley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNae, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheleva, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walkinshaw, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span> </span><span class="NLM_article-title">2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1662</span><span class="NLM_x">â</span> <span class="NLM_lpage">1675</span><span class="refDoi">Â DOI: 10.1021/jm0309957</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0309957" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1662-1675&author=S.+Wangauthor=C.+Meadesauthor=G.+Woodauthor=A.+Osnowskiauthor=S.+Andersonauthor=R.+Yuillauthor=M.+Thomasauthor=M.+Meznaauthor=W.+Jacksonauthor=C.+Midgleyauthor=G.+Griffithsauthor=I.+Flemingauthor=S.+Greenauthor=I.+McNaeauthor=S.+Y.+Wuauthor=C.+McInnesauthor=D.+Zhelevaauthor=M.+D.+Walkinshawauthor=P.+M.+Fischer&title=2-Anilino-4-%28thiazol-5-yl%29pyrimidine+CDK+inhibitors%3A+synthesis%2C+SAR+analysis%2C+X-ray+crystallography%2C+and+biological+activity&doi=10.1021%2Fjm0309957"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm0309957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0309957%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMeades%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DG.%26aulast%3DOsnowski%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DYuill%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DMezna%26aufirst%3DM.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DMidgley%26aufirst%3DC.%26aulast%3DGriffiths%26aufirst%3DG.%26aulast%3DFleming%26aufirst%3DI.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DMcNae%26aufirst%3DI.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DZheleva%26aufirst%3DD.%26aulast%3DWalkinshaw%26aufirst%3DM.%2BD.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3D2-Anilino-4-%2528thiazol-5-yl%2529pyrimidine%2520CDK%2520inhibitors%253A%2520synthesis%252C%2520SAR%2520analysis%252C%2520X-ray%2520crystallography%252C%2520and%2520biological%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1662%26epage%3D1675%26doi%3D10.1021%2Fjm0309957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Shao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hole, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">640</span><span class="NLM_x">â</span> <span class="NLM_lpage">659</span><span class="refDoi">Â DOI: 10.1021/jm301475f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301475f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=640-659&author=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=A.+J.+Holeauthor=A.+Y.+Abbasauthor=S.+Baumliauthor=X.+Liuauthor=F.+Lamauthor=D.+W.+Foleyauthor=P.+M.+Fischerauthor=M.+Nobleauthor=J.+A.+Endicottauthor=C.+Pepperauthor=S.+Wang&title=Substituted+4-%28thiazol-5-yl%29-2-%28phenylamino%29pyrimidines+are+highly+active+CDK9+inhibitors%3A+synthesis%2C+X-ray+crystal+structures%2C+structure-activity+relationship%2C+and+anticancer+activities&doi=10.1021%2Fjm301475f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm301475f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301475f%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DAbbas%26aufirst%3DA.%2BY.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DFoley%26aufirst%3DD.%2BW.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DNoble%26aufirst%3DM.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DSubstituted%25204-%2528thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidines%2520are%2520highly%2520active%2520CDK9%2520inhibitors%253A%2520synthesis%252C%2520X-ray%2520crystal%2520structures%252C%2520structure-activity%2520relationship%252C%2520and%2520anticancer%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D640%26epage%3D659%26doi%3D10.1021%2Fjm301475f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Midgley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabarek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingram, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kontopidis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClue, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLachlan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheleva, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glover, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span> </span><span class="NLM_article-title">Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1111</span><span class="NLM_x">â</span> <span class="NLM_lpage">1121</span><span class="refDoi">Â DOI: 10.1016/j.chembiol.2010.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.chembiol.2010.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=21035734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKhtLfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=1111-1121&author=S.+Wangauthor=G.+Griffithsauthor=C.+A.+Midgleyauthor=A.+L.+Barnettauthor=M.+Cooperauthor=J.+Grabarekauthor=L.+Ingramauthor=W.+Jacksonauthor=G.+Kontopidisauthor=S.+J.+McClueauthor=C.+McInnesauthor=J.+McLachlanauthor=C.+Meadesauthor=M.+Meznaauthor=I.+Stuartauthor=M.+P.+Thomasauthor=D.+I.+Zhelevaauthor=D.+P.+Laneauthor=R.+C.+Jacksonauthor=D.+M.+Gloverauthor=D.+G.+Blakeauthor=P.+M.+Fischer&title=Discovery+and+characterization+of+2-anilino-4-+%28thiazol-5-yl%29pyrimidine+transcriptional+CDK+inhibitors+as+anticancer+agents&doi=10.1016%2Fj.chembiol.2010.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of 2-Anilino-4- (Thiazol-5-yl)Pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents</span></div><div class="casAuthors">Wang, Shu-Dong; Griffiths, Gary; Midgley, Carol A.; Barnett, Anna L.; Cooper, Michael; Grabarek, Joanna; Ingram, Laura; Jackson, Wayne; Kontopidis, George; McClue, Steven J.; McInnes, Campbell; McLachlan, Janice; Meades, Christopher; Mezna, Mokdad; Stuart, Iain; Thomas, Mark P.; Zheleva, Daniella I.; Lane, David P.; Jackson, Robert C.; Glover, David M.; Blake, David G.; Fischer, Peter M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1111-1121</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The main difficulty in the development of ATP antagonist kinase inhibitors is target specificity, since the ATP-binding motif is present in many proteins.  We introduce a strategy that has allowed us to identify compds. from a kinase inhibitor library that block the cyclin-dependent kinases responsible for regulating transcription, i.e., CDK7 and esp. CDK9.  The screening cascade employs cellular phenotypic assays based on mitotic index and nuclear p53 protein accumulation.  This permitted us to classify compds. into transcriptional, cell cycle, and mitotic inhibitor groups.  We describe the characterization of the transcriptional inhibitor class in terms of kinase inhibition profile, cellular mode of action, and selectivity for transformed cells.  A structural selectivity rationale was used to optimize potency and biopharmaceutical properties and led to the development of a transcriptional inhibitor, 3,4-dimethyl-5-[2-(4-piperazin-1-yl-phenylamino)-pyrimidin-4-yl]-3H-thiazol-2-one, with anticancer activity in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryOG4LTevHibVg90H21EOLACvtfcHk0lhvHIHeslUCVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKhtLfL&md5=08aff2706f6eda4ba1038327267a361e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DGriffiths%26aufirst%3DG.%26aulast%3DMidgley%26aufirst%3DC.%2BA.%26aulast%3DBarnett%26aufirst%3DA.%2BL.%26aulast%3DCooper%26aufirst%3DM.%26aulast%3DGrabarek%26aufirst%3DJ.%26aulast%3DIngram%26aufirst%3DL.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DMcClue%26aufirst%3DS.%2BJ.%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DMcLachlan%26aufirst%3DJ.%26aulast%3DMeades%26aufirst%3DC.%26aulast%3DMezna%26aufirst%3DM.%26aulast%3DStuart%26aufirst%3DI.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DZheleva%26aufirst%3DD.%2BI.%26aulast%3DLane%26aufirst%3DD.%2BP.%26aulast%3DJackson%26aufirst%3DR.%2BC.%26aulast%3DGlover%26aufirst%3DD.%2BM.%26aulast%3DBlake%26aufirst%3DD.%2BG.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DDiscovery%2520and%2520characterization%2520of%25202-anilino-4-%2520%2528thiazol-5-yl%2529pyrimidine%2520transcriptional%2520CDK%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D1111%26epage%3D1121%26doi%3D10.1016%2Fj.chembiol.2010.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Muller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikuad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">The ins and outs of selective kinase inhibitor development</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">818</span><span class="NLM_x">â</span> <span class="NLM_lpage">821</span><span class="refDoi">Â DOI: 10.1038/nchembio.1938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1038%2Fnchembio.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=26485069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ykt7fF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=818-821&author=S.+Mullerauthor=A.+Chaikuadauthor=N.+S.+Grayauthor=S.+Knapp&title=The+ins+and+outs+of+selective+kinase+inhibitor+development&doi=10.1038%2Fnchembio.1938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The ins and outs of selective kinase inhibitor development</span></div><div class="casAuthors">Muller, Susanne; Chaikuad, Apirat; Gray, Nathanael S.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">818-821</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases have emerged as one of the most successful families of drug targets.  To date, most selective kinase inhibitors have been discovered serendipitously either through broad selectivity screening or through the discovery of unique binding modes.  Here the authors discuss design strategies that could lead to a broader coverage of the kinome with selective inhibitors and to a more rational approach for developing them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQzaMrxSYx_rVg90H21EOLACvtfcHk0lhvHIHeslUCVg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ykt7fF&md5=f5adf0bbaa388c87b26bae23cfad0bae</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1938%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DThe%2520ins%2520and%2520outs%2520of%2520selective%2520kinase%2520inhibitor%2520development%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D818%26epage%3D821%26doi%3D10.1038%2Fnchembio.1938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, M. H.</span><span> </span><span class="NLM_article-title">FDA-approved small-molecule kinase inhibitors</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">422</span><span class="NLM_x">â</span> <span class="NLM_lpage">439</span><span class="refDoi">Â DOI: 10.1016/j.tips.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.tips.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=25975227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=422-439&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=FDA-approved+small-molecule+kinase+inhibitors&doi=10.1016%2Fj.tips.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-approved small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">422-439</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases have emerged as one of the most intensively pursued targets in current pharmacol. research, esp. for cancer, due to their crit. roles in cellular signaling.  To date, the US FDA has approved 28 small-mol. kinase inhibitors, half of which were approved in the past 3 years.  While the clin. data of these approved mols. are widely presented and structure-activity relationship (SAR) has been reported for individual mols., an updated review that analyzes all approved mols. and summarizes current achievements and trends in the field has yet to be found.  Here we present all approved small-mol. kinase inhibitors with an emphasis on binding mechanism and structural features, summarize current challenges, and discuss future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrudyvM3eO09bVg90H21EOLACvtfcHk0lhRPaLuUmvArA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D&md5=a6aa3dbb11e6fe3001fa5fa03a4c950a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DFDA-approved%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D422%26epage%3D439%26doi%3D10.1016%2Fj.tips.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">â</span> <span class="NLM_lpage">1051</span><span class="refDoi">Â DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0lhRPaLuUmvArA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">McInnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâBoyle, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kontopidis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span> </span><span class="NLM_article-title">Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">525</span><span class="NLM_x">â</span> <span class="NLM_lpage">534</span><span class="refDoi">Â DOI: 10.1016/j.chembiol.2004.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.chembiol.2004.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=15123247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1Cms74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=525-534&author=C.+McInnesauthor=S.+Wangauthor=S.+Andersonauthor=J.+O%E2%80%99Boyleauthor=W.+Jacksonauthor=G.+Kontopidisauthor=C.+Meadesauthor=M.+Meznaauthor=M.+Thomasauthor=G.+Woodauthor=D.+P.+Laneauthor=P.+M.+Fischer&title=Structural+determinants+of+CDK4+inhibition+and+design+of+selective+ATP+competitive+inhibitors&doi=10.1016%2Fj.chembiol.2004.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Determinants of CDK4 Inhibition and Design of Selective ATP Competitive Inhibitors</span></div><div class="casAuthors">McInnes, Campbell; Wang, Shudong; Anderson, Sian; O'Boyle, Janice; Jackson, Wayne; Kontopidis, George; Meades, Christopher; Mezna, Mokdad; Thomas, Mark; Wood, Gavin; Lane, David P.; Fischer, Peter M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">525-534</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A no. of selective inhibitors of the CDK4/cyclin D1 complex have been reported recently.  Due to the absence of an exptl. CDK4 structure, the ligand and protein determinants contributing to CDK4 selectivity are poorly understood at present.  Here, we report the use of computational methods to elucidate the characteristics of selectivity and to derive the structural basis for specific, high-affinity binding of inhibitors to the CDK4 active site.  From these data, the hypothesis emerged that appropriate incorporation of an ionizable function into a CDK2 inhibitor results in more favorable binding to CDK4.  This knowledge was applied to the design of compds. in the otherwise CDK2-selective 2-anilino-4-(thiazol-5-yl)pyrimidine pharmacophore that are potent and highly selective ATP antagonists of CDK4/cyclin D1.  The findings of this study also have significant implications in the design of CDK4 mimic structures based on CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU07M2Ugw65bVg90H21EOLACvtfcHk0lhRPaLuUmvArA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1Cms74%253D&md5=94d613c28266a51507bf63d34965d792</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DMeades%26aufirst%3DC.%26aulast%3DMezna%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DG.%26aulast%3DLane%26aufirst%3DD.%2BP.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DStructural%2520determinants%2520of%2520CDK4%2520inhibition%2520and%2520design%2520of%2520selective%2520ATP%2520competitive%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D525%26epage%3D534%26doi%3D10.1016%2Fj.chembiol.2004.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Cho, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angove, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brain, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dagostin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giraldes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiscock, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovats, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewry, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luzzio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniara, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortenson, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benning, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâReilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolford, A. J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrona, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, S.</span><span> </span><span class="NLM_article-title">Fragment-based discovery of 7-azabenzimidazoles as potent, highly selective, and orally active CDK4/6 inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">â</span> <span class="NLM_lpage">449</span><span class="refDoi">Â DOI: 10.1021/ml200241a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200241a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=445-449&author=Y.+S.+Choauthor=H.+Angoveauthor=C.+Brainauthor=C.+H.+T.+Chenauthor=H.+Chengauthor=R.+Chengauthor=R.+Chopraauthor=K.+Chungauthor=M.+Congreveauthor=C.+Dagostinauthor=D.+J.+Davisauthor=R.+Feltellauthor=J.+Giraldesauthor=S.+D.+Hiscockauthor=S.+Kimauthor=S.+Kovatsauthor=B.+Laguauthor=K.+Lewryauthor=A.+Looauthor=Y.+Luauthor=M.+Luzzioauthor=W.+Maniaraauthor=R.+McMenaminauthor=P.+N.+Mortensonauthor=R.+Benningauthor=M.+O%E2%80%99Reillyauthor=D.+C.+Reesauthor=J.+Shenauthor=T.+Smithauthor=Y.+Wangauthor=G.+Williamsauthor=A.+J.+A.+Woolfordauthor=W.+Wronaauthor=M.+Xuauthor=F.+Yangauthor=S.+Howard&title=Fragment-based+discovery+of+7-azabenzimidazoles+as+potent%2C+highly+selective%2C+and+orally+active+CDK4%2F6+inhibitors&doi=10.1021%2Fml200241a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fml200241a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200241a%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DY.%2BS.%26aulast%3DAngove%26aufirst%3DH.%26aulast%3DBrain%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%2BH.%2BT.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DChung%26aufirst%3DK.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DDagostin%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DFeltell%26aufirst%3DR.%26aulast%3DGiraldes%26aufirst%3DJ.%26aulast%3DHiscock%26aufirst%3DS.%2BD.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKovats%26aufirst%3DS.%26aulast%3DLagu%26aufirst%3DB.%26aulast%3DLewry%26aufirst%3DK.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLuzzio%26aufirst%3DM.%26aulast%3DManiara%26aufirst%3DW.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DMortenson%26aufirst%3DP.%2BN.%26aulast%3DBenning%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%2BA.%26aulast%3DWrona%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DHoward%26aufirst%3DS.%26atitle%3DFragment-based%2520discovery%2520of%25207-azabenzimidazoles%2520as%2520potent%252C%2520highly%2520selective%252C%2520and%2520orally%2520active%2520CDK4%252F6%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D445%26epage%3D449%26doi%3D10.1021%2Fml200241a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Toogood, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repine, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanderWel, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">â</span> <span class="NLM_lpage">2406</span><span class="refDoi">Â DOI: 10.1021/jm049354h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+potent+and+selective+inhibitor+of+cyclin-dependent+kinase+4%2F6&doi=10.1021%2Fjm049354h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0lhb_tjDj-JHOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406%26doi%3D10.1021%2Fjm049354h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Munch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pittelkow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boas, U.</span><span> </span><span class="NLM_article-title">A new efficient synthesis of isothiocyanates from amines using di-<i>tert</i>-butyl dicarbonate</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3117</span><span class="NLM_x">â</span> <span class="NLM_lpage">3119</span><span class="refDoi">Â DOI: 10.1016/j.tetlet.2008.03.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.tetlet.2008.03.045" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=3117-3119&author=H.+Munchauthor=J.+S.+Hansenauthor=M.+Pittelkowauthor=J.+B.+Christensenauthor=U.+Boas&title=A+new+efficient+synthesis+of+isothiocyanates+from+amines+using+di-tert-butyl+dicarbonate&doi=10.1016%2Fj.tetlet.2008.03.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2008.03.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2008.03.045%26sid%3Dliteratum%253Aachs%26aulast%3DMunch%26aufirst%3DH.%26aulast%3DHansen%26aufirst%3DJ.%2BS.%26aulast%3DPittelkow%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DJ.%2BB.%26aulast%3DBoas%26aufirst%3DU.%26atitle%3DA%2520new%2520efficient%2520synthesis%2520of%2520isothiocyanates%2520from%2520amines%2520using%2520di-tert-butyl%2520dicarbonate%26jtitle%3DTetrahedron%2520Lett.%26date%3D2008%26volume%3D49%26spage%3D3117%26epage%3D3119%26doi%3D10.1016%2Fj.tetlet.2008.03.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Mozolis, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iokubaitite, S.</span><span> </span><span class="NLM_article-title">Preparation of <i>N</i>-substituted thiourea. <i>Russ</i></span> <span class="citation_source-journal">Russ. Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">â</span> <span class="NLM_lpage">595</span><span class="refDoi">Â DOI: 10.1070/RC1973v042n07ABEH002677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1070%2FRC1973v042n07ABEH002677" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1973&pages=587-595&author=V.+Mozolisauthor=S.+Iokubaitite&title=Preparation+of+N-substituted+thiourea.+Russ&doi=10.1070%2FRC1973v042n07ABEH002677"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1070%2FRC1973v042n07ABEH002677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1070%252FRC1973v042n07ABEH002677%26sid%3Dliteratum%253Aachs%26aulast%3DMozolis%26aufirst%3DV.%26aulast%3DIokubaitite%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520N-substituted%2520thiourea.%2520Russ%26jtitle%3DRuss.%2520Chem.%2520Rev.%26date%3D1973%26volume%3D42%26spage%3D587%26epage%3D595%26doi%3D10.1070%2FRC1973v042n07ABEH002677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Hantzsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traumann, V.</span><span> </span><span class="NLM_article-title">Amidothiazole aus sulfoharnstoff und halogenisirten ketonen, resp. Aldehyden</span> <span class="citation_source-journal">Ber. Dtsch. Chem. Ges.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1888</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">938</span><span class="NLM_x">â</span> <span class="NLM_lpage">941</span><span class="refDoi">Â DOI: 10.1002/cber.188802101178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1002%2Fcber.188802101178" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1888&pages=938-941&author=A.+Hantzschauthor=V.+Traumann&title=Amidothiazole+aus+sulfoharnstoff+und+halogenisirten+ketonen%2C+resp.+Aldehyden&doi=10.1002%2Fcber.188802101178"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fcber.188802101178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcber.188802101178%26sid%3Dliteratum%253Aachs%26aulast%3DHantzsch%26aufirst%3DA.%26aulast%3DTraumann%26aufirst%3DV.%26atitle%3DAmidothiazole%2520aus%2520sulfoharnstoff%2520und%2520halogenisirten%2520ketonen%252C%2520resp.%2520Aldehyden%26jtitle%3DBer.%2520Dtsch.%2520Chem.%2520Ges.%26date%3D1888%26volume%3D21%26spage%3D938%26epage%3D941%26doi%3D10.1002%2Fcber.188802101178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Nabana, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Togo, H.</span><span> </span><span class="NLM_article-title">Reactivities of novel [hydroxy(tosyloxy)iodo]arenes and [hydroxy(phosphoryloxy)iodo]arenes for alpha-tosyloxylation and alpha-phosphoryloxylation of ketones</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4362</span><span class="NLM_x">â</span> <span class="NLM_lpage">4365</span><span class="refDoi">Â DOI: 10.1021/jo0200670</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0200670" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2002&pages=4362-4365&author=T.+Nabanaauthor=H.+Togo&title=Reactivities+of+novel+%5Bhydroxy%28tosyloxy%29iodo%5Darenes+and+%5Bhydroxy%28phosphoryloxy%29iodo%5Darenes+for+alpha-tosyloxylation+and+alpha-phosphoryloxylation+of+ketones&doi=10.1021%2Fjo0200670"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjo0200670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0200670%26sid%3Dliteratum%253Aachs%26aulast%3DNabana%26aufirst%3DT.%26aulast%3DTogo%26aufirst%3DH.%26atitle%3DReactivities%2520of%2520novel%2520%255Bhydroxy%2528tosyloxy%2529iodo%255Darenes%2520and%2520%255Bhydroxy%2528phosphoryloxy%2529iodo%255Darenes%2520for%2520alpha-tosyloxylation%2520and%2520alpha-phosphoryloxylation%2520of%2520ketones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2002%26volume%3D67%26spage%3D4362%26epage%3D4365%26doi%3D10.1021%2Fjo0200670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Midgley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ScaÃ«rou, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabarek, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kontopidis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClue, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plater, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheleva, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glover, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-phenyl-4-(thiazol-5-yl) pyrimidin-2-amine aurora kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4367</span><span class="NLM_x">â</span> <span class="NLM_lpage">4378</span><span class="refDoi">Â DOI: 10.1021/jm901913s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901913s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4367-4378&author=S.+Wangauthor=C.+A.+Midgleyauthor=F.+Sca%C3%ABrouauthor=J.+B.+Grabarekauthor=G.+Griffithsauthor=W.+Jacksonauthor=G.+Kontopidisauthor=S.+J.+McClueauthor=C.+McInnesauthor=C.+Meadesauthor=M.+Meznaauthor=A.+Platerauthor=I.+Stuartauthor=M.+P.+Thomasauthor=G.+Woodauthor=R.+G.+Clarkeauthor=D.+G.+Blakeauthor=D.+I.+Zhelevaauthor=D.+P.+Laneauthor=R.+C.+Jacksonauthor=D.+M.+Gloverauthor=P.+M.+Fischer&title=Discovery+of+N-phenyl-4-%28thiazol-5-yl%29+pyrimidin-2-amine+aurora+kinase+inhibitors&doi=10.1021%2Fjm901913s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm901913s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901913s%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMidgley%26aufirst%3DC.%2BA.%26aulast%3DSca%25C3%25ABrou%26aufirst%3DF.%26aulast%3DGrabarek%26aufirst%3DJ.%2BB.%26aulast%3DGriffiths%26aufirst%3DG.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DMcClue%26aufirst%3DS.%2BJ.%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DMeades%26aufirst%3DC.%26aulast%3DMezna%26aufirst%3DM.%26aulast%3DPlater%26aufirst%3DA.%26aulast%3DStuart%26aufirst%3DI.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DWood%26aufirst%3DG.%26aulast%3DClarke%26aufirst%3DR.%2BG.%26aulast%3DBlake%26aufirst%3DD.%2BG.%26aulast%3DZheleva%26aufirst%3DD.%2BI.%26aulast%3DLane%26aufirst%3DD.%2BP.%26aulast%3DJackson%26aufirst%3DR.%2BC.%26aulast%3DGlover%26aufirst%3DD.%2BM.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DDiscovery%2520of%2520N-phenyl-4-%2528thiazol-5-yl%2529%2520pyrimidin-2-amine%2520aurora%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4367%26epage%3D4378%26doi%3D10.1021%2Fjm901913s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Bredereck, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Effenberger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botsch, H.</span><span> </span><span class="NLM_article-title">Acid amide reactions. XLV. Reactivity of formamidines, dimethylformamide diethyl acetal (amide acetal), and bis (dimethylamino) methoxymethane (aminal ester)</span> <span class="citation_source-journal">Chem. Ber.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1964</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">3397</span><span class="NLM_x">â</span> <span class="NLM_lpage">3406</span><span class="refDoi">Â DOI: 10.1002/cber.19640971220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1002%2Fcber.19640971220" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=1964&pages=3397-3406&author=H.+Bredereckauthor=F.+Effenbergerauthor=H.+Botsch&title=Acid+amide+reactions.+XLV.+Reactivity+of+formamidines%2C+dimethylformamide+diethyl+acetal+%28amide+acetal%29%2C+and+bis+%28dimethylamino%29+methoxymethane+%28aminal+ester%29&doi=10.1002%2Fcber.19640971220"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fcber.19640971220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcber.19640971220%26sid%3Dliteratum%253Aachs%26aulast%3DBredereck%26aufirst%3DH.%26aulast%3DEffenberger%26aufirst%3DF.%26aulast%3DBotsch%26aufirst%3DH.%26atitle%3DAcid%2520amide%2520reactions.%2520XLV.%2520Reactivity%2520of%2520formamidines%252C%2520dimethylformamide%2520diethyl%2520acetal%2520%2528amide%2520acetal%2529%252C%2520and%2520bis%2520%2528dimethylamino%2529%2520methoxymethane%2520%2528aminal%2520ester%2529%26jtitle%3DChem.%2520Ber.%26date%3D1964%26volume%3D97%26spage%3D3397%26epage%3D3406%26doi%3D10.1002%2Fcber.19640971220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Swanson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubin, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasser, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dax, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jetter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenbucher, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzolio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogenstaetter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Codd, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplan, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span> </span><span class="NLM_article-title">Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1857</span><span class="NLM_x">â</span> <span class="NLM_lpage">1872</span><span class="refDoi">Â DOI: 10.1021/jm0495071</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0495071" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD2cXps1Ogu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1857-1872&author=D.+M.+Swansonauthor=A.+E.+Dubinauthor=C.+Shahauthor=N.+Nasserauthor=L.+Changauthor=S.+L.+Daxauthor=M.+Jetterauthor=J.+G.+Breitenbucherauthor=C.+Liuauthor=C.+Mazurauthor=B.+Lordauthor=L.+Gonzalesauthor=K.+Hoeyauthor=M.+Rizzolioauthor=M.+Bogenstaetterauthor=E.+E.+Coddauthor=D.+H.+Leeauthor=S.+P.+Zhangauthor=S.+R.+Chaplanauthor=N.+I.+Carruthers&title=Identification+and+biological+evaluation+of+4-%283-trifluoromethylpyridin-2-yl%29piperazine-1-carboxylic+acid+%285-trifluoromethylpyridin-2-yl%29amide%2C+a+high+affinity+TRPV1+%28VR1%29+vanilloid+receptor+antagonist&doi=10.1021%2Fjm0495071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist</span></div><div class="casAuthors">Swanson, Devin M.; Dubin, Adrienne E.; Shah, Chandra; Nasser, Nadia; Chang, Leon; Dax, Scott L.; Jetter, Michele; Breitenbucher, J. Guy; Liu, Changlu; Mazur, Curt; Lord, Brian; Gonzales, Lisa; Hoey, Kenway; Rizzolio, Michele; Bogenstaetter, Michael; Codd, Ellen E.; Lee, Doo H.; Zhang, Sui-Po; Chaplan, Sandra R.; Carruthers, Nicholas I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1857-1872</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High throughput screening using the recombinant human TRPV1 receptor was used to identify a series of pyridinylpiperazine ureas as TRPV1 vanilloid receptor ligands.  Exploration of the structure-activity relationships by parallel synthesis identified the essential pharmacophoric elements for antagonism that permitted further optimization via targeted synthesis to provide a potent orally bioavailable and selective TRPV1 modulator 41 active in several in vivo models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_mnRdFjQEq7Vg90H21EOLACvtfcHk0lj__0k9MIz3Zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXps1Ogu7g%253D&md5=068c51ef0f08d6885921032a66e90c64</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm0495071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0495071%26sid%3Dliteratum%253Aachs%26aulast%3DSwanson%26aufirst%3DD.%2BM.%26aulast%3DDubin%26aufirst%3DA.%2BE.%26aulast%3DShah%26aufirst%3DC.%26aulast%3DNasser%26aufirst%3DN.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DDax%26aufirst%3DS.%2BL.%26aulast%3DJetter%26aufirst%3DM.%26aulast%3DBreitenbucher%26aufirst%3DJ.%2BG.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DMazur%26aufirst%3DC.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DGonzales%26aufirst%3DL.%26aulast%3DHoey%26aufirst%3DK.%26aulast%3DRizzolio%26aufirst%3DM.%26aulast%3DBogenstaetter%26aufirst%3DM.%26aulast%3DCodd%26aufirst%3DE.%2BE.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DZhang%26aufirst%3DS.%2BP.%26aulast%3DChaplan%26aufirst%3DS.%2BR.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26atitle%3DIdentification%2520and%2520biological%2520evaluation%2520of%25204-%25283-trifluoromethylpyridin-2-yl%2529piperazine-1-carboxylic%2520acid%2520%25285-trifluoromethylpyridin-2-yl%2529amide%252C%2520a%2520high%2520affinity%2520TRPV1%2520%2528VR1%2529%2520vanilloid%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1857%26epage%3D1872%26doi%3D10.1021%2Fjm0495071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Levallet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerpiniere, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, S. Y.</span><span> </span><span class="NLM_article-title">The HgCl<sub>2</sub>-promoted guanylation reaction: the scope and limitations</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5291</span><span class="NLM_x">â</span> <span class="NLM_lpage">5304</span><span class="refDoi">Â DOI: 10.1016/S0040-4020(97)00193-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2FS0040-4020%2897%2900193-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADyaK2sXis1Wis7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=5291-5304&author=C.+Levalletauthor=J.+Lerpiniereauthor=S.+Y.+Ko&title=The+HgCl2-promoted+guanylation+reaction%3A+the+scope+and+limitations&doi=10.1016%2FS0040-4020%2897%2900193-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The HgCl2-promoted guanylation reaction: the scope and limitations</span></div><div class="casAuthors">Levallet, Catherine; Lerpiniere, Joanne; Ko, Soo Y.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5291-5304</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The HgCl2-promoted guanylation reaction was studied with various substituted thiourea starting materials and the scope and limitations are presented.  The process was found to be effective with thioureas contg. at least one N-conjugated substituent.  Such activating groups include N-carbonyl- (acyl, alkoxycarbonyl, carbamoyl, etc.), N-cyano-, N-sulfonyl-, and N-aryl- substituents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8BjIpnQK3WLVg90H21EOLACvtfcHk0lj__0k9MIz3Zg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1Wis7o%253D&md5=f95b2f9a2dcca9c544376595c0260178</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2897%2900193-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252897%252900193-2%26sid%3Dliteratum%253Aachs%26aulast%3DLevallet%26aufirst%3DC.%26aulast%3DLerpiniere%26aufirst%3DJ.%26aulast%3DKo%26aufirst%3DS.%2BY.%26atitle%3DThe%2520HgCl2-promoted%2520guanylation%2520reaction%253A%2520the%2520scope%2520and%2520limitations%26jtitle%3DTetrahedron%26date%3D1997%26volume%3D53%26spage%3D5291%26epage%3D5304%26doi%3D10.1016%2FS0040-4020%2897%2900193-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Li, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, L. H.</span><span> </span><span class="NLM_article-title">A practical Buchwald-Hartwig amination of 2-bromopyridines with volatile amines</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">3606</span><span class="NLM_x">â</span> <span class="NLM_lpage">3607</span><span class="refDoi">Â DOI: 10.1021/jo070366v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo070366v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=3606-3607&author=J.+J.+Liauthor=Z.+Wangauthor=L.+H.+Mitchell&title=A+practical+Buchwald-Hartwig+amination+of+2-bromopyridines+with+volatile+amines&doi=10.1021%2Fjo070366v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjo070366v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo070366v%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMitchell%26aufirst%3DL.%2BH.%26atitle%3DA%2520practical%2520Buchwald-Hartwig%2520amination%2520of%25202-bromopyridines%2520with%2520volatile%2520amines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D3606%26epage%3D3607%26doi%3D10.1021%2Fjo070366v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Voets, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demmers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijersbergen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolthuis, R.</span><span> </span><span class="NLM_article-title">The lethal response to Cdk1 inhibition depends on sister chromatid alignment errors generated by KIF4 and isoform 1 of PRC1</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">14798</span><span class="refDoi">Â DOI: 10.1038/srep14798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1038%2Fsrep14798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=26423135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2ktrfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=14798&author=E.+Voetsauthor=J.+Marsmanauthor=J.+Demmersauthor=R.+Beijersbergenauthor=R.+Wolthuis&title=The+lethal+response+to+Cdk1+inhibition+depends+on+sister+chromatid+alignment+errors+generated+by+KIF4+and+isoform+1+of+PRC1&doi=10.1038%2Fsrep14798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The lethal response to Cdk1 inhibition depends on sister chromatid alignment errors generated by KIF4 and isoform 1 of PRC1</span></div><div class="casAuthors">Voets, Erik; Marsman, Judith; Demmers, Jeroen; Beijersbergen, Roderick; Wolthuis, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14798</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 1 (Cdk1) is absolutely essential for cell division.  Complete ablation of Cdk1 precludes the entry of G2 phase cells into mitosis, and is early embryonic lethal in mice.  Dampening Cdk1 activation, by reducing gene expression or upon treatment with cell-permeable Cdk1 inhibitors, is also detrimental for proliferating cells, but has been assocd. with defects in mitotic progression, and the formation of aneuploid daughter cells.  Here, we used a large-scale RNAi screen to identify the human genes that critically det. the cellular toxicity of Cdk1 inhibition.  We show that Cdk1 inhibition leads to fatal sister chromatid alignment errors and mitotic arrest in the spindle checkpoint.  These problems start early in mitosis and are alleviated by depletion of isoform 1 of PRC1 (PRC1-1), by gene ablation of its binding partner KIF4, or by abrogation of KIF4 motor activity.  Our results show that, normally, Cdk1 activity must rise above the level required for mitotic entry.  This prevents KIF4-dependent PRC1-1 translocation to astral microtubule tips and safeguards proper chromosome congression.  We conclude that cell death in response to Cdk1 inhibitors directly relates to chromosome alignment defects generated by insufficient repression of PRC1-1 and KIF4 during prometaphase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqreZKiNNRPibVg90H21EOLACvtfcHk0lh4uDTWkV_KEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2ktrfJ&md5=f252d4d44ecd64b062c9da0c8b775908</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fsrep14798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep14798%26sid%3Dliteratum%253Aachs%26aulast%3DVoets%26aufirst%3DE.%26aulast%3DMarsman%26aufirst%3DJ.%26aulast%3DDemmers%26aufirst%3DJ.%26aulast%3DBeijersbergen%26aufirst%3DR.%26aulast%3DWolthuis%26aufirst%3DR.%26atitle%3DThe%2520lethal%2520response%2520to%2520Cdk1%2520inhibition%2520depends%2520on%2520sister%2520chromatid%2520alignment%2520errors%2520generated%2520by%2520KIF4%2520and%2520isoform%25201%2520of%2520PRC1%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D14798%26doi%3D10.1038%2Fsrep14798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze-Gahmen, U.</span><span> </span><span class="NLM_article-title">Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3826</span><span class="NLM_x">â</span> <span class="NLM_lpage">3831</span><span class="refDoi">Â DOI: 10.1021/jm0600388</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0600388" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD28XltVKgtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3826-3831&author=H.+Luauthor=U.+Schulze-Gahmen&title=Toward+understanding+the+structural+basis+of+cyclin-dependent+kinase+6+specific+inhibition&doi=10.1021%2Fjm0600388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Understanding the Structural Basis of Cyclin-Dependent Kinase 6 Specific Inhibition</span></div><div class="casAuthors">Lu, Heshu; Schulze-Gahmen, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3826-3831</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are key players in cell cycle control, and genetic alterations of CDKs and their regulators have been linked to a variety of cancers.  Hence, CDKs are obvious targets for therapeutic intervention in various proliferative diseases, including cancer.  To date, drug design efforts have mostly focused on CDK2 because methods for crystn. of its inhibitor complexes have been well established.  CDK4 and CDK6, however, may be at least as important as enzymes for cell cycle regulation and could provide alternative treatment options.  We describe here two complex structures of human CDK6 with a very specific kinase inhibitor, PD0332991, which is based on a pyrido[2,3-d]pyrimidin-7-one scaffold, and with the less specific aminopurvalanol inhibitor.  Anal. of the structures suggests that relatively small conformational differences between CDK2 and CDK6 in the hinge region are contributing to the inhibitor specificity by inducing changes in the inhibitor orientation that lead to sterical clashes in CDK2 but not CDK6.  These complex structures provide valuable insights for the future development of CDK-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt5qOCDA_blLVg90H21EOLACvtfcHk0lh4uDTWkV_KEA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltVKgtbk%253D&md5=218bcdfeac3e7371e3ae16ab0a5799db</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm0600388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0600388%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DSchulze-Gahmen%26aufirst%3DU.%26atitle%3DToward%2520understanding%2520the%2520structural%2520basis%2520of%2520cyclin-dependent%2520kinase%25206%2520specific%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3826%26epage%3D3831%26doi%3D10.1021%2Fjm0600388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Walsby, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fegan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepper, C.</span><span> </span><span class="NLM_article-title">A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">â</span> <span class="NLM_lpage">385</span><span class="refDoi">Â DOI: 10.18632/oncotarget.1568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.18632%2Foncotarget.1568" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=375-385&author=E.+Walsbyauthor=G.+Prattauthor=H.+Shaoauthor=A.+Y.+Abbasauthor=P.+M.+Fischerauthor=T.+D.+Bradshawauthor=P.+Brennanauthor=C.+Feganauthor=S.+Wangauthor=C.+Pepper&title=A+novel+Cdk9+inhibitor+preferentially+targets+tumor+cells+and+synergizes+with+fludarabine&doi=10.18632%2Foncotarget.1568"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1568%26sid%3Dliteratum%253Aachs%26aulast%3DWalsby%26aufirst%3DE.%26aulast%3DPratt%26aufirst%3DG.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DAbbas%26aufirst%3DA.%2BY.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DBradshaw%26aufirst%3DT.%2BD.%26aulast%3DBrennan%26aufirst%3DP.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DPepper%26aufirst%3DC.%26atitle%3DA%2520novel%2520Cdk9%2520inhibitor%2520preferentially%2520targets%2520tumor%2520cells%2520and%2520synergizes%2520with%2520fludarabine%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D375%26epage%3D385%26doi%3D10.18632%2Foncotarget.1568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Li, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iarossi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noll, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahaman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">To, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAndrea, R. J.</span><span> </span><span class="NLM_article-title">Investigation of a novel cyclin-dependent-kinase (CDK) inhibitor Cdki-73 as an effective treatment option for MLL-AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">1365</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=1365&author=K.+L.+Liauthor=S.+C.+Brayauthor=D.+Iarossiauthor=J.+Adamsauthor=L.+Zhongauthor=B.+Nollauthor=M.+H.+Rahamanauthor=J.+Richmondauthor=L.+B.+Toauthor=I.+D.+Lewisauthor=R.+B.+Lockauthor=S.+Wangauthor=R.+J.+D%E2%80%99Andrea&title=Investigation+of+a+novel+cyclin-dependent-kinase+%28CDK%29+inhibitor+Cdki-73+as+an+effective+treatment+option+for+MLL-AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DK.%2BL.%26aulast%3DBray%26aufirst%3DS.%2BC.%26aulast%3DIarossi%26aufirst%3DD.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DNoll%26aufirst%3DB.%26aulast%3DRahaman%26aufirst%3DM.%2BH.%26aulast%3DRichmond%26aufirst%3DJ.%26aulast%3DTo%26aufirst%3DL.%2BB.%26aulast%3DLewis%26aufirst%3DI.%2BD.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DR.%2BJ.%26atitle%3DInvestigation%2520of%2520a%2520novel%2520cyclin-dependent-kinase%2520%2528CDK%2529%2520inhibitor%2520Cdki-73%2520as%2520an%2520effective%2520treatment%2520option%2520for%2520MLL-AML%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D1365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Finlay, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acton, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dennis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaton, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karoutchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loddick, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, H. M.</span><span> </span><span class="NLM_article-title">Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4442</span><span class="NLM_x">â</span> <span class="NLM_lpage">4446</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2008.06.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.bmcl.2008.06.027" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4442-4446&author=M.+R.+Finlayauthor=D.+G.+Actonauthor=D.+M.+Andrewsauthor=A.+J.+Barkerauthor=M.+Dennisauthor=E.+Fisherauthor=M.+A.+Grahamauthor=C.+P.+Greenauthor=D.+W.+Heatonauthor=G.+Karoutchiauthor=S.+A.+Loddickauthor=R.+Morgentinauthor=A.+Robertsauthor=J.+A.+Tuckerauthor=H.+M.+Weir&title=Imidazole+piperazines%3A+SAR+and+development+of+a+potent+class+of+cyclin-dependent+kinase+inhibitors+with+a+novel+binding+mode&doi=10.1016%2Fj.bmcl.2008.06.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.06.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.06.027%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DActon%26aufirst%3DD.%2BG.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DDennis%26aufirst%3DM.%26aulast%3DFisher%26aufirst%3DE.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26aulast%3DGreen%26aufirst%3DC.%2BP.%26aulast%3DHeaton%26aufirst%3DD.%2BW.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DLoddick%26aufirst%3DS.%2BA.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DRoberts%26aufirst%3DA.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26atitle%3DImidazole%2520piperazines%253A%2520SAR%2520and%2520development%2520of%2520a%2520potent%2520class%2520of%2520cyclin-dependent%2520kinase%2520inhibitors%2520with%2520a%2520novel%2520binding%2520mode%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4442%26epage%3D4446%26doi%3D10.1016%2Fj.bmcl.2008.06.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Sathe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koshy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thalgott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzenbock, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holm, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gschwend, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Retz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nawroth, R.</span><span> </span><span class="NLM_article-title">CDK4/6 inhibition controls proliferation of bladder cancer and transcription of RB1</span> <span class="citation_source-journal">J. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">195</span><span class="NLM_x">, </span> <span class="NLM_fpage">771</span><span class="NLM_x">â</span> <span class="NLM_lpage">779</span><span class="refDoi">Â DOI: 10.1016/j.juro.2015.08.082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.juro.2015.08.082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=26318986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOqsr7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2016&pages=771-779&author=A.+Satheauthor=N.+Koshyauthor=S.+C.+Schmidauthor=M.+Thalgottauthor=S.+M.+Schwarzenbockauthor=B.+J.+Krauseauthor=P.+S.+Holmauthor=J.+E.+Gschwendauthor=M.+Retzauthor=R.+Nawroth&title=CDK4%2F6+inhibition+controls+proliferation+of+bladder+cancer+and+transcription+of+RB1&doi=10.1016%2Fj.juro.2015.08.082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1</span></div><div class="casAuthors">Sathe, Anuja; Koshy, Nicole; Schmid, Sebastian C.; Thalgott, Mark; Schwarzenboeck, Sarah M.; Krause, Bernd J.; Holm, Per S.; Gschwend, Juergen E.; Retz, Margitta; Nawroth, Roman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">771-779</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The retinoblastoma signaling network is frequently altered in advanced bladder cancer.  We investigated the potential of CDK4/6 as a therapeutic target and detd. biomarkers for patient stratification.  Genetic alterations were analyzed using public databases, including TCGA (The Cancer Genome Atlas), COSMIC (Catalog of Somatic Mutations in Cancer) and CCLE (Cancer Cell Line Encyclopedia).  Effects of the CDK4/6-inhibitor PD-0332991 or LY2835219 were examd. in 10 bladder cancer cell lines by immunoblot, cell viability, apoptosis and cell cycle progression.  Efficacy of the PD-0332991 and cisplatin combination was analyzed using the combination index.  Gene expression level was detd. by quant. polymerase chain reaction.  Cytomegalovirus promoter regulated recombinant retinoblastoma was used for reconstitution.  Three-dimensional xenografts were grown on chicken chorioallantoic membrane and analyzed by measuring tumor wt. and immunohistochem. expression of total retinoblastoma and Ki-67.  PD-0332991 treatment decreased the proliferation of retinoblastoma pos. bladder cancer cell lines and was synergistic in combination with cisplatin.  PD-0332991 or LY2835219 treatment decreased the phosphorylation, total protein and transcript level of retinoblastoma.  Treatment resulted in a decrease in E2F target gene expression (CCNA2 and CCNE2) and cell cycle progression from G0/G1 to the S-phase but did not affect apoptosis.  In retinoblastoma neg. cells reconstituted with recombinant retinoblastoma PD-0332991 affected only phosphorylation and not the total retinoblastoma level.  These cells remained resistant to treatment.  In 3-dimensional retinoblastoma xenografts, treatment resulted in reduced tumor wt. and decreased expression of total retinoblastoma and Ki-67.  We provide preclin. evidence that CDK4/6 inhibition is a potential therapeutic strategy for retinoblastoma pos. bladder cancer that probably acts by neg. regulating retinoblastoma transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXXQ64fNhPSLVg90H21EOLACvtfcHk0liPrRubom9uxA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOqsr7O&md5=7b141310df974995067f1fc1a369f676</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2015.08.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2015.08.082%26sid%3Dliteratum%253Aachs%26aulast%3DSathe%26aufirst%3DA.%26aulast%3DKoshy%26aufirst%3DN.%26aulast%3DSchmid%26aufirst%3DS.%2BC.%26aulast%3DThalgott%26aufirst%3DM.%26aulast%3DSchwarzenbock%26aufirst%3DS.%2BM.%26aulast%3DKrause%26aufirst%3DB.%2BJ.%26aulast%3DHolm%26aufirst%3DP.%2BS.%26aulast%3DGschwend%26aufirst%3DJ.%2BE.%26aulast%3DRetz%26aufirst%3DM.%26aulast%3DNawroth%26aufirst%3DR.%26atitle%3DCDK4%252F6%2520inhibition%2520controls%2520proliferation%2520of%2520bladder%2520cancer%2520and%2520transcription%2520of%2520RB1%26jtitle%3DJ.%2520Urol.%26date%3D2016%26volume%3D195%26spage%3D771%26epage%3D779%26doi%3D10.1016%2Fj.juro.2015.08.082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anders, L.</span><span> </span><span class="NLM_article-title">Signaling through cyclin D-dependent kinases</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1890</span><span class="NLM_x">â</span> <span class="NLM_lpage">1903</span><span class="refDoi">Â DOI: 10.1038/onc.2013.137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1038%2Fonc.2013.137" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=1890-1903&author=Y.+J.+Choiauthor=L.+Anders&title=Signaling+through+cyclin+D-dependent+kinases&doi=10.1038%2Fonc.2013.137"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.137%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DAnders%26aufirst%3DL.%26atitle%3DSignaling%2520through%2520cyclin%2520D-dependent%2520kinases%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D1890%26epage%3D1903%26doi%3D10.1038%2Fonc.2013.137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Nemoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furukawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akahane, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honna-Oshiro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakahata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heike, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inukai, T.</span><span> </span><span class="NLM_article-title">Specific antileukemic activity of PD0332991, a CDK4/6 inhibitor, against Philadelphia Chromosome-Positive lymphoid leukemia</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">â</span> <span class="NLM_lpage">105</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-14-1065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1158%2F1535-7163.MCT-14-1065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=26637365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslCjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=94-105&author=A.+Nemotoauthor=S.+Saidaauthor=I.+Katoauthor=J.+Kikuchiauthor=Y.+Furukawaauthor=Y.+Maedaauthor=K.+Akahaneauthor=H.+Honna-Oshiroauthor=K.+Goiauthor=K.+Kagamiauthor=S.+Kimuraauthor=Y.+Satoauthor=S.+Okabeauthor=A.+Niwaauthor=K.+Watanabeauthor=T.+Nakahataauthor=T.+Heikeauthor=K.+Sugitaauthor=T.+Inukai&title=Specific+antileukemic+activity+of+PD0332991%2C+a+CDK4%2F6+inhibitor%2C+against+Philadelphia+Chromosome-Positive+lymphoid+leukemia&doi=10.1158%2F1535-7163.MCT-14-1065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia</span></div><div class="casAuthors">Nemoto, Atsushi; Saida, Satoshi; Kato, Itaru; Kikuchi, Jiro; Furukawa, Yusuke; Maeda, Yasuhiro; Akahane, Koshi; Honna-Oshiro, Hiroko; Goi, Kumiko; Kagami, Keiko; Kimura, Shinya; Sato, Yuko; Okabe, Seiichi; Niwa, Akira; Watanabe, Kenichiro; Nakahata, Tatsutoshi; Heike, Toshio; Sugita, Kanji; Inukai, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-105</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">S-phase progression of the cell cycle is accelerated in tumors through various genetic abnormalities, and, thus, pharmacol. inhibition of altered cell-cycle progression would be an effective strategy to control tumors.  In the current study, we analyzed the antileukemic activity of three available small mols. targeting CDK4/CDK6 against lymphoid crisis of chronic myeloid leukemia (CML-LC) and Philadelphia chromosome-pos. acute lymphoblastic leukemia (Ph+ ALL), and found that all three mols. showed specific activities against leukemic cell lines derived from CML-LC and Ph+ ALL.  In particular, PD0332991 exhibited extremely high antileukemic activity against CML-LC and Ph+ ALL cell lines in the nanomolar range by the induction of G0-G1 arrest and partially cell death through dephosphorylation of pRb and downregulation of the genes that are involved in S-phase transition.  As an underlying mechanism for favorable sensitivity to the small mols. targeting CDK4/CDK6, cell-cycle progression of Ph+ lymphoid leukemia cells was regulated by transcriptional and posttranscriptional modulation of CDK4 as well as Cyclin D2 gene expression under the control of BCR-ABL probably through the PI3K pathway.  Consistently, the gene expression level of Cyclin D2 in Ph+ lymphoid leukemia cells was significantly higher than that in Ph- lymphoid leukemia cells.  Of note, three Ph+ ALL cell lines having the T315I mutation also showed sensitivity to PD0332991.  In a xenograft model, PD0332991, but not imatinib, suppressed dissemination of Ph+ ALL having the T315I mutation and prolonged survival, demonstrating that this reagent would be a new therapeutic modality for relapsed CML-LC and Ph+ ALL patients after treatment with tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlKt6ulfSTQrVg90H21EOLACvtfcHk0liPrRubom9uxA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslCjsA%253D%253D&md5=6745483a8536b59af2948072fbfadb22</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-1065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-1065%26sid%3Dliteratum%253Aachs%26aulast%3DNemoto%26aufirst%3DA.%26aulast%3DSaida%26aufirst%3DS.%26aulast%3DKato%26aufirst%3DI.%26aulast%3DKikuchi%26aufirst%3DJ.%26aulast%3DFurukawa%26aufirst%3DY.%26aulast%3DMaeda%26aufirst%3DY.%26aulast%3DAkahane%26aufirst%3DK.%26aulast%3DHonna-Oshiro%26aufirst%3DH.%26aulast%3DGoi%26aufirst%3DK.%26aulast%3DKagami%26aufirst%3DK.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DOkabe%26aufirst%3DS.%26aulast%3DNiwa%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DNakahata%26aufirst%3DT.%26aulast%3DHeike%26aufirst%3DT.%26aulast%3DSugita%26aufirst%3DK.%26aulast%3DInukai%26aufirst%3DT.%26atitle%3DSpecific%2520antileukemic%2520activity%2520of%2520PD0332991%252C%2520a%2520CDK4%252F6%2520inhibitor%252C%2520against%2520Philadelphia%2520Chromosome-Positive%2520lymphoid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D94%26epage%3D105%26doi%3D10.1158%2F1535-7163.MCT-14-1065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Yung-Chi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prusoff, W. H.</span><span> </span><span class="NLM_article-title">Relationship between the inhibition constant (<i>K</i>I) and the concentration of inhibitor which causes 50% inhibition (<i>I</i><sub>50</sub>) of an enzymatic reaction</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3099</span><span class="NLM_x">â</span> <span class="NLM_lpage">3108</span><span class="refDoi">Â DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=4202581" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=C.+Yung-Chiauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28KI%29+and+the+concentration+of+inhibitor+which+causes+50%25+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DYung-Chi%26aufirst%3DC.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528KI%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2525%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Yu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basnet, S. K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumarasiri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diab, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">â</span> <span class="NLM_lpage">126</span><span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.03.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.ejmech.2015.03.032" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=116-126&author=M.+Yuauthor=P.+Liauthor=S.+K.+C.+Basnetauthor=M.+Kumarasiriauthor=S.+Diabauthor=T.+Teoauthor=H.+Albrechtauthor=S.+Wang&title=Discovery+of+4-%28dihydropyridinon-3-yl%29amino-5-methylthieno%5B2%2C3-d%5Dpyrimidine+derivatives+as+potent+Mnk+inhibitors%3A+synthesis%2C+structure-activity+relationship+analysis+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2015.03.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.032%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DBasnet%26aufirst%3DS.%2BK.%2BC.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%25204-%2528dihydropyridinon-3-yl%2529amino-5-methylthieno%255B2%252C3-d%255Dpyrimidine%2520derivatives%2520as%2520potent%2520Mnk%2520inhibitors%253A%2520synthesis%252C%2520structure-activity%2520relationship%2520analysis%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D116%26epage%3D126%26doi%3D10.1016%2Fj.ejmech.2015.03.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Teo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillam, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sykes, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">â</span> <span class="NLM_lpage">623</span><span class="refDoi">Â DOI: 10.1016/j.canlet.2014.12.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.canlet.2014.12.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=25527453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislKguw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2015&pages=612-623&author=T.+Teoauthor=M.+Yuauthor=Y.+Yangauthor=T.+Gillamauthor=F.+Lamauthor=M.+J.+Sykesauthor=S.+Wang&title=Pharmacologic+co-inhibition+of+Mnks+and+mTORC1+synergistically+suppresses+proliferation+and+perturbs+cell+cycle+progression+in+blast+crisis-chronic+myeloid+leukemia+cells&doi=10.1016%2Fj.canlet.2014.12.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells</span></div><div class="casAuthors">Teo, Theodosia; Yu, Mingfeng; Yang, Yuchao; Gillam, Todd; Lam, Frankie; Sykes, Matthew J.; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">612-623</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The Ras/Raf/MAPK and PI3K/Akt/mTORC1 cascades are two most aberrantly regulated pathways in cancers.  As MAPK-interacting kinases (Mnks) are part of the convergent node of these two pathways, and play a pivotal role in cellular transformation, targeting Mnks has emerged as a potential therapeutic strategy.  Herein, a dual-specific Mnk1/2 inhibitor MNKI-57 and a potent Mnk2-specific inhibitor MNKI-4 were selected for a panel screen against 28 human cancer cell lines.  The study reveals that MNKI-57 and MNKI-4 are most potent against leukemia cells KYO-1 (i.e. BC-CML) and KG-1 (i.e. AML).  Interestingly, we found that sensitivity of selected leukemia cells to Mnk inhibitors is correlated with the level of phosphorylated 4E-BP1 at Thr70.  The anti-proliferative effects of Mnk inhibitors are cytostatic in the sensitive KYO-1 cells, inducing significant G1 arrest via down-regulation of cyclin D1 expression.  In KYO-1 cells where Akt is not constitutively active, Mnk inhibitors increase the sensitivity of cells to rapamycin, resulting in a more pronounced anti-proliferative activity.  Remarkably, the synergistic anti-proliferative effects are assocd. with a marked de-phosphorylation of 4E-BP1 at Thr70.  Collectively, these data highlight the importance of 4E-BP1 as a key integrator in the MAPK and mTORC1 cascades, and suggest that a combined pharmacol. inhibition of mTORC1 and Mnk kinases offers an innovative therapeutic opportunity in BC-CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonXVLjuzQn5rVg90H21EOLACvtfcHk0lj2qf-Wfnk27A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislKguw%253D%253D&md5=a6b1457af0a8430b7976195e8e1b9c5d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2014.12.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2014.12.029%26sid%3Dliteratum%253Aachs%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGillam%26aufirst%3DT.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DSykes%26aufirst%3DM.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DPharmacologic%2520co-inhibition%2520of%2520Mnks%2520and%2520mTORC1%2520synergistically%2520suppresses%2520proliferation%2520and%2520perturbs%2520cell%2520cycle%2520progression%2520in%2520blast%2520crisis-chronic%2520myeloid%2520leukemia%2520cells%26jtitle%3DCancer%2520Lett.%26date%3D2015%26volume%3D357%26spage%3D612%26epage%3D623%26doi%3D10.1016%2Fj.canlet.2014.12.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Sorota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margulis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priestley, T.</span><span> </span><span class="NLM_article-title">Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">â</span> <span class="NLM_lpage">57</span><span class="refDoi">Â DOI: 10.1089/adt.2005.3.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1089%2Fadt.2005.3.47" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2005&pages=47-57&author=S.+Sorotaauthor=X.+S.+Zhangauthor=M.+Margulisauthor=K.+Tuckerauthor=T.+Priestley&title=Characterization+of+a+hERG+screen+using+the+IonWorks+HT%3A+comparison+to+a+hERG+rubidium+efflux+screen&doi=10.1089%2Fadt.2005.3.47"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1089%2Fadt.2005.3.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2005.3.47%26sid%3Dliteratum%253Aachs%26aulast%3DSorota%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%2BS.%26aulast%3DMargulis%26aufirst%3DM.%26aulast%3DTucker%26aufirst%3DK.%26aulast%3DPriestley%26aufirst%3DT.%26atitle%3DCharacterization%2520of%2520a%2520hERG%2520screen%2520using%2520the%2520IonWorks%2520HT%253A%2520comparison%2520to%2520a%2520hERG%2520rubidium%2520efflux%2520screen%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2005%26volume%3D3%26spage%3D47%26epage%3D57%26doi%3D10.1089%2Fadt.2005.3.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Moody, G. C.</span><span> </span><span class="NLM_article-title">Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">â</span> <span class="NLM_lpage">75</span><span class="refDoi">Â DOI: 10.1080/004982599238812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1080%2F004982599238812" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1999&pages=53-75&author=G.+C.+Moody&title=Fully+automated+analysis+of+activities+catalysed+by+the+major+human+liver+cytochrome+P450+%28CYP%29+enzymes%3A+assessment+of+human+CYP+inhibition+potential&doi=10.1080%2F004982599238812"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1080%2F004982599238812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F004982599238812%26sid%3Dliteratum%253Aachs%26aulast%3DMoody%26aufirst%3DG.%2BC.%26atitle%3DFully%2520automated%2520analysis%2520of%2520activities%2520catalysed%2520by%2520the%2520major%2520human%2520liver%2520cytochrome%2520P450%2520%2528CYP%2529%2520enzymes%253A%2520assessment%2520of%2520human%2520CYP%2520inhibition%2520potential%26jtitle%3DXenobiotica%26date%3D1999%26volume%3D29%26spage%3D53%26epage%3D75%26doi%3D10.1080%2F004982599238812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, H. M.</span><span> </span><span class="NLM_article-title">Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1507</span><span class="NLM_x">â</span> <span class="NLM_lpage">1514</span><span class="refDoi">Â DOI: 10.1111/j.1745-7254.2008.00908.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1111%2Fj.1745-7254.2008.00908.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=19026171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisF2jsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=1507-1514&author=L.+Zhangauthor=M.+J.+Weiauthor=C.+Y.+Zhaoauthor=H.+M.+Qi&title=Determination+of+the+inhibitory+potential+of+6+fluoroquinolones+on+CYP1A2+and+CYP2C9+in+human+liver+microsomes&doi=10.1111%2Fj.1745-7254.2008.00908.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes</span></div><div class="casAuthors">Zhang, Li; Wei, Min-ji; Zhao, Cai-yun; Qi, Hui-min</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1507-1514</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim: To det. the inhibitory potential of 2 new fluoroquinolones, caderofloxacin and antofloxacin, together with 4 marketed fluoroquinolones, moxifloxacin, gatifloxacin, levofloxacin, and ciprofloxacin, on the activity of cytochrome P 450 isoforms 1A2 (CYP1A2) and 2C9 (CYP2C9).  Methods: Probe substrates, phenacetin (CYP1A2), and tolbutamide (CYP2C9) were incubated with human liver microsomes and the metabolites were analyzed by liq. chromatog./mass spectrometry using electrospray ionization in pos. or neg. mode.  Glipizide was used as the internal std. in both modes.  The inhibitory potential of fluoroquinolones on CYP1A2 and CYP2C9 was investigated.  Results: The IC50 values (Î¼mol/L) detd. with the cocktail were in agreement with individual probe substrates (Î±-naphthoflavone: 0.27 vs 0.26; sulfaphenazole: 0.49 vs 0.37).  Ciprofloxacin showed weak inhibition on both the activity of CYP1A2 (IC50 135 Î¼mol/L) and CYP2C9 (IC50 180 Î¼mol/L), whereas levofloxacin inhibited only CYP2C9 (IC50 210 Î¼mol/L).  Caderofloxacin, antofloxacin, moxifloxacin, and gatifloxacin showed little or no inhibition on the activity of CYP1A2 or CYP2C9 when tested at comparable concns. (0-200 mg/L).  Conclusion: Caderofloxacin, antofloxacin, moxifloxacin, and gatifloxacin are negligible inhibitors to CYP1A2 and CYP2C9.  The in vitro system can be used as a high-throughput model to screen similar compds. for the early identification of drug-drug interaction potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibxhJIO3TTLVg90H21EOLACvtfcHk0liS_5yjAizxBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisF2jsQ%253D%253D&md5=43594f01970c6087eeaead09e7467cd9</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1111%2Fj.1745-7254.2008.00908.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1745-7254.2008.00908.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DM.%2BJ.%26aulast%3DZhao%26aufirst%3DC.%2BY.%26aulast%3DQi%26aufirst%3DH.%2BM.%26atitle%3DDetermination%2520of%2520the%2520inhibitory%2520potential%2520of%25206%2520fluoroquinolones%2520on%2520CYP1A2%2520and%2520CYP2C9%2520in%2520human%2520liver%2520microsomes%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2008%26volume%3D29%26spage%3D1507%26epage%3D1514%26doi%3D10.1111%2Fj.1745-7254.2008.00908.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Dearden, J. C.</span><span> </span><span class="NLM_article-title">Partitioning and lipophilicity in quantitative structure-activity relationships</span> <span class="citation_source-journal">Environ. Health Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">â</span> <span class="NLM_lpage">228</span><span class="refDoi">Â DOI: 10.1289/ehp.8561203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1289%2Fehp.8561203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=3905374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADyaL2MXmtVGitbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1985&pages=203-228&author=J.+C.+Dearden&title=Partitioning+and+lipophilicity+in+quantitative+structure-activity+relationships&doi=10.1289%2Fehp.8561203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Partitioning and lipophilicity in quantitative structure-activity relationships</span></div><div class="casAuthors">Dearden, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Environmental Health Perspectives</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">203-28</span>CODEN:
                <span class="NLM_cas:coden">EVHPAZ</span>;
        ISSN:<span class="NLM_cas:issn">0091-6765</span>.
    </div><div class="casAbstract">A review with 171 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroyh1jdHUsxLVg90H21EOLACvtfcHk0liS_5yjAizxBg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXmtVGitbo%253D&md5=08c7f76452d6a5348be3d1f09b3c4a43</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1289%2Fehp.8561203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1289%252Fehp.8561203%26sid%3Dliteratum%253Aachs%26aulast%3DDearden%26aufirst%3DJ.%2BC.%26atitle%3DPartitioning%2520and%2520lipophilicity%2520in%2520quantitative%2520structure-activity%2520relationships%26jtitle%3DEnviron.%2520Health%2520Perspect.%26date%3D1985%26volume%3D61%26spage%3D203%26epage%3D228%26doi%3D10.1289%2Fehp.8561203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">SchÃ¶nherr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollatz, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haznar-Garbacz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanke, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitschies, W.</span><span> </span><span class="NLM_article-title">Characterisation of selected active agents regarding pKa values, solubility concentrations and pH profiles by SiriusT3</span> <span class="citation_source-journal">Eur. J. Pharm. Biopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">â</span> <span class="NLM_lpage">170</span><span class="refDoi">Â DOI: 10.1016/j.ejpb.2015.02.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.ejpb.2015.02.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=25758123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A280%3ADC%252BC2MnivVKlsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2015&pages=155-170&author=D.+Sch%C3%B6nherrauthor=U.+Wollatzauthor=D.+Haznar-Garbaczauthor=U.+Hankeauthor=K.+J.+Boxauthor=R.+Taylorauthor=R.+Ruizauthor=S.+Beatoauthor=D.+Beckerauthor=W.+Weitschies&title=Characterisation+of+selected+active+agents+regarding+pKa+values%2C+solubility+concentrations+and+pH+profiles+by+SiriusT3&doi=10.1016%2Fj.ejpb.2015.02.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Characterisation of selected active agents regarding pKa values, solubility concentrations and pH profiles by SiriusT3</span></div><div class="casAuthors">Schonherr D; Wollatz U; Haznar-Garbacz D; Hanke U; Box K J; Taylor R; Ruiz R; Beato S; Becker D; Weitschies W</div><div class="citationInfo"><span class="NLM_cas:title">European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The aim of this work was to determine pKa values and solubility properties of 34active agents using the SiriusT3 apparatus.  The selected drug substances belong to the groups of ACE-inhibitors, Î²-blockers, antidiabetics and lipid lowering substances.  Experimentally obtained pKa and intrinsic solubility values were compared to calculated values (program ACD/ChemSketch) and pKa values to published data as well.  Solubility-pH profiles were generated to visualise the substance solubility over the gastrointestinal pH range.  The relationship between the solubility characteristic of a substance, its bioavailability and categorisation according to the Biopharmaceutics Classification System (BCS) was examined as well.  The results showed a good agreement between experimentally obtained, calculated and published pKa values.  The measured and calculated intrinsic solubility values indicated several major deviations.  All solubility-pH profiles showed the expected shape and appearance for acids, bases or zwitterionic substances.  The obtained results for the pKa and solubility measurements of the examined active agents may help to predict their physicochemical behaviour in vivo, and to understand the bioavailability of the substances according to their BCS categorisation.  The easy and reproducible determination of pKa and solubility values makes the SiriusT3 apparatus a useful tool in early stages of drug and formulation development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0tGrDkvlZJ-2qxNLjzXe8fW6udTcc2eazlJiowHo-LLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnivVKlsw%253D%253D&md5=02100c72ca191e1039faa3b20d5714d8</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ejpb.2015.02.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejpb.2015.02.028%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25B6nherr%26aufirst%3DD.%26aulast%3DWollatz%26aufirst%3DU.%26aulast%3DHaznar-Garbacz%26aufirst%3DD.%26aulast%3DHanke%26aufirst%3DU.%26aulast%3DBox%26aufirst%3DK.%2BJ.%26aulast%3DTaylor%26aufirst%3DR.%26aulast%3DRuiz%26aufirst%3DR.%26aulast%3DBeato%26aufirst%3DS.%26aulast%3DBecker%26aufirst%3DD.%26aulast%3DWeitschies%26aufirst%3DW.%26atitle%3DCharacterisation%2520of%2520selected%2520active%2520agents%2520regarding%2520pKa%2520values%252C%2520solubility%2520concentrations%2520and%2520pH%2520profiles%2520by%2520SiriusT3%26jtitle%3DEur.%2520J.%2520Pharm.%2520Biopharm.%26date%3D2015%26volume%3D92%26spage%3D155%26epage%3D170%26doi%3D10.1016%2Fj.ejpb.2015.02.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Gan, L. S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thakker, D. R.</span><span> </span><span class="NLM_article-title">Applications of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">â</span> <span class="NLM_lpage">98</span><span class="refDoi">Â DOI: 10.1016/S0169-409X(96)00427-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2FS0169-409X%2896%2900427-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=77-98&author=L.+S.+L.+Ganauthor=D.+R.+Thakker&title=Applications+of+the+Caco-2+model+in+the+design+and+development+of+orally+active+drugs%3A+elucidation+of+biochemical+and+physical+barriers+posed+by+the+intestinal+epithelium&doi=10.1016%2FS0169-409X%2896%2900427-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900427-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900427-9%26sid%3Dliteratum%253Aachs%26aulast%3DGan%26aufirst%3DL.%2BS.%2BL.%26aulast%3DThakker%26aufirst%3DD.%2BR.%26atitle%3DApplications%2520of%2520the%2520Caco-2%2520model%2520in%2520the%2520design%2520and%2520development%2520of%2520orally%2520active%2520drugs%253A%2520elucidation%2520of%2520biochemical%2520and%2520physical%2520barriers%2520posed%2520by%2520the%2520intestinal%2520epithelium%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D77%26epage%3D98%26doi%3D10.1016%2FS0169-409X%2896%2900427-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Bansal, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bansal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ying, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsoum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swords, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battiwalla, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padmanabhan, S.</span><span> </span><span class="NLM_article-title">Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">4591</span><span class="NLM_x">â</span> <span class="NLM_lpage">4599</span><span class="refDoi">Â DOI: 10.1182/blood-2009-10-247239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1182%2Fblood-2009-10-247239" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=4591-4599&author=H.+Bansalauthor=S.+Bansalauthor=M.+Raoauthor=K.+P.+Foleyauthor=J.+Sangauthor=D.+A.+Proiaauthor=R.+K.+Blackmanauthor=W.+Yingauthor=J.+Barsoumauthor=M.+R.+Baerauthor=K.+Kellyauthor=R.+Swordsauthor=G.+E.+Tomlinsonauthor=M.+Battiwallaauthor=F.+J.+Gilesauthor=K.+P.+Leeauthor=S.+Padmanabhan&title=Heat+shock+protein+90+regulates+the+expression+of+Wilms+tumor+1+protein+in+myeloid+leukemias&doi=10.1182%2Fblood-2009-10-247239"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-10-247239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-10-247239%26sid%3Dliteratum%253Aachs%26aulast%3DBansal%26aufirst%3DH.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DRao%26aufirst%3DM.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DYing%26aufirst%3DW.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26aulast%3DKelly%26aufirst%3DK.%26aulast%3DSwords%26aufirst%3DR.%26aulast%3DTomlinson%26aufirst%3DG.%2BE.%26aulast%3DBattiwalla%26aufirst%3DM.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DLee%26aufirst%3DK.%2BP.%26aulast%3DPadmanabhan%26aufirst%3DS.%26atitle%3DHeat%2520shock%2520protein%252090%2520regulates%2520the%2520expression%2520of%2520Wilms%2520tumor%25201%2520protein%2520in%2520myeloid%2520leukemias%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D4591%26epage%3D4599%26doi%3D10.1182%2Fblood-2009-10-247239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 32 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Tao Yang, Mengshi Hu, Wenyan Qi, Zhuang Yang, Minghai Tang, Jun He, Yong Chen, Peng Bai, Xue Yuan, Chufeng Zhang, Kongjun Liu, Yulin Lu, Mingli Xiang, <span class="NLM_string-name hlFld-ContribAuthor">Lijuan Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (22)
                                     , 10305-10320. <a href="https://doi.org/10.1021/acs.jmedchem.9b01348" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01348</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01348%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BOrally%252BEffective%252BDual%252BJanus%252BKinase%252B2%25252FFLT3%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BAcute%252BMyelogenous%252BLeukemia%252Band%252BMyeloproliferative%252BNeoplasms%26aulast%3DYang%26aufirst%3DTao%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D15082019%26date%3D08112019%26date%3D31102019%26volume%3D62%26issue%3D22%26spage%3D10305%26epage%3D10320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sally-Ann  Poulsen</span>  . </span><span class="cited-content_cbyCitation_article-title">Editorial: Excellence in Medicinal Chemistry from Australia. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (20)
                                     , 8253-8256. <a href="https://doi.org/10.1021/acs.jmedchem.7b01439" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01439</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01439%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DEditorial%25253A%252BExcellence%252Bin%252BMedicinal%252BChemistry%252Bfrom%252BAustralia%26aulast%3DPoulsen%26aufirst%3DSally-Ann%26date%3D2017%26date%3D2017%26date%3D06102017%26date%3D09102017%26date%3D26102017%26volume%3D60%26issue%3D20%26spage%3D8253%26epage%3D8256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eclair Venturini  Filho</span>, <span class="hlFld-ContribAuthor ">Erick M.C.  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Sergio  Pinheiro</span>, <span class="hlFld-ContribAuthor ">Sandro J.  Greco</span>. </span><span class="cited-content_cbyCitation_article-title">Aminopyrimidines: Recent synthetic procedures and anticancer activities. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2021,</strong> <em>92 </em>, 132256. <a href="https://doi.org/10.1016/j.tet.2021.132256" title="DOI URL">https://doi.org/10.1016/j.tet.2021.132256</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2021.132256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2021.132256%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DAminopyrimidines%25253A%252BRecent%252Bsynthetic%252Bprocedures%252Band%252Banticancer%252Bactivities%26aulast%3DFilho%26aufirst%3DEclair%2BVenturini%26date%3D2021%26volume%3D92%26spage%3D132256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nancy Y.  Guerrero-Pepinosa</span>, <span class="hlFld-ContribAuthor ">MarÃ­a C.  Cardona-Trujillo</span>, <span class="hlFld-ContribAuthor ">Sandra C.  GarzÃ³n-CastaÃ±o</span>, <span class="hlFld-ContribAuthor ">Luz Angela  Veloza</span>, <span class="hlFld-ContribAuthor ">Juan C.  SepÃºlveda-Arias</span>. </span><span class="cited-content_cbyCitation_article-title">Antiproliferative activity of thiazole and oxazole derivatives: A systematic review of in vitro and in vivo studies. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2021,</strong> <em>138 </em>, 111495. <a href="https://doi.org/10.1016/j.biopha.2021.111495" title="DOI URL">https://doi.org/10.1016/j.biopha.2021.111495</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2021.111495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2021.111495%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3DAntiproliferative%252Bactivity%252Bof%252Bthiazole%252Band%252Boxazole%252Bderivatives%25253A%252BA%252Bsystematic%252Breview%252Bof%252Bin%252Bvitro%252Band%252Bin%252Bvivo%252Bstudies%26aulast%3DGuerrero-Pepinosa%26aufirst%3DNancy%2BY.%26date%3D2021%26volume%3D138%26spage%3D111495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingfeng  Yu</span>, <span class="hlFld-ContribAuthor ">Yi  Long</span>, <span class="hlFld-ContribAuthor ">Yuchao  Yang</span>, <span class="hlFld-ContribAuthor ">Manjun  Li</span>, <span class="hlFld-ContribAuthor ">Theodosia  Teo</span>, <span class="hlFld-ContribAuthor ">Benjamin  Noll</span>, <span class="hlFld-ContribAuthor ">Stephen  Philip</span>, <span class="hlFld-ContribAuthor ">Shudong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a potent, highly selective, and orally bioavailable inhibitor of CDK8 through a structure-based optimisation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>218 </em>, 113391. <a href="https://doi.org/10.1016/j.ejmech.2021.113391" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113391</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113391%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252Bpotent%25252C%252Bhighly%252Bselective%25252C%252Band%252Borally%252Bbioavailable%252Binhibitor%252Bof%252BCDK8%252Bthrough%252Ba%252Bstructure-based%252Boptimisation%26aulast%3DYu%26aufirst%3DMingfeng%26date%3D2021%26volume%3D218%26spage%3D113391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yi  Long</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Yu</span>, <span class="hlFld-ContribAuthor ">Aleksandra M.  Ochnik</span>, <span class="hlFld-ContribAuthor ">Jasmine D.  Karanjia</span>, <span class="hlFld-ContribAuthor ">Sunita KC.  Basnet</span>, <span class="hlFld-ContribAuthor ">Alemwork A.  Kebede</span>, <span class="hlFld-ContribAuthor ">Lianmeng  Kou</span>, <span class="hlFld-ContribAuthor ">Shudong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 4-azaaryl-N-phenylpyrimidin-2-amine derivatives as potent and selective FLT3 inhibitors for acute myeloid leukaemia with FLT3 mutations. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113215. <a href="https://doi.org/10.1016/j.ejmech.2021.113215" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113215</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113215%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B4-azaaryl-N-phenylpyrimidin-2-amine%252Bderivatives%252Bas%252Bpotent%252Band%252Bselective%252BFLT3%252Binhibitors%252Bfor%252Bacute%252Bmyeloid%252Bleukaemia%252Bwith%252BFLT3%252Bmutations%26aulast%3DLong%26aufirst%3DYi%26date%3D2021%26volume%3D213%26spage%3D113215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alessandra  Ammazzalorso</span>, <span class="hlFld-ContribAuthor ">Mariangela  Agamennone</span>, <span class="hlFld-ContribAuthor ">Barbara  De Filippis</span>, <span class="hlFld-ContribAuthor ">Marialuigia  Fantacuzzi</span>. </span><span class="cited-content_cbyCitation_article-title">Development of CDK4/6 Inhibitors: A Five Years Update. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (5)
                                     , 1488. <a href="https://doi.org/10.3390/molecules26051488" title="DOI URL">https://doi.org/10.3390/molecules26051488</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26051488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26051488%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DDevelopment%252Bof%252BCDK4%25252F6%252BInhibitors%25253A%252BA%252BFive%252BYears%252BUpdate%26aulast%3DAmmazzalorso%26aufirst%3DAlessandra%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D5%26spage%3D1488" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingfeng  Yu</span>, <span class="hlFld-ContribAuthor ">Theodosia  Teo</span>, <span class="hlFld-ContribAuthor ">Yuchao  Yang</span>, <span class="hlFld-ContribAuthor ">Manjun  Li</span>, <span class="hlFld-ContribAuthor ">Yi  Long</span>, <span class="hlFld-ContribAuthor ">Stephen  Philip</span>, <span class="hlFld-ContribAuthor ">Benjamin  Noll</span>, <span class="hlFld-ContribAuthor ">Gary K.  Heinemann</span>, <span class="hlFld-ContribAuthor ">Sarah  Diab</span>, <span class="hlFld-ContribAuthor ">Preethi  Eldi</span>, <span class="hlFld-ContribAuthor ">Laychiluh  Mekonnen</span>, <span class="hlFld-ContribAuthor ">Abel T.  Anshabo</span>, <span class="hlFld-ContribAuthor ">Muhammed H.  Rahaman</span>, <span class="hlFld-ContribAuthor ">Robert  Milne</span>, <span class="hlFld-ContribAuthor ">John D.  Hayball</span>, <span class="hlFld-ContribAuthor ">Shudong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113248. <a href="https://doi.org/10.1016/j.ejmech.2021.113248" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113248</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113248&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113248%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPotent%252Band%252Borally%252Bbioavailable%252BCDK8%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bstructure-activity%252Brelationship%252Banalysis%252Band%252Bbiological%252Bevaluation%26aulast%3DYu%26aufirst%3DMingfeng%26date%3D2021%26volume%3D214%26spage%3D113248" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaojiao  Luo</span>, <span class="hlFld-ContribAuthor ">Yu  Zhao</span>, <span class="hlFld-ContribAuthor ">Pan  Tang</span>, <span class="hlFld-ContribAuthor ">Xingkai  Du</span>, <span class="hlFld-ContribAuthor ">Feng  Li</span>, <span class="hlFld-ContribAuthor ">Qingying  Wang</span>, <span class="hlFld-ContribAuthor ">Rong  Li</span>, <span class="hlFld-ContribAuthor ">Jun  He</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of new small-molecule cyclin-dependent kinase 6 inhibitors through computational approaches. </span><span class="cited-content_cbyCitation_journal-name">Molecular Diversity</span><span> <strong>2021,</strong> <em>25 </em>
                                    (1)
                                     , 367-382. <a href="https://doi.org/10.1007/s11030-020-10120-3" title="DOI URL">https://doi.org/10.1007/s11030-020-10120-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11030-020-10120-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11030-020-10120-3%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Diversity%26atitle%3DDiscovery%252Bof%252Bnew%252Bsmall-molecule%252Bcyclin-dependent%252Bkinase%252B6%252Binhibitors%252Bthrough%252Bcomputational%252Bapproaches%26aulast%3DLuo%26aufirst%3DXiaojiao%26date%3D2021%26date%3D2020%26volume%3D25%26issue%3D1%26spage%3D367%26epage%3D382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kai  Yuan</span>, <span class="hlFld-ContribAuthor ">Xiao  Wang</span>, <span class="hlFld-ContribAuthor ">Haojie  Dong</span>, <span class="hlFld-ContribAuthor ">Wenjian  Min</span>, <span class="hlFld-ContribAuthor ">Haiping  Hao</span>, <span class="hlFld-ContribAuthor ">Peng  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     , 30-54. <a href="https://doi.org/10.1016/j.apsb.2020.05.001" title="DOI URL">https://doi.org/10.1016/j.apsb.2020.05.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2020.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2020.05.001%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DSelective%252Binhibition%252Bof%252BCDK4%25252F6%25253A%252BA%252Bsafe%252Band%252Beffective%252Bstrategy%252Bfor%252Bdeveloping%252Banticancer%252Bdrugs%26aulast%3DYuan%26aufirst%3DKai%26date%3D2021%26volume%3D11%26issue%3D1%26spage%3D30%26epage%3D54" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Wang</span>, <span class="hlFld-ContribAuthor ">Tongtong  Liu</span>, <span class="hlFld-ContribAuthor ">Shiming  Chen</span>, <span class="hlFld-ContribAuthor ">Mingfei  Wu</span>, <span class="hlFld-ContribAuthor ">Jianfei  Han</span>, <span class="hlFld-ContribAuthor ">Zeng  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of 3-(4-pyridyl)-5-(4-sulfamido-phenyl)-1,2,4-oxadiazole derivatives as novel GSK-3Î² inhibitors and evaluation of their potential as multifunctional anti-Alzheimer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>209 </em>, 112874. <a href="https://doi.org/10.1016/j.ejmech.2020.112874" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112874</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112874&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112874%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252B3-%2525284-pyridyl%252529-5-%2525284-sulfamido-phenyl%252529-1%25252C2%25252C4-oxadiazole%252Bderivatives%252Bas%252Bnovel%252BGSK-3%2525CE%2525B2%252Binhibitors%252Band%252Bevaluation%252Bof%252Btheir%252Bpotential%252Bas%252Bmultifunctional%252Banti-Alzheimer%252Bagents%26aulast%3DWang%26aufirst%3DMin%26date%3D2021%26volume%3D209%26spage%3D112874" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amany  Belal</span>. </span><span class="cited-content_cbyCitation_article-title">3D-Pharmacophore Modeling, Molecular Docking, and Virtual Screening for Discovery of Novel CDK4/6 Selective Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>47 </em>
                                    (1)
                                     , 317-333. <a href="https://doi.org/10.1134/S1068162021330013" title="DOI URL">https://doi.org/10.1134/S1068162021330013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1068162021330013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1068162021330013%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Bioorganic%2520Chemistry%26atitle%3D3D-Pharmacophore%252BModeling%25252C%252BMolecular%252BDocking%25252C%252Band%252BVirtual%252BScreening%252Bfor%252BDiscovery%252Bof%252BNovel%252BCDK4%25252F6%252BSelective%252BInhibitors%26aulast%3DBelal%26aufirst%3DAmany%26date%3D2021%26date%3D2021%26volume%3D47%26issue%3D1%26spage%3D317%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Besufekad  Abebe</span>, <span class="hlFld-ContribAuthor ">Solomon  Tadesse</span>, <span class="hlFld-ContribAuthor ">Ariaya  Hymete</span>, <span class="hlFld-ContribAuthor ">Daniel  Bisrat</span>, . </span><span class="cited-content_cbyCitation_article-title">Antiproliferative Effects of Alkaloids from the Bulbs of Crinum abyscinicum Hochst. ExA. Rich. </span><span class="cited-content_cbyCitation_journal-name">Evidence-Based Complementary and Alternative Medicine</span><span> <strong>2020,</strong> <em>2020 </em>, 1-8. <a href="https://doi.org/10.1155/2020/2529730" title="DOI URL">https://doi.org/10.1155/2020/2529730</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2020/2529730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2020%2F2529730%26sid%3Dliteratum%253Aachs%26jtitle%3DEvidence-Based%2520Complementary%2520and%2520Alternative%2520Medicine%26atitle%3DAntiproliferative%252BEffects%252Bof%252BAlkaloids%252Bfrom%252Bthe%252BBulbs%252Bof%252BCrinum%252Babyscinicum%252BHochst.%252BExA.%252BRich%26aulast%3DAbebe%26aufirst%3DBesufekad%26date%3D2020%26volume%3D2020%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brilliant N.  Marak</span>, <span class="hlFld-ContribAuthor ">Jayanta  Dowarah</span>, <span class="hlFld-ContribAuthor ">Laldingluaia  Khiangte</span>, <span class="hlFld-ContribAuthor ">Ved Prakash  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112571. <a href="https://doi.org/10.1016/j.ejmech.2020.112571" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112571</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112571&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112571%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bcomprehensive%252Binsight%252Bon%252Bthe%252Brecent%252Bdevelopment%252Bof%252BCyclic%252BDependent%252BKinase%252Binhibitors%252Bas%252Banticancer%252Bagents%26aulast%3DMarak%26aufirst%3DBrilliant%2BN.%26date%3D2020%26volume%3D203%26spage%3D112571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kai  Yuan</span>, <span class="hlFld-ContribAuthor ">Wenjian  Min</span>, <span class="hlFld-ContribAuthor ">Xiao  Wang</span>, <span class="hlFld-ContribAuthor ">Jiaxing  Li</span>, <span class="hlFld-ContribAuthor ">Wenbin  Kuang</span>, <span class="hlFld-ContribAuthor ">Fang  Zhang</span>, <span class="hlFld-ContribAuthor ">Shengnan  Xie</span>, <span class="hlFld-ContribAuthor ">Peng  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (12)
                                     , 1121-1136. <a href="https://doi.org/10.4155/fmc-2020-0011" title="DOI URL">https://doi.org/10.4155/fmc-2020-0011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2020-0011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2020-0011%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Band%252Bselective%252BCDK4%25252F6%252Binhibitors%252Bby%252Bpharmacophore%252Band%252Bstructure-based%252Bvirtual%252Bscreening%26aulast%3DYuan%26aufirst%3DKai%26date%3D2020%26volume%3D12%26issue%3D12%26spage%3D1121%26epage%3D1136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chen  Shi</span>, <span class="hlFld-ContribAuthor ">Qian  Wang</span>, <span class="hlFld-ContribAuthor ">Xuemei  Liao</span>, <span class="hlFld-ContribAuthor ">Hui  Ge</span>, <span class="hlFld-ContribAuthor ">Guoyong  Huo</span>, <span class="hlFld-ContribAuthor ">Leduo  Zhang</span>, <span class="hlFld-ContribAuthor ">Na  Chen</span>, <span class="hlFld-ContribAuthor ">Xiong  Zhai</span>, <span class="hlFld-ContribAuthor ">Yuan  Hong</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Zhe  Wang</span>, <span class="hlFld-ContribAuthor ">Weijun  Shi</span>, <span class="hlFld-ContribAuthor ">Yu  Mao</span>, <span class="hlFld-ContribAuthor ">Jianxin  Yu</span>, <span class="hlFld-ContribAuthor ">Ying  Ke</span>, <span class="hlFld-ContribAuthor ">Guangxin  Xia</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a novel series of imidazo[1â²,2â:1,6]pyrido[2,3-d]pyrimidin derivatives as potent cyclin-dependent kinase 4/6 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>193 </em>, 112239. <a href="https://doi.org/10.1016/j.ejmech.2020.112239" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112239</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112239%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252Bnovel%252Bseries%252Bof%252Bimidazo%25255B1%2525E2%252580%2525B2%25252C2%2525E2%252580%252599%25253A1%25252C6%25255Dpyrido%25255B2%25252C3-d%25255Dpyrimidin%252Bderivatives%252Bas%252Bpotent%252Bcyclin-dependent%252Bkinase%252B4%25252F6%252Binhibitors%26aulast%3DShi%26aufirst%3DChen%26date%3D2020%26volume%3D193%26spage%3D112239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Steinebach</span>, <span class="hlFld-ContribAuthor ">Yuen Lam Dora  Ng</span>, <span class="hlFld-ContribAuthor ">Izidor  SosiÄ</span>, <span class="hlFld-ContribAuthor ">Chih-Shia  Lee</span>, <span class="hlFld-ContribAuthor ">Sirui  Chen</span>, <span class="hlFld-ContribAuthor ">Stefanie  Lindner</span>, <span class="hlFld-ContribAuthor ">Lan Phuong  Vu</span>, <span class="hlFld-ContribAuthor ">AleÅ¡a  Bricelj</span>, <span class="hlFld-ContribAuthor ">Reza  Haschemi</span>, <span class="hlFld-ContribAuthor ">Marius  Monschke</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Steinwarz</span>, <span class="hlFld-ContribAuthor ">Karl G.  Wagner</span>, <span class="hlFld-ContribAuthor ">Gerd  Bendas</span>, <span class="hlFld-ContribAuthor ">Ji  Luo</span>, <span class="hlFld-ContribAuthor ">Michael  GÃ¼tschow</span>, <span class="hlFld-ContribAuthor ">Jan  KrÃ¶nke</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2020,</strong> <em>11 </em>
                                    (13)
                                     , 3474-3486. <a href="https://doi.org/10.1039/D0SC00167H" title="DOI URL">https://doi.org/10.1039/D0SC00167H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0SC00167H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0SC00167H%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DSystematic%252Bexploration%252Bof%252Bdifferent%252BE3%252Bubiquitin%252Bligases%25253A%252Ban%252Bapproach%252Btowards%252Bpotent%252Band%252Bselective%252BCDK6%252Bdegraders%26aulast%3DSteinebach%26aufirst%3DChristian%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D13%26spage%3D3474%26epage%3D3486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ramar  Sivaramakarthikeyan</span>, <span class="hlFld-ContribAuthor ">Ayyanar  Karuppasamy</span>, <span class="hlFld-ContribAuthor ">Shunmugam  Iniyaval</span>, <span class="hlFld-ContribAuthor ">Krishnaraj  Padmavathy</span>, <span class="hlFld-ContribAuthor ">Wei-Meng  Lim</span>, <span class="hlFld-ContribAuthor ">Chun-Wai  Mai</span>, <span class="hlFld-ContribAuthor ">Chennan  Ramalingan</span>. </span><span class="cited-content_cbyCitation_article-title">Phenothiazine and amide-ornamented novel nitrogen heterocyclic hybrids: synthesis, biological and molecular docking studies. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2020,</strong> <em>44 </em>
                                    (10)
                                     , 4049-4060. <a href="https://doi.org/10.1039/C9NJ05489H" title="DOI URL">https://doi.org/10.1039/C9NJ05489H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9NJ05489H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9NJ05489H%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DPhenothiazine%252Band%252Bamide-ornamented%252Bnovel%252Bnitrogen%252Bheterocyclic%252Bhybrids%25253A%252Bsynthesis%25252C%252Bbiological%252Band%252Bmolecular%252Bdocking%252Bstudies%26aulast%3DSivaramakarthikeyan%26aufirst%3DRamar%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D10%26spage%3D4049%26epage%3D4060" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qing-Lan  Zhao</span>, <span class="hlFld-ContribAuthor ">Peng-Jiu  Xia</span>, <span class="hlFld-ContribAuthor ">Lan  Zheng</span>, <span class="hlFld-ContribAuthor ">Zhen-Zhen  Xie</span>, <span class="hlFld-ContribAuthor ">Yuan-Zhuo  Hu</span>, <span class="hlFld-ContribAuthor ">Guang-Jian  Chen</span>, <span class="hlFld-ContribAuthor ">Xiao-Qing  Chen</span>, <span class="hlFld-ContribAuthor ">Hao-Yue  Xiang</span>, <span class="hlFld-ContribAuthor ">Hua  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">A BHT-regulated chemoselective access to monofluorinated chromones. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2020,</strong> <em>76 </em>
                                    (8)
                                     , 130833. <a href="https://doi.org/10.1016/j.tet.2019.130833" title="DOI URL">https://doi.org/10.1016/j.tet.2019.130833</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2019.130833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2019.130833%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DA%252BBHT-regulated%252Bchemoselective%252Baccess%252Bto%252Bmonofluorinated%252Bchromones%26aulast%3DZhao%26aufirst%3DQing-Lan%26date%3D2020%26volume%3D76%26issue%3D8%26spage%3D130833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pingping  Chen</span>, <span class="hlFld-ContribAuthor ">Yinqiu  Xu</span>, <span class="hlFld-ContribAuthor ">Xuanyi  Li</span>, <span class="hlFld-ContribAuthor ">Hequan  Yao</span>, <span class="hlFld-ContribAuthor ">Kejiang  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Development and strategies of CDK4/6 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (2)
                                     , 127-145. <a href="https://doi.org/10.4155/fmc-2019-0062" title="DOI URL">https://doi.org/10.4155/fmc-2019-0062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0062%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Band%252Bstrategies%252Bof%252BCDK4%25252F6%252Binhibitors%26aulast%3DChen%26aufirst%3DPingping%26date%3D2020%26volume%3D12%26issue%3D2%26spage%3D127%26epage%3D145" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed M.  Abdelaziz</span>, <span class="hlFld-ContribAuthor ">Sunita K.C.  Basnet</span>, <span class="hlFld-ContribAuthor ">Saiful  Islam</span>, <span class="hlFld-ContribAuthor ">Manjun  Li</span>, <span class="hlFld-ContribAuthor ">Solomon  Tadesse</span>, <span class="hlFld-ContribAuthor ">Hugo  Albrecht</span>, <span class="hlFld-ContribAuthor ">Cobus  Gerber</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Yu</span>, <span class="hlFld-ContribAuthor ">Shudong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of 2â²H-spiro[cyclohexane-1,3â²-imidazo[1,5-a]pyridine]-1â²,5â²-dione derivatives as Mnk inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>29 </em>
                                    (18)
                                     , 2650-2654. <a href="https://doi.org/10.1016/j.bmcl.2019.07.043" title="DOI URL">https://doi.org/10.1016/j.bmcl.2019.07.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2019.07.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2019.07.043%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252B2%2525E2%252580%2525B2H-spiro%25255Bcyclohexane-1%25252C3%2525E2%252580%2525B2-imidazo%25255B1%25252C5-a%25255Dpyridine%25255D-1%2525E2%252580%2525B2%25252C5%2525E2%252580%2525B2-dione%252Bderivatives%252Bas%252BMnk%252Binhibitors%26aulast%3DAbdelaziz%26aufirst%3DAhmed%2BM.%26date%3D2019%26volume%3D29%26issue%3D18%26spage%3D2650%26epage%3D2654" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chen  Shi</span>, <span class="hlFld-ContribAuthor ">Qian  Wang</span>, <span class="hlFld-ContribAuthor ">Xuemei  Liao</span>, <span class="hlFld-ContribAuthor ">Hui  Ge</span>, <span class="hlFld-ContribAuthor ">Guoyong  Huo</span>, <span class="hlFld-ContribAuthor ">Leduo  Zhang</span>, <span class="hlFld-ContribAuthor ">Na  Chen</span>, <span class="hlFld-ContribAuthor ">Xiong  Zhai</span>, <span class="hlFld-ContribAuthor ">Yuan  Hong</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Yanan  Han</span>, <span class="hlFld-ContribAuthor ">Wenbo  Xiao</span>, <span class="hlFld-ContribAuthor ">Zhe  Wang</span>, <span class="hlFld-ContribAuthor ">Weijun  Shi</span>, <span class="hlFld-ContribAuthor ">Yu  Mao</span>, <span class="hlFld-ContribAuthor ">Jianxin  Yu</span>, <span class="hlFld-ContribAuthor ">Guangxin  Xia</span>, <span class="hlFld-ContribAuthor ">Yanjun  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>178 </em>, 352-364. <a href="https://doi.org/10.1016/j.ejmech.2019.06.005" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.005%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B6-%2525282-%252528dimethylamino%252529ethyl%252529-N-%2525285-fluoro-4-%2525284-fluoro-1-isopropyl-2-methyl-1H-benzo%25255Bd%25255Dimidazole-6-yl%252529pyrimidin-2-yl%252529-5%25252C6%25252C7%25252C8-tetrahydro-1%25252C6-naphthyridin-2-amine%252Bas%252Ba%252Bhighly%252Bpotent%252Bcyclin-dependent%252Bkinase%252B4%25252F6%252Binhibitor%252Bfor%252Btreatment%252Bof%252Bcancer%26aulast%3DShi%26aufirst%3DChen%26date%3D2019%26volume%3D178%26spage%3D352%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jubo  Wang</span>, <span class="hlFld-ContribAuthor ">Tinghan  Li</span>, <span class="hlFld-ContribAuthor ">Tengteng  Zhao</span>, <span class="hlFld-ContribAuthor ">Tizhi  Wu</span>, <span class="hlFld-ContribAuthor ">Chuang  Liu</span>, <span class="hlFld-ContribAuthor ">Hong  Ding</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>. </span><span class="cited-content_cbyCitation_article-title">Design of wogonin-inspired selective cyclin-dependent kinase 9 (CDK9) inhibitors with potent inÂ vitro and inÂ vivo antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>178 </em>, 782-801. <a href="https://doi.org/10.1016/j.ejmech.2019.06.024" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.024%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Bof%252Bwogonin-inspired%252Bselective%252Bcyclin-dependent%252Bkinase%252B9%252B%252528CDK9%252529%252Binhibitors%252Bwith%252Bpotent%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Bantitumor%252Bactivity%26aulast%3DWang%26aufirst%3DJubo%26date%3D2019%26volume%3D178%26spage%3D782%26epage%3D801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammed H.  Rahaman</span>, <span class="hlFld-ContribAuthor ">Yingyi  Yu</span>, <span class="hlFld-ContribAuthor ">Longjin  Zhong</span>, <span class="hlFld-ContribAuthor ">Julian  Adams</span>, <span class="hlFld-ContribAuthor ">Frankie  Lam</span>, <span class="hlFld-ContribAuthor ">Peng  Li</span>, <span class="hlFld-ContribAuthor ">Ben  Noll</span>, <span class="hlFld-ContribAuthor ">Robert  Milne</span>, <span class="hlFld-ContribAuthor ">Jun  Peng</span>, <span class="hlFld-ContribAuthor ">Shudong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Investigational New Drugs</span><span> <strong>2019,</strong> <em>37 </em>
                                    (4)
                                     , 625-635. <a href="https://doi.org/10.1007/s10637-018-0661-2" title="DOI URL">https://doi.org/10.1007/s10637-018-0661-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10637-018-0661-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10637-018-0661-2%26sid%3Dliteratum%253Aachs%26jtitle%3DInvestigational%2520New%2520Drugs%26atitle%3DCDKI-73%25253A%252Ban%252Borally%252Bbioavailable%252Band%252Bhighly%252Befficacious%252BCDK9%252Binhibitor%252Bagainst%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DRahaman%26aufirst%3DMuhammed%2BH.%26date%3D2019%26date%3D2018%26volume%3D37%26issue%3D4%26spage%3D625%26epage%3D635" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Florian  Bourriquen</span>, <span class="hlFld-ContribAuthor ">Antoine  BruneauâVoisine</span>, <span class="hlFld-ContribAuthor ">AliÃ©nor  Jeandin</span>, <span class="hlFld-ContribAuthor ">Etienne  Stihle</span>, <span class="hlFld-ContribAuthor ">Serena  Fantasia</span>. </span><span class="cited-content_cbyCitation_article-title">Streamlined Synthesis of Diaminopyridines by PdâCatalyzed Ammonia Coupling with Deactivated AminoâChloropyridines. </span><span class="cited-content_cbyCitation_journal-name">Chemistry â A European Journal</span><span> <strong>2019,</strong> <em>25 </em>
                                    (38)
                                     , 9006-9011. <a href="https://doi.org/10.1002/chem.201902147" title="DOI URL">https://doi.org/10.1002/chem.201902147</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201902147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201902147%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DStreamlined%252BSynthesis%252Bof%252BDiaminopyridines%252Bby%252BPd%2525E2%252580%252590Catalyzed%252BAmmonia%252BCoupling%252Bwith%252BDeactivated%252BAmino%2525E2%252580%252590Chloropyridines%26aulast%3DBourriquen%26aufirst%3DFlorian%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D38%26spage%3D9006%26epage%3D9011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefano  Fogli</span>, <span class="hlFld-ContribAuthor ">Marzia  Del Re</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Curigliano</span>, <span class="hlFld-ContribAuthor ">Ron H.  van Schaik</span>, <span class="hlFld-ContribAuthor ">Patrizio  Lancellotti</span>, <span class="hlFld-ContribAuthor ">Romano  Danesi</span>. </span><span class="cited-content_cbyCitation_article-title">Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Cancer Treatment Reviews</span><span> <strong>2019,</strong> <em>74 </em>, 21-28. <a href="https://doi.org/10.1016/j.ctrv.2019.01.006" title="DOI URL">https://doi.org/10.1016/j.ctrv.2019.01.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ctrv.2019.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ctrv.2019.01.006%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Treatment%2520Reviews%26atitle%3DDrug-drug%252Binteractions%252Bin%252Bbreast%252Bcancer%252Bpatients%252Btreated%252Bwith%252BCDK4%25252F6%252Binhibitors%26aulast%3DFogli%26aufirst%3DStefano%26date%3D2019%26volume%3D74%26spage%3D21%26epage%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pradip  Bera</span>, <span class="hlFld-ContribAuthor ">Paula  BrandÃ£o</span>, <span class="hlFld-ContribAuthor ">Gopinath  Mondal</span>, <span class="hlFld-ContribAuthor ">Ananyakumari  Santra</span>, <span class="hlFld-ContribAuthor ">Abhimanyu  Jana</span>, <span class="hlFld-ContribAuthor ">Raveendra Babu  Mokhamatam</span>, <span class="hlFld-ContribAuthor ">Sunil Kumar  Manna</span>, <span class="hlFld-ContribAuthor ">Tarun Kanti  Mandal</span>, <span class="hlFld-ContribAuthor ">Pulakesh  Bera</span>. </span><span class="cited-content_cbyCitation_article-title">An unusual iminoacylation of 2-amino pyridyl thiazole: Synthesis, X-ray crystallography and DFT study of copper(II) amidine complexes and their cytotoxicity, DNA binding and cleavage study. </span><span class="cited-content_cbyCitation_journal-name">Polyhedron</span><span> <strong>2019,</strong> <em>159 </em>, 436-445. <a href="https://doi.org/10.1016/j.poly.2018.11.069" title="DOI URL">https://doi.org/10.1016/j.poly.2018.11.069</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.poly.2018.11.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.poly.2018.11.069%26sid%3Dliteratum%253Aachs%26jtitle%3DPolyhedron%26atitle%3DAn%252Bunusual%252Biminoacylation%252Bof%252B2-amino%252Bpyridyl%252Bthiazole%25253A%252BSynthesis%25252C%252BX-ray%252Bcrystallography%252Band%252BDFT%252Bstudy%252Bof%252Bcopper%252528II%252529%252Bamidine%252Bcomplexes%252Band%252Btheir%252Bcytotoxicity%25252C%252BDNA%252Bbinding%252Band%252Bcleavage%252Bstudy%26aulast%3DBera%26aufirst%3DPradip%26date%3D2019%26volume%3D159%26spage%3D436%26epage%3D445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neil  Portman</span>, <span class="hlFld-ContribAuthor ">Sarah  Alexandrou</span>, <span class="hlFld-ContribAuthor ">Emma  Carson</span>, <span class="hlFld-ContribAuthor ">Shudong  Wang</span>, <span class="hlFld-ContribAuthor ">Elgene  Lim</span>, <span class="hlFld-ContribAuthor ">C Elizabeth  Caldon</span>. </span><span class="cited-content_cbyCitation_article-title">Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Endocrine-Related Cancer</span><span> <strong>2019,</strong> <em>26 </em>
                                    (1)
                                     , R15-R30. <a href="https://doi.org/10.1530/ERC-18-0317" title="DOI URL">https://doi.org/10.1530/ERC-18-0317</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1530/ERC-18-0317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1530%2FERC-18-0317%26sid%3Dliteratum%253Aachs%26jtitle%3DEndocrine-Related%2520Cancer%26atitle%3DOvercoming%252BCDK4%25252F6%252Binhibitor%252Bresistance%252Bin%252BER-positive%252Bbreast%252Bcancer%26aulast%3DPortman%26aufirst%3DNeil%26date%3D2019%26volume%3D26%26issue%3D1%26spage%3DR15%26epage%3DR30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Solomon  Tadesse</span>, <span class="hlFld-ContribAuthor ">Laychiluh  Bantie</span>, <span class="hlFld-ContribAuthor ">Khamis  Tomusange</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Yu</span>, <span class="hlFld-ContribAuthor ">Saiful  Islam</span>, <span class="hlFld-ContribAuthor ">Nataliya  Bykovska</span>, <span class="hlFld-ContribAuthor ">Benjamin  Noll</span>, <span class="hlFld-ContribAuthor ">Ge  Zhu</span>, <span class="hlFld-ContribAuthor ">Peng  Li</span>, <span class="hlFld-ContribAuthor ">Frankie  Lam</span>, <span class="hlFld-ContribAuthor ">Malika  Kumarasiri</span>, <span class="hlFld-ContribAuthor ">Robert  Milne</span>, <span class="hlFld-ContribAuthor ">Shudong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and pharmacological characterization of a novel series of highly selective inhibitors of cyclin-dependent kinases 4 and 6 as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">British Journal of Pharmacology</span><span> <strong>2018,</strong> <em>175 </em>
                                    (12)
                                     , 2399-2413. <a href="https://doi.org/10.1111/bph.13974" title="DOI URL">https://doi.org/10.1111/bph.13974</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/bph.13974&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fbph.13974%26sid%3Dliteratum%253Aachs%26jtitle%3DBritish%2520Journal%2520of%2520Pharmacology%26atitle%3DDiscovery%252Band%252Bpharmacological%252Bcharacterization%252Bof%252Ba%252Bnovel%252Bseries%252Bof%252Bhighly%252Bselective%252Binhibitors%252Bof%252Bcyclin-dependent%252Bkinases%252B4%252Band%252B6%252Bas%252Banticancer%252Bagents%26aulast%3DTadesse%26aufirst%3DSolomon%26date%3D2018%26date%3D2018%26volume%3D175%26issue%3D12%26spage%3D2399%26epage%3D2413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Huan  He</span>, <span class="hlFld-ContribAuthor ">Juan  Xu</span>, <span class="hlFld-ContribAuthor ">Wen  Xie</span>, <span class="hlFld-ContribAuthor ">Qing-Lian  Guo</span>, <span class="hlFld-ContribAuthor ">Feng-Lei  Jiang</span>, <span class="hlFld-ContribAuthor ">Yi  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Reduced state transition barrier of CDK6 from open to closed state induced by Thr177 phosphorylation and its implication in binding modes of inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - General Subjects</span><span> <strong>2018,</strong> <em>1862 </em>
                                    (3)
                                     , 501-512. <a href="https://doi.org/10.1016/j.bbagen.2017.11.001" title="DOI URL">https://doi.org/10.1016/j.bbagen.2017.11.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbagen.2017.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbagen.2017.11.001%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520General%2520Subjects%26atitle%3DReduced%252Bstate%252Btransition%252Bbarrier%252Bof%252BCDK6%252Bfrom%252Bopen%252Bto%252Bclosed%252Bstate%252Binduced%252Bby%252BThr177%252Bphosphorylation%252Band%252Bits%252Bimplication%252Bin%252Bbinding%252Bmodes%252Bof%252Binhibitors%26aulast%3DHe%26aufirst%3DHuan%26date%3D2018%26volume%3D1862%26issue%3D3%26spage%3D501%26epage%3D512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">P.  Muthuraja</span>, <span class="hlFld-ContribAuthor ">M.  Himesh</span>, <span class="hlFld-ContribAuthor ">S.  Prakash</span>, <span class="hlFld-ContribAuthor ">U.  Venkatasubramanian</span>, <span class="hlFld-ContribAuthor ">P.  Manisankar</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of N-(1-(6-acetamido-5-phenylpyrimidin-4-yl) piperidin-3-yl) amide derivatives as potential inhibitors for mitotic kinesin spindle protein. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>148 </em>, 106-115. <a href="https://doi.org/10.1016/j.ejmech.2018.02.010" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.010%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Bof%252BN-%2525281-%2525286-acetamido-5-phenylpyrimidin-4-yl%252529%252Bpiperidin-3-yl%252529%252Bamide%252Bderivatives%252Bas%252Bpotential%252Binhibitors%252Bfor%252Bmitotic%252Bkinesin%252Bspindle%252Bprotein%26aulast%3DMuthuraja%26aufirst%3DP.%26date%3D2018%26volume%3D148%26spage%3D106%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Solomon  Tadesse</span>, <span class="hlFld-ContribAuthor ">Ge  Zhu</span>, <span class="hlFld-ContribAuthor ">Laychiluh B  Mekonnen</span>, <span class="hlFld-ContribAuthor ">Jimma L  Lenjisa</span>, <span class="hlFld-ContribAuthor ">Mingfeng  Yu</span>, <span class="hlFld-ContribAuthor ">Michael P  Brown</span>, <span class="hlFld-ContribAuthor ">Shudong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">A novel series of
              N
              -(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amines as highly potent CDK4/6 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2017,</strong> <em>9 </em>
                                    (13)
                                     , 1495-1506. <a href="https://doi.org/10.4155/fmc-2017-0076" title="DOI URL">https://doi.org/10.4155/fmc-2017-0076</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2017-0076&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2017-0076%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DA%252Bnovel%252Bseries%252Bof%252BN%252B-%252528pyridin-2-yl%252529-4-%252528thiazol-5-yl%252529pyrimidin-2-amines%252Bas%252Bhighly%252Bpotent%252BCDK4%25252F6%252Binhibitors%26aulast%3DTadesse%26aufirst%3DSolomon%26date%3D2017%26volume%3D9%26issue%3D13%26spage%3D1495%26epage%3D1506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of the advanced clinical CDK4/6 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structural modifications to 2-anilino-4-(thiazol-5-yl)pyrimidine pharmacophore.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. ATP binding site of CDK6 in complex with the inhibitor palbociclib (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2EUF">2EUF</a>) aligned with that of CDK4 (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2W96">2W96</a>). CDK6 is shown in brown and CDK4 in cyan. Palbociclib, shown in green and bound in the ATP binding pocket of the kinases, forms two hydrogen bonds with conserved Val101 and one hydrogen bond with conserved Asp163. The hydrogen bonds are shown in black dashed lines. His95, Asp99, Thr102, and Glu144 of CDK4 are shown in cyan sticks. The figure was prepared using PyMOL1.3 (SchrÃ¶dinger Inc., 2013).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0010.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Enaminones <b>13</b>â<b>20</b> and Pyrimidin-2-amines <b>21</b> and <b>22</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>Reagents and conditions: (a) CS<sub>2</sub>, NEt<sub>3</sub>, Boc<sub>2</sub>O, DMAP, EtOH, rt, 30 min, ice bath, 15 min, rt, 30 min; (b) NH<sub>3</sub>, H<sub>2</sub>O, MeOH, rt, 24 h; (c) 3-chloro-2,4-pentadione, pyridine, MeOH, rt, 4â48 h, or 1,1,1-trifluoropentane-2,4-dione, hydroxyl(tosyloxyl)iodobenzene, MeCN, reflux, 1 h; (d) DMF-DMA, reflux, 3â36 h, or microwave, 150 Â°C, 30 min, or Bredereckâs reagent, reflux, 6 h; (e) SelectFluor, MeOH, ice bath, 4 h; (f) <b>13</b> or <b>14</b>, guanidine hydrochloride, NaOH, 2-methoxyethanol, reflux, 6 h.</p><p><span class="fn-label">Scheme b</span>Intermediates <b>3</b> and <b>7</b> were obtained from commercial sources.</p><p class="last"><span class="fn-label">Scheme c</span>Most likely from dicyclopentylcarbamodithioate, which is formed by the reaction between cyclopentyl(dithiocarboxy)amide intermediate and a halocyclopentane (minor contaminant of cyclopentylamine starting material).</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0011.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Guanidine Derivatives <b>67</b>â<b>77</b> and 4-Thiazol-<i>N</i>-(pyridin-2-yl)pyrimidin-2-amines <b>78</b>â<b>112</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 5-bromo-2-nitropyridine, Et<sub>3</sub>N, DMSO, 120 Â°C, 16 h; (b) Boc<sub>2</sub>O, DMAP, Et<sub>3</sub>N, DCM, o/n, rt; (c) H<sub>2</sub>, 10% Pd/C, MeOH, o/n, rt; (d) <i>N</i>,<i>N</i>â²-bis-Boc-<i>S</i>-methylisothiourea, HgCl<sub>2</sub>, Et<sub>3</sub>N, DCM, 0 Â°C to rt, 14 h; (e) TFA/DCM (1:1), reflux, 16 h; (f) <b>13</b>â<b>20</b>, NaOH, 2-methoxyethanol, microwave, 180 Â°C, 1 h.</p><p><span class="fn-label">Scheme b</span>No substitution on carbon 5 of the pyridine ring and obtained from commercial source.</p><p><span class="fn-label">Scheme c</span>No substitution on carbon 5 of the pyridine ring.</p><p class="last"><span class="fn-label">Scheme d</span>See <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>, and <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a> for the structures of <b>78</b>â<b>112</b>.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0012.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>115</b> and <b>116</b> via BuchwaldâHartwig Amination<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethylpiperazine, sodium triacetoxyborohydride, DCM, 0 Â°C to rt, 12 h; (b) <b>21</b> or <b>22</b>, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, <i>t</i>-BuONa, 1,4-dioxane, microwave, 150 Â°C, 1 h.</p></p></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cell cycle analysis of <b>78</b>. Compound <b>78</b> induced G1 cell cycle accumulation in MV4-11 cells. The cells were treated with increasing concentrations of <b>78</b> or palbociclib (Palb) for 24 h and analyzed by flow cytometry. The experiments were repeated twice and representative data were presented.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Kinome-wide selectivity of <b>83</b> at 1 Î¼M. Red, yellow, and green colors indicate kinase residual activity of <10%, 10â20%, and >20%, respectively. Individual kinase residual activity values are given in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.6b01670/suppl_file/jm6b01670_si_001.pdf" class="ext-link">Table S2</a>. The human kinome map is adapted with permission from Reaction Biology Corp.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Western blot analysis of MV4-11 cancer cells following treatment with <b>83</b> or palbociclib for 12 or 24 h. Both <b>83</b> and palbociclib (palb) inhibited the phosphorylation of Rb at Ser780. Î²-Actin was used as a loading control. The data are representative of two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Cell cycle effects of <b>83</b> and palbociclib on MV4-11 cells. Cells were treated with increasing concentrations of <b>83</b> or palbociclib (palb) for 24 h, harvested, fixed, and stained with propidium iodide prior to flow cytometric analysis. The experiments were repeated twice. Representative data were selected to generate this figure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Effects of <b>83</b> and palbociclib on the induction of apoptosis. Treatment with <b>83</b> or palbociclib (palb) showed little effect on the induction of apoptosis in MV4-11 cells. The cells were exposed to increasing concentrations of each compound for 24 h and analyzed by annexin V/propidium iodide double staining. The data are representative of two independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/medium/jm-2016-01670b_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vivo anticancer efficacy of <b>83</b>. (A) Female nude (nu/nu) BALB/c mice at 6â8 weeks of age with subcutaneously implanted MV4-11 leukemia xenograft were orally treated with 100 mg/kg of <b>83</b> (<i>n</i> = 9) or vehicle (1% CMC, <i>n</i> = 9) daily for 33 days. Treatment with <b>83</b> significantly reduced tumor burden in comparison to vehicle-treated controls. Significant reduction in tumor volume (<i>p</i> < 0.05) was observed in drug treated group from day 5 until the end of experiment when compared with vehicle treated group. (B) Tumor volumes of each mouse on day 31. (C) KaplanâMeier analysis of animal survival following treatment with <b>83</b> or vehicle. (D) <b>83</b> was well tolerated without causing a negative effect on body weight in MV4-11 leukemia xenograft bearing mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-5/acs.jmedchem.6b01670/20170303/images/large/jm-2016-01670b_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01670&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i147">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31378" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31378" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 51 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Pardee, A. B. A.</span><span> </span><span class="NLM_article-title">Restriction point for control of normal animal cell proliferation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1974</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">1286</span><span class="NLM_x">â</span> <span class="NLM_lpage">1290</span><span class="refDoi">Â DOI: 10.1073/pnas.71.4.1286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1073%2Fpnas.71.4.1286" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1974&pages=1286-1290&author=A.+B.+A.+Pardee&title=Restriction+point+for+control+of+normal+animal+cell+proliferation&doi=10.1073%2Fpnas.71.4.1286"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1073%2Fpnas.71.4.1286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.71.4.1286%26sid%3Dliteratum%253Aachs%26aulast%3DPardee%26aufirst%3DA.%2BB.%2BA.%26atitle%3DRestriction%2520point%2520for%2520control%2520of%2520normal%2520animal%2520cell%2520proliferation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1974%26volume%3D71%26spage%3D1286%26epage%3D1290%26doi%3D10.1073%2Fpnas.71.4.1286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Sisken, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morasca, L.</span><span> </span><span class="NLM_article-title">Intrapopulation kinetics of the mitotic cycle</span> <span class="citation_source-journal">J. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1965</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">â</span> <span class="NLM_lpage">189</span><span class="refDoi">Â DOI: 10.1083/jcb.25.2.179</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1083%2Fjcb.25.2.179" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1965&pages=179-189&author=J.+E.+Siskenauthor=L.+Morasca&title=Intrapopulation+kinetics+of+the+mitotic+cycle&doi=10.1083%2Fjcb.25.2.179"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1083%2Fjcb.25.2.179&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.25.2.179%26sid%3Dliteratum%253Aachs%26aulast%3DSisken%26aufirst%3DJ.%2BE.%26aulast%3DMorasca%26aufirst%3DL.%26atitle%3DIntrapopulation%2520kinetics%2520of%2520the%2520mitotic%2520cycle%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D1965%26volume%3D25%26spage%3D179%26epage%3D189%26doi%3D10.1083%2Fjcb.25.2.179" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Bartek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartkova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lukas, J.</span><span> </span><span class="NLM_article-title">The retinoblastoma protein pathway in cell cycle control and cancer</span> <span class="citation_source-journal">Exp. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">237</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">â</span> <span class="NLM_lpage">6</span><span class="refDoi">Â DOI: 10.1006/excr.1997.3776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1006%2Fexcr.1997.3776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=9417859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADyaK2sXnvFWmur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=1997&pages=1-6&author=J.+Bartekauthor=J.+Bartkovaauthor=J.+Lukas&title=The+retinoblastoma+protein+pathway+in+cell+cycle+control+and+cancer&doi=10.1006%2Fexcr.1997.3776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The retinoblastoma protein pathway in cell cycle control and cancer</span></div><div class="casAuthors">Bartek, Jiri; Bartkova, Jirina; Lukas, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">237</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-6</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">A review, with 51 refs.  Recent discoveries in diverse fields of biomedical research have merged to reveal the mol. basis of cell cycle control and a crit. role of subverting this homeostatic mechanism in cancer development.  At the heart of these processes lies a late G1 checkpoint governed by the "RB pathway" whose mol. compn., functions, and cancer-assocd. defects are briefly evaluated in this review.  This exciting new knowledge raises a plethora of conceptual issues in cell biol., with potential practical implications for biotechnol. and medicine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe8MqG3R3qQLVg90H21EOLACvtfcHk0lgxvnwhVuXRpw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnvFWmur4%253D&md5=33d6b7002b41757ade047792873efbf6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1006%2Fexcr.1997.3776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fexcr.1997.3776%26sid%3Dliteratum%253Aachs%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DBartkova%26aufirst%3DJ.%26aulast%3DLukas%26aufirst%3DJ.%26atitle%3DThe%2520retinoblastoma%2520protein%2520pathway%2520in%2520cell%2520cycle%2520control%2520and%2520cancer%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D1997%26volume%3D237%26spage%3D1%26epage%3D6%26doi%3D10.1006%2Fexcr.1997.3776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">222</span><span class="NLM_x">â</span> <span class="NLM_lpage">231</span><span class="refDoi">Â DOI: 10.1038/35106065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1038%2F35106065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=11902577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=222-231&author=M.+Malumbresauthor=M.+Barbacid&title=Milestones+in+cell+division%3A+to+cycle+or+not+to+cycle%3A+a+critical+decision+in+cancer&doi=10.1038%2F35106065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Milestones in cell division: to cycle or not to cycle: a critical decision in cancer</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">222-231</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor cells undergo uncontrolled proliferation, yet tumors most often originate from adult tissues, in which most cells are quiescent.  So, the proliferative advantage of tumor cells arises from their ability to bypass quiescence.  This can be due to increased mitogenic signaling and/or alterations that lower the threshold required for cell-cycle commitment.  Understanding the mol. mechanisms that underlie this commitment should provide important insights into how normal cells become tumorigenic and how new anticancer strategies can be devised.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI2EOLFB2ULbVg90H21EOLACvtfcHk0lhzAk3Rt5pEqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XlvF2qtrg%253D&md5=2bd8961854332a30c814f8ac2f9bd6f4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2F35106065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35106065%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DMilestones%2520in%2520cell%2520division%253A%2520to%2520cycle%2520or%2520not%2520to%2520cycle%253A%2520a%2520critical%2520decision%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2001%26volume%3D1%26spage%3D222%26epage%3D231%26doi%3D10.1038%2F35106065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Ortega, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cyclin D-dependent kinases, INK4 inhibitors and cancer</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1602</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">â</span> <span class="NLM_lpage">87</span><span class="refDoi">Â DOI: 10.1016/S0304-419X(02)00037-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2FS0304-419X%2802%2900037-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=11960696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD38XktVKgu7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1602&publication_year=2002&pages=73-87&author=S.+Ortegaauthor=M.+Malumbresauthor=M.+Barbacid&title=Cyclin+D-dependent+kinases%2C+INK4+inhibitors+and+cancer&doi=10.1016%2FS0304-419X%2802%2900037-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin D-dependent kinases, INK4 inhibitors and cancer</span></div><div class="casAuthors">Ortega, Sagrario; Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Reviews on Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1602</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">73-87</span>CODEN:
                <span class="NLM_cas:coden">BBACEU</span>;
        ISSN:<span class="NLM_cas:issn">0304-419X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The Cyclin D-Cdk4,6/INK4/Rb/E2F pathway plays a key role in controlling cell growth by integrating multiple mitogenic and antimitogenic stimuli.  The components of this pathway are gene families with a high level of structural and functional redundancy and are expressed in an overlapping fashion in most tissues and cell types.  Using classical transgenic technol. as well as gene-targeting in ES cells, a series of mouse models have been developed to study the in vivo function of individual components of this pathway in both normal homeostasis and tumor development.  These models have proven to be useful to define specific as well as redundant roles among members of these cell cycle regulatory gene families.  This pathway is deregulated in the vast majority of human tumors by genetic and epigenetic alterations that target at least some of its key members such as Cyclin D1, Cdk4, INK4a and INK4b, pRb etc.  As a consequence, some of these mols. are currently being considered as targets for cancer therapy, and several novel mols., such as Cdk inhibitors, are under development as potential anti-cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpizIeKkGlMJLVg90H21EOLACvtfcHk0lhzAk3Rt5pEqQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XktVKgu7o%253D&md5=8f5ab2839d58abcb3a7df53269af2913</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2FS0304-419X%2802%2900037-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-419X%252802%252900037-9%26sid%3Dliteratum%253Aachs%26aulast%3DOrtega%26aufirst%3DS.%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCyclin%2520D-dependent%2520kinases%252C%2520INK4%2520inhibitors%2520and%2520cancer%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Rev.%2520Cancer%26date%3D2002%26volume%3D1602%26spage%3D73%26epage%3D87%26doi%3D10.1016%2FS0304-419X%2802%2900037-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortega, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors</span> <span class="citation_source-journal">Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">381</span><span class="NLM_x">, </span> <span class="NLM_fpage">827</span><span class="NLM_x">â</span> <span class="NLM_lpage">838</span><span class="refDoi">Â DOI: 10.1515/BC.2000.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1515%2FBC.2000.105" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2000&pages=827-838&author=M.+Malumbresauthor=S.+Ortegaauthor=M.+Barbacid&title=Genetic+analysis+of+mammalian+cyclin-dependent+kinases+and+their+inhibitors&doi=10.1515%2FBC.2000.105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1515%2FBC.2000.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1515%252FBC.2000.105%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DOrtega%26aufirst%3DS.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DGenetic%2520analysis%2520of%2520mammalian%2520cyclin-dependent%2520kinases%2520and%2520their%2520inhibitors%26jtitle%3DBiol.%2520Chem.%26date%3D2000%26volume%3D381%26spage%3D827%26epage%3D838%26doi%3D10.1515%2FBC.2000.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, W. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meade, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trachet, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albassam, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leopold, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pryer, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toogood, P. L.</span><span> </span><span class="NLM_article-title">Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1427</span><span class="NLM_x">â</span> <span class="NLM_lpage">1438</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=15542782" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpslCkt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=1427-1438&author=D.+W.+Fryauthor=P.+J.+Harveyauthor=P.+R.+Kellerauthor=W.+L.+Elliottauthor=M.+Meadeauthor=E.+Trachetauthor=M.+Albassamauthor=X.+Zhengauthor=W.+R.+Leopoldauthor=N.+K.+Pryerauthor=P.+L.+Toogood&title=Specific+inhibition+of+cyclin-dependent+kinase+4%2F6+by+PD+0332991+and+associated+antitumor+activity+in+human+tumor+xenografts"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts</span></div><div class="casAuthors">Fry, David W.; Harvey, Patricia J.; Keller, Paul R.; Elliott, William L.; Meade, MaryAnne; Trachet, Erin; Albassam, Mudher; Zheng, XianXian; Leopold, Wilbur R.; Pryer, Nancy K.; Toogood, Peter L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1427-1438</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PD 0332991 is a highly specific inhibitor of cyclin-dependent kinase 4 (Cdk4) (IC50, 0.011 Î¼mol/L) and Cdk6 (IC50, 0.016 Î¼mol/L), having no activity against a panel of 36 addnl. protein kinases.  It is a potent antiproliferative agent against retinoblastoma (Rb)-pos. tumor cells in vitro, inducing an exclusive G1 arrest, with a concomitant redn. of phospho-Ser780/Ser795 on the Rb protein.  Oral administration of PD 0332991 to mice bearing the Colo-205 human colon carcinoma produces marked tumor regression.  Therapeutic doses of PD 0332991 cause elimination of phospho-Rb and the proliferative marker Ki-67 in tumor tissue and down-regulation of genes under the transcriptional control of E2F.  The results indicate that inhibition of Cdk4/6 alone is sufficient to cause tumor regression and a net redn. in tumor burden in some tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9TOgbe4wrBLVg90H21EOLACvtfcHk0ljLoAI0iTdvow"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpslCkt7c%253D&md5=70931ebc6abd1c59bf1cc29748b7945f</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DMeade%26aufirst%3DM.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DAlbassam%26aufirst%3DM.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DPryer%26aufirst%3DN.%2BK.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26atitle%3DSpecific%2520inhibition%2520of%2520cyclin-dependent%2520kinase%25204%252F6%2520by%2520PD%25200332991%2520and%2520associated%2520antitumor%2520activity%2520in%2520human%2520tumor%2520xenografts%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2004%26volume%3D3%26spage%3D1427%26epage%3D1438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Malumbres, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbacid, M.</span><span> </span><span class="NLM_article-title">Cell cycle, CDKs and cancer: a changing paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">153</span><span class="NLM_x">â</span> <span class="NLM_lpage">166</span><span class="refDoi">Â DOI: 10.1038/nrc2602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1038%2Fnrc2602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=19238148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=153-166&author=M.+Malumbresauthor=M.+Barbacid&title=Cell+cycle%2C+CDKs+and+cancer%3A+a+changing+paradigm&doi=10.1038%2Fnrc2602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle, CDKs and cancer: a changing paradigm</span></div><div class="casAuthors">Malumbres, Marcos; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">153-166</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Tumor-assocd. cell cycle defects are often mediated by alterations in cyclin-dependent kinase (CDK) activity.  Misregulated CDKs induce unscheduled proliferation as well as genomic and chromosomal instability.  According to current models, mammalian CDKs are essential for driving each cell cycle phase, so therapeutic strategies that block CDK activity are unlikely to selectively target tumor cells.  However, recent genetic evidence has revealed that, whereas CDK1 is required for the cell cycle, interphase CDKs are only essential for proliferation of specialized cells.  Emerging evidence suggests that tumor cells may also require specific interphase CDKs for proliferation.  Thus, selective CDK inhibition may provide therapeutic benefit against certain human neoplasias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzlIKlbCPWnLVg90H21EOLACvtfcHk0likvvICDsUOog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1ans78%253D&md5=2a7eb34b2381e288b3f43ec1bffc0aec</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnrc2602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2602%26sid%3Dliteratum%253Aachs%26aulast%3DMalumbres%26aufirst%3DM.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DCell%2520cycle%252C%2520CDKs%2520and%2520cancer%253A%2520a%2520changing%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2009%26volume%3D9%26spage%3D153%26epage%3D166%26doi%3D10.1038%2Fnrc2602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Nevins, J. R.</span><span> </span><span class="NLM_article-title">The Rb/E2F pathway and cancer</span> <span class="citation_source-journal">Hum. Mol. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">699</span><span class="NLM_x">â</span> <span class="NLM_lpage">703</span><span class="refDoi">Â DOI: 10.1093/hmg/10.7.699</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1093%2Fhmg%2F10.7.699" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=11257102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD3MXjt1ajsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2001&pages=699-703&author=J.+R.+Nevins&title=The+Rb%2FE2F+pathway+and+cancer&doi=10.1093%2Fhmg%2F10.7.699"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">The Rb/E2F pathway and cancer</span></div><div class="casAuthors">Nevins, Joseph R.</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7, Rev. Issue</span>),
    <span class="NLM_cas:pages">699-703</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">A review.  Over the past decade, studies focusing on the mechanisms controlling cellular proliferation have converged with equally intensive efforts directed at the anal. of oncogenic pathways assocd. with human cancer.  These convergent studies have revealed the central role played by the pathway that controls the activity of the retinoblastoma tumor suppressor protein (Rb), which in turn regulates the E2F transcription factor.  In particular, it is now clear that the Rb/E2F pathway is crit. in regulating the initiation of DNA replication.  It is also clear that the control of the pathway is disrupted in virtually all human cancers.  Questions remain, however, as to the specific role played by individual activities within the pathway in the control of cell growth and their participation in the development of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0WsC_lYCINLVg90H21EOLACvtfcHk0likvvICDsUOog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXjt1ajsb4%253D&md5=debc3fe6c76f56f488c6a8dada95666e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2F10.7.699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252F10.7.699%26sid%3Dliteratum%253Aachs%26aulast%3DNevins%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520Rb%252FE2F%2520pathway%2520and%2520cancer%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2001%26volume%3D10%26spage%3D699%26epage%3D703%26doi%3D10.1093%2Fhmg%2F10.7.699" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Tadesse, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumarasiri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Targeting CDK6 in cancer: state of the art and new insights</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">3220</span><span class="NLM_x">â</span> <span class="NLM_lpage">3230</span><span class="refDoi">Â DOI: 10.1080/15384101.2015.1084445</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1080%2F15384101.2015.1084445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=26315616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVKrsbrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=3220-3230&author=S.+Tadesseauthor=M.+Yuauthor=M.+Kumarasiriauthor=B.+T.+Leauthor=S.+Wang&title=Targeting+CDK6+in+cancer%3A+state+of+the+art+and+new+insights&doi=10.1080%2F15384101.2015.1084445"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK6 in cancer: State of the art and new insights</span></div><div class="casAuthors">Tadesse, Solomon; Yu, Mingfeng; Kumarasiri, Malika; Le, Bich Thuy; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3220-3230</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1551-4005</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 6 (CDK6) plays a vital role in regulating the progression of the cell cycle.  More recently, CDK6 has also been shown to have a transcriptional role in tumor angiogenesis.  Up-regulated CDK6 activity is assocd. with the development of several types of cancers.  While CDK6 is over-expressed in cancer cells, it has a low detectable level in non-cancerous cells and CDK6-null mice develop normally, suggesting a specific oncogenic role of CDK6, and that its inhibition may represent an ideal mechanism-based and low toxic therapeutic strategy in cancer treatment.  Identification of selective small mol. inhibitors of CDK6 is thus needed for drug development.  Herein, we review the latest understandings of the biol. regulation and oncogenic roles of CDK6.  The potential clin. relevance of CDK6 inhibition, the progress in the development of small-mol. CDK6 inhibitors and the rational design of potential selective CDK6 inhibitors are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV1uu9UWb3XrVg90H21EOLACvtfcHk0likvvICDsUOog"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVKrsbrN&md5=eefeeab43ed50693886447c122e5002d</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1080%2F15384101.2015.1084445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F15384101.2015.1084445%26sid%3Dliteratum%253Aachs%26aulast%3DTadesse%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DLe%26aufirst%3DB.%2BT.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DTargeting%2520CDK6%2520in%2520cancer%253A%2520state%2520of%2520the%2520art%2520and%2520new%2520insights%26jtitle%3DCell%2520Cycle%26date%3D2015%26volume%3D14%26spage%3D3220%26epage%3D3230%26doi%3D10.1080%2F15384101.2015.1084445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">DiPippo, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, C. M.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibitors for the treatment of breast cancer: past, present, and future</span> <span class="citation_source-journal">Pharmacotherapy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">652</span><span class="NLM_x">â</span> <span class="NLM_lpage">667</span><span class="refDoi">Â DOI: 10.1002/phar.1756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1002%2Fphar.1756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=27087139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A280%3ADC%252BC28bgslCksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=652-667&author=A.+J.+DiPippoauthor=N.+K.+Patelauthor=C.+M.+Barnett&title=Cyclin-dependent+kinase+inhibitors+for+the+treatment+of+breast+cancer%3A+past%2C+present%2C+and+future&doi=10.1002%2Fphar.1756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future</span></div><div class="casAuthors">DiPippo Adam J; Patel Neelam K; Barnett Chad M</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacotherapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">652-67</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of metastatic breast cancer (MBC) that is resistant to endocrine therapy presents a significant clinical challenge.  The well-known role of cell cycle dysregulation in these patients is partly mediated by cyclin-dependent kinase (CDK) activity.  Specific cyclin and CDK complexes regulate cell cycle progression by managing the transition through the cell cycle, and inhibition of CDKs represents an important target for novel agents.  First-generation CDK inhibitors (e.g., flavopiridol) were relatively nonselective and had an unacceptable toxicity profile in early trials.  Second-generation CDK inhibitors were designed to target the CDK4 and CDK6 (CDK4/6) pathway and have shown promising clinical activity with an acceptable toxicity profile in patients with MBC.  Palbociclib is a first-in-class CDK4/6 inhibitor that was granted accelerated U.S.  Food and Drug Administration approval in combination with letrozole for the treatment of MBC in the first-line setting (February 2015) as well as in combination with fulvestrant for MBC that had progressed on previous endocrine therapy (February 2016).  Other CDK4/6 inhibitors, including ribociclib and abemaciclib, are under investigation as monotherapy and in combination with endocrine or anti-human epidermal growth receptor 2 therapy for the treatment of MBC.  Ongoing clinical trials should provide additional information to guide the appropriate use of these agents and identify patient populations that could derive the most benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSYivEamzCCty86Js-BCLiifW6udTcc2ebQv6JAhAuJEbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bgslCksA%253D%253D&md5=cc590c6fb21bbdc1e5384e4020a4123f</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fphar.1756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fphar.1756%26sid%3Dliteratum%253Aachs%26aulast%3DDiPippo%26aufirst%3DA.%2BJ.%26aulast%3DPatel%26aufirst%3DN.%2BK.%26aulast%3DBarnett%26aufirst%3DC.%2BM.%26atitle%3DCyclin-dependent%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%253A%2520past%252C%2520present%252C%2520and%2520future%26jtitle%3DPharmacotherapy%26date%3D2016%26volume%3D36%26spage%3D652%26epage%3D667%26doi%3D10.1002%2Fphar.1756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Uras, I. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheicher, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellutti, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prchal-Murphy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tigan, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidel, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubicek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frohling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sexl, V.</span><span> </span><span class="NLM_article-title">Palbociclib treatment of FLT3-ITD<sup>+</sup> AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">2890</span><span class="NLM_x">â</span> <span class="NLM_lpage">2902</span><span class="refDoi">Â DOI: 10.1182/blood-2015-11-683581</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1182%2Fblood-2015-11-683581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=27099147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhs1ars7zP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2016&pages=2890-2902&author=I.+Z.+Urasauthor=G.+J.+Walterauthor=R.+Scheicherauthor=F.+Belluttiauthor=M.+Prchal-Murphyauthor=A.+S.+Tiganauthor=P.+Valentauthor=F.+H.+Heidelauthor=S.+Kubicekauthor=C.+Schollauthor=S.+Frohlingauthor=V.+Sexl&title=Palbociclib+treatment+of+FLT3-ITD%2B+AML+cells+uncovers+a+kinase-dependent+transcriptional+regulation+of+FLT3+and+PIM1+by+CDK6&doi=10.1182%2Fblood-2015-11-683581"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6</span></div><div class="casAuthors">Uras, Iris Z.; Walter, Gina J.; Scheicher, Ruth; Bellutti, Florian; Prchal-Murphy, Michaela; Tigan, Anca S.; Valent, Peter; Heidel, Florian H.; Kubicek, Stefan; Scholl, Claudia; Froehling, Stefan; Sexl, Veronika</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2890-2902</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">1528-0020</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Up to 30% of patients with acute myeloid leukemia have constitutively activating internal tandem duplications (ITDs) of the FLT3 receptor tyrosine kinase.  Such mutations are assocd. with a poor prognosis and a high propensity to relapse after remission.  FLT3 inhibitors are being developed as targeted therapy for FLT3-ITD+ acute myeloid leukemia; however, their use is complicated by rapid development of resistance, which illustrates the need for addnl. therapeutic targets.  We show that the US Food and Drug Administration-approved CDK4/6 kinase inhibitor palbociclib induces apoptosis of FLT3-ITD leukemic cells.  The effect is specific for FLT3-mutant cells and is ascribed to the transcriptional activity of CDK6: CDK6 but not its functional homolog CDK4 is found at the promoters of the FLT3 and PIM1 genes, another important leukemogenic driver.  There CDK6 regulates transcription in a kinase-dependent manner.  Of potential clin. relevance, combined treatment with palbociclib and FLT3 inhibitors results in synergistic cytotoxicity.  Simultaneously targeting two crit. signaling nodes in leukemogenesis could represent a therapeutic breakthrough, leading to complete remission and overcoming resistance to FLT3 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsmyPMjz8SYLVg90H21EOLACvtfcHk0lgKsuNnrxE_WQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhs1ars7zP&md5=63ac18917c968342abf1600403eed3e9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1182%2Fblood-2015-11-683581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2015-11-683581%26sid%3Dliteratum%253Aachs%26aulast%3DUras%26aufirst%3DI.%2BZ.%26aulast%3DWalter%26aufirst%3DG.%2BJ.%26aulast%3DScheicher%26aufirst%3DR.%26aulast%3DBellutti%26aufirst%3DF.%26aulast%3DPrchal-Murphy%26aufirst%3DM.%26aulast%3DTigan%26aufirst%3DA.%2BS.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DHeidel%26aufirst%3DF.%2BH.%26aulast%3DKubicek%26aufirst%3DS.%26aulast%3DScholl%26aufirst%3DC.%26aulast%3DFrohling%26aufirst%3DS.%26aulast%3DSexl%26aufirst%3DV.%26atitle%3DPalbociclib%2520treatment%2520of%2520FLT3-ITD%252B%2520AML%2520cells%2520uncovers%2520a%2520kinase-dependent%2520transcriptional%2520regulation%2520of%2520FLT3%2520and%2520PIM1%2520by%2520CDK6%26jtitle%3DBlood%26date%3D2016%26volume%3D127%26spage%3D2890%26epage%3D2902%26doi%3D10.1182%2Fblood-2015-11-683581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Goel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolaney, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dillon, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmer, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuzugullu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varadan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuck, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sicinski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winer, E. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krop, I. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. J.</span><span> </span><span class="NLM_article-title">Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">255</span><span class="NLM_x">â</span> <span class="NLM_lpage">269</span><span class="refDoi">Â DOI: 10.1016/j.ccell.2016.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.ccell.2016.02.006" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=255-269&author=S.+Goelauthor=Q.+Wangauthor=A.+C.+Wattauthor=S.+M.+Tolaneyauthor=D.+A.+Dillonauthor=W.+Liauthor=S.+Rammauthor=A.+C.+Palmerauthor=H.+Yuzugulluauthor=V.+Varadanauthor=D.+Tuckauthor=L.+N.+Harrisauthor=K.+K.+Wongauthor=X.+S.+Liuauthor=P.+Sicinskiauthor=E.+P.+Winerauthor=I.+E.+Kropauthor=J.+J.+Zhao&title=Overcoming+therapeutic+resistance+in+HER2-positive+breast+cancers+with+CDK4%2F6+inhibitors&doi=10.1016%2Fj.ccell.2016.02.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DGoel%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWatt%26aufirst%3DA.%2BC.%26aulast%3DTolaney%26aufirst%3DS.%2BM.%26aulast%3DDillon%26aufirst%3DD.%2BA.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DRamm%26aufirst%3DS.%26aulast%3DPalmer%26aufirst%3DA.%2BC.%26aulast%3DYuzugullu%26aufirst%3DH.%26aulast%3DVaradan%26aufirst%3DV.%26aulast%3DTuck%26aufirst%3DD.%26aulast%3DHarris%26aufirst%3DL.%2BN.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DLiu%26aufirst%3DX.%2BS.%26aulast%3DSicinski%26aufirst%3DP.%26aulast%3DWiner%26aufirst%3DE.%2BP.%26aulast%3DKrop%26aufirst%3DI.%2BE.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DOvercoming%2520therapeutic%2520resistance%2520in%2520HER2-positive%2520breast%2520cancers%2520with%2520CDK4%252F6%2520inhibitors%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D29%26spage%3D255%26epage%3D269%26doi%3D10.1016%2Fj.ccell.2016.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Sumi, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuenzi, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knezevic, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Remsing Rix, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span> </span><span class="NLM_article-title">Chemoproteomics reveals novel protein and lipid kinase targets of clinical CDK4/6 inhibitors in lung cancer</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2680</span><span class="NLM_x">â</span> <span class="NLM_lpage">2686</span><span class="refDoi">Â DOI: 10.1021/acschembio.5b00368</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.5b00368" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=2680-2686&author=N.+J.+Sumiauthor=B.+M.+Kuenziauthor=C.+E.+Knezevicauthor=L.+L.+Remsing+Rixauthor=U.+Rix&title=Chemoproteomics+reveals+novel+protein+and+lipid+kinase+targets+of+clinical+CDK4%2F6+inhibitors+in+lung+cancer&doi=10.1021%2Facschembio.5b00368"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facschembio.5b00368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.5b00368%26sid%3Dliteratum%253Aachs%26aulast%3DSumi%26aufirst%3DN.%2BJ.%26aulast%3DKuenzi%26aufirst%3DB.%2BM.%26aulast%3DKnezevic%26aufirst%3DC.%2BE.%26aulast%3DRemsing%2BRix%26aufirst%3DL.%2BL.%26aulast%3DRix%26aufirst%3DU.%26atitle%3DChemoproteomics%2520reveals%2520novel%2520protein%2520and%2520lipid%2520kinase%2520targets%2520of%2520clinical%2520CDK4%252F6%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2015%26volume%3D10%26spage%3D2680%26epage%3D2686%26doi%3D10.1021%2Facschembio.5b00368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diehl, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanArsdale, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Spectrum and degree of CDK drug interactions predicts clinical performance</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2273</span><span class="NLM_x">â</span> <span class="NLM_lpage">2281</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-16-0300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1158%2F1535-7163.MCT-16-0300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=27496135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGisbjK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2273-2281&author=P.+Chenauthor=N.+Leeauthor=W.+Huauthor=M.+Xuauthor=R.+A.+Ferreauthor=H.+Lamauthor=S.+Bergqvistauthor=J.+Solowiejauthor=W.+Diehlauthor=Y.+A.+Heauthor=X.+Yuauthor=A.+Nagataauthor=T.+VanArsdaleauthor=B.+W.+Murray&title=Spectrum+and+degree+of+CDK+drug+interactions+predicts+clinical+performance&doi=10.1158%2F1535-7163.MCT-16-0300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance</span></div><div class="casAuthors">Chen, Ping; Lee, Nathan V.; Hu, Wenyue; Xu, Meirong; Ferre, Rose Ann; Lam, Hieu; Bergqvist, Simon; Solowiej, James; Diehl, Wade; He, You-Ai; Yu, Xiu; Nagata, Asako; Van Arsdale, Todd; Murray, Brion W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2273-2281</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Therapeutically targeting aberrant intracellular kinase signaling is attractive from a biol. perspective but drug development is often hindered by toxicities and inadequate efficacy.  Predicting drug behaviors using cellular and animal models is confounded by redundant kinase activities, a lack of unique substrates, and cell-specific signaling networks.  Cyclin-dependent kinase (CDK) drugs exemplify this phenomenon because they are reported to target common processes yet have distinct clin. activities.  Tumor cell studies of ATP-competitive CDK drugs (dinaciclib, AG-024322, abemaciclib, palbociclib, ribociclib) indicate similar pharmacol. while analyses in untransformed cells illuminates significant differences.  To resolve this apparent disconnect, drug behaviors are described at the mol. level.  Nonkinase binding studies and kinome interaction anal. (recombinant and endogenous kinases) reveal that proteins outside of the CDK family appear to have little role in dinaciclib/palbociclib/ribociclib pharmacol., may contribute for abemaciclib, and confounds AG-024322 anal.  CDK2 and CDK6 cocrystal structures with the drugs identify the mol. interactions responsible for potency and kinase selectivity.  Efficient drug binding to the unique hinge architecture of CDKs enables selectivity toward most of the human kinome.  Selectivity between CDK family members is achieved through interactions with nonconserved elements of the ATP-binding pocket.  Integrating clin. drug exposures into the anal. predicts that both palbociclib and ribociclib are CDK4/6 inhibitors, abemaciclib inhibits CDK4/6/9, and dinaciclib is a broad-spectrum CDK inhibitor (CDK2/3/4/6/9).  Understanding the mol. components of potency and selectivity also facilitates rational design of future generations of kinase-directed drugs.  Mol Cancer Ther; 15(10); 2273-81.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3TbbI98T8v7Vg90H21EOLACvtfcHk0liPP_ud3nVb6w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGisbjK&md5=112e9e46bb33393516fa94620e6383c6</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0300%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DN.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DLam%26aufirst%3DH.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DY.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DVanArsdale%26aufirst%3DT.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DSpectrum%2520and%2520degree%2520of%2520CDK%2520drug%2520interactions%2520predicts%2520clinical%2520performance%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2273%26epage%3D2281%26doi%3D10.1158%2F1535-7163.MCT-16-0300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osnowski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuill, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Midgley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fleming, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNae, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheleva, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walkinshaw, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span> </span><span class="NLM_article-title">2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1662</span><span class="NLM_x">â</span> <span class="NLM_lpage">1675</span><span class="refDoi">Â DOI: 10.1021/jm0309957</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0309957" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1662-1675&author=S.+Wangauthor=C.+Meadesauthor=G.+Woodauthor=A.+Osnowskiauthor=S.+Andersonauthor=R.+Yuillauthor=M.+Thomasauthor=M.+Meznaauthor=W.+Jacksonauthor=C.+Midgleyauthor=G.+Griffithsauthor=I.+Flemingauthor=S.+Greenauthor=I.+McNaeauthor=S.+Y.+Wuauthor=C.+McInnesauthor=D.+Zhelevaauthor=M.+D.+Walkinshawauthor=P.+M.+Fischer&title=2-Anilino-4-%28thiazol-5-yl%29pyrimidine+CDK+inhibitors%3A+synthesis%2C+SAR+analysis%2C+X-ray+crystallography%2C+and+biological+activity&doi=10.1021%2Fjm0309957"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm0309957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0309957%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMeades%26aufirst%3DC.%26aulast%3DWood%26aufirst%3DG.%26aulast%3DOsnowski%26aufirst%3DA.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DYuill%26aufirst%3DR.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DMezna%26aufirst%3DM.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DMidgley%26aufirst%3DC.%26aulast%3DGriffiths%26aufirst%3DG.%26aulast%3DFleming%26aufirst%3DI.%26aulast%3DGreen%26aufirst%3DS.%26aulast%3DMcNae%26aufirst%3DI.%26aulast%3DWu%26aufirst%3DS.%2BY.%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DZheleva%26aufirst%3DD.%26aulast%3DWalkinshaw%26aufirst%3DM.%2BD.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3D2-Anilino-4-%2528thiazol-5-yl%2529pyrimidine%2520CDK%2520inhibitors%253A%2520synthesis%252C%2520SAR%2520analysis%252C%2520X-ray%2520crystallography%252C%2520and%2520biological%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1662%26epage%3D1675%26doi%3D10.1021%2Fjm0309957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Shao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hole, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">640</span><span class="NLM_x">â</span> <span class="NLM_lpage">659</span><span class="refDoi">Â DOI: 10.1021/jm301475f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301475f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=640-659&author=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=A.+J.+Holeauthor=A.+Y.+Abbasauthor=S.+Baumliauthor=X.+Liuauthor=F.+Lamauthor=D.+W.+Foleyauthor=P.+M.+Fischerauthor=M.+Nobleauthor=J.+A.+Endicottauthor=C.+Pepperauthor=S.+Wang&title=Substituted+4-%28thiazol-5-yl%29-2-%28phenylamino%29pyrimidines+are+highly+active+CDK9+inhibitors%3A+synthesis%2C+X-ray+crystal+structures%2C+structure-activity+relationship%2C+and+anticancer+activities&doi=10.1021%2Fjm301475f"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm301475f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301475f%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DAbbas%26aufirst%3DA.%2BY.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DFoley%26aufirst%3DD.%2BW.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DNoble%26aufirst%3DM.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DSubstituted%25204-%2528thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidines%2520are%2520highly%2520active%2520CDK9%2520inhibitors%253A%2520synthesis%252C%2520X-ray%2520crystal%2520structures%252C%2520structure-activity%2520relationship%252C%2520and%2520anticancer%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D640%26epage%3D659%26doi%3D10.1021%2Fjm301475f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Midgley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabarek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingram, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kontopidis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClue, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLachlan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheleva, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glover, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span> </span><span class="NLM_article-title">Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1111</span><span class="NLM_x">â</span> <span class="NLM_lpage">1121</span><span class="refDoi">Â DOI: 10.1016/j.chembiol.2010.07.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.chembiol.2010.07.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=21035734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKhtLfL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=1111-1121&author=S.+Wangauthor=G.+Griffithsauthor=C.+A.+Midgleyauthor=A.+L.+Barnettauthor=M.+Cooperauthor=J.+Grabarekauthor=L.+Ingramauthor=W.+Jacksonauthor=G.+Kontopidisauthor=S.+J.+McClueauthor=C.+McInnesauthor=J.+McLachlanauthor=C.+Meadesauthor=M.+Meznaauthor=I.+Stuartauthor=M.+P.+Thomasauthor=D.+I.+Zhelevaauthor=D.+P.+Laneauthor=R.+C.+Jacksonauthor=D.+M.+Gloverauthor=D.+G.+Blakeauthor=P.+M.+Fischer&title=Discovery+and+characterization+of+2-anilino-4-+%28thiazol-5-yl%29pyrimidine+transcriptional+CDK+inhibitors+as+anticancer+agents&doi=10.1016%2Fj.chembiol.2010.07.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of 2-Anilino-4- (Thiazol-5-yl)Pyrimidine Transcriptional CDK Inhibitors as Anticancer Agents</span></div><div class="casAuthors">Wang, Shu-Dong; Griffiths, Gary; Midgley, Carol A.; Barnett, Anna L.; Cooper, Michael; Grabarek, Joanna; Ingram, Laura; Jackson, Wayne; Kontopidis, George; McClue, Steven J.; McInnes, Campbell; McLachlan, Janice; Meades, Christopher; Mezna, Mokdad; Stuart, Iain; Thomas, Mark P.; Zheleva, Daniella I.; Lane, David P.; Jackson, Robert C.; Glover, David M.; Blake, David G.; Fischer, Peter M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1111-1121</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The main difficulty in the development of ATP antagonist kinase inhibitors is target specificity, since the ATP-binding motif is present in many proteins.  We introduce a strategy that has allowed us to identify compds. from a kinase inhibitor library that block the cyclin-dependent kinases responsible for regulating transcription, i.e., CDK7 and esp. CDK9.  The screening cascade employs cellular phenotypic assays based on mitotic index and nuclear p53 protein accumulation.  This permitted us to classify compds. into transcriptional, cell cycle, and mitotic inhibitor groups.  We describe the characterization of the transcriptional inhibitor class in terms of kinase inhibition profile, cellular mode of action, and selectivity for transformed cells.  A structural selectivity rationale was used to optimize potency and biopharmaceutical properties and led to the development of a transcriptional inhibitor, 3,4-dimethyl-5-[2-(4-piperazin-1-yl-phenylamino)-pyrimidin-4-yl]-3H-thiazol-2-one, with anticancer activity in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryOG4LTevHibVg90H21EOLACvtfcHk0ljRsYwgSShjQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKhtLfL&md5=08aff2706f6eda4ba1038327267a361e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2010.07.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2010.07.016%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DGriffiths%26aufirst%3DG.%26aulast%3DMidgley%26aufirst%3DC.%2BA.%26aulast%3DBarnett%26aufirst%3DA.%2BL.%26aulast%3DCooper%26aufirst%3DM.%26aulast%3DGrabarek%26aufirst%3DJ.%26aulast%3DIngram%26aufirst%3DL.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DMcClue%26aufirst%3DS.%2BJ.%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DMcLachlan%26aufirst%3DJ.%26aulast%3DMeades%26aufirst%3DC.%26aulast%3DMezna%26aufirst%3DM.%26aulast%3DStuart%26aufirst%3DI.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DZheleva%26aufirst%3DD.%2BI.%26aulast%3DLane%26aufirst%3DD.%2BP.%26aulast%3DJackson%26aufirst%3DR.%2BC.%26aulast%3DGlover%26aufirst%3DD.%2BM.%26aulast%3DBlake%26aufirst%3DD.%2BG.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DDiscovery%2520and%2520characterization%2520of%25202-anilino-4-%2520%2528thiazol-5-yl%2529pyrimidine%2520transcriptional%2520CDK%2520inhibitors%2520as%2520anticancer%2520agents%26jtitle%3DChem.%2520Biol.%26date%3D2010%26volume%3D17%26spage%3D1111%26epage%3D1121%26doi%3D10.1016%2Fj.chembiol.2010.07.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Muller, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaikuad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">The ins and outs of selective kinase inhibitor development</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">818</span><span class="NLM_x">â</span> <span class="NLM_lpage">821</span><span class="refDoi">Â DOI: 10.1038/nchembio.1938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1038%2Fnchembio.1938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=26485069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1ykt7fF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2015&pages=818-821&author=S.+Mullerauthor=A.+Chaikuadauthor=N.+S.+Grayauthor=S.+Knapp&title=The+ins+and+outs+of+selective+kinase+inhibitor+development&doi=10.1038%2Fnchembio.1938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The ins and outs of selective kinase inhibitor development</span></div><div class="casAuthors">Muller, Susanne; Chaikuad, Apirat; Gray, Nathanael S.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">818-821</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Protein kinases have emerged as one of the most successful families of drug targets.  To date, most selective kinase inhibitors have been discovered serendipitously either through broad selectivity screening or through the discovery of unique binding modes.  Here the authors discuss design strategies that could lead to a broader coverage of the kinome with selective inhibitors and to a more rational approach for developing them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQzaMrxSYx_rVg90H21EOLACvtfcHk0ljRsYwgSShjQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1ykt7fF&md5=f5adf0bbaa388c87b26bae23cfad0bae</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1938%26sid%3Dliteratum%253Aachs%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DChaikuad%26aufirst%3DA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DThe%2520ins%2520and%2520outs%2520of%2520selective%2520kinase%2520inhibitor%2520development%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2015%26volume%3D11%26spage%3D818%26epage%3D821%26doi%3D10.1038%2Fnchembio.1938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, M. H.</span><span> </span><span class="NLM_article-title">FDA-approved small-molecule kinase inhibitors</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">422</span><span class="NLM_x">â</span> <span class="NLM_lpage">439</span><span class="refDoi">Â DOI: 10.1016/j.tips.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.tips.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=25975227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=422-439&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=FDA-approved+small-molecule+kinase+inhibitors&doi=10.1016%2Fj.tips.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-approved small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">422-439</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases have emerged as one of the most intensively pursued targets in current pharmacol. research, esp. for cancer, due to their crit. roles in cellular signaling.  To date, the US FDA has approved 28 small-mol. kinase inhibitors, half of which were approved in the past 3 years.  While the clin. data of these approved mols. are widely presented and structure-activity relationship (SAR) has been reported for individual mols., an updated review that analyzes all approved mols. and summarizes current achievements and trends in the field has yet to be found.  Here we present all approved small-mol. kinase inhibitors with an emphasis on binding mechanism and structural features, summarize current challenges, and discuss future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrudyvM3eO09bVg90H21EOLACvtfcHk0ljQm_DRzn-fRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D&md5=a6aa3dbb11e6fe3001fa5fa03a4c950a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DFDA-approved%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D422%26epage%3D439%26doi%3D10.1016%2Fj.tips.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">â</span> <span class="NLM_lpage">1051</span><span class="refDoi">Â DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0ljQm_DRzn-fRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">McInnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâBoyle, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kontopidis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span> </span><span class="NLM_article-title">Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">525</span><span class="NLM_x">â</span> <span class="NLM_lpage">534</span><span class="refDoi">Â DOI: 10.1016/j.chembiol.2004.03.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.chembiol.2004.03.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=15123247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjt1Cms74%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2004&pages=525-534&author=C.+McInnesauthor=S.+Wangauthor=S.+Andersonauthor=J.+O%E2%80%99Boyleauthor=W.+Jacksonauthor=G.+Kontopidisauthor=C.+Meadesauthor=M.+Meznaauthor=M.+Thomasauthor=G.+Woodauthor=D.+P.+Laneauthor=P.+M.+Fischer&title=Structural+determinants+of+CDK4+inhibition+and+design+of+selective+ATP+competitive+inhibitors&doi=10.1016%2Fj.chembiol.2004.03.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Determinants of CDK4 Inhibition and Design of Selective ATP Competitive Inhibitors</span></div><div class="casAuthors">McInnes, Campbell; Wang, Shudong; Anderson, Sian; O'Boyle, Janice; Jackson, Wayne; Kontopidis, George; Meades, Christopher; Mezna, Mokdad; Thomas, Mark; Wood, Gavin; Lane, David P.; Fischer, Peter M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">525-534</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A no. of selective inhibitors of the CDK4/cyclin D1 complex have been reported recently.  Due to the absence of an exptl. CDK4 structure, the ligand and protein determinants contributing to CDK4 selectivity are poorly understood at present.  Here, we report the use of computational methods to elucidate the characteristics of selectivity and to derive the structural basis for specific, high-affinity binding of inhibitors to the CDK4 active site.  From these data, the hypothesis emerged that appropriate incorporation of an ionizable function into a CDK2 inhibitor results in more favorable binding to CDK4.  This knowledge was applied to the design of compds. in the otherwise CDK2-selective 2-anilino-4-(thiazol-5-yl)pyrimidine pharmacophore that are potent and highly selective ATP antagonists of CDK4/cyclin D1.  The findings of this study also have significant implications in the design of CDK4 mimic structures based on CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqU07M2Ugw65bVg90H21EOLACvtfcHk0ljQm_DRzn-fRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjt1Cms74%253D&md5=94d613c28266a51507bf63d34965d792</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.03.022%26sid%3Dliteratum%253Aachs%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DAnderson%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Boyle%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DMeades%26aufirst%3DC.%26aulast%3DMezna%26aufirst%3DM.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DG.%26aulast%3DLane%26aufirst%3DD.%2BP.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DStructural%2520determinants%2520of%2520CDK4%2520inhibition%2520and%2520design%2520of%2520selective%2520ATP%2520competitive%2520inhibitors%26jtitle%3DChem.%2520Biol.%26date%3D2004%26volume%3D11%26spage%3D525%26epage%3D534%26doi%3D10.1016%2Fj.chembiol.2004.03.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Cho, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angove, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brain, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C. H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chopra, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dagostin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feltell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giraldes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiscock, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovats, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lagu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewry, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luzzio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniara, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McMenamin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortenson, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benning, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">OâReilly, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woolford, A. J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrona, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, S.</span><span> </span><span class="NLM_article-title">Fragment-based discovery of 7-azabenzimidazoles as potent, highly selective, and orally active CDK4/6 inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">445</span><span class="NLM_x">â</span> <span class="NLM_lpage">449</span><span class="refDoi">Â DOI: 10.1021/ml200241a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200241a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=445-449&author=Y.+S.+Choauthor=H.+Angoveauthor=C.+Brainauthor=C.+H.+T.+Chenauthor=H.+Chengauthor=R.+Chengauthor=R.+Chopraauthor=K.+Chungauthor=M.+Congreveauthor=C.+Dagostinauthor=D.+J.+Davisauthor=R.+Feltellauthor=J.+Giraldesauthor=S.+D.+Hiscockauthor=S.+Kimauthor=S.+Kovatsauthor=B.+Laguauthor=K.+Lewryauthor=A.+Looauthor=Y.+Luauthor=M.+Luzzioauthor=W.+Maniaraauthor=R.+McMenaminauthor=P.+N.+Mortensonauthor=R.+Benningauthor=M.+O%E2%80%99Reillyauthor=D.+C.+Reesauthor=J.+Shenauthor=T.+Smithauthor=Y.+Wangauthor=G.+Williamsauthor=A.+J.+A.+Woolfordauthor=W.+Wronaauthor=M.+Xuauthor=F.+Yangauthor=S.+Howard&title=Fragment-based+discovery+of+7-azabenzimidazoles+as+potent%2C+highly+selective%2C+and+orally+active+CDK4%2F6+inhibitors&doi=10.1021%2Fml200241a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fml200241a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200241a%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DY.%2BS.%26aulast%3DAngove%26aufirst%3DH.%26aulast%3DBrain%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DC.%2BH.%2BT.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DR.%26aulast%3DChopra%26aufirst%3DR.%26aulast%3DChung%26aufirst%3DK.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DDagostin%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DD.%2BJ.%26aulast%3DFeltell%26aufirst%3DR.%26aulast%3DGiraldes%26aufirst%3DJ.%26aulast%3DHiscock%26aufirst%3DS.%2BD.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DKovats%26aufirst%3DS.%26aulast%3DLagu%26aufirst%3DB.%26aulast%3DLewry%26aufirst%3DK.%26aulast%3DLoo%26aufirst%3DA.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLuzzio%26aufirst%3DM.%26aulast%3DManiara%26aufirst%3DW.%26aulast%3DMcMenamin%26aufirst%3DR.%26aulast%3DMortenson%26aufirst%3DP.%2BN.%26aulast%3DBenning%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Reilly%26aufirst%3DM.%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWilliams%26aufirst%3DG.%26aulast%3DWoolford%26aufirst%3DA.%2BJ.%2BA.%26aulast%3DWrona%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DHoward%26aufirst%3DS.%26atitle%3DFragment-based%2520discovery%2520of%25207-azabenzimidazoles%2520as%2520potent%252C%2520highly%2520selective%252C%2520and%2520orally%2520active%2520CDK4%252F6%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D445%26epage%3D449%26doi%3D10.1021%2Fml200241a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Toogood, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harvey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repine, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheehan, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">VanderWel, S. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNamara, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barvian, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span> </span><span class="NLM_article-title">Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">2388</span><span class="NLM_x">â</span> <span class="NLM_lpage">2406</span><span class="refDoi">Â DOI: 10.1021/jm049354h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm049354h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=2388-2406&author=P.+L.+Toogoodauthor=P.+J.+Harveyauthor=J.+T.+Repineauthor=D.+J.+Sheehanauthor=S.+N.+VanderWelauthor=H.+Zhouauthor=P.+R.+Kellerauthor=D.+J.+McNamaraauthor=D.+Sherryauthor=T.+Zhuauthor=J.+Brodfuehrerauthor=C.+Choiauthor=M.+R.+Barvianauthor=D.+W.+Fry&title=Discovery+of+a+potent+and+selective+inhibitor+of+cyclin-dependent+kinase+4%2F6&doi=10.1021%2Fjm049354h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6</span></div><div class="casAuthors">Toogood, Peter L.; Harvey, Patricia J.; Repine, Joseph T.; Sheehan, Derek J.; VanderWel, Scott N.; Zhou, Hairong; Keller, Paul R.; McNamara, Dennis J.; Sherry, Debra; Zhu, Tong; Brodfuehrer, Joanne; Choi, Chung; Barvian, Mark R.; Fry, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2388-2406</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A pharmacol. approach to inhibition of cyclin-dependent kinases 4 and 6 (Cdk4/6) using highly selective small mol. inhibitors has the potential to provide novel cancer therapies for clin. use.  Achieving high levels of selectivity for Cdk4/6, vs. other ATP-dependent kinases, presents a significant challenge.  The pyrido[2,3-d]pyrimidin-7-one template provides an effective platform for the inhibition of a broad cross-section of kinases, including Cdks.  It is now demonstrated that the modification of pyrido[2,3-d]pyrimidin-7-ones to include a 2-aminopyridine side chain at the C2-position provides inhibitors with exquisite selectivity for Cdk4/6 in vitro.  This selectivity profile is recapitulated in cells where the most selective inhibitors create a G1 block at concns. up to 100-fold the IC50 for cell proliferation.  On the basis of its selectivity profile and pharmacokinetic profile, compd. I (PD 0332991) was identified as a drug candidate for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoX577J5U0r97Vg90H21EOLACvtfcHk0linMkTR9SbEDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitVGisL0%253D&md5=23cbe58426ff1975695712db7c1b128a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm049354h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049354h%26sid%3Dliteratum%253Aachs%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DRepine%26aufirst%3DJ.%2BT.%26aulast%3DSheehan%26aufirst%3DD.%2BJ.%26aulast%3DVanderWel%26aufirst%3DS.%2BN.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DSherry%26aufirst%3DD.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DC.%26aulast%3DBarvian%26aufirst%3DM.%2BR.%26aulast%3DFry%26aufirst%3DD.%2BW.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520cyclin-dependent%2520kinase%25204%252F6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D2388%26epage%3D2406%26doi%3D10.1021%2Fjm049354h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Munch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pittelkow, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boas, U.</span><span> </span><span class="NLM_article-title">A new efficient synthesis of isothiocyanates from amines using di-<i>tert</i>-butyl dicarbonate</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3117</span><span class="NLM_x">â</span> <span class="NLM_lpage">3119</span><span class="refDoi">Â DOI: 10.1016/j.tetlet.2008.03.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.tetlet.2008.03.045" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=3117-3119&author=H.+Munchauthor=J.+S.+Hansenauthor=M.+Pittelkowauthor=J.+B.+Christensenauthor=U.+Boas&title=A+new+efficient+synthesis+of+isothiocyanates+from+amines+using+di-tert-butyl+dicarbonate&doi=10.1016%2Fj.tetlet.2008.03.045"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2008.03.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2008.03.045%26sid%3Dliteratum%253Aachs%26aulast%3DMunch%26aufirst%3DH.%26aulast%3DHansen%26aufirst%3DJ.%2BS.%26aulast%3DPittelkow%26aufirst%3DM.%26aulast%3DChristensen%26aufirst%3DJ.%2BB.%26aulast%3DBoas%26aufirst%3DU.%26atitle%3DA%2520new%2520efficient%2520synthesis%2520of%2520isothiocyanates%2520from%2520amines%2520using%2520di-tert-butyl%2520dicarbonate%26jtitle%3DTetrahedron%2520Lett.%26date%3D2008%26volume%3D49%26spage%3D3117%26epage%3D3119%26doi%3D10.1016%2Fj.tetlet.2008.03.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Mozolis, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iokubaitite, S.</span><span> </span><span class="NLM_article-title">Preparation of <i>N</i>-substituted thiourea. <i>Russ</i></span> <span class="citation_source-journal">Russ. Chem. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">â</span> <span class="NLM_lpage">595</span><span class="refDoi">Â DOI: 10.1070/RC1973v042n07ABEH002677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1070%2FRC1973v042n07ABEH002677" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1973&pages=587-595&author=V.+Mozolisauthor=S.+Iokubaitite&title=Preparation+of+N-substituted+thiourea.+Russ&doi=10.1070%2FRC1973v042n07ABEH002677"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1070%2FRC1973v042n07ABEH002677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1070%252FRC1973v042n07ABEH002677%26sid%3Dliteratum%253Aachs%26aulast%3DMozolis%26aufirst%3DV.%26aulast%3DIokubaitite%26aufirst%3DS.%26atitle%3DPreparation%2520of%2520N-substituted%2520thiourea.%2520Russ%26jtitle%3DRuss.%2520Chem.%2520Rev.%26date%3D1973%26volume%3D42%26spage%3D587%26epage%3D595%26doi%3D10.1070%2FRC1973v042n07ABEH002677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Hantzsch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Traumann, V.</span><span> </span><span class="NLM_article-title">Amidothiazole aus sulfoharnstoff und halogenisirten ketonen, resp. Aldehyden</span> <span class="citation_source-journal">Ber. Dtsch. Chem. Ges.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1888</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">938</span><span class="NLM_x">â</span> <span class="NLM_lpage">941</span><span class="refDoi">Â DOI: 10.1002/cber.188802101178</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1002%2Fcber.188802101178" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1888&pages=938-941&author=A.+Hantzschauthor=V.+Traumann&title=Amidothiazole+aus+sulfoharnstoff+und+halogenisirten+ketonen%2C+resp.+Aldehyden&doi=10.1002%2Fcber.188802101178"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1002%2Fcber.188802101178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcber.188802101178%26sid%3Dliteratum%253Aachs%26aulast%3DHantzsch%26aufirst%3DA.%26aulast%3DTraumann%26aufirst%3DV.%26atitle%3DAmidothiazole%2520aus%2520sulfoharnstoff%2520und%2520halogenisirten%2520ketonen%252C%2520resp.%2520Aldehyden%26jtitle%3DBer.%2520Dtsch.%2520Chem.%2520Ges.%26date%3D1888%26volume%3D21%26spage%3D938%26epage%3D941%26doi%3D10.1002%2Fcber.188802101178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Nabana, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Togo, H.</span><span> </span><span class="NLM_article-title">Reactivities of novel [hydroxy(tosyloxy)iodo]arenes and [hydroxy(phosphoryloxy)iodo]arenes for alpha-tosyloxylation and alpha-phosphoryloxylation of ketones</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4362</span><span class="NLM_x">â</span> <span class="NLM_lpage">4365</span><span class="refDoi">Â DOI: 10.1021/jo0200670</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0200670" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2002&pages=4362-4365&author=T.+Nabanaauthor=H.+Togo&title=Reactivities+of+novel+%5Bhydroxy%28tosyloxy%29iodo%5Darenes+and+%5Bhydroxy%28phosphoryloxy%29iodo%5Darenes+for+alpha-tosyloxylation+and+alpha-phosphoryloxylation+of+ketones&doi=10.1021%2Fjo0200670"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjo0200670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0200670%26sid%3Dliteratum%253Aachs%26aulast%3DNabana%26aufirst%3DT.%26aulast%3DTogo%26aufirst%3DH.%26atitle%3DReactivities%2520of%2520novel%2520%255Bhydroxy%2528tosyloxy%2529iodo%255Darenes%2520and%2520%255Bhydroxy%2528phosphoryloxy%2529iodo%255Darenes%2520for%2520alpha-tosyloxylation%2520and%2520alpha-phosphoryloxylation%2520of%2520ketones%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2002%26volume%3D67%26spage%3D4362%26epage%3D4365%26doi%3D10.1021%2Fjo0200670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Midgley, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">ScaÃ«rou, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grabarek, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Griffiths, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kontopidis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McClue, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McInnes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meades, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mezna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plater, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blake, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheleva, D. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glover, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span> </span><span class="NLM_article-title">Discovery of <i>N</i>-phenyl-4-(thiazol-5-yl) pyrimidin-2-amine aurora kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">4367</span><span class="NLM_x">â</span> <span class="NLM_lpage">4378</span><span class="refDoi">Â DOI: 10.1021/jm901913s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901913s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=4367-4378&author=S.+Wangauthor=C.+A.+Midgleyauthor=F.+Sca%C3%ABrouauthor=J.+B.+Grabarekauthor=G.+Griffithsauthor=W.+Jacksonauthor=G.+Kontopidisauthor=S.+J.+McClueauthor=C.+McInnesauthor=C.+Meadesauthor=M.+Meznaauthor=A.+Platerauthor=I.+Stuartauthor=M.+P.+Thomasauthor=G.+Woodauthor=R.+G.+Clarkeauthor=D.+G.+Blakeauthor=D.+I.+Zhelevaauthor=D.+P.+Laneauthor=R.+C.+Jacksonauthor=D.+M.+Gloverauthor=P.+M.+Fischer&title=Discovery+of+N-phenyl-4-%28thiazol-5-yl%29+pyrimidin-2-amine+aurora+kinase+inhibitors&doi=10.1021%2Fjm901913s"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm901913s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901913s%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMidgley%26aufirst%3DC.%2BA.%26aulast%3DSca%25C3%25ABrou%26aufirst%3DF.%26aulast%3DGrabarek%26aufirst%3DJ.%2BB.%26aulast%3DGriffiths%26aufirst%3DG.%26aulast%3DJackson%26aufirst%3DW.%26aulast%3DKontopidis%26aufirst%3DG.%26aulast%3DMcClue%26aufirst%3DS.%2BJ.%26aulast%3DMcInnes%26aufirst%3DC.%26aulast%3DMeades%26aufirst%3DC.%26aulast%3DMezna%26aufirst%3DM.%26aulast%3DPlater%26aufirst%3DA.%26aulast%3DStuart%26aufirst%3DI.%26aulast%3DThomas%26aufirst%3DM.%2BP.%26aulast%3DWood%26aufirst%3DG.%26aulast%3DClarke%26aufirst%3DR.%2BG.%26aulast%3DBlake%26aufirst%3DD.%2BG.%26aulast%3DZheleva%26aufirst%3DD.%2BI.%26aulast%3DLane%26aufirst%3DD.%2BP.%26aulast%3DJackson%26aufirst%3DR.%2BC.%26aulast%3DGlover%26aufirst%3DD.%2BM.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DDiscovery%2520of%2520N-phenyl-4-%2528thiazol-5-yl%2529%2520pyrimidin-2-amine%2520aurora%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D4367%26epage%3D4378%26doi%3D10.1021%2Fjm901913s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Bredereck, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Effenberger, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botsch, H.</span><span> </span><span class="NLM_article-title">Acid amide reactions. XLV. Reactivity of formamidines, dimethylformamide diethyl acetal (amide acetal), and bis (dimethylamino) methoxymethane (aminal ester)</span> <span class="citation_source-journal">Chem. Ber.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1964</span><span class="NLM_x">, </span> <span class="NLM_volume">97</span><span class="NLM_x">, </span> <span class="NLM_fpage">3397</span><span class="NLM_x">â</span> <span class="NLM_lpage">3406</span><span class="refDoi">Â DOI: 10.1002/cber.19640971220</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1002%2Fcber.19640971220" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=1964&pages=3397-3406&author=H.+Bredereckauthor=F.+Effenbergerauthor=H.+Botsch&title=Acid+amide+reactions.+XLV.+Reactivity+of+formamidines%2C+dimethylformamide+diethyl+acetal+%28amide+acetal%29%2C+and+bis+%28dimethylamino%29+methoxymethane+%28aminal+ester%29&doi=10.1002%2Fcber.19640971220"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fcber.19640971220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcber.19640971220%26sid%3Dliteratum%253Aachs%26aulast%3DBredereck%26aufirst%3DH.%26aulast%3DEffenberger%26aufirst%3DF.%26aulast%3DBotsch%26aufirst%3DH.%26atitle%3DAcid%2520amide%2520reactions.%2520XLV.%2520Reactivity%2520of%2520formamidines%252C%2520dimethylformamide%2520diethyl%2520acetal%2520%2528amide%2520acetal%2529%252C%2520and%2520bis%2520%2528dimethylamino%2529%2520methoxymethane%2520%2528aminal%2520ester%2529%26jtitle%3DChem.%2520Ber.%26date%3D1964%26volume%3D97%26spage%3D3397%26epage%3D3406%26doi%3D10.1002%2Fcber.19640971220" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Swanson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubin, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nasser, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dax, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jetter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitenbucher, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lord, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoey, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rizzolio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogenstaetter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Codd, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplan, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carruthers, N. I.</span><span> </span><span class="NLM_article-title">Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1857</span><span class="NLM_x">â</span> <span class="NLM_lpage">1872</span><span class="refDoi">Â DOI: 10.1021/jm0495071</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0495071" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD2cXps1Ogu7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1857-1872&author=D.+M.+Swansonauthor=A.+E.+Dubinauthor=C.+Shahauthor=N.+Nasserauthor=L.+Changauthor=S.+L.+Daxauthor=M.+Jetterauthor=J.+G.+Breitenbucherauthor=C.+Liuauthor=C.+Mazurauthor=B.+Lordauthor=L.+Gonzalesauthor=K.+Hoeyauthor=M.+Rizzolioauthor=M.+Bogenstaetterauthor=E.+E.+Coddauthor=D.+H.+Leeauthor=S.+P.+Zhangauthor=S.+R.+Chaplanauthor=N.+I.+Carruthers&title=Identification+and+biological+evaluation+of+4-%283-trifluoromethylpyridin-2-yl%29piperazine-1-carboxylic+acid+%285-trifluoromethylpyridin-2-yl%29amide%2C+a+high+affinity+TRPV1+%28VR1%29+vanilloid+receptor+antagonist&doi=10.1021%2Fjm0495071"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist</span></div><div class="casAuthors">Swanson, Devin M.; Dubin, Adrienne E.; Shah, Chandra; Nasser, Nadia; Chang, Leon; Dax, Scott L.; Jetter, Michele; Breitenbucher, J. Guy; Liu, Changlu; Mazur, Curt; Lord, Brian; Gonzales, Lisa; Hoey, Kenway; Rizzolio, Michele; Bogenstaetter, Michael; Codd, Ellen E.; Lee, Doo H.; Zhang, Sui-Po; Chaplan, Sandra R.; Carruthers, Nicholas I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1857-1872</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">High throughput screening using the recombinant human TRPV1 receptor was used to identify a series of pyridinylpiperazine ureas as TRPV1 vanilloid receptor ligands.  Exploration of the structure-activity relationships by parallel synthesis identified the essential pharmacophoric elements for antagonism that permitted further optimization via targeted synthesis to provide a potent orally bioavailable and selective TRPV1 modulator 41 active in several in vivo models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_mnRdFjQEq7Vg90H21EOLACvtfcHk0lg2IhO01FjLqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXps1Ogu7g%253D&md5=068c51ef0f08d6885921032a66e90c64</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm0495071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0495071%26sid%3Dliteratum%253Aachs%26aulast%3DSwanson%26aufirst%3DD.%2BM.%26aulast%3DDubin%26aufirst%3DA.%2BE.%26aulast%3DShah%26aufirst%3DC.%26aulast%3DNasser%26aufirst%3DN.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DDax%26aufirst%3DS.%2BL.%26aulast%3DJetter%26aufirst%3DM.%26aulast%3DBreitenbucher%26aufirst%3DJ.%2BG.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DMazur%26aufirst%3DC.%26aulast%3DLord%26aufirst%3DB.%26aulast%3DGonzales%26aufirst%3DL.%26aulast%3DHoey%26aufirst%3DK.%26aulast%3DRizzolio%26aufirst%3DM.%26aulast%3DBogenstaetter%26aufirst%3DM.%26aulast%3DCodd%26aufirst%3DE.%2BE.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DZhang%26aufirst%3DS.%2BP.%26aulast%3DChaplan%26aufirst%3DS.%2BR.%26aulast%3DCarruthers%26aufirst%3DN.%2BI.%26atitle%3DIdentification%2520and%2520biological%2520evaluation%2520of%25204-%25283-trifluoromethylpyridin-2-yl%2529piperazine-1-carboxylic%2520acid%2520%25285-trifluoromethylpyridin-2-yl%2529amide%252C%2520a%2520high%2520affinity%2520TRPV1%2520%2528VR1%2529%2520vanilloid%2520receptor%2520antagonist%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1857%26epage%3D1872%26doi%3D10.1021%2Fjm0495071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Levallet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lerpiniere, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ko, S. Y.</span><span> </span><span class="NLM_article-title">The HgCl<sub>2</sub>-promoted guanylation reaction: the scope and limitations</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">5291</span><span class="NLM_x">â</span> <span class="NLM_lpage">5304</span><span class="refDoi">Â DOI: 10.1016/S0040-4020(97)00193-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2FS0040-4020%2897%2900193-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADyaK2sXis1Wis7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1997&pages=5291-5304&author=C.+Levalletauthor=J.+Lerpiniereauthor=S.+Y.+Ko&title=The+HgCl2-promoted+guanylation+reaction%3A+the+scope+and+limitations&doi=10.1016%2FS0040-4020%2897%2900193-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">The HgCl2-promoted guanylation reaction: the scope and limitations</span></div><div class="casAuthors">Levallet, Catherine; Lerpiniere, Joanne; Ko, Soo Y.</div><div class="citationInfo"><span class="NLM_cas:title">Tetrahedron</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5291-5304</span>CODEN:
                <span class="NLM_cas:coden">TETRAB</span>;
        ISSN:<span class="NLM_cas:issn">0040-4020</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The HgCl2-promoted guanylation reaction was studied with various substituted thiourea starting materials and the scope and limitations are presented.  The process was found to be effective with thioureas contg. at least one N-conjugated substituent.  Such activating groups include N-carbonyl- (acyl, alkoxycarbonyl, carbamoyl, etc.), N-cyano-, N-sulfonyl-, and N-aryl- substituents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8BjIpnQK3WLVg90H21EOLACvtfcHk0lg2IhO01FjLqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXis1Wis7o%253D&md5=f95b2f9a2dcca9c544376595c0260178</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2FS0040-4020%2897%2900193-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0040-4020%252897%252900193-2%26sid%3Dliteratum%253Aachs%26aulast%3DLevallet%26aufirst%3DC.%26aulast%3DLerpiniere%26aufirst%3DJ.%26aulast%3DKo%26aufirst%3DS.%2BY.%26atitle%3DThe%2520HgCl2-promoted%2520guanylation%2520reaction%253A%2520the%2520scope%2520and%2520limitations%26jtitle%3DTetrahedron%26date%3D1997%26volume%3D53%26spage%3D5291%26epage%3D5304%26doi%3D10.1016%2FS0040-4020%2897%2900193-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Li, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, L. H.</span><span> </span><span class="NLM_article-title">A practical Buchwald-Hartwig amination of 2-bromopyridines with volatile amines</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">3606</span><span class="NLM_x">â</span> <span class="NLM_lpage">3607</span><span class="refDoi">Â DOI: 10.1021/jo070366v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo070366v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=3606-3607&author=J.+J.+Liauthor=Z.+Wangauthor=L.+H.+Mitchell&title=A+practical+Buchwald-Hartwig+amination+of+2-bromopyridines+with+volatile+amines&doi=10.1021%2Fjo070366v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjo070366v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo070366v%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DMitchell%26aufirst%3DL.%2BH.%26atitle%3DA%2520practical%2520Buchwald-Hartwig%2520amination%2520of%25202-bromopyridines%2520with%2520volatile%2520amines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2007%26volume%3D72%26spage%3D3606%26epage%3D3607%26doi%3D10.1021%2Fjo070366v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Voets, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marsman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demmers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beijersbergen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolthuis, R.</span><span> </span><span class="NLM_article-title">The lethal response to Cdk1 inhibition depends on sister chromatid alignment errors generated by KIF4 and isoform 1 of PRC1</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">14798</span><span class="refDoi">Â DOI: 10.1038/srep14798</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1038%2Fsrep14798" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=26423135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2ktrfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=14798&author=E.+Voetsauthor=J.+Marsmanauthor=J.+Demmersauthor=R.+Beijersbergenauthor=R.+Wolthuis&title=The+lethal+response+to+Cdk1+inhibition+depends+on+sister+chromatid+alignment+errors+generated+by+KIF4+and+isoform+1+of+PRC1&doi=10.1038%2Fsrep14798"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The lethal response to Cdk1 inhibition depends on sister chromatid alignment errors generated by KIF4 and isoform 1 of PRC1</span></div><div class="casAuthors">Voets, Erik; Marsman, Judith; Demmers, Jeroen; Beijersbergen, Roderick; Wolthuis, Rob</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14798</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 1 (Cdk1) is absolutely essential for cell division.  Complete ablation of Cdk1 precludes the entry of G2 phase cells into mitosis, and is early embryonic lethal in mice.  Dampening Cdk1 activation, by reducing gene expression or upon treatment with cell-permeable Cdk1 inhibitors, is also detrimental for proliferating cells, but has been assocd. with defects in mitotic progression, and the formation of aneuploid daughter cells.  Here, we used a large-scale RNAi screen to identify the human genes that critically det. the cellular toxicity of Cdk1 inhibition.  We show that Cdk1 inhibition leads to fatal sister chromatid alignment errors and mitotic arrest in the spindle checkpoint.  These problems start early in mitosis and are alleviated by depletion of isoform 1 of PRC1 (PRC1-1), by gene ablation of its binding partner KIF4, or by abrogation of KIF4 motor activity.  Our results show that, normally, Cdk1 activity must rise above the level required for mitotic entry.  This prevents KIF4-dependent PRC1-1 translocation to astral microtubule tips and safeguards proper chromosome congression.  We conclude that cell death in response to Cdk1 inhibitors directly relates to chromosome alignment defects generated by insufficient repression of PRC1-1 and KIF4 during prometaphase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqreZKiNNRPibVg90H21EOLACvtfcHk0lg2IhO01FjLqg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2ktrfJ&md5=f252d4d44ecd64b062c9da0c8b775908</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fsrep14798&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep14798%26sid%3Dliteratum%253Aachs%26aulast%3DVoets%26aufirst%3DE.%26aulast%3DMarsman%26aufirst%3DJ.%26aulast%3DDemmers%26aufirst%3DJ.%26aulast%3DBeijersbergen%26aufirst%3DR.%26aulast%3DWolthuis%26aufirst%3DR.%26atitle%3DThe%2520lethal%2520response%2520to%2520Cdk1%2520inhibition%2520depends%2520on%2520sister%2520chromatid%2520alignment%2520errors%2520generated%2520by%2520KIF4%2520and%2520isoform%25201%2520of%2520PRC1%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D14798%26doi%3D10.1038%2Fsrep14798" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Lu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schulze-Gahmen, U.</span><span> </span><span class="NLM_article-title">Toward understanding the structural basis of cyclin-dependent kinase 6 specific inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">3826</span><span class="NLM_x">â</span> <span class="NLM_lpage">3831</span><span class="refDoi">Â DOI: 10.1021/jm0600388</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0600388" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD28XltVKgtbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=3826-3831&author=H.+Luauthor=U.+Schulze-Gahmen&title=Toward+understanding+the+structural+basis+of+cyclin-dependent+kinase+6+specific+inhibition&doi=10.1021%2Fjm0600388"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Toward Understanding the Structural Basis of Cyclin-Dependent Kinase 6 Specific Inhibition</span></div><div class="casAuthors">Lu, Heshu; Schulze-Gahmen, Ursula</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3826-3831</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) are key players in cell cycle control, and genetic alterations of CDKs and their regulators have been linked to a variety of cancers.  Hence, CDKs are obvious targets for therapeutic intervention in various proliferative diseases, including cancer.  To date, drug design efforts have mostly focused on CDK2 because methods for crystn. of its inhibitor complexes have been well established.  CDK4 and CDK6, however, may be at least as important as enzymes for cell cycle regulation and could provide alternative treatment options.  We describe here two complex structures of human CDK6 with a very specific kinase inhibitor, PD0332991, which is based on a pyrido[2,3-d]pyrimidin-7-one scaffold, and with the less specific aminopurvalanol inhibitor.  Anal. of the structures suggests that relatively small conformational differences between CDK2 and CDK6 in the hinge region are contributing to the inhibitor specificity by inducing changes in the inhibitor orientation that lead to sterical clashes in CDK2 but not CDK6.  These complex structures provide valuable insights for the future development of CDK-specific inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt5qOCDA_blLVg90H21EOLACvtfcHk0lizh21VUTcC_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XltVKgtbk%253D&md5=218bcdfeac3e7371e3ae16ab0a5799db</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm0600388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0600388%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DSchulze-Gahmen%26aufirst%3DU.%26atitle%3DToward%2520understanding%2520the%2520structural%2520basis%2520of%2520cyclin-dependent%2520kinase%25206%2520specific%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D3826%26epage%3D3831%26doi%3D10.1021%2Fjm0600388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Walsby, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradshaw, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fegan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepper, C.</span><span> </span><span class="NLM_article-title">A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">375</span><span class="NLM_x">â</span> <span class="NLM_lpage">385</span><span class="refDoi">Â DOI: 10.18632/oncotarget.1568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.18632%2Foncotarget.1568" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=375-385&author=E.+Walsbyauthor=G.+Prattauthor=H.+Shaoauthor=A.+Y.+Abbasauthor=P.+M.+Fischerauthor=T.+D.+Bradshawauthor=P.+Brennanauthor=C.+Feganauthor=S.+Wangauthor=C.+Pepper&title=A+novel+Cdk9+inhibitor+preferentially+targets+tumor+cells+and+synergizes+with+fludarabine&doi=10.18632%2Foncotarget.1568"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.1568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.1568%26sid%3Dliteratum%253Aachs%26aulast%3DWalsby%26aufirst%3DE.%26aulast%3DPratt%26aufirst%3DG.%26aulast%3DShao%26aufirst%3DH.%26aulast%3DAbbas%26aufirst%3DA.%2BY.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DBradshaw%26aufirst%3DT.%2BD.%26aulast%3DBrennan%26aufirst%3DP.%26aulast%3DFegan%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DPepper%26aufirst%3DC.%26atitle%3DA%2520novel%2520Cdk9%2520inhibitor%2520preferentially%2520targets%2520tumor%2520cells%2520and%2520synergizes%2520with%2520fludarabine%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D375%26epage%3D385%26doi%3D10.18632%2Foncotarget.1568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Li, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iarossi, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noll, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahaman, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">To, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, I. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lock, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DâAndrea, R. J.</span><span> </span><span class="NLM_article-title">Investigation of a novel cyclin-dependent-kinase (CDK) inhibitor Cdki-73 as an effective treatment option for MLL-AML</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">126</span><span class="NLM_x">, </span> <span class="NLM_fpage">1365</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=1365&author=K.+L.+Liauthor=S.+C.+Brayauthor=D.+Iarossiauthor=J.+Adamsauthor=L.+Zhongauthor=B.+Nollauthor=M.+H.+Rahamanauthor=J.+Richmondauthor=L.+B.+Toauthor=I.+D.+Lewisauthor=R.+B.+Lockauthor=S.+Wangauthor=R.+J.+D%E2%80%99Andrea&title=Investigation+of+a+novel+cyclin-dependent-kinase+%28CDK%29+inhibitor+Cdki-73+as+an+effective+treatment+option+for+MLL-AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DK.%2BL.%26aulast%3DBray%26aufirst%3DS.%2BC.%26aulast%3DIarossi%26aufirst%3DD.%26aulast%3DAdams%26aufirst%3DJ.%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DNoll%26aufirst%3DB.%26aulast%3DRahaman%26aufirst%3DM.%2BH.%26aulast%3DRichmond%26aufirst%3DJ.%26aulast%3DTo%26aufirst%3DL.%2BB.%26aulast%3DLewis%26aufirst%3DI.%2BD.%26aulast%3DLock%26aufirst%3DR.%2BB.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DR.%2BJ.%26atitle%3DInvestigation%2520of%2520a%2520novel%2520cyclin-dependent-kinase%2520%2528CDK%2529%2520inhibitor%2520Cdki-73%2520as%2520an%2520effective%2520treatment%2520option%2520for%2520MLL-AML%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D1365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Finlay, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Acton, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dennis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaton, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karoutchi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loddick, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgentin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weir, H. M.</span><span> </span><span class="NLM_article-title">Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">4442</span><span class="NLM_x">â</span> <span class="NLM_lpage">4446</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2008.06.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.bmcl.2008.06.027" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=4442-4446&author=M.+R.+Finlayauthor=D.+G.+Actonauthor=D.+M.+Andrewsauthor=A.+J.+Barkerauthor=M.+Dennisauthor=E.+Fisherauthor=M.+A.+Grahamauthor=C.+P.+Greenauthor=D.+W.+Heatonauthor=G.+Karoutchiauthor=S.+A.+Loddickauthor=R.+Morgentinauthor=A.+Robertsauthor=J.+A.+Tuckerauthor=H.+M.+Weir&title=Imidazole+piperazines%3A+SAR+and+development+of+a+potent+class+of+cyclin-dependent+kinase+inhibitors+with+a+novel+binding+mode&doi=10.1016%2Fj.bmcl.2008.06.027"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.06.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.06.027%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DActon%26aufirst%3DD.%2BG.%26aulast%3DAndrews%26aufirst%3DD.%2BM.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DDennis%26aufirst%3DM.%26aulast%3DFisher%26aufirst%3DE.%26aulast%3DGraham%26aufirst%3DM.%2BA.%26aulast%3DGreen%26aufirst%3DC.%2BP.%26aulast%3DHeaton%26aufirst%3DD.%2BW.%26aulast%3DKaroutchi%26aufirst%3DG.%26aulast%3DLoddick%26aufirst%3DS.%2BA.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DRoberts%26aufirst%3DA.%26aulast%3DTucker%26aufirst%3DJ.%2BA.%26aulast%3DWeir%26aufirst%3DH.%2BM.%26atitle%3DImidazole%2520piperazines%253A%2520SAR%2520and%2520development%2520of%2520a%2520potent%2520class%2520of%2520cyclin-dependent%2520kinase%2520inhibitors%2520with%2520a%2520novel%2520binding%2520mode%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D4442%26epage%3D4446%26doi%3D10.1016%2Fj.bmcl.2008.06.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Sathe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koshy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thalgott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwarzenbock, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krause, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holm, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gschwend, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Retz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nawroth, R.</span><span> </span><span class="NLM_article-title">CDK4/6 inhibition controls proliferation of bladder cancer and transcription of RB1</span> <span class="citation_source-journal">J. Urol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">195</span><span class="NLM_x">, </span> <span class="NLM_fpage">771</span><span class="NLM_x">â</span> <span class="NLM_lpage">779</span><span class="refDoi">Â DOI: 10.1016/j.juro.2015.08.082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.juro.2015.08.082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=26318986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOqsr7O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=195&publication_year=2016&pages=771-779&author=A.+Satheauthor=N.+Koshyauthor=S.+C.+Schmidauthor=M.+Thalgottauthor=S.+M.+Schwarzenbockauthor=B.+J.+Krauseauthor=P.+S.+Holmauthor=J.+E.+Gschwendauthor=M.+Retzauthor=R.+Nawroth&title=CDK4%2F6+inhibition+controls+proliferation+of+bladder+cancer+and+transcription+of+RB1&doi=10.1016%2Fj.juro.2015.08.082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1</span></div><div class="casAuthors">Sathe, Anuja; Koshy, Nicole; Schmid, Sebastian C.; Thalgott, Mark; Schwarzenboeck, Sarah M.; Krause, Bernd J.; Holm, Per S.; Gschwend, Juergen E.; Retz, Margitta; Nawroth, Roman</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Urology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">195</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">771-779</span>CODEN:
                <span class="NLM_cas:coden">JOURAA</span>;
        ISSN:<span class="NLM_cas:issn">0022-5347</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The retinoblastoma signaling network is frequently altered in advanced bladder cancer.  We investigated the potential of CDK4/6 as a therapeutic target and detd. biomarkers for patient stratification.  Genetic alterations were analyzed using public databases, including TCGA (The Cancer Genome Atlas), COSMIC (Catalog of Somatic Mutations in Cancer) and CCLE (Cancer Cell Line Encyclopedia).  Effects of the CDK4/6-inhibitor PD-0332991 or LY2835219 were examd. in 10 bladder cancer cell lines by immunoblot, cell viability, apoptosis and cell cycle progression.  Efficacy of the PD-0332991 and cisplatin combination was analyzed using the combination index.  Gene expression level was detd. by quant. polymerase chain reaction.  Cytomegalovirus promoter regulated recombinant retinoblastoma was used for reconstitution.  Three-dimensional xenografts were grown on chicken chorioallantoic membrane and analyzed by measuring tumor wt. and immunohistochem. expression of total retinoblastoma and Ki-67.  PD-0332991 treatment decreased the proliferation of retinoblastoma pos. bladder cancer cell lines and was synergistic in combination with cisplatin.  PD-0332991 or LY2835219 treatment decreased the phosphorylation, total protein and transcript level of retinoblastoma.  Treatment resulted in a decrease in E2F target gene expression (CCNA2 and CCNE2) and cell cycle progression from G0/G1 to the S-phase but did not affect apoptosis.  In retinoblastoma neg. cells reconstituted with recombinant retinoblastoma PD-0332991 affected only phosphorylation and not the total retinoblastoma level.  These cells remained resistant to treatment.  In 3-dimensional retinoblastoma xenografts, treatment resulted in reduced tumor wt. and decreased expression of total retinoblastoma and Ki-67.  We provide preclin. evidence that CDK4/6 inhibition is a potential therapeutic strategy for retinoblastoma pos. bladder cancer that probably acts by neg. regulating retinoblastoma transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXXQ64fNhPSLVg90H21EOLACvtfcHk0ljYtl01kFy37Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOqsr7O&md5=7b141310df974995067f1fc1a369f676</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.juro.2015.08.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.juro.2015.08.082%26sid%3Dliteratum%253Aachs%26aulast%3DSathe%26aufirst%3DA.%26aulast%3DKoshy%26aufirst%3DN.%26aulast%3DSchmid%26aufirst%3DS.%2BC.%26aulast%3DThalgott%26aufirst%3DM.%26aulast%3DSchwarzenbock%26aufirst%3DS.%2BM.%26aulast%3DKrause%26aufirst%3DB.%2BJ.%26aulast%3DHolm%26aufirst%3DP.%2BS.%26aulast%3DGschwend%26aufirst%3DJ.%2BE.%26aulast%3DRetz%26aufirst%3DM.%26aulast%3DNawroth%26aufirst%3DR.%26atitle%3DCDK4%252F6%2520inhibition%2520controls%2520proliferation%2520of%2520bladder%2520cancer%2520and%2520transcription%2520of%2520RB1%26jtitle%3DJ.%2520Urol.%26date%3D2016%26volume%3D195%26spage%3D771%26epage%3D779%26doi%3D10.1016%2Fj.juro.2015.08.082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anders, L.</span><span> </span><span class="NLM_article-title">Signaling through cyclin D-dependent kinases</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1890</span><span class="NLM_x">â</span> <span class="NLM_lpage">1903</span><span class="refDoi">Â DOI: 10.1038/onc.2013.137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1038%2Fonc.2013.137" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=1890-1903&author=Y.+J.+Choiauthor=L.+Anders&title=Signaling+through+cyclin+D-dependent+kinases&doi=10.1038%2Fonc.2013.137"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.137%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DAnders%26aufirst%3DL.%26atitle%3DSignaling%2520through%2520cyclin%2520D-dependent%2520kinases%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D1890%26epage%3D1903%26doi%3D10.1038%2Fonc.2013.137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Nemoto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saida, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furukawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akahane, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Honna-Oshiro, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kagami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niwa, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watanabe, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakahata, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heike, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugita, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inukai, T.</span><span> </span><span class="NLM_article-title">Specific antileukemic activity of PD0332991, a CDK4/6 inhibitor, against Philadelphia Chromosome-Positive lymphoid leukemia</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">94</span><span class="NLM_x">â</span> <span class="NLM_lpage">105</span><span class="refDoi">Â DOI: 10.1158/1535-7163.MCT-14-1065</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1158%2F1535-7163.MCT-14-1065" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=26637365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslCjsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=94-105&author=A.+Nemotoauthor=S.+Saidaauthor=I.+Katoauthor=J.+Kikuchiauthor=Y.+Furukawaauthor=Y.+Maedaauthor=K.+Akahaneauthor=H.+Honna-Oshiroauthor=K.+Goiauthor=K.+Kagamiauthor=S.+Kimuraauthor=Y.+Satoauthor=S.+Okabeauthor=A.+Niwaauthor=K.+Watanabeauthor=T.+Nakahataauthor=T.+Heikeauthor=K.+Sugitaauthor=T.+Inukai&title=Specific+antileukemic+activity+of+PD0332991%2C+a+CDK4%2F6+inhibitor%2C+against+Philadelphia+Chromosome-Positive+lymphoid+leukemia&doi=10.1158%2F1535-7163.MCT-14-1065"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia</span></div><div class="casAuthors">Nemoto, Atsushi; Saida, Satoshi; Kato, Itaru; Kikuchi, Jiro; Furukawa, Yusuke; Maeda, Yasuhiro; Akahane, Koshi; Honna-Oshiro, Hiroko; Goi, Kumiko; Kagami, Keiko; Kimura, Shinya; Sato, Yuko; Okabe, Seiichi; Niwa, Akira; Watanabe, Kenichiro; Nakahata, Tatsutoshi; Heike, Toshio; Sugita, Kanji; Inukai, Takeshi</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">94-105</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">S-phase progression of the cell cycle is accelerated in tumors through various genetic abnormalities, and, thus, pharmacol. inhibition of altered cell-cycle progression would be an effective strategy to control tumors.  In the current study, we analyzed the antileukemic activity of three available small mols. targeting CDK4/CDK6 against lymphoid crisis of chronic myeloid leukemia (CML-LC) and Philadelphia chromosome-pos. acute lymphoblastic leukemia (Ph+ ALL), and found that all three mols. showed specific activities against leukemic cell lines derived from CML-LC and Ph+ ALL.  In particular, PD0332991 exhibited extremely high antileukemic activity against CML-LC and Ph+ ALL cell lines in the nanomolar range by the induction of G0-G1 arrest and partially cell death through dephosphorylation of pRb and downregulation of the genes that are involved in S-phase transition.  As an underlying mechanism for favorable sensitivity to the small mols. targeting CDK4/CDK6, cell-cycle progression of Ph+ lymphoid leukemia cells was regulated by transcriptional and posttranscriptional modulation of CDK4 as well as Cyclin D2 gene expression under the control of BCR-ABL probably through the PI3K pathway.  Consistently, the gene expression level of Cyclin D2 in Ph+ lymphoid leukemia cells was significantly higher than that in Ph- lymphoid leukemia cells.  Of note, three Ph+ ALL cell lines having the T315I mutation also showed sensitivity to PD0332991.  In a xenograft model, PD0332991, but not imatinib, suppressed dissemination of Ph+ ALL having the T315I mutation and prolonged survival, demonstrating that this reagent would be a new therapeutic modality for relapsed CML-LC and Ph+ ALL patients after treatment with tyrosine kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlKt6ulfSTQrVg90H21EOLACvtfcHk0ljYtl01kFy37Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslCjsA%253D%253D&md5=6745483a8536b59af2948072fbfadb22</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-1065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-1065%26sid%3Dliteratum%253Aachs%26aulast%3DNemoto%26aufirst%3DA.%26aulast%3DSaida%26aufirst%3DS.%26aulast%3DKato%26aufirst%3DI.%26aulast%3DKikuchi%26aufirst%3DJ.%26aulast%3DFurukawa%26aufirst%3DY.%26aulast%3DMaeda%26aufirst%3DY.%26aulast%3DAkahane%26aufirst%3DK.%26aulast%3DHonna-Oshiro%26aufirst%3DH.%26aulast%3DGoi%26aufirst%3DK.%26aulast%3DKagami%26aufirst%3DK.%26aulast%3DKimura%26aufirst%3DS.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DOkabe%26aufirst%3DS.%26aulast%3DNiwa%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DK.%26aulast%3DNakahata%26aufirst%3DT.%26aulast%3DHeike%26aufirst%3DT.%26aulast%3DSugita%26aufirst%3DK.%26aulast%3DInukai%26aufirst%3DT.%26atitle%3DSpecific%2520antileukemic%2520activity%2520of%2520PD0332991%252C%2520a%2520CDK4%252F6%2520inhibitor%252C%2520against%2520Philadelphia%2520Chromosome-Positive%2520lymphoid%2520leukemia%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D94%26epage%3D105%26doi%3D10.1158%2F1535-7163.MCT-14-1065" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Yung-Chi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prusoff, W. H.</span><span> </span><span class="NLM_article-title">Relationship between the inhibition constant (<i>K</i>I) and the concentration of inhibitor which causes 50% inhibition (<i>I</i><sub>50</sub>) of an enzymatic reaction</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3099</span><span class="NLM_x">â</span> <span class="NLM_lpage">3108</span><span class="refDoi">Â DOI: 10.1016/0006-2952(73)90196-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2F0006-2952%2873%2990196-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=4202581" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=C.+Yung-Chiauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28KI%29+and+the+concentration+of+inhibitor+which+causes+50%25+inhibition+%28I50%29+of+an+enzymatic+reaction&doi=10.1016%2F0006-2952%2873%2990196-2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2873%2990196-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252873%252990196-2%26sid%3Dliteratum%253Aachs%26aulast%3DYung-Chi%26aufirst%3DC.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528KI%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2525%2520inhibition%2520%2528I50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108%26doi%3D10.1016%2F0006-2952%2873%2990196-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Yu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basnet, S. K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumarasiri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diab, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Discovery of 4-(dihydropyridinon-3-yl)amino-5-methylthieno[2,3-d]pyrimidine derivatives as potent Mnk inhibitors: synthesis, structure-activity relationship analysis and biological evaluation</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">116</span><span class="NLM_x">â</span> <span class="NLM_lpage">126</span><span class="refDoi">Â DOI: 10.1016/j.ejmech.2015.03.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.ejmech.2015.03.032" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2015&pages=116-126&author=M.+Yuauthor=P.+Liauthor=S.+K.+C.+Basnetauthor=M.+Kumarasiriauthor=S.+Diabauthor=T.+Teoauthor=H.+Albrechtauthor=S.+Wang&title=Discovery+of+4-%28dihydropyridinon-3-yl%29amino-5-methylthieno%5B2%2C3-d%5Dpyrimidine+derivatives+as+potent+Mnk+inhibitors%3A+synthesis%2C+structure-activity+relationship+analysis+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2015.03.032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.03.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.03.032%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DBasnet%26aufirst%3DS.%2BK.%2BC.%26aulast%3DKumarasiri%26aufirst%3DM.%26aulast%3DDiab%26aufirst%3DS.%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DAlbrecht%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DDiscovery%2520of%25204-%2528dihydropyridinon-3-yl%2529amino-5-methylthieno%255B2%252C3-d%255Dpyrimidine%2520derivatives%2520as%2520potent%2520Mnk%2520inhibitors%253A%2520synthesis%252C%2520structure-activity%2520relationship%2520analysis%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D95%26spage%3D116%26epage%3D126%26doi%3D10.1016%2Fj.ejmech.2015.03.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Teo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillam, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sykes, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">612</span><span class="NLM_x">â</span> <span class="NLM_lpage">623</span><span class="refDoi">Â DOI: 10.1016/j.canlet.2014.12.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.canlet.2014.12.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=25527453" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislKguw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2015&pages=612-623&author=T.+Teoauthor=M.+Yuauthor=Y.+Yangauthor=T.+Gillamauthor=F.+Lamauthor=M.+J.+Sykesauthor=S.+Wang&title=Pharmacologic+co-inhibition+of+Mnks+and+mTORC1+synergistically+suppresses+proliferation+and+perturbs+cell+cycle+progression+in+blast+crisis-chronic+myeloid+leukemia+cells&doi=10.1016%2Fj.canlet.2014.12.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells</span></div><div class="casAuthors">Teo, Theodosia; Yu, Mingfeng; Yang, Yuchao; Gillam, Todd; Lam, Frankie; Sykes, Matthew J.; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">612-623</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The Ras/Raf/MAPK and PI3K/Akt/mTORC1 cascades are two most aberrantly regulated pathways in cancers.  As MAPK-interacting kinases (Mnks) are part of the convergent node of these two pathways, and play a pivotal role in cellular transformation, targeting Mnks has emerged as a potential therapeutic strategy.  Herein, a dual-specific Mnk1/2 inhibitor MNKI-57 and a potent Mnk2-specific inhibitor MNKI-4 were selected for a panel screen against 28 human cancer cell lines.  The study reveals that MNKI-57 and MNKI-4 are most potent against leukemia cells KYO-1 (i.e. BC-CML) and KG-1 (i.e. AML).  Interestingly, we found that sensitivity of selected leukemia cells to Mnk inhibitors is correlated with the level of phosphorylated 4E-BP1 at Thr70.  The anti-proliferative effects of Mnk inhibitors are cytostatic in the sensitive KYO-1 cells, inducing significant G1 arrest via down-regulation of cyclin D1 expression.  In KYO-1 cells where Akt is not constitutively active, Mnk inhibitors increase the sensitivity of cells to rapamycin, resulting in a more pronounced anti-proliferative activity.  Remarkably, the synergistic anti-proliferative effects are assocd. with a marked de-phosphorylation of 4E-BP1 at Thr70.  Collectively, these data highlight the importance of 4E-BP1 as a key integrator in the MAPK and mTORC1 cascades, and suggest that a combined pharmacol. inhibition of mTORC1 and Mnk kinases offers an innovative therapeutic opportunity in BC-CML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonXVLjuzQn5rVg90H21EOLACvtfcHk0lhyWQeZaw-QQg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislKguw%253D%253D&md5=a6b1457af0a8430b7976195e8e1b9c5d</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2014.12.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2014.12.029%26sid%3Dliteratum%253Aachs%26aulast%3DTeo%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DGillam%26aufirst%3DT.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DSykes%26aufirst%3DM.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DPharmacologic%2520co-inhibition%2520of%2520Mnks%2520and%2520mTORC1%2520synergistically%2520suppresses%2520proliferation%2520and%2520perturbs%2520cell%2520cycle%2520progression%2520in%2520blast%2520crisis-chronic%2520myeloid%2520leukemia%2520cells%26jtitle%3DCancer%2520Lett.%26date%3D2015%26volume%3D357%26spage%3D612%26epage%3D623%26doi%3D10.1016%2Fj.canlet.2014.12.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Sorota, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margulis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priestley, T.</span><span> </span><span class="NLM_article-title">Characterization of a hERG screen using the IonWorks HT: comparison to a hERG rubidium efflux screen</span> <span class="citation_source-journal">Assay Drug Dev. Technol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">47</span><span class="NLM_x">â</span> <span class="NLM_lpage">57</span><span class="refDoi">Â DOI: 10.1089/adt.2005.3.47</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1089%2Fadt.2005.3.47" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2005&pages=47-57&author=S.+Sorotaauthor=X.+S.+Zhangauthor=M.+Margulisauthor=K.+Tuckerauthor=T.+Priestley&title=Characterization+of+a+hERG+screen+using+the+IonWorks+HT%3A+comparison+to+a+hERG+rubidium+efflux+screen&doi=10.1089%2Fadt.2005.3.47"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1089%2Fadt.2005.3.47&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fadt.2005.3.47%26sid%3Dliteratum%253Aachs%26aulast%3DSorota%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DX.%2BS.%26aulast%3DMargulis%26aufirst%3DM.%26aulast%3DTucker%26aufirst%3DK.%26aulast%3DPriestley%26aufirst%3DT.%26atitle%3DCharacterization%2520of%2520a%2520hERG%2520screen%2520using%2520the%2520IonWorks%2520HT%253A%2520comparison%2520to%2520a%2520hERG%2520rubidium%2520efflux%2520screen%26jtitle%3DAssay%2520Drug%2520Dev.%2520Technol.%26date%3D2005%26volume%3D3%26spage%3D47%26epage%3D57%26doi%3D10.1089%2Fadt.2005.3.47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Moody, G. C.</span><span> </span><span class="NLM_article-title">Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential</span> <span class="citation_source-journal">Xenobiotica</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">â</span> <span class="NLM_lpage">75</span><span class="refDoi">Â DOI: 10.1080/004982599238812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1080%2F004982599238812" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1999&pages=53-75&author=G.+C.+Moody&title=Fully+automated+analysis+of+activities+catalysed+by+the+major+human+liver+cytochrome+P450+%28CYP%29+enzymes%3A+assessment+of+human+CYP+inhibition+potential&doi=10.1080%2F004982599238812"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1080%2F004982599238812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F004982599238812%26sid%3Dliteratum%253Aachs%26aulast%3DMoody%26aufirst%3DG.%2BC.%26atitle%3DFully%2520automated%2520analysis%2520of%2520activities%2520catalysed%2520by%2520the%2520major%2520human%2520liver%2520cytochrome%2520P450%2520%2528CYP%2529%2520enzymes%253A%2520assessment%2520of%2520human%2520CYP%2520inhibition%2520potential%26jtitle%3DXenobiotica%26date%3D1999%26volume%3D29%26spage%3D53%26epage%3D75%26doi%3D10.1080%2F004982599238812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, H. M.</span><span> </span><span class="NLM_article-title">Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes</span> <span class="citation_source-journal">Acta Pharmacol. Sin.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1507</span><span class="NLM_x">â</span> <span class="NLM_lpage">1514</span><span class="refDoi">Â DOI: 10.1111/j.1745-7254.2008.00908.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1111%2Fj.1745-7254.2008.00908.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=19026171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisF2jsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=1507-1514&author=L.+Zhangauthor=M.+J.+Weiauthor=C.+Y.+Zhaoauthor=H.+M.+Qi&title=Determination+of+the+inhibitory+potential+of+6+fluoroquinolones+on+CYP1A2+and+CYP2C9+in+human+liver+microsomes&doi=10.1111%2Fj.1745-7254.2008.00908.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes</span></div><div class="casAuthors">Zhang, Li; Wei, Min-ji; Zhao, Cai-yun; Qi, Hui-min</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1507-1514</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Aim: To det. the inhibitory potential of 2 new fluoroquinolones, caderofloxacin and antofloxacin, together with 4 marketed fluoroquinolones, moxifloxacin, gatifloxacin, levofloxacin, and ciprofloxacin, on the activity of cytochrome P 450 isoforms 1A2 (CYP1A2) and 2C9 (CYP2C9).  Methods: Probe substrates, phenacetin (CYP1A2), and tolbutamide (CYP2C9) were incubated with human liver microsomes and the metabolites were analyzed by liq. chromatog./mass spectrometry using electrospray ionization in pos. or neg. mode.  Glipizide was used as the internal std. in both modes.  The inhibitory potential of fluoroquinolones on CYP1A2 and CYP2C9 was investigated.  Results: The IC50 values (Î¼mol/L) detd. with the cocktail were in agreement with individual probe substrates (Î±-naphthoflavone: 0.27 vs 0.26; sulfaphenazole: 0.49 vs 0.37).  Ciprofloxacin showed weak inhibition on both the activity of CYP1A2 (IC50 135 Î¼mol/L) and CYP2C9 (IC50 180 Î¼mol/L), whereas levofloxacin inhibited only CYP2C9 (IC50 210 Î¼mol/L).  Caderofloxacin, antofloxacin, moxifloxacin, and gatifloxacin showed little or no inhibition on the activity of CYP1A2 or CYP2C9 when tested at comparable concns. (0-200 mg/L).  Conclusion: Caderofloxacin, antofloxacin, moxifloxacin, and gatifloxacin are negligible inhibitors to CYP1A2 and CYP2C9.  The in vitro system can be used as a high-throughput model to screen similar compds. for the early identification of drug-drug interaction potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibxhJIO3TTLVg90H21EOLACvtfcHk0ljjf9vzBEKGKQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisF2jsQ%253D%253D&md5=43594f01970c6087eeaead09e7467cd9</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1111%2Fj.1745-7254.2008.00908.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1745-7254.2008.00908.x%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DM.%2BJ.%26aulast%3DZhao%26aufirst%3DC.%2BY.%26aulast%3DQi%26aufirst%3DH.%2BM.%26atitle%3DDetermination%2520of%2520the%2520inhibitory%2520potential%2520of%25206%2520fluoroquinolones%2520on%2520CYP1A2%2520and%2520CYP2C9%2520in%2520human%2520liver%2520microsomes%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2008%26volume%3D29%26spage%3D1507%26epage%3D1514%26doi%3D10.1111%2Fj.1745-7254.2008.00908.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Dearden, J. C.</span><span> </span><span class="NLM_article-title">Partitioning and lipophilicity in quantitative structure-activity relationships</span> <span class="citation_source-journal">Environ. Health Perspect.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">203</span><span class="NLM_x">â</span> <span class="NLM_lpage">228</span><span class="refDoi">Â DOI: 10.1289/ehp.8561203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1289%2Fehp.8561203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=3905374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A528%3ADyaL2MXmtVGitbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=1985&pages=203-228&author=J.+C.+Dearden&title=Partitioning+and+lipophilicity+in+quantitative+structure-activity+relationships&doi=10.1289%2Fehp.8561203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Partitioning and lipophilicity in quantitative structure-activity relationships</span></div><div class="casAuthors">Dearden, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Environmental Health Perspectives</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">203-28</span>CODEN:
                <span class="NLM_cas:coden">EVHPAZ</span>;
        ISSN:<span class="NLM_cas:issn">0091-6765</span>.
    </div><div class="casAbstract">A review with 171 refs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroyh1jdHUsxLVg90H21EOLACvtfcHk0ljjf9vzBEKGKQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2MXmtVGitbo%253D&md5=08c7f76452d6a5348be3d1f09b3c4a43</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1289%2Fehp.8561203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1289%252Fehp.8561203%26sid%3Dliteratum%253Aachs%26aulast%3DDearden%26aufirst%3DJ.%2BC.%26atitle%3DPartitioning%2520and%2520lipophilicity%2520in%2520quantitative%2520structure-activity%2520relationships%26jtitle%3DEnviron.%2520Health%2520Perspect.%26date%3D1985%26volume%3D61%26spage%3D203%26epage%3D228%26doi%3D10.1289%2Fehp.8561203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">SchÃ¶nherr, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollatz, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haznar-Garbacz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanke, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruiz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beato, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weitschies, W.</span><span> </span><span class="NLM_article-title">Characterisation of selected active agents regarding pKa values, solubility concentrations and pH profiles by SiriusT3</span> <span class="citation_source-journal">Eur. J. Pharm. Biopharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">155</span><span class="NLM_x">â</span> <span class="NLM_lpage">170</span><span class="refDoi">Â DOI: 10.1016/j.ejpb.2015.02.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2Fj.ejpb.2015.02.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=25758123" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=1%3ACAS%3A280%3ADC%252BC2MnivVKlsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2015&pages=155-170&author=D.+Sch%C3%B6nherrauthor=U.+Wollatzauthor=D.+Haznar-Garbaczauthor=U.+Hankeauthor=K.+J.+Boxauthor=R.+Taylorauthor=R.+Ruizauthor=S.+Beatoauthor=D.+Beckerauthor=W.+Weitschies&title=Characterisation+of+selected+active+agents+regarding+pKa+values%2C+solubility+concentrations+and+pH+profiles+by+SiriusT3&doi=10.1016%2Fj.ejpb.2015.02.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Characterisation of selected active agents regarding pKa values, solubility concentrations and pH profiles by SiriusT3</span></div><div class="casAuthors">Schonherr D; Wollatz U; Haznar-Garbacz D; Hanke U; Box K J; Taylor R; Ruiz R; Beato S; Becker D; Weitschies W</div><div class="citationInfo"><span class="NLM_cas:title">European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-70</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The aim of this work was to determine pKa values and solubility properties of 34active agents using the SiriusT3 apparatus.  The selected drug substances belong to the groups of ACE-inhibitors, Î²-blockers, antidiabetics and lipid lowering substances.  Experimentally obtained pKa and intrinsic solubility values were compared to calculated values (program ACD/ChemSketch) and pKa values to published data as well.  Solubility-pH profiles were generated to visualise the substance solubility over the gastrointestinal pH range.  The relationship between the solubility characteristic of a substance, its bioavailability and categorisation according to the Biopharmaceutics Classification System (BCS) was examined as well.  The results showed a good agreement between experimentally obtained, calculated and published pKa values.  The measured and calculated intrinsic solubility values indicated several major deviations.  All solubility-pH profiles showed the expected shape and appearance for acids, bases or zwitterionic substances.  The obtained results for the pKa and solubility measurements of the examined active agents may help to predict their physicochemical behaviour in vivo, and to understand the bioavailability of the substances according to their BCS categorisation.  The easy and reproducible determination of pKa and solubility values makes the SiriusT3 apparatus a useful tool in early stages of drug and formulation development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0tGrDkvlZJ-2qxNLjzXe8fW6udTcc2eblrS9wxGEAN7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MnivVKlsw%253D%253D&md5=02100c72ca191e1039faa3b20d5714d8</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.ejpb.2015.02.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejpb.2015.02.028%26sid%3Dliteratum%253Aachs%26aulast%3DSch%25C3%25B6nherr%26aufirst%3DD.%26aulast%3DWollatz%26aufirst%3DU.%26aulast%3DHaznar-Garbacz%26aufirst%3DD.%26aulast%3DHanke%26aufirst%3DU.%26aulast%3DBox%26aufirst%3DK.%2BJ.%26aulast%3DTaylor%26aufirst%3DR.%26aulast%3DRuiz%26aufirst%3DR.%26aulast%3DBeato%26aufirst%3DS.%26aulast%3DBecker%26aufirst%3DD.%26aulast%3DWeitschies%26aufirst%3DW.%26atitle%3DCharacterisation%2520of%2520selected%2520active%2520agents%2520regarding%2520pKa%2520values%252C%2520solubility%2520concentrations%2520and%2520pH%2520profiles%2520by%2520SiriusT3%26jtitle%3DEur.%2520J.%2520Pharm.%2520Biopharm.%26date%3D2015%26volume%3D92%26spage%3D155%26epage%3D170%26doi%3D10.1016%2Fj.ejpb.2015.02.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Gan, L. S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thakker, D. R.</span><span> </span><span class="NLM_article-title">Applications of the Caco-2 model in the design and development of orally active drugs: elucidation of biochemical and physical barriers posed by the intestinal epithelium</span> <span class="citation_source-journal">Adv. Drug Delivery Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">77</span><span class="NLM_x">â</span> <span class="NLM_lpage">98</span><span class="refDoi">Â DOI: 10.1016/S0169-409X(96)00427-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1016%2FS0169-409X%2896%2900427-9" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1997&pages=77-98&author=L.+S.+L.+Ganauthor=D.+R.+Thakker&title=Applications+of+the+Caco-2+model+in+the+design+and+development+of+orally+active+drugs%3A+elucidation+of+biochemical+and+physical+barriers+posed+by+the+intestinal+epithelium&doi=10.1016%2FS0169-409X%2896%2900427-9"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2FS0169-409X%2896%2900427-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0169-409X%252896%252900427-9%26sid%3Dliteratum%253Aachs%26aulast%3DGan%26aufirst%3DL.%2BS.%2BL.%26aulast%3DThakker%26aufirst%3DD.%2BR.%26atitle%3DApplications%2520of%2520the%2520Caco-2%2520model%2520in%2520the%2520design%2520and%2520development%2520of%2520orally%2520active%2520drugs%253A%2520elucidation%2520of%2520biochemical%2520and%2520physical%2520barriers%2520posed%2520by%2520the%2520intestinal%2520epithelium%26jtitle%3DAdv.%2520Drug%2520Delivery%2520Rev.%26date%3D1997%26volume%3D23%26spage%3D77%26epage%3D98%26doi%3D10.1016%2FS0169-409X%2896%2900427-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Bansal, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bansal, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proia, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackman, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ying, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barsoum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swords, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomlinson, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Battiwalla, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giles, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padmanabhan, S.</span><span> </span><span class="NLM_article-title">Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">4591</span><span class="NLM_x">â</span> <span class="NLM_lpage">4599</span><span class="refDoi">Â DOI: 10.1182/blood-2009-10-247239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;key=10.1182%2Fblood-2009-10-247239" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2010&pages=4591-4599&author=H.+Bansalauthor=S.+Bansalauthor=M.+Raoauthor=K.+P.+Foleyauthor=J.+Sangauthor=D.+A.+Proiaauthor=R.+K.+Blackmanauthor=W.+Yingauthor=J.+Barsoumauthor=M.+R.+Baerauthor=K.+Kellyauthor=R.+Swordsauthor=G.+E.+Tomlinsonauthor=M.+Battiwallaauthor=F.+J.+Gilesauthor=K.+P.+Leeauthor=S.+Padmanabhan&title=Heat+shock+protein+90+regulates+the+expression+of+Wilms+tumor+1+protein+in+myeloid+leukemias&doi=10.1182%2Fblood-2009-10-247239"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-10-247239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-10-247239%26sid%3Dliteratum%253Aachs%26aulast%3DBansal%26aufirst%3DH.%26aulast%3DBansal%26aufirst%3DS.%26aulast%3DRao%26aufirst%3DM.%26aulast%3DFoley%26aufirst%3DK.%2BP.%26aulast%3DSang%26aufirst%3DJ.%26aulast%3DProia%26aufirst%3DD.%2BA.%26aulast%3DBlackman%26aufirst%3DR.%2BK.%26aulast%3DYing%26aufirst%3DW.%26aulast%3DBarsoum%26aufirst%3DJ.%26aulast%3DBaer%26aufirst%3DM.%2BR.%26aulast%3DKelly%26aufirst%3DK.%26aulast%3DSwords%26aufirst%3DR.%26aulast%3DTomlinson%26aufirst%3DG.%2BE.%26aulast%3DBattiwalla%26aufirst%3DM.%26aulast%3DGiles%26aufirst%3DF.%2BJ.%26aulast%3DLee%26aufirst%3DK.%2BP.%26aulast%3DPadmanabhan%26aufirst%3DS.%26atitle%3DHeat%2520shock%2520protein%252090%2520regulates%2520the%2520expression%2520of%2520Wilms%2520tumor%25201%2520protein%2520in%2520myeloid%2520leukemias%26jtitle%3DBlood%26date%3D2010%26volume%3D116%26spage%3D4591%26epage%3D4599%26doi%3D10.1182%2Fblood-2009-10-247239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2EUF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2EUF','PDB','2EUF'); return false;">PDB: 2EUF</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2W96" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2W96','PDB','2W96'); return false;">PDB: 2W96</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i142"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01670">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_11186"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01670">10.1021/acs.jmedchem.6b01670</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Percentages of residual kinase activities of <b>78</b>, <b>83</b>, <b>107</b>, and <b>112</b>, kinome-wide selectivity of <b>83</b>, plasma concentrationâtime curves of <b>83</b> in mice and in rats, NMR spectra and HPLC analysis results for <b>83</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01670/suppl_file/jm6b01670_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01670/suppl_file/jm6b01670_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01670/suppl_file/jm6b01670_si_001.pdf">jm6b01670_si_001.pdf (1.04 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01670/suppl_file/jm6b01670_si_002.csv">jm6b01670_si_002.csv (4.72 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01670&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01670" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01670" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799263e6b9622a8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
